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The tumour microenvironment plays a key role in tumour progression. In this thesis 
acute myeloid leukaemia (AML) was used as a model system to investigate the interplay 
between stromal and cancer cells. AML is a heterogeneous clonal disorder of haematopoietic 
undifferentiated progenitor cells or ‘blast cells’, which accumulate in the bone marrow and lead 
to the reduced output of crucial haematopoietic elements. Due to its heterogeneity (at least in 
part), treatment of the disease has not witnessed great innovation in the past 30 years. The bone 
marrow microenvironment (BMM) has a key role in the haematological malignancies 
contributing to the survival of leukaemic blasts. Relapse in AML occurs because of residual 
disease and evidence suggests that this resistance is facilitated through leukaemic cells ability 
to reside in BMM niches. To understand the precise role of the BMM in AML progression and 
therefore target any supportive mechanisms requires knowledge of how AML cells 
communicate with their microenvironment. In the work presented in this thesis I undertook a 
multi-proteomic approach that utilised liquid chromatography tandem mass spectrometry (LC-
MS/MS) to assess the interplay between AML and BMM cell signalling.  
 This thesis shows the results of a secretomic analysis of stromal cell lines, which 
identified a previously uncharacterized panel of six stromal secreted proteins (BMP-1, CSF-1, 
CTGF, HGF, S100-A4 and S100-A11) that support primary AML cell survival and proliferation in 
culture. Comparison of AML cell signalling (using global phosphoproteomic methods) following 
treatment with the newly identified growth factors revealed that these signalling proteins elicit 
multi-nodular activation of signalling networks with known anti-apoptotic activity. Consistent 
with the cell signalling proteomics data, cell viability studies as a function of pharmacological 
kinase inhibitor treatment determined that the sensitivity of AML to targeted kinase inhibitors 
was modulated by the supportive stromal conditioned media.  
 To investigate heterotypic signalling between cell populations, AML/stromal cell co-
cultures were designed, tested and optimised. These studies identified additional activated 
pathways in AML cells that were only present when AML cells had physical interaction with 
stroma. Complementary analysis of the stromal cells which had been first cultured with AML 
cells revealed that despite heterogeneity there is an emerging stromal phospho-proteomic 
signature that is different in BMM independent AML cells vs BMM interactive AML cells.  
 Collectively these findings evidence the influence that the BMM can have on AML 
signalling. Although evidence for the influence of BMM in modulating AML resistance to 
standard chemotherapy exists, this study highlights specific BMM components that contribute 
to the ability of AML cells to circumvent current treatments based on kinase targeted drugs. 
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Chapter 1: Introduction 
1.1 Acute myeloid leukaemia 
1.1.1 Overview 
Acute myeloid leukaemia (AML) is a haematopoietic stem cell (HSC) malignancy that is 
characterised by impaired haematopoiesis and bone marrow failure (1). In the western world 
this disease accounts for ~25% of all adult-onset leukaemias, with an incidence of 3 to 5 cases 
per 100,000 people per year and a median age of onset of 69 years (2-5). Once deemed 
incurable, AML is now considered curable in 35-40% of adults under 60 years of age, however, 
in patients over 60 years of age, prognosis is bleak with ‘cure’ rates at 5-15% (1). The reduced 
survival that older patients experience is representative of current treatment options, where 
despite significant progress in our understanding of AML biology, there has been little 
meaningful therapeutic advance. High intensity, poorly tolerated therapies remain the most 
curative options (6). AML is a cancer, and it is a disease of the elderly who cannot tolerate 
current therapies, this demonstrates an unmet clinical need for new approaches to treat this 
disease. 
1.1.2 Pathogenesis 
AML is a heterogeneous clonal disorder characterised by the expansion of 
undifferentiated haematopoietic progenitor cells or ‘blast cells’ (7). These blast cells can exhibit 
various degrees of stagnated differentiation while accumulating in the bone marrow (BM), 
which leads to the reduced output of crucial haematopoietic elements (8-10). Their proliferative 
nature eventually leads to infiltration of the peripheral blood and other tissues (11).  
AML blasts are thought to be part of clonal populations that arise from leukaemic stem 
cells (LSCs), which due to chromosomal aberrations harbour mutations that characterise the 
phenotype of the disease (12-15). Oncogenic mutations are described as either class I mutations, 
which confer a proliferative/survival advantage such as the well described FLT3-ITD genotype, 
or class II mutations, which cause an impairment in haematopoietic differentiation and 
subsequently prevent apoptosis; class II mutations tend to be loss of function mutations in 
transcriptional regulators (16, 17). These classes of mutation were thought to occur in a ‘two-
hit model’ where the two mutation types were required to initiate the disease (18). It has since 
become clear the disease can manifest without class I mutations, while there are also commonly 
mutations in epigenetic regulators (DNMT3A, IDH1) as well as tumour suppressors (TP53) (19).    
In addition to the successive genomic events in AML propagation, there are also 
epigenetic factors and external cues from the microenvironment that influence disease 
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behaviour (19). Finally, it is also possible for multiple malignant clones to co-exist, thus making 
this a very heterogeneous disease that is prone to treatment resistance (20). These mechanisms 
of propagation are summarised in Figure 1.1. 
 
Figure 1.1: AML Pathogenesis. This schema provides a simplified view of the progression that occurs 
during AML. It reflects the departure from normal blood cell producing haematopoiesis, characterised by 
a lack of differentiation and an increase in proliferation. This is initiated by a myriad of genetic events that 
lead to the formation of an LSC that has the potential for self-renewal. Clonal expansion from these 
leukaemia initiating cells combined with the pressures of the environment lead to the heterogeneous 
forms of leukaemia that patients present with.  
1.1.3 Classification 
The criteria for AML diagnosis has evolved over the years with multiple revisions of the 
classifications. A diagnosis is made if myeloblasts are found to comprise at least 20% of the total 
number of nucleated cells in the BM (21). Diagnosis can also be determined by morphological 
assessment of BM specimens and blood smears, these criteria underpinned the previous French 
American British (FAB) classification (Table 1.1) (8).  
 
Table 1.1:  FAB AML classification. AML was divided into subtypes, M0 (minimally differentiated) through 
to M7 (differentiated), based on the type of cell from which the leukaemia developed and how 




Advances in cytogenetic testing and genetic screening means that the most recent 
classification according to the World Health Organisation (WHO) of AML builds on the previous 
FAB criteria, but also incorporates the cytogenetic and molecular understanding that has been 
garnered over the past 30 years (Table 1.2) (22). The main categories becoming, AML with 
recurrent genetic abnormalities, AML with myelodysplasia (MDS) related changes, therapy-
related AML, and AML not otherwise specified.    
WHO classification of AML 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
APL with PML-RARA 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, Not Otherwise Specified  
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis (TAM) 
Myeloid leukaemia associated with Down syndrome 
 
Table 1.2: The WHO classification, 2016 update. A more encompassing classification that is based upon 
a combination of morphology, immune-phenotype, genetics, and clinical features (21).  
 
1.1.4 Genomic landscape 
The underlying genetic landscape has to date defined the way this disease is studied and 
has profoundly influenced the way the disease is classified, managed and targeted (21, 23). Since 
the introduction of next generation sequencing there have been a number of comprehensive 
sequencing studies that have collectively identified many leukaemia associated genes; however, 
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these are infrequent mutations and patients typically present with more than one of them (13, 
18, 20, 24). One aspect of AML evolution that could explain this genetic heterogeneity is that 
most cases of AML exhibit clonal heterogeneity at the time of diagnosis, with at least a founding 
clone and a further subclone observed (18). The presence of these additional clones is also 
thought to play a significant role in patient relapse and subsequent resistance to previously 
effective therapies (19).  
Cytogenetics has played a prominent role in diagnosing and managing AML, as non-
random chromosomal abnormalities (deletions and translocations) are observed in ~52% of 
adult AML patients and are thought to be aberrations that significantly contribute to disease 
severity (25). Cytogenetic abnormalities such as t(8;21)(q22;q22), inv(16) and t(15;17) are 
predominantly associated with longer remissions and longer patient survival (26). Whereas, 
deletions in 5q or 7q chromosomes, or the accumulation of >3 alterations (complex) 
chromosomal abnormalities are often associated with poor treatment responses and adverse 
patient outcome (27). In contrast, around 40-50% of AML cases exhibit normal cytogenetics and 
thus, are a very heterogeneous group of patients in terms of treatment response and outcome 
(28). Although this patient group possess normal cytogenetics, that does not mean they do not 
harbour molecular abnormalities and these mutations can offer crucial prognostic information 
(18, 25, 29, 30). 
Twenty years ago, cytogenetics determined how AML from a genetic perspective was 
perceived, since the introduction of next generation sequencing however, the genetic landscape 
of AML has become more defined, particularly in those individuals that do not possess 
cytogenetic abnormalities. These studies have come to recognise that each case on average has 
13 mutations, with 8 of them typically being randomly accrued mutations that can be termed 
‘passenger’ mutations, and 5 that will be recurrent mutations observed in AML, these get 
termed ‘driver’ mutations (18). This knowledge is now incorporated into the WHO classification 
and, when possible, it is used to direct patient treatment (23).  
The largest study undertaken to date to define the genomic landscape in AML was 
performed by Papaemmanuil et al., using next generation sequencing, 1540 patients were both 
screened for 111 cancer genes and cytogenetically screened to profile their genomes (31). This 
study identified 5234 driver mutations across 76 genes, with 2 or more drivers identified in 86% 
of the cohort. Patterns of co-mutations could then be grouped into 11 different groups, with 
class-defining mutations contributing independently and additively to outcome (Figure 1.2). 
Notably it was found that co-mutations could significantly alter the impact of other mutations 
(gene-gene interactions): the combination of DNA methyl-transferase-3A (DNMT3A) and 
nucleophosmin 1 (NPM1) aberrations did not markedly affect survival, but the addition of a 
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mutation in FMS-related tyrosine kinase 3 (FLT3) to these two mutations significantly reduced 
survival (31). 
 
Figure 1.2: Molecular subgroups in AML defined by genomic landscape. Genetic profiling of 1540 
patients screening 111 cancer genes and cytogenetics defines 13 genomic categories listed along x-axis. 
Each column represents a patient and rows represent a different genetic lesion, with purple lines denoting 
observed mutations. Orange lines separate respective genomically defined groups. Colour key represents 
known function of mutated driver gene. Figure adapted from (31). 
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There are a number of mutations that are frequently recurrent in AML and these can be 
classified into functional groups, which collectively go some way to explaining the classical 
features of AML such as the proliferation, stagnated differentiation and the aversion to cell 
death, these are summarised in Table 1.3.  
Functional class Specific example mutations 
Signalling and kinase 
pathway 
FLT3, KRAS, NRAS, 
KIT, NF1, PTPN11 
Epigenetic modifiers 
DNMT3A, IDH1, 















Table 1.3: Recurrent AML mutations grouped into functional sets. The five most frequently mutated 
genes highlighted in red.  
           Mutations in signalling pathways occur in approximately two-thirds of AML cases (the 
most common mutational subset) and are believed to contribute to the aberrant activation and 
proliferation tied to these pathways (32). These mutations are thought to be subclonal, 
therefore indicating that they are late clonal events in disease evolution, this suggests these are 
not disease causing alterations (33). The most frequently mutated signalling gene is FLT3 which 
is mutated in nearly one-third of all AML patients and presents with either mutations in the 
tyrosine kinase domain (TKD), thought to be kinase activating events, or internal tandem 
duplicates (ITD), insertions of variable length in the juxta-membrane domain that render the 
protein constituently active (34).  
          The family of RAS oncogenes (NRAS, KRAS, PTPN11 and NF1) are mutated in 10-15% of all 
AML cases. Like FLT3 mutations these are believed to cause aberrant proliferative signalling 
through activation of the RAS/RAF/MEK/ERK pathway, these mutations tend to be associated 
with poor prognosis due to co-occurrence during MDS transformation to AML – which are 
always considered to have adverse outcomes (35). KIT mutations are observed in a small subset 
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of AML patients - in 20% of patients that have core binding factor translocations and these are 
frequently associated with poor prognosis (36). 
              The high frequency of mutations in signalling proteins (such as FLT3, c-KIT and RAS) 
whose functions correlate with the characteristic features of AML coupled with the adverse 
prognosis that has been associated with such events has led these proteins to become the focus 
of AML targeted therapies (37). Additionally, many large-scale genome projects conclude that 
awareness of the complete genomic landscape will be necessary to stratify patients and know 
when to target such drivers (31, 38-40). 
1.1.5 Treatment 
Treatment of the AML has not witnessed great innovation in the past 40 years, with the 
standard treatment of cytarabine-based chemotherapy (41, 42) and allogeneic stem cell 
transplant (SCT) remaining relatively constant  (8, 43). This approach is considered appropriate 
for all “medically fit” individuals (including older patients); for older “medically unfit” patients - 
traditionally the cohort with least treatment options, due to treatment related morbidity - 
hypomethylating agent strategies as a frontline therapy are looking very promising with 
Azacitidine treatment providing better outcomes now than no leukaemia-directed therapy (44, 
45). 
Current therapy eventually fails for most patients as it preferentially targets rapidly 
dividing cells, while exerting minimal effects on the leukaemic and pre-leukaemic stem cells due 
to their quiescent nature (42, 46-48). LSCs are thought to be responsible for disease initiation 
and relapse, and therefore there is a need for novel therapies that can target the LSCs thus 
maintaining remission and ultimately improving survival (20). 
The notable exception in AML therapy is for a subtype named acute promyelocytic 
leukaemia (APL) where the introduction of All Trans Retinoic Acid therapy (ATRA) has proved a 
very effective means of long-term therapy (19). APL though, only represents a small proportion 
of all AML cases. Consequently, long-term survival rates in AML are around 40% in the young 
and 5% in patients above 60 years of age (this disease is predominantly observed in the elderly) 
(10, 49).  
In recent years, our knowledge of the underlying cancer biology in AML has greatly 
improved. The identification of genetic aberrations relevant to the tumour has made it possible 
to stratify patients into risk groups, which has helped to improve disease management (23) 
(Table 1.4). However, this has not managed to meet satisfactory levels with patients presenting 
with favourable cytogenetics correlating with a 5-year overall survival (OS) ~60%, intermediate 
30-40% and adverse only 5-10% respectively.  
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Risk Category Genetic abnormality 
Favourable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow 
Biallelic mutated CEBPA 
Intermediate Mutated NPM1 and FLT3-ITDhigh 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse-
risk genetic lesions 
t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favourable or adverse 
Adverse t(6;9)(p23;q34.1); DEK-NUP214 
t(v;11q23.3); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 
-5 or del(5q); -7; -17/abn(17p) 
Complex karyotype, monosomal karyotype 




Table 1.4: ELN defined AML risk groups. Current stratification of cytogenetic and molecular genetic 
alterations (as per ELN guidelines). Risk profile will help direct treatment with risk profile usually indicative 
of patient response (23). # Not adverse if occurs with favourable abnormalities. 
Increased understanding of the disease has not yet translated into effective new 
therapies (42); however, that is not to say there has not been a plethora of new approaches 
devised. There is a growing focus on targeted treatments that aim to address underlying 
genomic aberrations. In the US as recent as April 2017, Midostaurin a multi-kinase inhibitor was 
approved by the FDA for patients that harbour mutations in the FLT3 gene. The field of AML 
targeted therapies currently focuses on trying to target disease-initiating and co-operating 
mutations with the aim of eliminating those founding clones and sub-clones (20, 42), with 
popular targets including FLT3 (50-54), CD33(55-57), CXCR4 (58-60), DNA methylation (18, 61-
64) and tyrosine-protein kinase Kit (c-KIT) (65-68).  
Although some of these drugs look promising (Table 1.5), to date none of these targeted 
therapies have been more efficacious than current treatment regimens, including the recently 
approved use of Midostaurin in patients with FLT3 mutations (69). Many of these targets are 
crucial to normal cell development and physiological processes, and as such targeting these 
pathways without inducing toxicity is a challenge (42). One reason for the lack of efficacy in the 
targeted therapies could be the stratification criteria of patient groups. A number of genetic 
studies to date have reported that aberrations in the FLT3 gene lead to constituent activation or 
dysregulation of the protein, which in turn drives leukaemogenesis. The RATIFY trials (the data 
that led to Midostaurin approval in 2017) observed that patients with a FLT3 mutation given 
Midostaurin had a 22% lower-risk of death than patients with a FLT3 mutation not given 
 
 28 
Midostaurin (70). This trial did not assess Midostaurin efficacy in FLT3 wild-type (WT) patients, 
this is surprising as a previous phase 2 trial that used Midostaurin by Fischer T et al. did include 
FLT3 WT patients and observed WT response (71). Therefore, there are patients that respond to 
Midostaurin, but it is not dependent on FLT3 mutational status. 
Class of agent Agents Refs 
Protein kinase 
inhibitors 
 FLT3 inhibition (Midostaurin, Quizartinib, Gilteritinib, 
Crenolanib) 
 KIT inhibitors (Dasatinib) 
 PI3K/AKT/mTOR inhibitors (Everolimus, Sirolimus, API-2, 
GSK2141795) 
 MEK inhibition (Trametinib, selumetinib)  
 Aurora (Barasertib) and polo-like kinase (Volasertib) 
inhibitors, CDK4/6 (Palbociclib), CHK1 (SCH900776), WEE1 
(AZD1775) inhibitors 














 Hypomethylating agents (SGI-110) 
 HDAC inhibitors 
 IDH1 and IDH2 inhibitors (AG-221, AG-120) 
 DOT1L inhibitors (EPZ-5676) 















 Bcl-2, Bcl-xL, and Mcl-1 inhibitors 






 EVI1 targeting 
 NPM1 targeting 







 Monoclonal antibodies (CD33, CD44, CD47, CD123, CLEC12A) 
 Immunoconjugates (SGN33A) 
 BiTEs (AMG 330) and DARTs 
 CAR T cells 
 Immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4) 
 Anti-KIR antibody (IPH-2101) 








Therapies to disrupt 
AML environmental 
interaction 
 CXCR4 and CXCL12 antagonists (AMD 3100, 
LY2510924, LY2624587) 




Table 1.5 – Emerging therapies in AML treatment. Summary of the most promising agents currently in 
clinical trials, as well as novel approaches in pre-clinical development. 
These trials demonstrate that targeted compounds (such as Midostaurin) can be very 
effective, however, further research and understanding is required for better patient 
stratification. Instances of Midostaurin failure in FLT3 mutant patients, suggest a FLT3 mutation 
may not necessarily be sufficient for constitutive activation of the FLT3 substrates, as epigenetic 
events coupled with interactions with the microenvironment could potentially result in a net 
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effect of FLT3 mediated signalling not being crucial to disease propagation (127). In addition, the 
FLT3 protein may not be expressed in all the cases where a FLT3 mutation is present (69, 128). 
These reasons collectively could explain why Midostaurin did not provide a response in all FLT3 
mutant patients during  the RATIFY trials. 
1.1.6 Treatment resistance and relapse 
Treatment resistance (an inability to achieve complete remission [CR]) or relapse (CR 
initially achieved) is common in AML, with event free survival in patients remaining poor despite 
implementation of intensive myelosuppressive regimens and improvements to supportive care 
(129). Around 10-40% of newly diagnosed patients that undergo intense chemotherapy do not 
manage to achieve CR (<5% blast count following 2 cycles of intense induction chemotherapy) 
(130) and are considered treatment resistant (131). Patients can also develop early relapse (re-
emergence of AML blasts < 6 months after initially achieving CR) (132) and late relapse (re-
emergence of AML blasts > 6 months after initially achieving CR) and it has been shown that the 
time it takes for relapse can significantly alter which therapeutic intervention will be effective 
(133, 134). 
Relapse occurs due to minimal residual disease (MRD), which is defined as subclinical 
levels of leukaemia, cells that persist following treatment but are not present at detectable 
numbers, or do not induce clinically overt disease (135, 136). Mechanisms that underpin clinical 
relapse are not as simple as the re-emergence of a dominant clone or evolution from the original 
dominant clone (19). Relapse can also arise from minor subclones, develop as a second 
leukaemia from the same pre-leukaemic clone that the treated disease arose from or be an 
entirely separate therapy-related leukaemia (13, 14, 137). These separate sources of treatment 
related relapse highlight the importance of selecting targets that are considered to be initiating 
events in leukaemogenesis therefore, clonal sensitivity to treatments will be broader, and stable 
remission more likely (136).  
The leukaemic stem/initiator cell (LSC/LIC) was the first cancer stem cell to be described 
in 1994 by Lapidot et al. (11, 138, 139), and have capacities for self-renewal, proliferation and 
differentiation. Relapse is associated with the failure to eradicate this cell population as they are 
characterised by the ability to give rise to new leukemic blast populations (140-142). Whether 
these cells need to be rare stem cells is a polarising issue, as studies have shown that early 
progenitor cells possess the same colony forming traits (143). LICs are regularly chemo-resistant 
due to their infrequent cell divisions and the relationship they share with the microenvironment 
(144, 145), this behaviour enables survival in the presence of DNA damaging chemotherapy 
agents (11, 146, 147). 
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1.2 Tumour microenvironment 
1.2.1 Cellular Composition 
The concept of the bone marrow microenvironment (BMM) having a role in regulating 
haematopoietic cells is well established (148, 149). The BMM is composed of HSCs, endothelial 
cells, osteoblasts, osteoclasts, and mesenchymal stem cells (MSCs). The MSCs can differentiate 
into adipocytes, stromal cells, fibroblasts, and myocytes (150-155). These cells cluster to form 
defined niches that help in the development of haematopoietic cells (156).  
1.2.2 Role of microenvironment in AML progression 
The BMM has a key role in the haematological malignancies, and as discussed 
contributes to the survival and progression of leukaemic blasts (11, 157). Evidence is now 
emerging of the BMMs role in the initiation of myeloid malignancies including AML (158, 159). 
In these rare examples patients that have received BM transplants develop leukaemia as a pre-
existing dysregulated niche initiates leukaemogenesis (160). This concept is based on the idea 
that a healthy BMM keeps any abnormal clones with the potential to transform in check. 
However, following introduction into the recipients dysregulated BMM, the clone now has a 
competitive advantage and undergoes clonal selection, thus developing leukaemia (160).  
Relapse in AML occurs because of residual disease in the form of LSC that are unaffected 
by cytotoxic drugs, and evidence suggests that this resistance is facilitated through the LSCs 
ability to reside in BMM niches (13). It is thought that these niches promote chemo resistance, 
mediated through the promotion of LSCs quiescent hallmarks (remaining in G0), subsequently 
the LSCs are able to remain in such niches during regeneration (14, 161). 
These normal BM niches are usually where HSCs reside, but instead these spaces are 
hijacked by LSCs and blasts – this occurs particularly in the endosteal (EN) and vascular niches 
(VN). Stromal cells and osteoblasts produce the complex ECM that facilitates LSC adhesion to 
BM niches; whilst in the EN, osteoblasts promote dormancy. Osteoclasts maintain a high calcium 
concentration and provide transforming growth factor beta (TGF-β) that also aids in LSC and 
blasts localisation. T-regulatory cells occupy the EN surface helping to circumvent immune 
surveillance. While the release of other cytokines, growth factors (GFs) and chemokines (e.g. 
CXCL12) by stromal, endothelial, mesenchymal and CXCL12-abundant cells helps to orchestrate 





Figure 1.3: Bone marrow stromal microenvironment. Depicted are the different BM niches that LSCs and 
blasts can reside. These niches comprise multiple cell types including endothelial cells, MSCs, osteoclasts, 
osteoblasts, adipocytes, and stromal cells.  
BM niches are stabilised through a number of factors as well as interactions between 
the cells of the BMM (13). The BMM is believed to coax the cells into niches where aspects of 
the LSC can be modulated further. Migration to these niches has been documented through 
chemotaxis via the interaction between CXCR4 and stromal derived factor 1 (SDF-1/CXCL12) 
(15). Retention of leukaemic cells is possible through cellular adhesion molecules such as VLA-4, 
fibronectin, integrins and hyaluronic acid (16, 18, 19). The LSC dormancy is maintained through 
osteopontin, N-cadherins and angiopoietin-1 conferring chemo-resistance (20).  
1.2.3 Leukaemia induced remodelling of the microenvironment  
During overt disease, evidence indicates that malignant cells reshape and modify the 
microenvironment to suit the needs of disease progression, and this is at the expense of normal 
haematopoiesis (162, 163) (Figure 1.4). To achieve this environment, leukaemic cells drive 
remodelling of mesenchymal, endothelial and nerve components (164). These include the 
dysregulated expression of CXCL12 in mesenchymal and endothelial cells, while essential HSC 
factors are reduced (165-167). Neuropathy characterised by a decrease in sympathetic nerve 
fibres and unsheathing of schwann cells is believed to exacerbate homing and engraftment of 
LCSs, while normal HSCs are forced to the periphery (168, 169).   
Vascular remodelling within the BM is a unifying feature of the myeloid malignancies 
and increased micro vessel density is correlative with poor outcome in leukaemia (170, 171). 
The leukaemic cells have been shown to secrete pro-angiogenic factors such as Fibroblast 
growth factor (FGF), as well as pro-inflammatory cytokines; interleukin-6 (IL-6), IL-1β and 
tumour necrosis factor alpha (TNFα) which stimulate endothelial cell proliferation (172-174). In 
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turn, the expansion of endothelial cells that secrete granulocyte colony-stimulating factor (G-
CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) raises the concentrations 
of these cytokines that have been linked with destabilising vascular integrity, thus inducing 
vascular leakiness (175). All of which helps to perpetuate a pro-leukaemic environment.   
   
Figure 1.4: Model of the bone marrow microenvironment and the expansion of AML. The 
microenvironemnt is reshaped by maligncancy and undergoes remodelling that positively effects 
leukaemic expansion at the expense of normal haematopoiesis. 
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As a consequence of leukaemia directed mesenchymal remodelling various degrees of 
fibrosis can be observed in the BM, and the extent of BM fibrosis positively correlates with poor 
prognosis (176, 177). Under the influence of leukaemic cells, MSCs skew their differentiation in 
favour of osteoblastic generation and as a result their activity leads to fibrosis (178). Current 
evidence suggests that it is not necessarily the fibrosis that malignant cells require for disease 
propagation, but the support of disease-associated osteoblasts (179). 
Finally, leukaemia cells were recently described as being able to subsist by hijacking 
lipolytic processes in adipose tissue to fuel metabolic needs while evading chemotherapy 
induced apoptosis (180). It is described that leukaemia can bypass apoptosis in this scenario, as 
the fatty acid oxidation pathway interferes with the oligomerisation of pro-apoptotic proteins 
BAX and BAK (175, 181). 
1.3 Cell signalling and kinase networks 
1.3.1 Cell communication and molecular cross-talk  
A fundamental property of all organisms is their ability to adapt to their environment 
(182). This process is facilitated by the coordination of numerous proteins that receive, process 
and send signals with the environment. This communication mediates life and ranges from an 
organism interacting with the wider environment, to signals exchanged between two cells within 
an organism, down to intracellular interactions between regions of one cell – this is known as 
cell signalling.  
Cell signalling is fundamental to all cellular function. Homeostasis, metabolism, 
migration, cell death and countless other processes are regulated by cell signalling. Signalling 
pathways represent collections of kinases and signalling proteins that coordinate together in 
distinct groups to mediate a cellular function. The significance of kinase signalling is underscored 
by the human genome encoding for over 500 protein kinases and collectively comprise one 
largest groups of evolutionarily related proteins (183). 
Protein kinases regulate signalling networks through reversible protein phosphorylation 
of tyrosine, serine or threonine residues on target protein substrates (184) and lipid 
phosphorylation generates secondary messengers which in turn activate numerous downstream 
protein kinase cascades (185, 186). Protein phosphorylation is the most studied protein post-
translation modification (PTM) and regulates the transduction of signals from cell surface 
receptors to the nucleus where these signals can induce changes in gene expression, and 
therefore mediate cell behaviour (187, 188). Phosphorylation is not the only means of regulating 
signal transduction, as other PTMs (e.g. ubiquitination, methylation, and acetylation) and co-
regulators such as GTPases and secondary messengers are crucial for network activity (184, 185). 
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The role of kinases in AML is important as these proteins regularly harbour mutations in AML. 
These events have been described as leading to constituent activation of kinase regulated 
signalling pathways and their downstream targets. 
 As previously discussed leukaemic cells also rely upon the microenvironment for 
survival. To navigate, respond and shape the microenvironment, leukaemic cells utilise 
numerous means of cell signalling to drive these interactions. Principally, leukaemic cells will 
secrete factors (IL6, IL1β, TNFα) to mediate stromal behaviour (paracrine signalling), which in 
turn should result in the upregulation of pro-leukaemic secreted factors (G-CSF). This exchange 
is termed heterotypic signalling whereby one cell type activates another cell type to reciprocally 
induce signalling in the original cell. Leukaemic cells activate the FLT3 receptor and therefore, 
downstream pathways through secretion of FLT3 ligand (autocrine signalling) (189).  
 
Figure 1.5: AML blast and stromal cell “crosstalk”. A complex interplay that incorporates both the 
inherent cell biology and a heterogeneous cell population. 
Stromal cells have been documented as being able to inhibit proliferation and apoptosis 
in leukaemia cells through gap junctions formed by connexins (190). Connexins are widely 
expressed on the cell surface of leukaemic cells and play a role in mediating leukaemic 
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chemoresistance (191). Although many of these connexins (i.e. cx32, cx43) have functional roles 
in regulating key signalling pathways such as MAPK and PI3K, connexins role in AML cell 
signalling has yet to be unravelled (192). Leukaemic cells also rely upon juxtacrine signalling 
through extra-cellular matrix (ECM) components, integrins and adhesion molecules that enable 
migration and niche homing within the BMM (193-195). These signalling mechanisms that 
mediate “crosstalk” with the BMM are summarised in Figure 1.5. 
1.3.2 Canonical AML cell signalling 
One set of therapeutic targets in AML are protein kinases (196). Many protein kinases 
are implicated in AML leukaemogenesis, as their activation plays critical roles in the regulation 
of many cellular functions (proliferation, survival, differentiation, and migration). Therefore, 
aberrant activation of these pathways is a key component of haematopoietic disease (197) 
(Figure 1.6).  
Receptor Tyrosine Kinases (RTKs)  
Several elements of signal transduction pathways are mutated in AML, with the most 
common occurring in the RTKs such as those in FLT3. Frequent over activation of RTKs through 
activating mutations or the binding of cytokines, GFs and chemokines leads to increased 
activation of downstream signalling kinases; phospho-inositide 3-kinase (PI3K), mitogen-
activated protein kinases (MAPK) and the mechanistic target of rapamycin (mTOR) (197-202).  
The PI3K/AKT/mTOR pathway regulates cell growth, cell survival, and apoptosis. The 
phospholipid products of PI3K activate downstream targets, including phosphoinositide-
dependent kinase-1 (PDK1), AKT, and protein kinase c (PKC) (199, 203-205). The MAP-Kinase 
pathway can promote proliferation and malignant transformation in part due to the stimulation 
of cell growth (199). Ras is reported as being able to regulate both PI3K and MAPK (202). Raf 
activity is negatively regulated by AKT indicating a cross talk between the two pathways. Both 
PI3K and MAPK may result in the phosphorylation of many downstream targets and impose a 
role in the regulation of cell survival and proliferation (202). These pathways phosphorylate 
many key proteins involved in apoptosis (Bad, Bim, Bcl-1, caspases), which serve to potentiate 
AML cell survival. 
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Figure 1.6: Signalling pathways of significance in AML. The main pathways thought to be 
potentiating AML are the JAK/STAT, Ras/Raf/MEK/ERK and PI3K/AKT signalling pathways (50). 
These are activated by a variety of cytokines, GFs and chemokines that function to potentiate or 
inhibit haematopoiesis, which include IL-3 and IL-7, SCF, VEGF, FLT3-ligand, G-CSF, type I 
interferons (IFN), TGF-β and CXCL12 (197). The JAK/STAT pathway is stimulated by activation of 
a cytokine receptor (IL-6, G-CSF), which results in STAT transcription factor activity (203). 
Extracellular c-KIT mutations result in c-Kit receptor hyper-activation in response to 
stem cell factor (SCF) binding, this subsequently leads to strong activation of MAPK, PI3K and 
induces constitutive activation of signal transducers and activators of transcription 3 (STAT-3) 
(201). A result of which is the up regulation of Bcl-xL and c-MYC (197). AKT activates transcription 
of anti-apoptotic genes through the phosphorylation of IκB kinase (IKK) and regulation of nuclear 
factor-kappa B (NF-kB) (206). Oncogenic forms of FLT3 and KIT receptor activation are described 
as perpetuating a FAK/Tiam1/Rac1/PAK1 signalling axis, where by these signalling molecules 
play an essential role in regulating the nuclear translocation of STAT-5 in leukaemogenesis (207).  
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
The JAK/STAT pathway allows for direct signalling from the cytokine receptor to the 
nucleus, which has been implicated in AML blast proliferation (50). Receptor associated JAK 
kinases (JAK1-3) are stimulated by ligand-mediated multimerisation of a receptor. The pathway 
can be activated through ligand binding of growth hormone receptors, interferon receptors, 
RTKs and GPCRs; however, in AML it is predominantly cytokine receptors (IL-6R and GCSFR) that 
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are responsible for pathway activity (208). Activated JAK-cytokine receptor complexes then 
phosphorylate one of the seven STAT family members, this phosphorylation results in STAT 
dimerisation and translocation to the nucleus, which leads to increased transcriptional activity 
and inhibition of apoptosis (209). IL-6, G-CSF and thrombopoietin (TPO) binding to their 
namesake receptors activates STAT3 downstream, whereas granulocyte macrophage (GM–CSF), 
TPO, and IL-3 binding primarily activate STAT5 downstream (178). AML patients have been 
described with truncated G-CSFR receptors that lack a binding site for regulatory protein SOCS-
3, thus leading to increased pathway activity that favours proliferation (210). Increased STAT3 
activity has been observed in 20-50% AML of patients and is associated with a poor prognosis, 
findings that led to STAT3 being considered as a candidate for targeted therapy in some patients 
(211).  
The most frequently reported and therefore main pathways thought to potentiate AML are 
FLT3 driven PI3K/AKT, Ras/Raf/MEK/ERK and JAK/STAT signalling pathways (197). However, the 
particular kinase(s) that potentiate AML disease progression is not the same for all patients. 
With increased mechanistic understanding, targeting pathologically active protein kinases is a 
pharmacologically attractive approach, as manufacturing blockers to protein kinases is relatively 
simple due to the accessibility of kinase active sites (212, 213). 
1.3.3 Network rewiring and plasticity 
The proliferation of big data coupled with the integration of sophisticated 
computational bioinformatics has enabled the emergence of the systems biology paradigm, 
whereby network relationships are contextualised to account for crosstalk between nodes as 
opposed to the assumption of components acting in isolation. Consequently, the structure and 
topology of such networks are an expression of genomic information that can be modulated 
dynamically over time by both external (i.e. microenvironment) and internal perturbations 
(genomic aberrations).  The consideration of these properties as a whole, is then what defines 
the phenotype of a given system.  
Across time a number of factors can affect the activity and configuration of a network 
and these aspects will define how this system or network responds to internal and external 
elements. The plasticity of a kinase network and the potential for rewiring is broad and this is 
exemplified through the wirings of these networks being cell type specific that evolve during 
differentiation, ageing and in cancer (214-219) .  
Malignant cells can respond to targeted inhibition of kinases by increasing the 
expression/activity of its effectors or the kinases downstream of the target, thus compensating 
for any reduced signalling output. For example, an acquired amplification of eIF4E or MYC in 
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response to the PI3K/mTOR inhibition can provide resistance to PI3K inhibitors (220). Kinase 
networks can also respond to inhibition by activating branches and parallel pathways that are 
independent of the targeted pathway. This is a common form of treatment resistance; as the 
activation of compensatory pathways facilitates the circumvention of the block in the network 
(221-224). Further studies have also shown the acquired activation of intracellular kinases in 
response to chronic inhibition of several kinases (225). 
There are many mechanisms by which cancer cells can intrinsically circumvent, evolve 
resistance to, or engage the microenvironment to abrogate the pro-apoptotic effects or anti-
proliferative effects of a particular treatment - much of which has rendered targeted therapies 
in AML ineffective. Even with the advancement of next generation platforms the prediction of 
patient response to different therapies is a serious challenge. These studies have also 
highlighted the significant role and frequency of cross-talk that exists between signalling 
pathways, traditionally such pathways have been conceptualised as linear axes that function in 
isolation (226-228) (Figure 1.7A). To fully understand the way in which kinases signal at a 
fundamental level and the shifts that occur during disease, cell signalling networks must be 
studied as a whole, without bias and in a high-content nature (229-231). Thus, enabling 
visualisation of the plasticity and cross talk between signalling proteins, which more accurately 





Figure 1.7: Models of cell signalling. (A) Example of a canonical signalling cascade, whereby linear distinct 
pathways transmit signalling to adaptor proteins and kinases, inducing functional outputs (i.e. cell 
proliferation, transcriptional activity, cell growth, metabolism, etc.). (B) Empirically defined kinase 
signalling network of MCF7 cells illustrating experimentally identified activity markers specific for this cell 
line. Each large node represents a kinase and the smaller nodes kinase substrates, edges linking nodes 




1.4.1 Mass spectrometry-based proteomics 
Proteomics is the complete study of proteins of a biological system at a specific point in 
time.  Numerous techniques have been employed to study proteins, but the technology that has 
contributed the most in recent years to define proteomics is mass spectrometry (MS). MS is an 
analytical technique that measures the mass to charge ratio (m/z) of ions after they have been 
converted to the gas-phase. All MS are built around the same three core components: an ion 
source, a mass analyser and a detector, however, there are variants of each of these 
components, and the selection of which depends on the application. 
An MS experiment begins in the ion source, which converts the sample molecules from 
a liquid or solid phase into gas-phase ions. Upon entry into the MS ions are transported to the 
mass analyser via ion transfer optics at low pressure. Charged ions are then separated in the 
mass analyser according to their m/z, which allows discrimination between different molecular 
species. Ultimately, when each separated ion hits the detector, the relative ion abundance can 
be calculated by measuring the charge or current generated by the ion making contact with the 
detector. Plotting the relative ion intensity of ions against their m/z generates unique spectrums 
which can be used for compound identification.  
Analysis of mass spectra generated by MS experiments can be used to determine both 
qualitative and quantification aspects of molecules contained in a sample. In recent years there 
has been increased areas of MS application and this follows the continual improvement in speed, 
sensitivity and resolution of the instruments. At present day, MS techniques are used in both 
industry and academia for specific and unbiased analyses of complex chemical and biochemical 
mixtures.  
Electrospray ionisation (ESI) and matrix assisted laser desorption/ionisation (MALDI) are 
the two principal ionisation methods utilised in MS protein analysis, although ESI is more 
prevalent. ESI applies high voltage to a liquid-phase sample as it passes through an electrically 
conductive silica or capillary, to create a mist of charged ions that are in the gas phase (233). 
MALDI uses a laser to vaporise a crystallised solid phase sample which simultaneously ionises 
the sample before analysis (234). MALDI can capture spatial aspects of samples and accordingly 
is utilised for imaging applications (235). Although MALDI is used for peptide mass fingerprinting 
it is not as popular for high-throughput proteomic analysis, due to the lower time-efficiency of 
these instruments (236). ESI sources are more readily coupled to liquid-chromatography 
systems and reproducibility is far more reliable. Many laboratories now utilise an ESI variant 
termed “nano-ESI” for proteomic analysis, this variant of ESI is performed at lower flow rates 
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and increases the sensitivity of analysis due to higher ionisation efficiency, reduced ion 
suppression and higher analyte concentration by nanoflow LC (237, 238). 
MS systems employ a range of mass analysers to identify peptides within a complex 
sample, which include quadrupoles, time of flight (TOF), 3D and linear ion traps, Fourier 
transform ion cyclotron resonance (FT-ICR) and Orbitraps. To identify peptides within complex 
samples, peptide masses are measured, these “precursor ions” are then selected and 
fragmented, before subsequent measurements. Many MS today will use a combination of more 
than one mass analyser to identify peptides. 
A quadrupole ion trap consists of four rods which form a chamber where ions are 
trapped. Radio-frequency and electrical fields are applied to the rods to trap ions according to 
their m/z ratio while they move through the system at high speed. Quadrupoles are able to 
separate ions based on their unique m/z through manipulation of the radio-frequency voltages 
that are applied on the rods. The selection of specific voltage combinations allows for ions only 
of a particular m/z to maintain a stable trajectory when travelling through the quadrupole, prior 
to ion detection.   
TOF analysers initially accelerate ions using an electrical field before allowing ions to 
drift free-field, wherein they then separate according to m/z, as it is this that dictates the speed 
by which they travel. Ion trap analysers, trap ions in an oscillating electrical field, which then 
depending on settings will eject ions from the trap according to m/z. FT-ICR based instruments, 
trap ions within a magnetic field, while an electrical field is applied to the chamber. This is a 
variation of the quadrupole ion traps.  The m/z of each ion and the strength of the magnetic 
field determine the cyclotron frequency at which each ion rotates; rotating ions induce a charge 
on the detection electrodes, which can be converted into a mass spectrum using a Fourier 
transformation.  
Orbitraps are similar to the FT-ICR instruments, as Obitrap instruments first trap ions 
using an electric field, before ejection into the Orbitrap. Ions then oscillate around the central 
electrode according to their m/z. The current induced by the oscillating ions on the detection 
electrodes can be transformed by a Fourier transformation into a mass spectrum.   
The Linear Trap Quadrupole (LTQ)-Orbitrap, combines a linear quadrupole with an 
Orbitrap; here the intact masses are measured in the Orbitrap and precursor ions are 
fragmented in the quadrupole trap. Orbitraps have now become the benchmark analysers in the 
proteomics field, this is owing to their high mass resolution, high mass accuracy (1-2ppm), high 
sensitivity and relatively high dynamic range. 
 
 42 
1.4.1.1 Sample preparation 
For all MS experiments sample preparation is the critical step for successful proteomics 
analyses. Conceptually there are three principal approaches to preparing samples for proteomic 
analysis: bottom-up, middle-down and top-down (239). The bottom-up approach is the most 
commonly used in proteomics much like in genome sequencing; in this strategy proteins are 
proteolytically digested by a selected enzyme resulting in a complex mixture of variably sized 
peptides (depending the on protease). There are a number of different methods that include 
different proteases (trypsin, chymotrypsin, LysC, LysN, AspN, GluC and ArgC) to generate 
different peptide lengths which effect proteome coverage (240). The abundance and identity of 
the peptides can be extrapolated and inferences made after analysis, as to the quantitative and 
qualitative properties.  
 There are a number of factors that can affect method selection during bottom-up 
sample preparation (241). The first consideration regards protein extraction; if working with 
tissue then efficient steps need to be taken to ensure complete tissue disruption. If typically 
working with cells, then lysis is achieved with buffers that contain denaturing chaotropes (such 
as urea) to increase protein solubility or detergents. Following protein solubilisation, it is 
important to reduce chaotropes, detergents and contaminants as these can interfere with the 
efficiency of protein digestion, as chaotropes disrupt enzymatic activity. If proteins are 
immobilised on a solid support, removal of these elements can be achieved via two common 
strategies: polyacrylamide gel electrophoresis (PAGE) or filter-assisted sample preparation 
(FASP) (242)  
In-solution protein digestions instead rely upon the dilution of disrupting substances to 
avoid a negative impact on the proteolytic yield. Solubilised and denatured proteins are 
subsequently reduced and alkylated with agents such as dithiothreitol (DTT) and iodoacetamide 
(IAM), respectively. Once sufficient IAM has bound to the thiol group of cysteines (inhibiting 
disulphide bond formation), consideration is required for the selection of enzyme used to digest 
protein mixtures. The most commonly used enzyme is trypsin, which cleaves proteins at the C-
terminus of arginine (R) and lysine (K) residues (243). Other proteases, such as those mentioned 
previously, may be desired for certain proteomics experiments. Trypsin would not be ideal for 
the study of histone modifications given its cleavage of K residues or when the protein of interest 
has very few R/K residues (244). Some methods employ the utilisation of multiple proteases in 
parallel experiments thereby increasing coverage.  
Both top-down and middle-down sample preparation differ to bottom-up preparation. 
Top down proteomic approaches aim is to characterise native proteins structures, and therefore 
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this technique requires no digestion (245). Middle-down methods do employ a digestion step; 
however, the peptides produced are usually much bigger than those in a bottom-up strategy 
(246). These strategies can be particularly useful in distinguishing isoform variants and for the 
study of multiple PTMs. However, despite the perspectives that middle-down and top-down 
provide, the complexity of whole-protein/large peptide fragmentation can make analysis 
problematic. 
1.4.1.2 Liquid chromatography 
The deep sequencing of complex proteomes (e.g. mammalian proteomes) requires the 
coupling of a separation step before the analytes enter into the MS. This is because the dynamic 
range and resolution of mass spectrometers are still limited and attempts to distinguish both 
low and high abundant species at the same time would be extremely difficult. To separate 
proteins, chemical properties such as their inherent hydrophobicity, charge and polarity can be 
exploited to fractionate complex mixtures in order to reduce ion suppression and increase peak 
resolution. 
The most successful separation technique integrated with mass spectrometry, liquid 
chromatography (LC) is a widely used online (sample fractionation is directly coupled to the mass 
spectrometer) and offline method. LC-MS, separates molecular species based on the 
characteristics mention above - commonly hydrophobicity (as described here for reverse phase 
[RP] chromatography): a given sample when loaded on to a column containing a hydrophobic 
stationary phase, will bind with variable affinities under aqueous conditions. Elution will begin 
as a linearly increasing gradient of the organic mobile phase (acetonitrile [ACN] or methanol) is 
passed through the stationary phase. Peptides will elute as a function of their hydrophobicity. 
The time in which each species elutes from the column is termed the retention time (tR) and is 
a distinctive characteristic of each peptide: hydrophilic peptides elute earlier from the column 
and hydrophobic peptides are retained longer in the column. Hence, the chromatographic 
separation expands the dynamic range and sensitivity of mass spectrometers. This is 
summarised in Figure 1.8A. 
 In addition, offline methods such as immunological/inorganic affinity purification 
(antibody and metal oxide) or 2D chromatography (such as strong cation exchange [SCX] and 
hydrophilic interaction chromatography [HILIC]) can also substantially reduce sample 
complexity. But the integration of these steps greatly increase sample preparation and MS run 
time.  
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Figure 1.8:  Principles of LC-MS/MS. (A) Each sample is separated by reverse-phase liquid 
chromatography prior to ionisation and introduction into the MS. Complex peptide samples are separated 
via LC using analytical columns, where peptides bind to the non-polar stationary phase under aqueous 
buffer and elute at a given retention time through the organic gradient depending on their 
hydrophobicity. These hydrophobic peptides are retained longer in the column. (B) Eluted peptides pass 
through the ESI emitter where the voltage charges droplets produce gas phase ions that then pass through 
the ion transfer capillary and are directed into the MS. Ions enter into the mass spectrometer where m/z 
intensities are measured in the first MS scan (MS1). A precursor is selected and isolated for fragmentation 
and intensities of fragmented ions are measured in the second MS scan (MS2). Inference of the MS2 data 
and subsequent comparison with a database enables peptide identification. 
 
1.4.1.3 Qualitative MS proteomics 
Qualitative proteomics for the identification of proteins and peptides can be carried out 
either in a targeted or untargeted manner. Experiments designed for targeted proteomics 
usually aim to measure with high precision the amount of known proteins within a sample. 
Untargeted proteomics, conversely, allows the unbiased identification of tens of thousands of 
proteins at once within a relatively short time. 
 Qualitative assignment of peptides and protein sequences is possible due to the 
existence of tandem mass spectrometry (MS/MS or MS2) analysis, which separates and 
fragments ions in a multiple-step process. In the first step, peptide ions are selected for their 
fragmentation. Fragmentation, can select peptides using two methods, data dependent 
acquisition (DDA) and data independent acquisition (DIA).  
In DDA mode, the instrument is automated so that only a specific number of peptide 
ions, typically the “Top x” that generate a MS signal above a predefined intensity threshold are 
selected for fragmentation throughout the MS run. The DDA approach is limited by that fact 
A    B 
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performance deteriorates as sample complexity increases, due to an inherent bias against less 
abundant ions; which subsequently will limit peptide identification and quantification of the 
sample. The increased sensitivity of newer instruments is due to shorter duty cycles (time it 
takes to acquire signals in a given setting) which has greatly increased the output of this 
approach.  
In DIA strategies, all parent ions in an MS run are subjected to fragmentation. Peptides 
are identified by matching the transition ions to spectral repositories generated using previous 
DDA methods. The reported benefits of DIA are a broader dynamic range of signals, increased 
identification reproducibility and improved sensitivity and accuracy during quantification (247). 
The drawback is that this approach generates complex MS2 data that are difficult to interpret 
(248). An example of this approach is SWATH, which fragments and acquires all the ion spectra 
in sequential windows, through duration of the MS run (249) 
Following selection, ions are subjected to fragmentation. This can occur in-source 
(although rarely applied in proteomic MS applications) or post-source in the collision zone. There 
are numerous means by which to transfer kinetic energy into ions, the two most commonly used 
in proteomics are electron transfer dissociation (ETD)/electron capture dissociation (ECD) and 
collision-induced dissociation (CID)/ higher-energy collision dissociation (HCD). Selection of the 
fragmentation method depends on both the instrument used for analysis and the sample, as 
different types of fragment ion are produced by each method. The most popular method for 
fragmentation is CID, whereby peptides are broken at the amide-backbone, generating b- and 
y-ions, whereas in ETD peptides are broken at the carboxyl-backbone, which generates c- and z-
ions. HCD is similar to CID and specific to Orbitrap instruments, ions are transferred from the C-
trap to a HCD cell where a higher voltage is applied to ions. The ions return to the C-trap, before 
fragments are injected into the Orbitrap for the generation of MS2 spectra. (Figure 1.8B) 
MS2 spectra can be used to derive the sequence of amino acids that constitute the 
selected precursor ion without any prior knowledge (de novo sequencing). This is performed by 
calculating the difference in m/z between sequential peaks of the same ion type in a spectrum. 
This calculated difference in an ion series represents the loss of an amino acid, and therefore 
continuation through the series enables determination of a peptide sequence. This approach 
requires the identification of the ion series generated upon fragmentation, and is time 
consuming as until recently it was a manual operation. The pros of this approach are that novel 
peptides and peptide mutations can be revealed. The advent of recent software such as PEAKS 
(250) automates the process, making it a more user friendly approach. 
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The most common approach to undertake protein identification of large MS-based 
proteomics, is a database search approach, whereby the MS2 raw spectra are processed into 
peak lists. These lists are thereafter searched against a given database containing theoretical 
peptide spectra generated by in silico modelling of the experiment (251). This is highly 
automated and several software packages with different peptide identification scoring are 
available including Mascot (251), SEQUEST (252), X! Tandem(253), Andromeda (254). Until 
recently, Mascot was the most widely used of these software by the proteomics community 
(now Andromeda), and it scores a peak list using the MOWSE score. Initially, this search engine 
compares the experimentally produced peptide/proteome raw data with each entry in the 
database (± a given mass tolerance, defined by the user). The algorithm then calculates a 
probability score (P) that the peptide match is achieved by chance, and then converts P into a 
Mascot score as -10xlog10 (P) (the Mascot score is inversely proportional the P value). This 
approach is popular as it is relatively fast and produces high throughput identification of 
peptides.  
1.4.1.4 Quantitative MS proteomics  
Qualitative proteomic analysis provides immense value to research. However, it has 
been the large-scale quantification of proteomes that has enabled researchers to address 
fundamental questions of biological systems and increase the collective understanding of 
biochemical processes (255, 256). There are two main methods applied in quantitative 
proteomics: label-based and labelled-free techniques.  
Label-based approaches 
Label-based approaches often involve the introduction of affinity tags that are of known, 
distinctive isotopic mass. These differentially labelled proteins or peptides from samples to be 
compared are then combined and analysed in the same LC-MS/MS run, and it is their relative 
intensities compared to heavy ion peptides (in isotopic labelling) or to a reporter ion (in isobaric 
labelling) which permits the calculation of peptide abundances. 
Isotope-coded affinity tags (ICAT) (257) is an isotopic labelling method based on the 
covalent attachment at protein cysteine residues of heavy and light isotope tags (deuterium and 
hydrogen, respectively) which are attached to a biotin tag to enable purification. The mass 
difference between the heavy and light isotope-tagged samples can be resolved at the MS level. 
This processing at the MS level, leads to several technical limitations. These include the large tag 
interference that can occur during fragmentation and ICAT labelling is limited to cysteine-
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containing proteins. Additionally, ICAT has a tendency to under-represent hydrophobic proteins, 
as these proteins are poorly recovered from avidin.  
Isobaric labelling tandem mass tag (TMT) (258) and isobaric tags for relative and 
absolute quantitation (iTRAQ) (259) aim to address some of these limitations, by utilising 
reporter ions that are released during MS2. These reporter ions permit the identification and 
quantification of reporter groups (259). Despite popularity, TMT and iTRAQ present various 
drawbacks, primarily variability in labelling efficiency, limited identifications due to tag co-
isolation and false positive fragmentation of precursors that have similar mass (260). 
Stable isotope-labelled amino acids in cell culture (SILAC) (261), involves the 
incorporation of two differentially labelled amino acids into metabolically active cells during 
culture. One population of cells is cultured with media supplemented with unlabelled amino 
acids and the comparator population of cells is cultured with media supplemented with heavy 
amino acids (this mass shift is detectable by the mass spectrometer). Identical sample processing 
and equal protein mixing, enables the relative protein abundance to be calculated by comparing 
heavy labelled peptide ions to their unlabelled counterparts.  In this approach, proteins are 
labelled as they are synthesised, which remedies purification and labelling kinetics issues (261). 
The major limitations of the SILAC approach are firstly, that its application to primary tissue 
samples is limited and a number of cells cannot tolerate these conditions. Secondly, there are a 
limited number of comparisons possible within an experiment. Additional drawbacks with SILAC, 
include the variable efficiency that isotopic amino acids are incorporated and the limited ability 
to apply this technique in the presence of serum (FBS) unless dialysed (the removal of small 
molecules such as amino acids, hormones and cytokines). This is because FBS contains 
unlabelled-light amino acids that would cause interference in heavy-labelled amino acid 
containing media. Despite these limitations, there are examples of the successful application of 
SILAC, remarkably mouse models raised on a SILAC-diet led to the protein labelling of various 
body organs without affecting their development (262).  
Collectively, label-based approaches offer several options by which to perform 
quantitative proteomics analysis. Despite its feasibility and strength in particular experimental 
designs, there are crucial limitations. Namely, the increased complexity and time for sample 
preparation, limited experimental flexibility, labelling reagents that come at a relatively high cost 






Label-free methods as the name suggests, require none of the pre-processing that 
labelled approaches entail, and also do not combine comparator samples within the same MS 
run. These approaches aim to either compare the abundance of peptides/proteins between 
samples or to perform absolute protein quantification at a global scale (263) and there are two 
different strategies that are currently used for the label-free quantification of proteomes.  
The first approach, spectral counting, relies on the assumption that the abundance of a 
peptide selected for quantification is directly correlated with the number of MS2 scans triggered 
by that peptide (264). After counting the MS2 events for all peptides, the abundance of each 
particular protein is calculated by averaging the spectral counts of all peptides belonging to the 
given protein. This method is easy to implement. The limitation of the approach is that the 
quantitative capacity of spectral counting is often considered semi-quantitative, this is because 
the most abundant peptides are selected for MS2, thus neglecting low abundant peptides. 
Initiatives to improve and increase the usability of spectral counting for quantitation, include 
emPAI (exponentially modified PAI) (265) and APEX (Absolute Protein EXpression) (266). These 
methods try to correct the experimentally measured spectral counts with the expected peptides 
detection in silico.  
The second label-free approach, constructs extracted ion chromatograms (XICs) of the 
precursor peptide ions. To construct an XIC, the m/z is integrated over the chromatographic time 
for each peptide, the peptide abundance is then determined by calculating either the area of 
peak or peak height for each eluted peptide. The accuracy and performance of this approach 
depends on the, m/z tolerance and size of the retention time windows used to generate XICs. 
These are modulated by the MS1 performance. The size of the retention time windows is crucial 
when generating XICs from complex samples, as they can have isobaric peptides within a given 
retention time window. Therefore, narrowing the m/z window can reduce the erroneous 
selection of peaks for quantification, but reduce the window too much and the XIC generated 
could miss the target peptide. This principle is described in the accurate mass and time (AMT) 
tagging data analysis of mass spectrometry data method for the accurate selection of LC-MS 
parameters for peptide/protein quantification (267).  
A targeted label-free method that is conducted in triple quadrupoles instruments set in 
selection mode is called selective reaction monitoring (SRM), whereby sequential quadrupoles 
coordinate so that the first quadrupole specifically selects precursor ions to be fragmented, the 
second fragments the precursors and the third monitors to calculate abundance (268). 
 
 49 
Subsequently, the abundance of a specific peptide is calculated by its product ion of a specific 
m/z derived from its particular precursor ion. Multiple reaction monitoring (MRM) is a similar 
concept to SRM but provides greater confidence in the quantification as it monitors multiple 
product ions from a precursor ion.  
In the Cutillas lab, peptide quantification of label free LC-MS/MS data is facilitated by 
the  computer program PESCAL (Peak Statistic Calculator), which quantifies peptides of complex 
samples in an untargeted manner and automates the generation of XICs comprised by m/z 
values centred at the peptide tR (269). Initially, a database is populated of peptides identified in 
the LC-MS/MS raw data file, with each peptide m/z, charge state (z), tR and name that were 
identified. The retention times of common peptides are calculated across samples in order to 
normalise for variability in the chromatography. The retention times are then used to calculate 
the XICs.  To increase the accuracy of this method, peaks that are used to construct XICs must 
contain a minimum number of data points to pass QC. Furthermore, the ratios of the second 
and third isotopes of each peptide are correlated with the expected theoretical distribution. 
Incorporating this into the quantification improves the reliability and accuracy of peak-picking, 
helping to increase the correct assignation of isobaric peptides (269).  
The strength of label free quantification is exemplified in this approach. Primarily, unlike 
labelled quantification methods, the number of possible samples that can be compared using 
PESCAL is theoretically limitless. Additionally, this strategy can compensate for missing values 
and performs peptide quantification and identification even if the peptide was not selected for 
MS/MS fragmentation, which can help with overlooked low abundant peptides. The other issue 
with a labelled approach is the compatible cell types and material, that is not an issue using label 
free approaches.  
The limitations of large scale XIC quantification arise in the alignment of retention time 
shifts, this can be reduced by robust LC systems. Spurious peptide assignment to MS peaks can 
occur, although this will likely improve with the implementation of high mass-accuracy MS 
instruments. The caveat for all label-free methods, is that samples must be compared 
independently and controlling for intra-run discrepancies is a known issue with mass 
spectrometers. PESCAL by comparison is a highly reproducible, label-free quantification method 
that can report robust quantification and accurate quantitative readout (270), this has led to its  
successful implementation in addressing multiple biological questions (215, 271-273).    
1.4.2 Mass spectrometry-based secretomics 
The term secretome was coined by Tjalsma et al. (274), and was defined as the collective 
term for all the secreted proteins and secretory machinery of the bacteria cells being studied, 
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and has expanded to the repertoires of proteins that are secreted externally by cells (275). 
Secretomics is considered a branch of proteomics and publications in the area to date have 
focused predominantly on biomarker discovery, but secretomics can also be a powerful means 
to study disease progression and cell communication. 
There are a number of techniques currently available to study the secretome and the 
choice of approach will primarily depend on whether the secretory protein sequence(s) of 
interest are known. If a known protein is being investigated then RNA sequencing, DNA 
microarrays and in silico methods have been demonstrated as means to track expression or 
model potentially secreted proteins. When the proteins being measured are unknown then 
approaches such as serial analysis of gene expression (SAGE), protein arrays, secretory traps and 
MS are more typically used (Figure 1.9).  
 
Figure 1.9: Approaches to study secretome composition. Schematic representative of the methodologies 
that can be used to investigate the secretome. Selection is usually directed on the type of study being 
undertaken. 
Many secretomic studies begin with conditioned media (CM) and various enrichment 
strategies are employed (ultra-centrifugation, fractionation, ultra-filtration, protein 
precipitation, and lyophilisation) to concentrate secretory proteins and remove background 
material, as secreted proteins are present at very low concentration. Considerations (that will 
guide detection platform selection) need to be made regarding the system in which secreted 
proteins are collected, as the inclusion of serum introduces significant background that can mask 
proteins of interest during LC-MS detection. At the same time, serum starvation needs to be 
tolerable to cells, as excessive cell death leads to the release of proteins that will contaminate 
the secretome and confound results. Additionally, serum deprivation can induce differential 
responses in different cell types and alter the biology that is trying to be captured. 
 
 51 
To enable the inclusion of serum in secretomic MS-based experiments, methods for 
serum protein removal have previously been devised. These protocols can involve metabolic 
labelling of cells, so that their secretome can be differentiated from serum proteins. 
Alternatively serum albumin binding to specially designed resins can used to remove background 
serum proteins (276). The drawbacks of metabolic labelling are that it is both time-consuming 
and not compatible with many cell types. Resins designed to remove serum proteins, also risk 
the unintentional removal of important non-serum proteins.  
Although dependent on the nature of the study, an MS-based method offers 
unparalleled coverage when approaching secretome analysis in an unbiased manner. Protein 
arrays (antibody and bead) are very sensitive and robust; however, they are limited to measuring 
a defined set of proteins, of which need to be selected for analysis beforehand. RNA Sequencing 
and DNA microarrays have merit, but they are indirect read-outs of protein production/ 
secretion and secretomic relevance is inferred rather than directly measured. SAGE and 
secretion traps have historically been successful in identifying secretome components (277), but 
they are comparatively time-consuming methods that can be prone to error (259).  
LC-MS/MS approaches to identify secretory proteins can be separated into two main 
methods, gel based and gel-independent techniques. Gel based methods include two-
dimensional gel electrophoresis (2DE) and differential gel electrophoresis (DIGE), whereby 
secretomes are first separated to resolve discrete spots based on charge and mass, prior to gel 
extraction and identification using LC-MS/MS. This approach has proved successful in identifying 
secretory proteins in CM from numerous cells types including adipose stem cells, fibroblast 
feeder cells and leptin treated breast cancer cells (278-283). The advantages of this approach 
are that previously unknown proteins can be identified with high resolving power. 
Disadvantages include a low dynamic range that limits the identification of low abundant 
proteins, a relatively low-throughput, and reproducibility can be an issue. 
Gel-independent LC-MS/MS techniques include the isotopic labelling of cells prior to 
conditioning media, this allows for the quantification of proteins synthesised by the cell type of 
interest in different conditions, which are then combined to be measured in one MS run (257, 
284, 285). Common labelling strategies include the previously described SILAC, iTRAQ and ICAT. 
Examples of success using labelling approaches include the identification of secretory proteins 
from the microenvironment of glioma cells using ICAT (286), iTRAQ coupled LC-MS/MS which 
was used to decipher differences in the secretome of macrophages infected with influenza 
(287), and SILAC which was successfully used to study pancreatic and squamous cell carcinoma 
cancer secretomes (288, 289). Advantages to gel-independent methods include the ability to 
detect low abundance proteins coupled with high sequence coverage, and reproducibility is 
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increased by being able to include different biological conditions in the same MS run. The main 
disadvantage with label-based gel-independent techniques is that they are not always feasible 
in the cells of interest; SILAC media for example is not well tolerated by primary samples, ICAT 
is only appropriate for cysteine containing proteins (although ICAT is no longer popular).  
Overall, LC-MS/MS based approaches to study secretomes have been proven to be the 
most powerful and unbiased means to directly identify and subsequently quantify secreted 
proteins. The current challenges involve optimising the sample processing and enrichment of 
secretomes prior to LC-MS/MS analysis.  
1.5. Phosphoproteomics 
Numerous studies have now demonstrated that the expression of individual genes at 
the mRNA level correlates poorly with the expression of the proteins they encode (290, 291). 
On a similar train of logic, it has become increasingly apparent that the abundance of particular 
enzymes, in most cases, does not correlate with their actual activities (292). In contrast, 
knowledge of their spatial distribution, post-translational regulation, and the abundance of the 
products of the reactions they govern are now appreciated as more representative readouts of 
their catalytic activity. As a result, the study of sub-proteomes – either in terms of sub-cellular 
distributions or specific populations of PTM proteins – has become a popular area of research, 
particularly with the increasing accessibility of MS technologies that are able to define these. 
Such studies often involve the specific enrichment of proteins possessing the PTM of interest 
(e.g. phosphorylation, acetylation, or glycosylation), isolation of a particular class of protein (e.g. 
kinases or histones), or purification of specific cellular organelles/compartments (e.g. 
mitochondria or Golgi apparatus). 
Due to the long-known importance of protein phosphorylation in cellular signalling, its 
relatively simple and amenable chemistry, its relative abundance, and the development of ever 
more powerful MS and LC technologies, phosphoproteomics (the study of the entire 
complement of phosphorylated proteins in a biological system) has been perhaps the most 
studied sub-proteome in recent years. 
1.5.1 The implications of phosphorylation events 
The impact of phosphorylation on protein function is diverse in nature; (293) however, 
the main regulatory roles that have been demonstrated experimentally, are often tied to 
functional processes, demonstrating the importance of protein phosphorylation in cell function. 
Phosphorylation events play a key role in the propagation, amplification, and correct 





Figure 1.10: Molecular mechanisms that contribute to the activation of kinase signalling. Several 
molecular factors, in addition to expression, may affect kinase activity. Pathway activity may be influenced 
by somatic mutations, by upstream signals and by substrate availability. The action of protein 
phosphatases opposing the reaction may also be influenced by similar molecular events. Quantifying the 
phosphoprotein product of the kinase/phosphatase activity provides the most direct method of 
quantifying pathway activity. 
The occupancy of individual phosphorylation sites is governed by both the kinases and 
phosphatases that phosphorylate and dephosphorylate their substrates. The expression of a 
phosphorylation event encompasses the rate at which both the respective kinases and 
phosphatases to this substrate catalyse their respective reactions. Therefore, the overall 
equilibrium between protein and phosphorylated protein encompasses the activity of these 
processes at one moment in time (Figure 1.10) (294). However, in addition to these regulators 
the balance is also determined by other aspects of the system, including: epigenetic and genetic 
regulation, allosteric modulation and mutations amongst others, that impact upon one 
phosphorylation event (182).  
As the interaction between the kinases and phosphatases that regulate protein 
phosphorylation is complex, a proposed and now putative readout of their combined functions 
is through the quantification of the phosphorylated substrate (271, 295). MS has been 
instrumental in the unbiased assessment and global analysis of phosphorylation events, as tens 
of thousands of phosphorylation sites can be fully quantified in a single experiment, without the 
need of antibodies or arrays with preconceptions of targets. 
1.5.2 Phosphopeptide enrichment strategies for MS analysis 
When analysing phosphorylation events considerations need to be made regarding the 
fragile nature of the ATP gamma phosphate modification. This modification is unstable at both 
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high temperature and high pH due to -elimination that is driven by OH-. It is also crucial to 
inhibit phosphatases as they are still active following cell lysis and will act to remove phosphate 
groups from peptides (296). Therefore, to preserve and measure a representative 
phosphoproteome of the system being studied, it is essential to maintain a non-alkaline pH, 
inhibit phosphatase activity using inhibitors and keep samples below 4C.  
Against the backdrop of the proteome and complex peptide mixtures, phosphorylated 
peptides are at risk of being under sampled due to low stoichiometric abundance relative to 
other peptide species and MS technical issues. Principally ion suppression is what leads to less 
efficient phosphopeptide ionisation compared to unmodified species (297). Therefore, 
phosphopeptide-enrichment methods are required to increase the number of phosphopeptides 
that can be identified when undertaking phosphoproteomics. There are several approaches to 
enrich for phosphorylation events, namely chemical derivatisation, chromatography, 
immunological affinity purification and inorganic affinity purification (298). Approaches 
summarised in Figure 1.11. 
    Chemical derivatisation involves the removal and substitution of phosphate groups. The 
principle of this method is that substituting the phosphate group improves the peptide 
ionisation and MS2 fragmentation. The classical example involves β-elimination of phosphate 
mediated by providing OH- ions, followed by Michael addition of thiol-derived affinity tags (298). 
This technique has key deficiencies including sample loss, the addition of unwanted peptide 
modifications and a bias towards serine over threonine modifications.  
Immunological-based affinity purification relies on the selective recognition of 
phosphorylated residues by specific antibodies that recognise pSer/pThr or pTyr residues (299). 
Antibody purification of pTyr containing protein and peptides has been successfully used for the 
study of pTyr residues, although there is a paucity of alternative pTyr enrichment approaches 
(300, 301). pSer/pThr antibodies have been demonstrated to be quite poor and not particularly 
specific.  
Phosphopeptides can also be separated from unmodified species using different 
chromatography fractionation strategies, based on charge (SCX or strong anion exchange [SAX]), 
pKa or hydrophobicity (HILIC). Charge-based separation approaches exploit the differences in 
charge between phosphorylated and non-phosphorylated peptides. In SCX and SAX, peptide tR 
is proportional to the ionic strength of the mobile phase, and ions can be eluted using a pH or 
salt gradient. SCX chromatography selectively retains highly charged (+2 or higher) tryptic 
peptides, and as phosphopeptides have a net charge of 0 or +1 they will elute in the first fractions 
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while most unmodified species are retained (302). Whereas, SAX chromatography selectively 
retains phosphopeptides in the polar column to enrich for phosphopeptides (303). These 
fractionation approaches are effective when working with small amounts of phospho-material, 
or when coupled with other enrichment methods (304). The coupling of SCX and SAX with other 
methods (such as IMAC or TiO2) to overcome their lack specificity for phosphopeptide 
enrichment alone result in good coverage of the phosphoproteome as recently demonstrated 
by some pre-fractionation strategies (305). 
 
Figure 1.11: Established and alternative strategies for phosphopeptide enrichment. The selection of 
phospho-enrichment method depends on the sample and type of phosphopeptides. Established methods 
include purification based on protein binding domain affinity, antibody-based precipitation, immobilised 
metal ion affinity chromatography (IMAC), ion exchange and metal oxide affinity chromatography 
(MOAC). Alternative methods include chemical tags and affinity ligands.  
The pH-dependent, negatively-charged phosphate groups can also be enriched by 
chelation with positively-charged metal ions contained in solid affinity matrices. The most 
commonly used methods based on this principle are immobilised metal ion affinity 
chromatography (IMAC), metal oxide affinity chromatography (MOAC) or combinations of both. 
IMAC resins chelate metal ions such as Fe3+, Ni2+, Cu2+, and Ga2+ which in turn form ion-pair 
interactions with phosphate groups. Ti4+-IMAC has proved highly reproducible (306). Metal-
bound phosphopeptides can be recovered either by raising the pH or adding phosphatase ions 
(307). The specificity of IMAC to enrich for phosphopeptides can be limited due to the fact that 
some amino acids and acidic peptides bind to the transition metals.  
MOAC, as mentioned above is based on the affinity of metal oxides, (such as TiO2, ZrO2 
or AlO3) to phosphate groups. TiO2 remains the most widely used method given its high 
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enrichment efficiency (308). Similar to IMAC, specific and non-specific binding can occur in TiO2-
MOAC. The addition of TFA can reduce the binding of specific and non-specific acidic non-
phosphorylated peptides, improving the selectivity for phosphate groups (309). Although 
multiply-phosphorylated peptides tend to tightly bind to TiO2, efficient elution of 
phosphopeptides from TiO2-MOAC is usually achieved using basic eluents, such as NH4OH (310), 
and through the use of multiple round of elution steps (311). As a result, it is possible to achieve 
robust and sensitive label-free phosphoproteomic analysis using a single-shot TiO2-MOAC based 
method. An approach that is adopted by many groups for MS-based phosphoproteomics (270, 
312, 313). 
Considerations need to be taken during MS and bioinformatic analysis of 
phosphoproteomics data. Phosphopeptides are not fragmented as well as non-phosphorylated 
peptides, owing to their lower positive charge (as the phosphate group is negatively charged). 
When CID fragmentation methods are implemented, a β-elimination reaction is induced, leading 
to a neutral loss of HPO3, or H3PO4. This neutral loss results in an MS2 spectra with little sequence 
information and a very intense peptide peak (minus H2PO4). To compensate, fragmentation 
methods can be optimised for the sequencing of phosphopeptides, and such methods include 
neutral loss scanning or multistage activation.  
Improved CID-based activation methods such as multistage activation contribute to 
reducing the prevalence of neutral loss ions in the MS2 spectra by fragmenting both a 
phosphopeptide and its theoretical m/z value following neutral loss, corresponding spectra are 
then combined.  A HCD based fragmentation increases the accuracy of measured ions, as 
phosphopeptide sequences are measured in an Orbitrap mass analyser, generating more 
reproducible and site specific data (314). One drawback to the HCD fragmentation is its 
comparatively slow speed in most instruments compared to CID. This means in some systems a 
based CID approach can produce denser datasets.  
Separate to CID based approaches for phosphopeptide identification are ETD based 
methods. ETD based fragmentation dissociates substrate peptides by electron transfer from a 
donor molecule (often from fluoranthene). The benefit of using ETD to trigger peptide amide 
backbone fragmentation, is that it preserves labile PTMs. ETD; however, has limited applicability 
to peptides of charge state 2+ and 3+, often encountered in tryptic peptides (315).  
Collectively numerous ion fragmentation methods and computational approaches have 
been developed to improve the sequencing and accurate site localisation of phosphopeptides 
by MS, consideration of these strategies ensures the best possible coverage of the 
phosphoproteome can be achieved (316).  
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Computational methods to investigate cell signalling by phosphoproteomics have been 
developed in recent years (272), these approaches that can be used to estimate kinase activity 
directly from high-throughput MS data to understand the signalling response. These methods 
were recently tested as part of a benchmarking study by Hernandez-Armenta et al. (313). They 
compared the KSEA (kinase substrate enrichment analysis) method (developed in the Cutillas 
group) (271) with similar predictive algorithms (291) and reported a strong performance by all 
methods in correctly predicting kinase activity changes. The KSEA method assumes that the 
activity state of a given kinase can be inferred from the phosphorylation of its known substrates. 
As opposed to other techniques, this method does not directly measure kinases (317), but 
instead uses phosphoproteomic targets and kinase-substrate annotations (e.g. those included 
in PhosphoSitePlus, signor, or others (318)) to predict kinase activities. Hernandez-Armenta et 
al. also reported that the number known kinase substrates and the source of the evidence for 
interactions (in vivo, in vitro, or in silico) may influence the predictions (319). 
1.6  Aims 
The relationship between cells of the microenvironment and AML is complex, and 
studies discussed in this chapter have outlined the importance of this interaction and that 
successful future targeted therapeutic strategies will need to include means that can overcome 
the contribution of the BMM. In this PhD I undertook a multi-proteomic approach to understand 
the role of the microenvironment in AML, principally investigating how bone marrow stromal 












Chapter 2: Materials and Methods 
2.1 Reagents 
Name Manufacturer Product number Supplementary info 
CellTiter 96 AQueous non-
radioactive cell proliferation 
assay 
Promega  G5421 Cell viability assay reagent 
RPMI-1640 Gibco 11875093 Culture medium for AML cell lines 
DMEM Gibco 11965092 Culture medium for HS-5 cells 
IMDM Gibco 12440061 Culture medium for MS-5 cells and primary AML 
MEM α, no nucleosides Gibco 12561056 Culture media for MS-5 cells 
IMDM (no phenyl red) Gibco 21056023 Culture medium for secretome analysis 
Sodium Pyruvate (100 mM) Gibco 11360070 Media supplement 
L-Glutamine (200 mM) Gibco 25030081 Media supplement 
MEM Non-Essential Amino 
Acids Solution 
Gibco 11140035 Media supplement 
Heat-inactivated Foetal 
Bovine Serum (FBS), E.U 
approved  
Gibco 10500-064 
Serum used for maintenance and culturing of 
cells 
EDTA-trypsin (0.05%/0.02%) Sigma Aldrich L11-004/T4299 Detach adherent cell lines during cell culture 
Penicillin/streptomycin  Sigma Aldrich P4333 Antibiotics for cell culture 
Trypan Blue solution 0.4%, 
liquid, sterile-filtered, 
suitable for cell culture 
Sigma Aldrich T8154 
Cell viability assay reagent 
Table 2.1: A summary of cell culture reagents.  
 
Name Manufacturer Product # Primary Target Concentration 
Torin-1 Tocris 4247 mTORC1 / mTORC2 1 µM 
Trametinib Selleckchem S2673 MEK1/MEK2 1 µM 
Tofacitinib Selleckchem S5001 JAK 1-3 1 µM 
Midostaurin Selleckchem 2992 
PKC, PDFR, VEGFR2, Syk, 
Flt3 1 µM 
PF-3758309 Selleckchem S7094 Pan PAK 1 µM 
IPA-3 Tocris 3622 Pan PAK 2.5 µM 
FRAX-597 Selleckchem S7271 PAK1-4 20 nM 









number Lot number Source 
Mol.weight 
(kDa) Concentration 
Recombinant Human S100-A4 Abcam Ab191676 - E.coli 12 10ng/ml 
Recombinant Human S100-A4 




QEG0315111 E. coli 12.4 10ng/ml 
Recombinant Human S100-
A11 
Abcam Ab90612 - E.coli 11.7 10ng/ml 
Recombinant Human 
Connective tissue growth 
factor (CTGF) 
Abcam Ab50044 - E.coli 11 10-50ng/ml 
Human recombinant Bone 
morphogenic protein-1 (BMP-
1) 


























E.coli 36.8 10ng/ml 
Table 2.3: A summary of recombinant growth factors used in Chapter 4 experiments.  
 
Primary Target Code Technique Company Dilution 
Total CSF-1 ab9693 WB Abcam 1:1000 
Total S100-A4 ab41532 WB Abcam  1:250 
Phospho-ERK1/2 (Thr202; Tyr204)   4370 WB CST 1:1000 
Total p44/42 MAPK (Erk1/2) 9102 WB CST 1:1000 
Phospho-Akt (Ser473)  9271  WB CST 1:1000 
Total AKT 9272 WB CST 1:1000 
Total P70S6K 9202 WB CST 1:1000 
Phospho-p70/p85(Thr389;Thr412) 9206 WB CST 1:1000 
Phospho- 4EBP1 (Thr37; Thr46) 9459S WB CST 1:1000 
Phospho-PAK4 (Ser474) 3241 WB CST 1:1000 
Total PAK 1 2602 WB/ Co-IP CST 1:1000/1:50 
Total PAK 2 2615 WB/ Co-IP CST 1:1000/1:50 
Total PAK 3 2609 Co-IP CST 1:1000/1:50 
Total PAK 4 3242s WB/ Co-IP CST 1:1000/1:50 
Human/Mouse/Rat PAK4 (goat) AF4178-SP WB R+D Systems  1:200 
Histone H2B Antibody (N-20) polyclonal goat sc-8650 WB Santacruz 1:200 
Total Vinculin 4650 Co-Ip CST 1:50 
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phospho-PAK1/2 (ser199/204)/ (Ser192/197) 2605 WB CST 1:1000 
Phospho-PAK1(Thr423)/ PAK2(Thr402) 2601s WB CST 1:1000 
GAPDH – Loading control ab9485 WB Abcam 1:2500 
Lactate dehydrogenase – Loading control ab85319 WB Abcam 1:1000 
α-Tubulin – Loading control 2144 WB CST 1:1000 
β-actin – Loading control 4967 WB CST 1:2500 
 
Amersham ECL Rabbit IgG, HRP-linked whole Ab (from 
donkey) 
NA934 WB GE Healthcare 1:5000 
Amersham ECL Mouse IgG, HRP-linked whole Ab (from 
sheep) 
NA931 WB GE Healthcare 1:5000 
EasyBlot anti Goat IgG, HRP GTX628547-01-S WB Insight 
Biotech 
1:5000 
Table 2.4: A summary of antibodies used in western blots (WB) and co-immunoprecipitations (co-IP). 
 
Antigen Clone Metal 
CD19 HIB19 142Nd 
CD117 104D2 143Nd 
CD11b ICRF44 144Nd 
CD64 10.1 146Nd 
CD123 6H6 151Eu 
CD45 HI30 154Sm 
CD33 WM53 158Gd 
CD15 W6D3 164Dy 
CD34 581 166Er 
CD3 UCHT1 170Er 
CD44 IM7 171Yb 
CD38 HIT2 172Yb 
HLA-DR L243 174Yb 
CD184 12G5 175Lu 
CD14 M5E2 160Gd 
CD16 3G8 148Nd 
CD7 CD7-6B7 147Sm 








Name Manufacturer Product # Information 
4% Paraformaldehyde Santa cruz 30525-89-4 Fixing cells for CyTOF 
4-12% mini-GEL Invitrogen  Western blot 
ACQUITY UPLC Peptide BEH C18 
Column, 300Å, 1.7 µm, 2.1 mm X 50 
mm 
Waters 186003685 
Analytical column used for LC separations 
during LC-MS/MS on XL instrument 
nanoACQUITY UPLC Symmetry C18 
Trap Column, 100Å, 5 µm, 180 µm x 
20 mm 
Waters 186006527 
Trap column used for LC separations during 
LC-MS/MS on XL instrument 
Acclaim™ PepMap™ 100 C18 
analytical Column, 3µm, 100Å, 75 
µm x 25 cm 
Dionex 164261 
Analytical column used for LC separations 
during LC-MS/MS on Q-Exactive plus 
instrument 
Acclaim™ PepMap™ µ-Precolumns, 
5µm, 100Å, 300 µm x 5 mm 
Thermo Scientific 160454 
Trap column used for LC separations during 
LC-MS/MS on Q-Exactive plus instrument 
Bicinchoninic acid (BCA) assay  Thermo Scientific 23225 Protein concentration estimation  
C18 micro-spin columns Glygen TT2C18.96 Offline peptide desalting spin column 
C18/graphitic carbon TopTip micro-
spin columns 
Glygen TT2MC18.96 Offline peptide desalting spin column 
Deoxyribonuclease I from bovine 
pancreas, Type IV, lyophilized 
powder 
Sigma Aldrich D5025 
To stop clumping of cells during the thawing 
of primary AML samples  
Empty spin filter-tips TF2EMT Glygen TF2EMT 
Spin tips used for compacting TiO2 resin 
during phosphor-enrichment steps 





Low protein binding tubes for MS based 
proteomics to reduce protein loss 
epT.I.P.S.® LoRetention tips, 50 – 
1000 µL 
Sigma Aldrich 0030072030 
Low protein binding tips for MS based 
proteomics to reduce protein loss 
epT.I.P.S.® LoRetention tips, 2 – 
200 µL 
Sigma Aldrich 0030072022 
Low protein binding tips for MS based 
proteomics to reduce protein loss 
FUJI Film X100 RX X-RAY Film 
(18x24cm) 
Fisher 12715325 X-ray film for western blot analysis 
Guava ViaCount Reagent for Flow 
Cytometry 
Merck Millipore 4000-0040 
Reagent for Guava viacount viability and 
proliferation assays  
iBlot™ Transfer Stack, Nitrocellulose Invitrogen IB301001 PAGE reagent 
Immobilised trypsin-tosyl lysine 
chloromethylketone (TLCK)  
Thermo Scientific 20230 
Immobilised trypsin beads used for protein 
digestion  
mini-PROTEAN 12% PA-gels  Biorad 456-1044 PAGE reagent 
Novex NuPAGE 4-12% Bis-Tris midi 
gel 
Invitrogen WG1402BX10 PAGE reagent 
Novex NuPAGE 20X MOPS SDS 
running buffer 
Invitrogen NP0001 PAGE reagent 
Novex NuPAGE 20X Transfer buffer Invitrogen NP0006 PAGE reagent 
Novex NuPAGE Antioxidant  Invitrogen NP0005 PAGE reagent 
Oasis-HLB 1cc cartridges Waters WAT094225 Offline desalting method for peptide clean-up 
Okadaic acid  Calbiochem 495604 






Sigma Aldrich 93482 
Serine protease inhibitor added during cell 
lysis for western blot and coIP 
Phosphatase inhibitor cocktail I Sigma Aldrich P8340 
Inhibitor added during cell lysis for western 
blot and coIP 
Ponceau S Solution Sigma Aldrich 93482 
Reagent for checking transfer efficiency 
during western blot 
Protein A/G PLUS-Agarose Santa Cruz sc-2003 Solid support for co-IP complex pull-down 
PVDF membrane Millipore IPVH00010 Membrane used for western blot 
SuperSignal West Pico ECL substrate Thermo Scientifc 34080 
Horseradish peroxidase (HRP) reagent for 
western blot visualisation  
Titansphere TiO2 beads (10 µm) GL Science inc 5020-75010 
Material used to bind phosphor-peptides 
during phosphor-enrichmnet 
Trypsin from porcine pancreas Sigma Aldrich T6567 
Soluble trypsin used for co-IP protein 
digestion and on-bead elution 




Columns used for secretome purification via 
ultra-filtration 
Table 2.6: A summary of miscellaneous materials and reagents. 
2.2 Cell lines and primary patient samples 
Name Species Cell type Morphology Information Ref 
MS-5 Murine BMSC Adherent 
fibroblastic  
Established by irradiation of the adherent 
cells, derived from the BM of C3H/HeN 
strain mice. 
(320) 
HS-5 Human BMSC Adherent, 
fibroblastic 
HPV-16 E6/E7 transformed, derived from a 
healthy 30-year-old male. 
(321) 








Established through long-term culture from 
the blast cells of a 7-year-old male, with 
AML (M5 subtype). Carries t(10;ll)(pl3;ql4) 
leading to CALM-AF10 fusion gene and is 
considered a complex karyotype. 
(322) 








Established through long-term culture from 
the blast cells of a 10-year-old male with 
biphenotypic B-myelomonocytic leukaemia, 
M5 substype. Possesses a t(4;11)(q21;q23), 
+8, +19 karyotype, leads to MLL-AF4 fusion 
gene. 
(323) 







Established through long-term culture from 
the blasts of a 35-year-old female with 
AML, considered M2 FAB subtype. Cells 
possess a number of cytogenetic 
abnormalities leading to complex 
karyotype.  
(324) 








Established from the blast cells of a 13-
year-old female, with relapsed AML (M5 
subtype). Cells possess a number of 
cytogenetic events including 
t(6;11)(q27;q23). Possesses deletions of the 
T-cell receptor δ1 gene. 
(325) 




MV-411, HL-60, CTS and P31/FUJ cells were grown in RPMI 1640 media supplemented 
with 10% fetal bovine serum (FBS), penicillin and streptomycin (P/S) (each at 100 U/ml). Cells 
were maintained at a confluency of 0.5 - 2.0×106 cells/ml. Cell line incubated at 37°C in a 
humidified atmosphere at 5% CO2.  
MS-5 cells were grown in IMDM (clone 1) or α-MEM (clone 2) media supplemented with 
10% FBS, P/S (each at 100 U/ml), 2mM L-Glutamine, with cells maintained at a confluency of 
0.05 - 0.1x106 cells/ml. HS-5 cells were seeded in DMEM media supplemented with 10% FBS, P/S 
(each at 100 U/ml) and cell line were maintained at a confluency of 0.05 - 0.5x106 cells/ml. Cell 
line incubated at 37°C in a humidified atmosphere at 5% CO2. 
Primary cells were cultured in IMDM supplemented with 10% FBS, P/S (each at 100 
U/ml) or with CM (production of which is outlined below). Cells when reanimated following LN2 
preservation, were thawed in the presence of DNase to reduce cell clumping and washed with 
PBS supplemented with 10% FBS. Once resuspended in appropriate media cells were normalised 
through incubation at 37°C in a humidified atmosphere of 5% CO2 for 60 minutes, after this time 
cells were ready for experimentation. 
2.2.1 Seeding for experimentation 
For AML cell lines (MV4-11, HL-60, CTS, P31/FUJ) cells were harvested by transferring 
media to 50ml falcon tubes (no detachment required as suspension lines). Cells were centrifuged 
to pellets and old media aspirated before re-suspension in fresh media. The cells were then 
counted using a Beckman Coulter Vi-Cell cell viability analyser and seeded in fresh T75 flasks at 
a density of 0.5x106 cells/ml 24 hours prior to experimentation. 
2.2.2 Clinical features of primary samples 
Patients gave informed consent for the storage and use of their blood cells for research 
purposes. Experiments were performed in accordance with the Local Research Ethics 
Committee, as previous described (326). The clinical details of the 16 cases used in this study 
are shown below in Tables 2.7 and 2.8. Experiments were performed with primary samples in 









FAB Risk Group Cytogenetics Mutations 
0 M5 Adverse  T(6;11) 11Q23 - 
1 M4 Adverse 11Q23 No identified variants 
2 M4 Intermediate NORMAL FLT3-ITD 
3 M4 Favourable INV (16)(P13Q22) ;CBFB/MYH11  - 
4 M5 Adverse T(11;17) MLL (11Q23) - 
5 M4 Favourable INV (16) - 
6 M2 Adverse COMPLEX (inc T(8;9)) 
TET2 (p.P133Qfs*12, VAF = 
41.6%), NRAS (p.G13D, VAF 
= 43%) 
7 2ND AML Intermediate 11P-, + CLONAL T(2;3) 
IDH2 (p.R140Q, VAF = 
47%), NRAS (p.G13D, VAF = 
48%) 
8 2ND AML Adverse COMPLEX (inc -5,-7,-9,-10,-21) 
ASXL1 (p.A809Cfs*13, VAF 
= 23%) 
9 M5 Adverse T(6;11)(Q27;Q23) TET2 mutant, FLT3-WT 
10 2ND AML Adverse 5Q-, -7 No identified variants 
11 M5 Adverse 11Q29 No identified variants 
12 M0 Adverse INV(3)(Q21Q26) AND T(8;13)(P21;Q14) No identified variants 
13 - Adverse T(6;11) MLL-MLLT4 REARRANGEMENT - 
14 M2 Adverse T(6;9) - 
15 M5 Intermediate ADD(21)(P11.2) - 
Table 2.8: Cytogenetic and molecular features of the primary AML samples used in studies. If cell 
coloured grey, then patient sample was screened for variants outlined in Table 2.9. 2ND AML denotes 






























2 Intermediate PB 74 2 37 14 - - - 
3 Favourable PB 84 2 20 - - - - 
4 Adverse PB 64 1 27 - - - - 
5 Favourable PB 71 2 52 - - - - 
6 Adverse PB 64 1 62 9 Relapse CR Yes 
7 Intermediate - - - - 4.5 Relapse - Yes 




9 Adverse PB 98 1 36 12.5 Relapse - Yes 












13 Adverse PB 94 2 32 - - - - 
14 Adverse PB 16 1 29 - - CR - 
15 Intermediate PB 93 1 75 - - FAIL Yes 
Table 2.9: Clinical features of the included primary AML samples. PB = Peripheral blood, BM = Bone 
marrow, CR = Complete response, EP = Engraftment potential, - = information unavailable. 
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2.2.2.1 Panel Sequencing 
Targeted enrichment of a 25 gene myeloid panel was achieved using an in-house True 
SeqCustom Amplicon (TSCA) design (Illumina, San Diego, USA). Genes included in this panel are 
shown below.  
Gene Exons Gene Exons 
ASXL1 12 KRAS 2 + 3 
BCOR all MPL 10 
CALR 9 NPM1 12 
CBL 7 + 8 + 9 NRAS 2 + 3 
CEBPA all PDGFRA 12, 14, 18 
CSF3R 14 - 17 PHF6 all 
DNMT3A all PTPN11 3 + 13 
ETV6 all RUNX1 all 
EZH2 all SETBP1 4 
FLT3 14 + 15 + 20 SF3B1 12 - 16 
GATA2 all SRSF2 1 
GNAS 8 + 9 TET2 all 
IDH1 4 TP53 all 
IDH2 4 U2AF1 2 + 6 
IKZF1 all WT1 7 + 9 
JAK2 12 + 14 ZRSR2 all 
KIT 2, 8-11, 13 + 17   
Table 2.10: Selected genes that were screened for variants in patients #1, 2, 6-12. 
2.3 Stromal secretome production 
For the preparation of the CM, MS-5 or HS-5 cells were cultured until 60% confluent in 
their respective media. The growth medium was then removed, and cells washed with PBS. 
Fresh IMDM containing either 0.5% (v/v) FBS for starved conditions, 10% FBS for serum 
containing assays and 0% FBS for MS experiments was added. Cells were cultured for a further 
24-72 hours prior to CM collection. Supernatant were then centrifuged to pellet debris, media 
would then either proceed to secretome enrichment, be used as supportive CM immediately or 
it was stored at 80°C.  
Ultrafiltration – Vivaspin 20 columns 
The method for stromal secretome purification and filtration is described in Figure 2.1 
below. Subsequent LC-MS/MS analysis of the stromal secretome, was only conducted on >5kDa 
fraction of secretome containing no serum. Production and acquisition of the AML/MS-5 co-
culture secretomes and AML only secretomes is detailed in Figure 3.18. Following purification 
of co-culture secretomes all laboratory processing was the same as that described for 
experiments utilising the stromal secretome alone. 
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Figure 2.1: Protocol for producing MS-5 and HS-5 conditioned media and enrichment of secretome. 
Methanol/chloroform precipitation  
Following collection of CM, samples were mixed with methanol in a 1:4 ratio before 
undergoing vortex. Then 1 part chloroform was introduced prior to further vortex. Next 3 parts 
milliQ H2O was added and vortexing continued (at this point samples should appear cloudy). 
Samples were then centrifuged for 2 minutes at x 12,000 g. Following centrifugation, the sample 
should have separated into phases, the top aqueous layer was removed being sure not to disrupt 
the thin wafer protein layer. Another 3 parts of methanol were added followed by vortexing and 
centrifugation for 2 minutes at x 24,000 g. As much methanol as possible was removed without 
disturbing the protein pellet prior to solubilising with lysis buffer. 
2.4 Cell lysis 
Suspension cells were transferred to 50ml falcon tubes before being gently centrifuged 
and washed 3 times with ice-cold PBS (supplemented with 1 mM Na3VO4 and 1 mM NaF). The 
cell pellet was then lysed with 500µl lysis buffer/1x107cells. Each pellet was then solubilised via 
pipetting and left on ice for 40 minutes. Lysates were then sonicated using a diagenode 
bioruptor (40 cycles of 40 seconds on and 30 seconds off) and centrifuged at 20,000 x g for 10 
minutes (5°C), resulting supernatants were kept for further analysis. The protein concentration 
of each lysate was then determined via bicinchoninic acid (BCA) assay (Bovine serum albumin 










50mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA, 1% 
Triton/NP-40. Supplemented with phosphatase inhibitors 
(1mM Na3VO4, 1mM NaF, 10mM DTT, 200mM PMSF and 
1mM Okadaic Acid) and protease inhibitors (protease 
inhibitor cocktail; Sigma Aldrich-Aldrich) 
Western Blot 
Tris - CHAPS 
lysis buffer 
150mM NaCl, 50mM Tris-HCl(pH7.4), 0.3% CHAPS, 1mM 
EDTA. Supplemented with phosphatase inhibitors (1mM 
Na3VO4, 1mM NaF, 10mM DTT, 200mM PMSF and 1mM 
Okadaic Acid) and protease inhibitors (protease inhibitor 







0.3% CHAPS, 50mM Hepes (pH7.4), 150mM NaCl. 
Supplemented with phosphatase inhibitors (1mM Na3VO4, 
1mM NaF, 10mM DTT, 200mM PMSF, 1mM -glycerol 
phosphate, and 2.5mM Na2H2P2O7 and 1mM Okadaic Acid) 






8M Urea in 20 mM HEPES pH 8.0. Supplemented with 1 mM 






Table 2.11: A summary of lysis buffers, buffer composition and the applications for which they were 
applied. 
2.5 Western Blot 
40µg of protein lysate was mixed with 4X Laemmli buffer and heated to 95°C before 
being loaded into a 4-15% gradient gel and resolved by SDS–polyacrylamide gel electrophoresis. 
Subsequent proteins were transferred to polyvinylidene difluoride membranes (PVDF). Once 
blocked, membranes were incubated with primary and secondary antibodies (Table.2.2) and 
developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) 
exposing x-ray films (FUJI film) or imaged using a ChemiDoc system.  
2.6 Guava ViaCount 
Ex-vivo testing of cell lines and AML primary cells treated with CM (from HS-5 or MS-5 
cells), enriched secretomes (10g/ml), recombinant GFs (10ng/ml) or kinase inhibitor (1M) and 
cell proliferation, viability and apoptosis were measured with a Guava PCA cell analyser (Guava 
Technologies Inc.). Briefly assays were run in 96-well plates and cells seeded at a density of 2x104 
cells/well in 100ul. Results obtained using 75l/well Guava ViaCount reagent (Millipore) 
according to the manufacturer’s instructions. Seeding corrections made by normalising counts 
to Day 0 measurements of respective test condition. 
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2.7 Gene expression microarray 
Survival plots are produced using the BloodSpot database. This database provides gene 
expression profiles of genes and gene signatures in both healthy and malignant haematopoiesis. 
Kaplan-Meier survival analysis is based on gene expression above or below median for the six 
given gene queries using an AML dataset from The Cancer Genome Atlas (TCGA) that contains 
183 patients with AML. Input data produced on an Affymetrix U133 Plus 2 microarray platform 
used by the TCGA. 
2.8 CyTOF 
Primary cells were coated with metal conjugated antibodies, as indicated by the 
manufacturer. Mass cytometry was used to characterize CD markers in AML cells. Cells (4x106) 
were transferred to fresh tubes, washed twice with PBS and cells were then incubated with 1x 
Cell-ID™ Cisplatin6 solution (Fluidigm; Cat. 201064) for 5 minutes at room temperature (RT). 
Cells were washed with Maxpar Cell Staining buffer and pellets resuspended and incubated with 
50 μL of 20 μg/mL HAG (human γ-Globulins, Sigma-Aldrich; Cat. G4386-1G) for 20 minutes at RT. 
After adding 50 μL of antibody mix (1/50 dilution of each antibody; Table 2.5), samples were 
incubated for 30 minutes at RT. The cells were then washed twice with Maxpar Cell Staining 
buffer, pellets were resuspended in Fix and Perm Buffer and left overnight at 4oC. The following 
day, intercalator (Ir) was added to a final concentration of 1x and samples were incubated for 
20 minutes at RT. Permeabilised cells were washed twice with Maxpar Cell Staining buffer and 
twice with Maxpar water. Samples were analysed on a CyTOF2 mass cytometer (Fluidigm) and 
data were normalized using the normalizer within the DVS Sciences CyTOF Instrument Control 
Software (v 6.0.626).  
2.9 Co-immunoprecipitation (co-IP) 
Following protein quantification 250µg of protein in each lysate was normalised to a 
final volume of 500µl with fresh lysis buffer. After normalisation each sample was incubated 
with 10µl of target protein antibody for 40 minutes to overnight at 4°C with constant agitation 
(in some instances a pre-clear step was included). Next 40µl/sample of protein A/G sepharose 
beads (Santa-cruz) [pre-conditioned in lysis buffer] were incorporated and incubated a further 
20 mins at 4°C with constant agitation. The resultant complexes were captured and washed 3 
times each with the following: lysis buffer, lysis buffer (without detergent) and 25mM NH4HCO3.  
Samples analysed by LC-MS/MS underwent on-bead tryptic digestion. 
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2.10 Liquid Chromatography – Tandem Mass Spectrometry Sample 
preparation 
2.10.1 Secretome solubilisation 
 100µg of purified secretome proteins (>5kDa) were solubilised with 8M urea to a 
normalised volume or 500µg for phosphoproteomics. These proteins were then reduced 
through 30 minutes incubation at RT with 10mM DTT and alkylated with 17.5mM IAM under the 
same conditions. The samples were then diluted to bring urea concentration <2M. 
2.10.2 Tryptic Digestion 
For solubilised secretome samples, 80µg of TPCK-immobilised trypsin beads (Thermo  
Scientific)[preconditioned by washing beads 3 times with 20mM Hepes at 5°C] were added to 
each sample before incubating samples overnight with constant agitation at 37°C. Co-IP 
complexes for LC-MS/MS analysis after last 25mM NH4HCO3 wash and centrifugation at 5000 x 
g for 5 minutes 4°C were re-suspended in 150µl of NH4HCO3 that contained 170ng/sample of 
soluble trypsin (Sigma Aldrich) and incubated overnight with constant agitation at 37°C 
2.10.3 Peptide desalting utilising solid phase extraction 
Following tryptic digestion, samples underwent centrifugation to remove either 
immobilised trypsin beads or protein sepharose A/G beads (if soluble trypsin used then samples 
would be acidified with 1%TFA to inactivate trypsin). Samples were then desalted by means of 
reversed-phase solid-phase extraction, using either OASIS HLB cartridges for secretome samples 
(as larger volume) or carbon C18 spin-tips for co-IP lysates. 
OASIS HLB cartridges were held in a vacuum manifold (P = 5.0 in Hg 0.5) and conditioned 
with LC-MS grade ACN before equilibration with 99% H2O; 1% ACN; 0.1% TFA. Secretome, total 
proteomics or phospho-peptide samples were then loaded into individual cartridges and washed 
with 99% H2O; 1% ACN; 0.1% TFA to remove residual salts. The bound peptides were then eluted 
with 70% ACN, 30% H2O, 0.1% TFA. C18 spin tips underwent the same sequence of conditioning 
and equilibration before sample loading and elution, except the washes were achieved by 
centrifugation at 1500 x g for 2 minutes instead of a vacuum manifold. The eluted peptide 
solution was then snap-frozen on dry-ice for 15 minutes and lyophilised overnight with a 
speedvac. In the morning, peptide extracts were stored at -20°C. 
For phosphoproteomics the bound peptides were then eluted with 500µl 1M glycolic 
acid (50% ACN; 5%TFA) instead of 70% ACN; 30% H2O for proteomics. Desalted peptide samples 
for phosphoproteomics analysis were then normalised up to 500 µl through the addition of 1M 
glycolic acid (80% ACN; 5% TFA), and subsequently stored on ice prior to phospho-enrichment. 
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2.10.4 Phosphopeptide enrichment 
 Following desalting each sample was incubated with 50µg TiO2 resin/µg protein (1% 
TFA) at RT for 5 minutes, with constant agitation. The samples were centrifuged at 500 x g for 1 
minute, 400µl of the supernatant transferred to a fresh lo-bind Eppendorf on ice, and the 
remaining 100µl was used to re-suspend the TiO2. The 100µl resuspended sample (containing 
the resin) was then loaded into Glygen empty TF2EMT filter-tips (pre-washed with 100% ACN) 
and centrifuged at 1,500 x g for 3 minutes. Any residual TiO2 was resuspended with 200µl 1M 
glycolic acid (80% ACN; 5% TFA) and loaded into the Glygen tips as before. The reserved 400µl 
of each sample was then washed over the resin (2x washes of 200µl), centrifuging at 1,500 x g 
for 3 minutes between loading of each aliquot. Each TiO2 packed Glygen tip was then washed 
with 200µl 1M glycolic acid (80% ACN; 5% TFA) (this was to remove non-phosphorylated 
peptides). Then 200µl 100mM NH4CH3CO2 (75% H2O; 25% ACN) (this was to remove acidic non-
phosphorylated peptides). Then three 200 µl washes of (90% H2O; 10% ACN) (this was to ensure 
complete removal of any salts and bound non-phosphorylated peptides from the TiO2 layer prior 
to elution) – centrifuging at 1,500 x g for 2 minutes between each wash. The bound 
phosphopeptides were then eluted with four 50µl washes with 5% NH4OH (90% H2O; 10% ACN), 
200µl eluent in total. Each sample was then snap-frozen on dry ice for 15 minutes and lyophilised 
in speedvac. Samples were then stored in -80°C. 
2.11 Liquid Chromatography – Tandem Mass Spectrometry analysis 
2.11.1 Liquid chromatography separation 
Peptide extracts were re-suspended in 14-20μl of reconstitution buffer (97% H20, 3% 
ACN, 0.1% TFA, 50 fmol/µl-1 enolase peptide digest) and sonicated for 5 minutes at RT. 4μl was 
loaded onto a LC-MS/MS system. This consisted of a nanoflow ultrahigh pressure liquid 
chromatography system (UPLC, nanoAcquity, Waters) system coupled online to an Orbitrap XL 
mass spectrometer (Thermo Fisher Scientific) or UltiMate 3000 RSLCnano (Dionex) coupled to 
an Q Exactive Plus (Thermo Fisher Scientific).  
For Orbitrap XL experiments, the LC system delivered a flow of 2μL/min (loading) and 
300 nL/min (gradient elution) with a backpressure of ~ 4,000 psi. Samples were separated across 
a BEH 75 μm x 100 mm analytical column (Waters) using a gradient between solvents A and B. 
Solvent A (98% HPLC-MS grade H20, 2% ACN, 0.1% formic acid [FA]) and solvent B (80% ACN, 
20% H20, 0.1% FA). The gradient: 1% B for 5 min, 1% B to 35% B over 100 min, following elution 
the column was washed with 85% B for 5 min and equilibrated with 1% B for 7 min. 
For Q-Exactive Plus experiments, the LC system delivered a flow of 2 μL/min (loading) 
and 300 nL/min (gradient elution) with a backpressure of 15 bar. Samples were loaded into a 
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PepMap μ-Precolumn (Acclaim) and separated across a PepMap 100 column analytical column 
(Acclaim) using a gradient between solvents A and B. The gradient: 1% B for 5 min, 1% B to 35% 
B over 120 min, following elution the column was washed with 85% B for 7 min and equilibrated 
with 3% B for 7 min.  
2.11.2 Mass spectrometry analysis 
Following LC separation peptide ions were analysed on one of two mass spectrometers, 
the Thermo LTQ-Orbitrap XL or the Q exactive Plus. These two mass spectrometers both utilise 
a Orbitrap mass analyser; however, they differ in the assembly of the ion optics that proceeds 
detection as well as the LTQ-XL instruments coupling of a linear trap quadrupole (LTQ) prior to 
the Orbitrap (Figure 2.2).  
 
Figure 2.2: Schematics of the LTQ Orbitrap-XL and Q-Exactive Plus mass spectrometers. The major 
components of the LTQ -XL (A) and Q-Exactive plus (B) are displayed (not to scale). The features that 
distinguish these instruments from each other are in red text. Base diagrams sourced from 
thermofisher.com  
An Orbitrap consists of two electrodes, one a barrel-like electrode and the other a 
spindle like electrode. An ion will orbit around the spindle like electrode at a frequency that is 
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determined by the ion’s m/z ratio and the mass spectrum of the ions present within the Orbitrap 
is obtained by Fourier transformation of the current produced from the trapped ions. In the LTQ-
XL ions enter the system through electrospray ionisation and are focused using the ion optics to 
the LTQ linear ion trap, whereby ions are directed into the LTQ (Figure 2.2A). The ion frequency 
given by their m/z determines ion motion within the trap. The principle of a LTQ is to accumulate 
ions before sending them to the Orbitrap for mass analysis. In the Q-Exactive the ion optics are 
more sophisticated with the implementation of a stacked-ring ion guide (S-lens), this approach 
greatly improves the efficiency of ion transfer into the system as the series of lenses are capable 
of focussing ions. The Q-Exactive also incorporates a bend flatapole that helps to remove neutral 
species before ion selection in the quadrupoles (Figure 2.2B). Once ions reach the ion trap they 
are confined and proceed to orbit at a frequency directly related to their m/z. Precursor 
selection (MS1) and fragmentation in the LTQ- XL those occurs in the linear ion trap (CID 
fragmentation). Whereas in the Q-Exactive Plus, both MS1 and MS2 are acquired in the Orbitrap. 
The Q-Exactive approach permits almost instantaneous mass selection and expands the C-trap’s 
ability to store packets of ions derived from multiple precursor ions prior to injection into the 
Orbitrap mass analyser. 
For DDA using the LTQ-Orbitrap system full scan survey spectra (m/z 375-1,800) were 
acquired with a 30,000 resolution. A maximum of the 5 most abundant multiple charged ions 
registered in each survey spectrum were selected in a data-dependent manner, fragmented by 
collision induced dissociation (multi-stage activation enabled) with a normalized collision energy 
of 35% and scanned in the LTQ (m/z 50-2,000). Neutral losses of 98, 49, 32.7, and 24.5 were 
accounted for and dynamic exclusion was enabled therefore reducing analysis of the same 
precursor ion within 60 second windows. The Q-Exactive Plus system acquired full scan survey 
spectra (m/z 375-1,500) with a 70,000 resolution. The 20 most intense ions for each MS1 scan 
were selected for HCD using an isolation width of 1.6 Da and MS/MS analysis (m/z 200-2,000) 
with a resolution of 17,500. A 30 second dynamic exclusion was enabled with an exclusion list 
of 10 ppm mass window. This produced duty cycles of 2.1 seconds.  
When possible, experiments were conducted on the Q-Exactive plus platform due to 
its increased sensitivity and higher throughput. This is because its duty cycle is much shorter 
than that of the XL, thus enabling the identification of a greater number of peptides during the 
same chromatographic separation time.  
 
 73 
2.12 Data analysis 
2.12.1 Protein identification  
 Mascot Distiller 2.3.2 was used to fit an ideal isotopic distribution to the MS/MS data to 
maximise peptide identification and Mascot 2.5 search engine was used to match peaks to 
peptides in proteins present in the Uniprot/SwissProt Database (both human and mouse species 
for secretome distinction). The process was automated with Mascot Daemon 2.5.0, mass 
tolerance was set to ± 10 ppm, with variable modifications phospho (ST), phospho (Y) glnpyro-
glu (N-term Q) and oxidation (M) included in the search. Carbamidomethyl (C) as fixed 
modification. Trypsin was selected as digestion enzyme and 2 miss cleavages were allowed. Sites 
of modification are reported when they had delta scores >10. 
2.12.2 Protein quantification 
 Peptide and subsequent protein quantification was achieved using in-house developed 
PESCAL (Peak statistics calculator) software (127). PESCAL constructs extracted ion 
chromatograms (XICs) for each peptide identified with the MASCOT search engine. With each 
constructed XIC, peak heights could be calculated. These peptide peak heights were then 
normalised to the sum of the intensities for each individual sample and the average fold change 
between conditions could be determined. Statistical significance between conditions was 
considered significant when the Student T-Tests produced P <0.05. Further data processing and 
analysis was conducted within Microsoft Excel (2007/2010) or R (v3.3.2/v3.4.1 – reshape2, 
ggplot2, gplots, readXL, Hmisc and limma packages). 
2.12.3 Kinase substrate enrichment analysis 
Kinase substrate enrichment analysis (KSEA) algorithm was used to categorise 
phosphopeptides into groups that are recognised as substrate groups of a particular kinase. 
These substrate groups are defined by public repositories PhosphoSitePlus (318) (327), 
Phospho.ELM (328), and PhosphoPOINT (329), and through in-house experiments as defined by 
the CTAM database (215). The significance of each kinase enrichment were calculated using a Z-
score formula as previously described (330). KSEA can infer kinase activity by taking the log2 
mean intensities of phosphorylated peptides that are phosphorylated at sites exclusive to a 
particular kinase, these intensities are normalised to the SD of the phosphopeptide intensities 
in the whole dataset and by the number of known substrates of the given kinase. Z-scores were 
subsequently transformed to P-values using a function written in excel Visual Basic for 




                      Z- score = (mS−mP) x m1/2  
              d 
mS = the mean of each kinase group log2 fold-changes against control 
mP = the mean of log2 of the entire data set mean changes 
m = size of the substrate group  
d = SD of the mean abundances of the whole data set 
 
2.12.4 K-means clustering 
The K-means clustering algorithm was used as an unsupervised approach to distribute 
the quantified phosphopeptides across a number of clusters. Phosphopeptides would be 
assigned to the centroid that was within the nearest mean to each phosphopeptide, the space 
distance is calculated through Euclidean distribution. After each round of assignment, the 
centroids are redistributed to represent the new mean of the cluster and phosphopeptide 
cluster assignment is corrected for the new means, this process repeats until phosphopeptides 
no longer change cluster assignment. The significance of the k-means enrichment for kinase 
substrates, ontologies and pathways was determined for each cluster using an in-house VBA 
script. This script utilises a hypergeometric test approach to calculate the extent of enrichment 
using the formula:          
           Enrichment significance = Log2 ([a/b]/[c/d]) 
a = the number events of a particular ontology, pathway or group in a given cluster 
b = the total number of events in a cluster 
c = the number of events specific of the ontology, pathway or group  























Chapter 3: Characterising the composition of AML supportive 
secretomes derived from stromal MS-5 and HS-5 cell lines 
 
3.1 Introduction and aims of the study  
The BMM is recognised as a crucial component in the progression and development of 
AML (144, 145, 331, 332). Previous studies have mainly examined the niche contribution to AML 
behaviour, be that mediating treatment resistance through chemotaxis of AML clones to 
protection (333, 334), induction to a quiescent state (335, 336) or by remodelling of the 
surrounding vasculature altering the supply of other factors for AML survival (175, 337). This has 
led to great interest in chemotaxis inducing factors such as CXCL12/SDF-1 and various 
chemokines, as well as matrix metalloproteases that are hypothesised to be crucial in the 
remodelling of the environment that AML cells reside (338-340). These studies are leading to 
new therapeutic directions that focus on disrupting these interactions. However, such 
approaches are primarily focussed on the CXCL12-CXCR4 axis and means by which to interfere 
with this gradient (124, 341-344).  
Ex vivo observations of primary AML cells indicate that there is more to the stromal 
chemical mediated interactions with AML than just migration (345, 346). A large number of 
studies have described how bone marrow stromal cell (BMSC) CM is able to support the viability 
and proliferation of primary AML cells ex vivo (346-348). To this end a small number of cell lines 
have traditionally been utilised including MS-5, M2-10B4, HS-27, HESS-5, HS-27a and HS-5 in 
order to produce CM to support AML viability ex vivo (124, 321, 347, 349-351). Alternatively, a 
number of papers have supplemented AML cultures with exogenous GFs in an attempt to extend 
AML survival (352-354). These factors include Stem cell factor (SCF), IL-3, GM-CSF, G-CSF and IL-
6 (355-359). 
Previous publications have concluded that AML interactions with the stromal cytokine 
network and the release of other soluble mediators, are important for the proliferation of more 
primitive AML progenitors (164, 335, 360, 361). Therefore, in this chapter experiments first 
aimed to characterise the composition of the BMSC secretome (the totality of secreted proteins) 
using MS-based proteomics, which to date has not been undertaken. 
Having established proteins of the stromal secretome without any of the 
preconceptions that are required when designing a cytokine array, we then sought to identify 
the proteins that are responsible for maintaining AML blast survival ex vivo. Although, there are 
known factors that help to extend AML cell lines in culture, the majority of primary AML cell 
 
 76 
studies have demonstrated a need for either stromal CM or co-culture with stromal cells for 
primary material to be maintained for any length of time (346, 353, 354, 362, 363). Furthermore, 
as much of the currently described stromal secretome are signalling molecules, it was 
hypothesised that any novel proteins would likely activate signalling nodes. Therefore, knowing 
which precise nodes and the regularity that these nodes are activated could prove useful in 
future efforts to disrupt the AML support network.  
3.2 Validating supportive qualities of the MS-5 and HS-5 cell lines  
Following the acquisition of the BMSC lines MS-5 and HS-5 we needed to confirm that 
in our hands these support AML cells in culture. To ascertain supportive qualities, we first 
undertook viability assays with primary AML cells. These cells were maintained ex vivo for seven 
days with either HS-5 or MS-5 conditioned stromal media or unconditioned IMDM media 
(supplemented with 10% FBS). Figure 3.1 shows that there was a substantial increase in viable 
cell number at Day 7 when cells were maintained in HS-5 CM (p=0.0047) and MS-5 CM 
(p=0.0108) compared to seeding, whereas the unconditioned media was unable to sustain the 
initial viable cells incubated on Day 1 (p=0.0061). These results demonstrate the supportive 
capacity of BMSC CM in AML. 
                          
Figure 3.1: Stromal conditioned media extends primary AML cell survival ex vivo. HS-5 and MS-5 CM 
maintains primary AML cells in culture over 7 days. Viable cell numbers measured by Guava viacount assay 
on days 1 and 7. 2x104/well were seeded in technical triplicates for each patient in indicated media (No 
CM contained IMDM media, all samples contained 10% FBS), each condition run in n=4 biological 
replicates. 
To establish if these effects were mediated by the protein or metabolite component of 



















separates molecules by molecular weight. MV4-11 cells were then cultured in a serum starved 
environment containing the different secretome fractions. Figure 3.2 shows that, as expected, 
serum had a strong effect on AML cell growth. However, in the absence of serum (i.e. without 
the supportive role of GFs and cytokines), it was the >5kDa fraction of the CM (the protein 
component) that induced the greatest level of proliferation in the MV4-11 cells relative to the 
control. Incubation with the <5kDa fraction (metabolite component) led to a decrease in 
proliferation and the total unfractionated secretome had a moderate effect on proliferation. 
These results suggested that proteins, rather than small molecule metabolites, in the BMSC CM 
support AML viability and proliferation. 
                           
Figure 3.2: Dissection of the supportive role MS-5 secretome plays in AML cell survival. Effects of 
fractionated MS5 CM on the proliferation of MV4-11 cells (with/without 10% FBS). 100% 72hr MS-5 CM 
was fractionated with Vivaspin 20 columns to create >5kDa, <5kDa fractions. 2x104 cells/well were seeded 
in n=4 technical replicates for each condition and supplemented with 10µg/ml of indicated fraction or 
unfractionated MS-5 CM (+/- 10% FBS). Viable cells numbers were measured 1 hour after plating and 24 
hours later by Guava viacount assay, growth determined by calculating difference in viable count.   
3.3 Optimisation of stromal conditioned media 
Initial experiments had confirmed that the stromal cell lines we possessed support 
primary AML cells. However, to ensure we were realising optimal effects we set out to test a 
number of variables that may indeed affect the level of support the BMSCs can offer AML cells 
in an ex vivo environment. Aspects of CM production that were investigated during optimisation 










































Days of media conditioning in presence of stromal cells 
In the literature the length of conditioning regimens can be quite variable with studies 
choosing to condition media in the presence of stromal cells for a range of 3-5 days (321). In 
choosing an appropriate range of time points to measure supportive capacity, it was postulated 
that too short a period of time would lead to insufficient secretion of the factors that support 
primary AML cells. However, conditioning the media excessively would likely lead to the media 
being depleted of key essential amino acids, carbohydrates, as well as the 10% serum 
supplementation. All of which would start to produce a less supportive medium. With these 
considerations, HS-5 cells were used to condition media for 2, 3, 4 and 5 days before assessing 
the ability of the CMs to maintain primary AML cells in ex vivo culture.      
              











































Figure 3.3: Optimising the duration of stromal media conditioning. IMDM media (+10% FBS) was 
conditioned with HS-5 cells for 2, 3, 4 and 5 days, subsequently these HS-5 CMs were used to maintain 
2x104 primary AML cells from patient #0 ex vivo for 10 days. Graph displays the relative number of viable 
AML blasts measured by Beckman Coulter Vi-Cell counter at Day 10 compared Day 1 when using the 
different HS-5 CMs. Each condition run in technical triplicates. Red circle indicates supportive CM. 
Optimisation of the number of days required to sufficiently condition media with HS-5 
cells revealed that 2 days of conditioning was optimal. Results showed that 3 days of 
conditioning was also appropriate with the viable number of AML blasts at Day 3 still higher than 
that compared to Day 1. However, after 4 days of conditioning the CM lost its supportive 
qualities. This is likely due to the HS-5 cells utilisation of key components in the media, as well 

































Flask size, media volume and cell confluency 
A key consideration when conditioning media is the concentration of factors and how 
actively stromal cells are secreting supportive factors. Initially CM was prepared in T175 flasks 
and 20ml of IMDM media conditioned at a time. During optimisation steps, it was reasoned that 
this could be improved on. This volume (20ml) is quite a large volume of media, which introduces 
pros and cons: positively this will mean that the likelihood of key nutrients being depleted from 
the media is reduced, as well as any inhibitory secretions and metabolites being diluted. 
Adversely this also means that supportive factors will be diluted at these volumes. A large flask 
such as a T175 means that more cells can be seeded without the cells becoming too confluent, 
an important consideration also as both HS-5 and MS-5 cells have quite high proliferation rates 
and have been described as losing their supportive capacity following growth beyond a 
confluency of 85% (364). Therefore, making the system too small could compromise the 
supportive nature entirely. To assess whether the current method was optimal HS-5 cells were 
seeded in T175 flasks, as any smaller would quickly lead to confluent flasks at a range of densities 
from 0.3-1.0 x106 cells/flask. The cells were seeded with either 10, 15 or 20ml of media, lower 
volumes were not selected as there was concern as to whether such volumes would be sufficient 
to cover the area of the flask. Following 48 hours of conditioning, CM was collected used to 
maintain primary AML cells for 4 days in culture and the cells were then analysed for viability 
and cell number. 
 
Figure 3.4: Optimising stromal cell confluency and conditioned media volume. CM was obtained from 
HS-5 cells cultured in IMDM media (+10% FBS) following incubation for 48 hours in T175 flasks using cell 
densities described in the legend. The volume of CM also varied from 10-20 ml across the flasks. The 
resultant CM were used to maintain primary AML cells in culture for 4 days, after which cell numbers were 
measured using a guava viacount assays on a Guava flow cytometer. Each condition run in technical 
triplicates. Red circle represents most supportive conditions and blue circle least. 
Analysis comparing the ability of the different HS-5 CM to maintain primary AML blasts 












































with 1.0x106 HS-5 cells in 10ml of IMDM media (Figure 3.4). Additionally, similar results were 
observed when seeding 0.3x106 cells in 15ml of medium, although, this CM produced much 
higher error bars when assessing its ability to maintain AML. Interestingly seeding 0.3x106 HS-5 
cells did not produce very supportive media when grown in 10 or 20ml of media. A likely 
explanation is that 20ml of media diluted the supportive factors, as each cell density used to 
produce CM was observed as the least supportive conditions (blue circle). It is notable that the 
combination of high HS-5 cell densities and low media volumes (red circle) did not lead to less 
supportive CM. 
Inclusion of 0.22µM sterile filtration step 
Following the incubation with either MS-5 or HS-5 cells, collected supernatant would be 
centrifuged at high speed to pellet any debris before filtration through a 0.22µM filter to both 
ensure sterility of the media that would be added to the AML cells, and to ensure no stromal 
cells were being taken forward. Despite these benefits, there were concerns that potentially 
important proteins could bind to the filter and thus compromise the supportive capacity of the 
media. Therefore, CM produced by MS-5 cells was split, half of the CM was sterile filtered and 
half not, following filtration the media was used to maintain primary AML cells in culture. 
                
Figure 3.5: Determination of factor loss during filtration. MS-5 were used to condition IMDM media 
(+10% FBS) for 48 hours. CM was both sterile filtered and not filtered and in parallel used to maintain 
1x105 primary AML blasts in 2ml/well in culture. Cell numbers measured using Beckman Coulter Vi-Cell 
counter 48 hours later. Each condition run in n=5 technical replicates.  
Comparing viable AML cell numbers after culturing with the two differently processed 
CM showed that sterile filtration had no impact on the supportive properties of the media 
(Figure 3.5). It could be argued that not sterile filtering the media leads to more reproducible 
results, as the sterile filtered CM led to one replicate where the viable AML cell number was less 
than the number of viable AML cells seeded. However, as the difference was not statistically 
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significant the HS-5 and MS-5 CM in future experiments would continue to be sterile filtered as 
it reduces the chances of cellular debris being incubated with the AML cells in subsequent 
experiments. 
Fresh or frozen conditioned media 
One aspect of these experiments to be established was the impact of snap freezing the 
media between the time of production and being used in experiments. If snap freezing did not 
impact the supportive capacity of the CM, then practically this would be advantageous, as well 
help to control for variances between CM batches. However, it is widely accepted that the freeze 
thaw process leads to protein degradation and therefore it is likely to affect the composition of 
the CM. However, if it did not affect the components that are responsible for maintaining AML 
survival then it would still be a feasible approach. As with the sterile filtration optimisation, an 
identical batch of MS-5 CM was used both fresh and following a freeze thaw to maintain primary 
AML blasts ex vivo.  
                                    
Figure 3.6: Effects of the freeze thaw process on the ability of CM to maintain AML ex vivo. MS-5 cells 
were used to condition IMDM media (+10% FBS) for 48 hours. CM was both freeze thawed and used fresh 
in parallel to maintain 1x105 primary AML blasts in 2ml/well in culture. Graph displays the relative number 
of viable cells measured by Beckman Coulter Vi-Cell counter at Day 10 compared to seeding. Each 
condition run in n=4 technical replicates, * p<0.05. 
Analysis of the number of viable AML blasts following 10 days in culture showed that 
fresh MS-5 CM was a more reliable means of maintaining AML blasts in culture (Figure 3.6). CM 
that had been frozen was able to maintain AML cells in culture, however, on average, it did not 
work as well as fresh CM and the range in AML viability between each replicate was likely down 

































These experiments showed that it was important to use fresh CM in experiments, but the CM 
retained some supportive capacity if frozen between experiments. 
Cell lines, clones and AML co-culture 
Experiments up to this point had individually assessed the effects of MS-5 or HS-5 CM 
on maintaining AML blasts ex vivo. The opportunity arose whereby a new MS-5 clone became 
available and it was desirable to establish which stromal cell line produced the most supportive 
media. Collectively the lab possessed two MS-5 clones that shall be referred to as clone #1 and 
clone #2, as well as HS-5. At the same time as establishing the support of different clones it was 
postulated that stromal and AML cell line co-cultures may produce the most supportive media. 
This idea was based on the fact that heterotypic signalling between the cells can lead to the 
secretion of supportive factors that otherwise would not be released under cell independent 
stromal conditions (365). To assess this primary AML cells from patient #0 were maintained in 
culture using CM from each of MS-5 clone #1, clone #2 and HS-5 cells, additionally CM was 
collected from these cell types whilst being co-cultured with P31/FUJ cells (AML cell line). Patient 
#0 cells were kept in culture for seven days being measured by guava viacount assay on days 
one and seven.  
 
Figure 3.7: HS-5 stromal conditioned media is the optimum means of extending primary AML cell 
survival ex vivo. MS-5 (clones #1 and #2) and HS-5 cells ([+/-] P31/FUJ cells) were used to condition IMDM 
media (+10% FBS) for 48 hours. The resultant CM were used to culture patient #0 primary AML blasts over 
7 days, viable cell numbers measured by Guava viacount assay and reported relative to viable AML blast 
counts recorded on Day 1. Each condition were run in n=4 technical replicates. P values calculated using 

































Assessment of AML cell growth revealed that on this occasion CM from either of the 
MS-5 clones was unsupportive, with even the AML cells grown in unconditioned media 
performing better (Figure 3.7). At the time of this experiment, the MS-5 clone #1 was at passage 
20 and MS-5 cells were usually used in the range of passage 5-15, so it is possible that this clone 
has lost its supportive capabilities. The MS-5 clone #2 CM was also ineffective at maintaining 
primary AML cells over the course of seven days in culture, one key difference in this clone was 
that it required α-MEM media for maintenance, a departure from the previous IMDM media 
which primary AML cells are known to grow well in. HS-5 CM on the other hand was extremely 
successful at supporting AML growth with HS-5 CM leading to there being ~10.5 times more 
viable primary AML cells at day seven compared to day one. Finally, the inclusion of AML cells 
during stromal conditioning of the media was not a successful experiment; in all cases, this 
produced a less supportive CM. This was probably due to an increase in flask confluency, which 
would have inhibited the secretion of supportive components. Additionally, the P31/FUJ cell line 
has a high proliferation rate and likely stripped the media of crucial factors while releasing many 
acidic metabolites. Following utilisation of the key nutrients from the media, there would have 
been an increase in cell death, releasing inhibitory factors that could have had a negative effect 
on AML survival in later experiments.  
These experiments combined with previous experiments demonstrated that HS-5 media 
and earlier passages of MS-5 clone #1 (in all subsequent experiments that utilise MS-5 CM, 
capacity to support AML cells was verified first) produced the most supportive CM for 
maintaining AML ex vivo. Future experiments did not use CM from AML co-cultures and only 
known AML supportive media were used such as IMDM. These experiments also raised 
questions regarding the balance of pro-survival and pro-apoptotic factors secreted/released into 
the media during conditioning. 
Mixtures of conditioned media combined with fresh media  
The previous optimisation experiments raised the issue of the impact that pro-apoptotic 
content, acidic metabolites, and the stripping of serum, glutamine and essential amino acids 
from media. Optimisation strategies had shown that less complex cell mixtures, with moderate 
confluency and relatively short conditioning times were most effective at producing an optimal 
concentrated supportive medium.  
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Figure 3.8: Controlling for serum utilisation and accumulation of non-supportive components. HS-5 cells 
were used to condition IMDM media (+10% FBS) for 48 hours. The HS-5 CM was mixed with fresh IMDM 
media (FM) in ratios of 2:1 and 1:1. Mixed CM and unmixed HS-5 CM were then used to maintain 1x105 
primary AML blasts in 2ml/well. Graph displays the relative number of viable AML blasts measured by 
Beckman Coulter Vi-Cell counter at Day 10 compared to seeding. Each condition run in n=7 technical 
replicates, P values calculated using a repeated measures ANOVA; * p<0.05 **p<0.01 ***p<0.001. 
To counteract the negative components that are also part of CM, it was postulated that 
mixing CM with fresh complete media could replenish any key factors depleted from the media, 
while simultaneously diluting acidic metabolites. To investigate this HS-5 CM was mixed 2:1 and 
1:1 with fresh IMDM media and run in parallel with 100% HS-5 CM. 
             Mixing conditioned and fresh media produced a range of results with each condition 
producing varying levels of support. Analysis of the data revealed that on average, AML survival 
in each condition increased as the proportion of fresh media increased during ten days in culture 
(Figure 3.8). Using HS-5 CM mixed with fresh media in 2:1 and 1:1 ratios resulted in a statistically 
significant increase in AML supportive capacity when compared to using 100% HS-5 CM only to 
maintain primary AML ex vivo.  Notably the 1:1 ratio captured the dynamic nature of CM and 
the issue of batch effects, as there were instances where the supportive factors were either not 
present or present at lower abundances. 
3.4 Optimisation of secretome purification 
Once we established conditions that produced optimal BMSC CM (using both HS-5 and 
MS-5 cells), we next sought to purify the supportive component from the media for cell signalling 
experiments and LC-MS/MS analysis. Enrichment approaches included ultrafiltration of the CM 
using Vivaspin 20 columns that were used to concentrate the stromal secretome (Figure 2.1), 
and a methanol-chloroform based precipitation. Vivaspin columns (GE Healthcare) separate 








































































decided to split the media into two fractions, molecules that are >5kDa (proteins) and those 
<5kDa (metabolites and small peptides), as most cytokines and GFs are between 5-30kDa (in the 
>5kDa fraction).  
3.5 Western blot analysis of secretome effects on signalling nodes 
Following confirmation of the BMSC secretomes ability to support primary AML survival 
we next sought to establish effects that the stromal secretome has on signalling nodes 
commonly upregulated in AML, such as PAK1 which has previously been reported as one of the 
most active kinases in AML (271).  
Once ultra-filtration of the stromal secretome was optimised in my hands, experiments 
began investigating the effects of the stromal secretome on signalling in MV4-11 cells (chosen 
as were less profoundly affected by serum deprivation compared to P31/FUJ), with PAK 
phosphorylation chosen as a representative signalling readout. Figure 3.9 shows western blot 
analysis of phospho-PAK expression in MV4-11 cells following stimulation stromal secretome 








   
 
Figure 3.9: Increase in PAK phosphorylation in MV4-11 cells over secretome time-course. (A) MV4-11 
cells serum starved for 4 hours and then treated for 30 minutes with a titration of (0-100µg/ml) >5kDa 
MS-5 secretome. Cells then analysed by western blot (30µg/lane) to observe effects on PAK1 and PAK2 
phosphorylation. (B) Time course of >5kDa MS-5 secretome, measuring effects of 10μg/ml on PAK 
phosphorylation in MV4-11 cells across 60 minutes following 4 hours of serum starvation. Accordingly 
PAK1 and GAPDH included as loading controls. 
MV4-11 cells were serum starved for 4 hours before being incubated for 30 minutes 
with a titration of MS-5 stromal secretome (>5kDa) [Range of 0-100μg/ml] before lysing and 
measuring PAK phosphorylation. These experiments determined that 10 μg/ml of secretome 




optimum secretome concentration a secretome time-course was devised. Again MV4-11 cells 
were serum starved for 4 hours before being incubated over a time course of 60 minutes with 
10μg/mL of MS-5 stromal secretome (>5kDa) (Figure 3.9B). Western blot analysis using an 
antibody targeted against both pPAK1Thr423 and pPAK2Thr402 (phosphorylation sites that indicate 
kinase activation) showed that by 15 minutes levels of pPAK1Thr423 increase substantially 
compared to the control (time=0). Further pPAK2Thr402 levels increased over time suggesting that 
the secretome is a modulator of PAK activity and is either stimulating PAK or effects the 
regulation of PAK. 
3.6 LC-MS/MS analysis of MS-5 secretome 
Having demonstrated a method for secretome purification that modulates cell growth 
in guava assays, while simultaneously effecting cell signalling dynamics through western blot 
analysis, we next sought to establish specific factors that contribute to these biological 
observations in AML cells. To this end, MS-5 secretome was purified as described previously 
using Vivaspin 20 columns and 100µg of the MS-5 secretome was combined with 8M Urea. 
Proteins were then reduced, alkylated and digested overnight with immobilised trypsin. 
Secretome peptides were desalted offline using C18 spin columns as detailed in the methods 
(section 2.10) prior to LC-MS/MS separation and detection. Following a 180 minute gradient and 
selecting for the top 5 precursor ions to undergo fragmentation, the analysis yielded 11456 MS1 
scans and 9768 MS2 scans (Figure 3.10).  
The raw data was then searched using the MASCOT search engine and this protein 
identification data was combined with the quantification undertaken by PESCAL software, this 
generated a list of 2106 identified peptides with relative abundances. The peptides belonging to 
the same protein were concatenated and their relative abundance summed, proteins with a 
MASCOT score >50 (a confidence score for protein identification) and >2 unique peptides 




Figure 3.10: Base peak chromatogram produced during LC-MS/MS analysis of MS-5 secretome. 
Basepeak intensity displaying the most intense mass signal for a given mass spectrum, across a 180-
minute gradient on an LTQ-XL MC-MS/MS, analysing 80µg of trypsin digested MS-5 secretome.   
In order to extract biological significance from a list of 293 proteins, we performed an 
assessment of the most abundant proteins without normalising for protein size (Figure 3.11 and 
Table 3.1), this analysis showed that Fibronectin was the most abundant protein in the stromal 
secretome. Fibronectin is a very well established stromal secreted protein that forms a core 
component of the ECM and helps to keep blasts in niches (144). Other proteins identified in this 
analysis that have been implicated in cancer before were vimentin (366) and cathepsin B (367-
369), among many others.  
 
Figure 3.11: Relative abundance of secreted MS-5 proteins following LC-MS/MS analysis. Quantitative 
secretomic analysis of MS-5 secretome, quantifying MS ion intensity for all corresponding peptides of 
identified proteins. Scores normalised by the total ion chromatogram and ordered according to Log 
transformed relative abundance. Abundance averaged across n=3 technical replicates. The top 12 most 
abundant proteins are named.  
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The 12th most abundant protein identified in the analysis was Pigment epithelium 
derived factor (PEDF), which is a secreted glycoprotein, and unlike the other abundant proteins 
identified has previously been described as having anti-cancer activities (370). 
Protein ID Protein Mol. weight (kDa) 
FINC Fibrinogen 263 
TSP2 Thrombospondin-2 130 
ACTBL Beta-actin-like protein 2 42 
CO1A1 Collagen alpha-1(I) chain 139 
VIME Vimentin 54 
ACTS Actin, alpha skeletal muscle 42 
NFM Neurofilament medium polypeptide 102 
CATB Cathepsin B 38 
CO1A2 Collagen alpha-2(I) chain 129 
NID1 Nidogen-1 137 
NDKB Nucleoside diphosphate kinase B 16 
PEDF Pigment epithelium-derived factor 50 
Table 3.1: The most abundant proteins in secretome. 
When summed protein intensities were normalised to their respective molecular 
weights in analysis, large proteins such as fibronectin were no longer in the top 20 most 
abundant proteins. This allowed for the identification of signalling proteins such as Protein S100-




Figure 3.12: Relative abundance of secreted MS-5 proteins to total ion intensity. Quantitative secretomic 
analysis of MS-5 secretome, quantifying MS ion intensity for all corresponding peptides of identified 
proteins. Scores normalised by molecular weights and ordered according to Log transformed relative 
abundance. Abundance averaged across n=3 technical replicates. GFs of interest are coloured.  
 
Filtering for GFs and chemokines identified 14 proteins of interest (Figure 3.13). The 
most abundant of which was protein S100-A4 followed by PEDF. Protein S100-A4 supports VEGF 
via the RAGE receptor, promoting endothelial cell migration (371). Osteopontin, the next most 
abundant GF, has a well-described role in the BMSM helping to keep LSCs in a dormant state 
(372). Growth/differentiation factor 5 (GDF5) has previously been implicated in regulating TGF-
β dependant processes that influence LSC migration (373). Connective tissue growth factor is 
another signalling protein that is thought to enhance AML cell growth, via a mechanism that 
implicates pSmad1/5 signalling (374).  
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Figure 3.13: List of the most abundant secreted MS-5 growth factors. Calculated protein abundance 
normalised by molecular weight of GFs identified in the MS-5 secretome, proteins ordered according to 
Log transformed relative abundance. Abundance averaged across n=3 technical replicates.  
To fully characterise the MS-5 stromal secretome, analysis that incorporated gene 
ontology (GO) searches were undertaken. By submitting the identified MS-5 secretomic 
components to the Panther GO search engine it was possible to classify functions and processes 
for 208 of the identified proteins. These proteins were then assigned to 23 different protein 
classes as shown in Figure 3.14A, we were interested in the signalling molecules protein class. 
This group that consisted of 16 proteins could be subdivided into 4 further groups; cytokines, 
GFs, membrane-bound signalling molecules and peptide hormones (Figure 3.14B). This analysis 
made it possible to visualise the proportions of protein classes by which the secretome was 
composed, with signalling molecules being one of the largest classes. The identified signalling 
molecules did not differ significantly from those detailed in Figure 3.13, with the notable 
exception of SPRC and PR23C. SPARC (Osteonectin), was recently described as having a role in 
leukaemia cell self-renewal, whereby SPARC activation of the integrin-linked kinase/AKT 
(ILK/AKT) pathway, this subsequently activates β-catenin signalling (375). Prolactin-2C3 is only 
expressed in mice, therefore it is unlikely to be a protein of interest in the context of the present 




Figure 3.14: Panther gene ontology analysis of MS-5 secretome. Proteins of the MS-5 secretome 
identified by LC-MS/MS analysis were submitted to Panther gene ontology enrichment analysis. (A) 
Panther assigned 208 identified MS-5 proteins that met confidence criteria into protein class. (B) Enriched 
signalling molecules detected by panther analysis displayed with Log transformed relative abundance 
normalised by molecular weight. Abundance averaged across 3 technical replicates. 
Enrichment and LC-MS/MS analysis of the MS-5 secretome provided potential candidate 
factors that could be important in maintaining primary AML cell survival as well as activating 
signalling in these cells. However, we decided that a more quantitative approach was necessary 
in order to select proteins to investigate for biological function in AML.  
3.7 LC-MS/MS analysis of HS-5 secretome 
LC-MS/MS analysis of the MS-5 secretome was undertaken first and subsequent HS-5 
based experiments revealed that the CM produced by this cell line was superior for maintaining 
AML viability (Figure 3.7). This observation coupled with the successful use of both cell lines in 
the literature for sustaining AML ex vivo suggested that there were different factors being 
secreted by the two cell lines. To establish if this was true we also enriched the HS-5 secretome 
and conducted LC-MS/MS analysis. 
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The process of enriching proteins in the secretome from HS-5 or MS-5 CM can be 
achieved through a number of methods. Previous MS-5 secretome enrichment had been 
achieved using the Vivaspin 20 molecular weight cut off (MWCO) columns that separate proteins 
utilising size exclusion. During those experiments it was postulated that proteins may be lost 
through binding to the semi-permeable membrane that separates the >5kDa and <5kDa 
compartments. To investigate this, HS-5 secretome was processed both utilising the MWCO 
approach as well as the classical method of methanol chloroform (MC) precipitation to enrich 
for the protein component. 
 
Figure 3.15: Optimisation of secretome enrichment finds Vivaspin columns best approach. Methanol 
chloroform precipitation and Vivaspin 20 columns used to enrich for secretomes from HS-5 CM. (A) 
Number of identified proteins determined by LC-MS/MS and MASCOT analysis. Proteins counted if they 
returned a MASCOT score >50 and >2 unique peptides identified. (B) Protein identification consensus 
between approaches. n=3 samples run in analytical triplicates per approach. 
Utilising both approaches (although others were available, familiar protocols were 
undertaken) HS-5 CM was collected, proteins enriched, before proteins were processed for LC-
MS/MS analysis (as detailed in methods section 2.10). Once samples were analysed, peptides 
identified, and proteins determined (using MASCOT and bioinformatic tools), coverage of each 
approach was assessed. On average secretome assessment using the Vivaspin approach 
identified 705 HS-5 proteins and the MC precipitation only identified 171 HS-5 proteins at the 
end of analysis (Figure 3.15A). The difference between the approaches was stark and strongly 
supported proceeding to analyse the stromal secretome using the Vivaspin 20 columns.  
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To find merit within the MC approach, the coverage of the proteome that both methods 
conferred was assessed, as it may have been that the chemistry involved in the MC precipitation 
could capture proteins that are not possible to identify when employing the Vivaspin method. 
Analysis revealed that the MC precipitation approach identified 35 proteins that were not found 
in the Vivaspin approach. These proteins however, were keratins, collagens and myosins – likely 
present due to the increased sample handling in the MC precipitation. 136 proteins were 
identified using both approaches and 569 proteins were identified using the Vivapspin method 
that could not be detected using the MC precipitation method (Figure 3.15B). The results from 
these experiments suggested that the Vivaspin approach was indeed the best method in our 
hands to examine the stromal secretome. 
Analysis of the total HS-5 secretome using Vivaspin enrichment coupled to LC-MS/MS 
detection enabled the identification of 695 proteins, in which >2 unique peptides with a 
MASCOT score >50 were detected. Assessment of these proteins by abundance and 
normalisation for protein size produced a spread of data visualised in Figure 3.16A, with all 
potential signalling molecules coloured. In the HS-5 secretome there were substantially more 
signalling molecules identified compared to that identified in MS-5 based experiments.  
Closer consideration of the identified signalling molecules showed that by far the most 
abundant signalling proteins in the secretome were transforming growth factor-beta-induced 
protein ig-h3 (BGH3) previously described as playing a role in cell adhesion (376), TSP1 and TSP2 
commonly found in BM stromal media and Latent-transforming growth factor beta-binding 
proteins 1 and 2 (LTBP1, LTBP2) which were recently described as being crucial to invasion and 
proliferation in other cancer types (377) (Figure 3.16B). Other factors previously described as 
being important in leukaemia included IL6, IL8, NOV and OSTP (378-381).  Further, there were 
signalling proteins identified that were also detected during MS-5 secretome analysis including, 





Figure 3.16: List of the most abundant secreted HS-5 growth factors. (A) All 695 identified HS-5 proteins 
that met confidence criteria. Signalling molecules coloured. (B) Potential signalling molecules, ordered 
according to Log transformed relative abundance scores, which are normalised by molecular weights. 
Abundance averaged across 3 independent samples run in analytical triplicates.  
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To extract more biological insights from the data, Panther GO enrichment analysis was 
undertaken, in which all 682 proteins that were identified across all runs were submitted for GO 
annotation. This analysis sorted the proteins into 23 different protein classes, these included 
cytoskeletal proteins, extracellular matrix proteins, cell adhesion molecules and signalling 
molecules (Figure 3.17A). A total of 35 proteins were considered signalling molecules (this does 
not include calcium binding proteins, receptors, cell junction proteins, or transcription factors 
that can act as signalling molecules). The 35 signalling molecules could be further subdivided 
into cytokines (16), GFs (12), membrane-bound signalling molecules (4) and peptide hormones 
(3).  A detailed list of these 35 proteins is illustrated in (Figure 3.17B), with the 5 most abundant 
of these proteins being complement C3 (CO3), SPARC (SPRC), semaphorin-7A (SEM7A), inhibin 
beta A chain (INHBA) and NOV.  CO3 and SEM7A have roles in inflammation and the immune 
response, proteins SPARC, NOV and INHBA have a myriad of roles in development being 
described as modulators of growth, differentiation, migration and survival (375, 382, 383).  
To understand how these proteins may in concert direct cellular function, GO pathway 
analysis was implemented on the HS-5 secretome LC-MS/MS data. This showed that by fold 
enrichment the highest-ranking pathway was glycolysis, followed by the pentose phosphate 
pathway and the plasminogen-activating cascade (Figure 3.17C). From a signalling perspective 
the components of the HS-5 stromal secretome displayed enrichment towards integrin signalling 
pathways and cytoskeletal regulation by Rho GTPase. All of these had low p-values, however, 
there were processes involved (Parkinsons, Alzheimers, Huntington disease – although diseases 
with strong signalling elements) that suggested these BM stromal based experiments needed 




Figure 3.17: Panther gene ontology analysis of HS-5 secretome. (A) Protein class assignment for 695 
identified HS-5 proteins that met confidence criteria. (B Log transformed relative abundance normalised 
by molecular weights of all signalling molecules detected by panther analysis. Abundance averaged across 
3 independent samples run in analytical triplicates. (C) Top 10 Panther GO results for total HS-5 secretome 




3.8 Co-culture models to induce dynamic stromal protein expression 
Experiments so far enabled us to determine components of the MS-5 stromal secretome 
whilst under basal conditions. While it was possible to speculate as to which proteins likely 
supported AML blast survival it was still unclear which of these 502 proteins were responsible 
for inducing intracellular signalling (Figure 3.9) and whether these same proteins were 
responsible for the changes in MV4-11 cell viability and proliferation (Figure 3.2). 
To establish which proteins of the stromal secretome had relevance in AML, it was 
devised that we could produce secretomes of variable composition by culturing MS-5 mouse 
stromal cells with human AML cells both in the same environment and independently. It was 
postulated that any differences in secretome composition may give indications as to which 
proteins were more important to AML, with dynamic abundance between the secretomes acting 
as a surrogate marker for utilisation and/or positive feedback mechanisms for secretome 
production (Figure 3.18). 
Protein mass spectrometry can differentiate peptide sequences originating from 
different organisms provided tryptic peptides differ by at least one amino acid that changes the 
mass of the peptide. This contrasts with immunochemical methods where antibodies often 
cross-react with proteins of closely related organisms. Therefore, conducting the co-culture 
experiments with cell lines derived from different species enabled identification of which cells 
were responsible for the secretion of specific components of the secretome. Discrimination 
between the protein origins was possible because on average 1 in every 10 amino acids is 
different between human and murine proteins. These differences are small enough that most 
proteins share sufficient homology to interact with antibodies, yet the difference is still 
detectable by mass spectrometry. Therefore, the species of the proteins within the co-culture 
secretomes revealed if a protein was secreted by a stromal cell (mouse) or an AML cell (human). 
Finally, we decided to co-culture MS-5 cells with a panel of AML cell lines: MV4-11, P31/FUJ, HL-






Figure 3.18: Schematic for AML – MS-5 co-culture model. To create the co-culture MS-5 cells were seeded 
in flasks in complete media and left to grow for 24 hours. After stromal cells were established, the growth 
medium was removed, and cells were washed twice with PBS. In parallel AML blasts (P31/FUJ, MV4-11, 
HL-60, and CTS) were grown in culture for 24 hours before being harvested and pelleted to remove media. 
The appropriate number of blasts/flask were then re-suspended in fresh serum-free media and the 
suspension was then gently introduced into the flask containing MS-5 stromal cells. These populations 
were then left a further 24 hours before the supernatant was carefully collected from the flasks. As the 
supernatant contains the AML blasts, suspensions are gently centrifuged as to not stress the cells. The 
resultant CM was then harvested and underwent secretome purification steps as detailed previously. The 
remaining MS-5 cells were then washed with pre-warmed PBS and trypsinised before viability assays or 
cell lysis. AML blast pellets were re-suspended in media or PBS before further experimentation. 
 
3.9 Co-culture viability assays 
In parallel to the secretome digestion, the cells following co-culture were collected and 
assays were run to assess the effects of co-culture on cell viability. As serum proteins generate 
a lot of background during mass spectrometry analysis, serum was omitted from the co-cultures 
when producing the secretomes. This also allowed for the investigation of the supportive 
qualities that MS-5 cells and secreted proteins could provide. We assessed the viability of the 
cells prior to the experiments at time = 0, as well as AML blast viability in a serum starved 
environment alone and in co-culture with MS-5 cells. MS-5 cells were also cultured alone to 
establish if cells were detrimentally affected by the presence of AML blasts. Additionally, we 
wanted to see if the viability of the different AML types was consequential to the starvation-
stromal effect. 
Although the initial changes in cell viability were not large, they were statistically 
significant and demonstrate that after just 24 hours incubation MS-5 co-culture did positively 
affect AML cell viability. The assay only measured viability at the 24 hour time-point (as time of 
secretome harvesting), but the viability of MV4-11, P31/FUJ and CTS cells was dropping in the 
unsupported environment. In the stromal cell supported environment viability was maintained 
if not increased, suggesting that that co-culture was preventing the drop in AML viability in these 
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models (Figure 3.19). In contrast, the viability of HL60 cells was unaffected by the stromal 































































































































Figure 3.19: AML cell viability over 24 hours following serum starvation in culture alone or in co-culture 
with MS-5 stromal cells. 1x107 cells seeded in T175 flasks with and without 1x106 MS-5 cells in 20ml IMDM 
media (no serum as media collected for LC-MS/MS analysis). Following 24 hours (A) MV4-11 cell viability 
(B) P31/FUJ cell viability (C) CTS cell viability (D) HL60 cell viability, were measured with a Beckman Vi-cell 
counter. Each condition run in technical triplicates and cell counts run in analytical triplicates. * p<0.05 
3.10 LC-MS/MS analysis of co-culture secretomes 
LC-MS/MS analysis of MS-5 secretomes following co-culture with the AML cell lines 
identified 246 secreted proteins (with a MASCOT score >50 and >2 peptides identified) which 
were only detected exclusively from murine derived peptides (therefore secreted by stromal 
cells and not AML cells). Of these identifications 133 were found to be statistically significant 
changes in protein abundance across cultures following the co-culture experiment, these 
changes are represented as a heatmap in Figure 3.20. 











Figure 3.20: Hierarchical clustering analysis of the changes in protein expression in AML-MS5 co-
cultures. Heatmap displays the 133 proteins secreted by MS-5 cells (murine specific peptides) that 
significantly changed in abundance following 24 hours co-culture with AML cell lines compared to CM 
from MS-5 grown independently. Each co-culture run in technical triplicates and each replicate analysed 
by LC-MS/MS in analytical triplicates. Heatmap and dendrograms produced in R environment using 
‘ggplots’ package.  
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In the P31/FUJ cultures 6 stromal secreted proteins were significantly increased (at >2 
Log2 fold change and p<0.05) and 16 decreased (at <-2 Log2 fold and p<0.05) compared to 
secreted protein abundance in MS-5 independent cultures. Of the 6 stromal proteins that 
increased in abundance following AML co-culture there were some notable proteins that were 
observed in the MS-5 secretome only experiments too; these included S100-A4, S100-A6, S100-
A11 and BMP-1 (Figure 3.21A).  
 
Figure 3.21:  Volcano plots of stromal factors that significantly increase and decrease following co-
culture with P31/FUJ and HL60 cells. Murine derived proteins in the CM from MS-5 cells incubated with 
(A) P31/FUJ (B) HL60 cell lines for 24 hours and compared to CM from MS-5 only cultures. Markers red if 
protein abundance <2> Log2 fold change compared to control and above line if statistically significant. 
Each co-culture run in technical triplicates and each replicate analysed by LC-MS/MS in analytical 
triplicates.  
In the HL60 cultures 6 stromal secreted proteins were also significantly increased (at >2 
Log2 fold change and p<0.05) and 12 decreased (at <-2 Log2 fold and p<0.05) compared to 
secreted protein abundance in MS-5 independent cultures (Figure 3.21B). Notable proteins that 
increased in these cultures include renin receptor (RENR) a known component in BMSM that 
can become dysregulated in AML (384), and suprabasin (SBSN) previously described as a proto-
oncogene in other cancers that can aid in metastasis and invasion (385-388), and S100-A11. 
In the MV4-11 cultures 4 stromal secreted proteins were observed as significantly 
increased (at >2 Log2 fold change and p<0.05) and 17 decreased (at <-2 Log2 fold and p<0.05) 
compared to secreted protein abundance in MS-5 independent cultures (Figure 3.22A). Within 




the subset of proteins that increased in expression following AML co-culture the proteins S100-
A11, SBSN, and S100-A6 could potentially act as signalling proteins that augment AML survival 
and proliferation. Unlike the P31/FUJ and HL60 co-cultures, the abundance of a number of 
potential signalling molecules decreased in MV4-11 co-cultures. These included CTGF which in 
previous secretome analysis experiments was always one of the most abundant (Figure 3.16B), 
and CCL9 and Galectin-3 (LEG3) which are inflammatory chemokines that decreased in 
abundance.  
 
Figure 3.22: Volcano plots of stromal factors that significantly increase and decrease following co-
culture with MV4-11 and CTS cells. Murine derived proteins in the CM from MS-5 cells incubated with (A) 
MV4-11 (B) CTS cell lines for 24 hours and compared to CM from MS-5 only cultures. Markers red if protein 
abundance <2> Log2 fold change compared to control and above line if statistically significant. Each co-
culture run in technical triplicates and each replicate analysed by LC-MS/MS in analytical triplicates.  
Finally, in the CTS cultures only 1 stromal secreted protein significantly increased (at >2 
Log2 fold change and p<0.05) and 0 decreased (at <-2 Log2 fold and p<0.05) compared to 
secreted protein abundance in MS-5 independent cultures (Figure 3.22B). The MS-5 secretomes 
following CTS co-culture did not contain as many significantly modulated proteins as observed 
with other cell lines, with only VAS1 is the only change that is statistically significant. Although 
of the identified proteins, candidates such as S100-A4, BMP-1 and RENR exhibited high fold 
change differences between independent and co-culture CTS models. 




3.11 Panel of six stromal secretome proteins selected for further investigation 
Several of the secreted proteins that changed in abundance during co-cultures have 
previously been described as being secreted in other systems (371, 389, 390) and possess the 
capacity to act as signalling molecules. Consideration of this data coupled with the MS-5 and HS-
5 independent analysis (sections 3.6 and 3.7) six proteins were selected for further investigation 
including; S100-A4, S100-A11, connective tissue growth factor (CTGF), hepatocyte growth factor 
(HGF), bone morphogenic protein-1 (BMP-1), and colony stimulating factor-1 (CSF-1) (Figure 
3.23).  
 
Figure 3.23: Box plots of six chosen stromal proteins that changed dynamically across the co-cultures. 
CTFG, S100-A11, BMP-1, CSF-1, HGF, S100-A4 were the chosen proteins, all were murine specific in origin 
and did not appear in AML cell line only cultures. Boxplot values represent normalised quantified 
abundance of specified proteins in MS-5 only cultures and in the AML co-cultures; n=3 independent 
technical replicates; P value calculated by unpaired two-sided t test comparing co-cultures to MS-5 only 
samples * p<0.05 ** p<0.01. 
The first important characteristic that is common to these 6 growth proteins was that 
none of these were detected in the secretome of the AML cell lines that were grown in the 
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absence of MS-5 cells. This is a crucial property of these cells as this study is looking for means 
by which the microenvironment supports AML progression, therefore these proteins needed to 
be secreted by the stromal cells. Additionally, from a technical perspective if these candidates 
were being secreted by both cell types then any increases in abundance could just be due to 
having more cells present in culture, not necessarily because AML interaction induces increased 
secretion.   
S100-A4 was selected as firstly it was the most abundant signalling molecule identified 
in the MS-5 and HS-5 secretome (Figure 3.13). Secondly during AML/MS-5 co-culture 
experiments S100-A4 abundance changed dynamically across the co-cultures. In each of the 
AML co-cultures murine S100-A4 was elevated compared to the MS-5 only cultures. In 
particular, murine S100-A4 levels were very high in P31/FUJ and CTS cultures, while being 
variable in MV4-11 cultures (Figure 3.23). This potentially suggests that in different AML types 
S100-A4 has varying impact, with P31/FUJ cells possessing the feedback mechanisms to 
potentiate S100-A4 secretion that HL60 cells do not. Alternatively, S100-A4 may have more 
relevance to HL60 cells and the lower abundance is indicative of the utilisation of S100-A4. This 
pattern of expression coupled with previous reports describing S100-A4 as a metastatic 
potentiating factor in solid tumours make S100-A4 a suitable candidate for further investigation.  
CSF-1 became a candidate because, as with S100-A4, it was identified in all secretome 
experiments (Figure 3.14B) (Figure 3.16B). CSF-1 was unique as it had previously been implicated 
in haematopoietic precursor cell maintenance, and the receptor of which (CSF1R) has been 
suggested as a potential biomarker of disease outcome (391). Assessment of CSF-1 levels during 
co-culture revealed that MS-5 cells independently secrete relatively high levels of CSF-1 into the 
media. However, in the presence of AML cells (in particular P31/FUJ, CTS and HL60) CSF-1 levels 
decrease (Figure 3.23). This response could be due to utilisation of CSF-1 by these cell lines, with 
MV4-11 not experiencing the same reduction due to a lack of CSF1R expression. Alternatively, 
CSF-1 may elicit a regulatory function on AML growth and therefore, mechanisms may be 
activated to reduce its influence. 
The third protein to be investigated further was S100-A11. Another of the S100 protein 
family that was consistently one of the most statistically significant proteins to be elevated 
following stromal co-culture (Figure 3.21). Looking at the pattern of expression displayed across 
the co-cultures, this protein had a similar pattern of expression to CSF-1, with S100-A11 being 
recorded highest in MV4-11 cultures compared to the other cultures (Figure 3.23). However, like 
S100-A4 it was detected at very low levels in MS-5 cells grown alone, this suggests S100-A11 
expression was driven by AML and stromal cell interaction during co-culture.  
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HGF was selected as a protein for further investigation as the MET receptor (receptor to 
HGF) has previously been investigated in AML (392). In these studies, HGF and HGF co-binding 
proteins were identified in the HS-5 investigations. In co-culture experiments HGF was 
consistently abundant, which was also unique compared to other potential signalling molecules 
identified (Figure 3.23). 
CTGF selection was guided by its relative abundance in MS-5 (Figure 3.14B) and HS-5 
(Figure 3.16B) independent experiments. Functionally CTGF has been described previously as a 
signalling molecule and its oncogenic properties have been investigated, although not in the 
context of AML (393, 394). In the AML/MS-5 co-culture experiments, CTGF expression was 
unique to the other proteins. P31/FUJ and CTS co-cultures exhibited the same CTGF abundance 
as that recorded in MS-5 cells cultured alone (Figure 3.23). However, in the MV4-11 co-culture 
CTGF expression was not detected. CTGF expression was relatively high in the HL60 co-culture 
compared to the other cultures. HL60 is a representative model of APL, a form of AML that is 
distinct from other leukaemias. This observation made CTGF a protein of interest as its 
expression was potentially subtype specific expression.   
Finally, BMP-1 was chosen as it was detected in the MS-5 secretome experiments at low 
levels, but it was also very strongly expressed in the HS-5 secretome experiments (Figure 3.16A). 
In the co-culture experiments it was consistently elevated across AML cell lines (Figure 3.20). 
Additionally, in the AML co-culture experiments it was barely observed in the MS-5 only 
secretome and was consistently high in CTS secretome samples (Figure 3.23). BMP-1 is an 
astacin metalloprotease and has not previously been reported as a receptor agonist however, it 
is capable of indirectly activating BMP signalling cascades (395, 396). Additionally, we observed 
shifts in expression during co-culture experiments suggesting that BMP-1 had a role to play in 
AML/stromal cell interactions.  
It is important to state that other signalling molecules were identified in experiments 
conducted throughout this chapter, with a plethora of candidates raised in the HS-5 secretome 
following LC-MS/MS analysis. These proteins were not followed up as some candidates such as 
IL-6, SPARC and TSP1/2 had been previously investigated and to some degree characterised 
within the AML system (357, 375, 397, 398). For other candidates such as NOV, SBSN, S100-A6 
and LTBP1/2 it was not possible to acquire either biologically suitable recombinant versions or 
antibodies (including neutralising) at the time. 
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3.12 Western blot analysis of S100-A4 and CSF-1 presence in primary co-culture 
secretomes 
Following the identification and selection of six proteins from stromal secretomes, 
experiments were devised to establish if these factors are present in co-culture secretomes of 
primary AML and MS-5 cells. It was important to validate that these proteins are secreted in the 
presence of primary cells and not just when cultured in the presence of cell lines, thus providing 
evidence that these proteins were relevant in primary AML and that the dynamic behaviour of 
protein abundance was not unique to AML cell lines. CM was collected from primary AML co-
cultures with MS-5 cells and the secretome enrichment executed as described previously with 
Vivaspin 20 columns (section 2.3). These experiments focussed on CSF-1 and S100-A4 proteins, 
as suitable antibodies directed to these secreted proteins were readily available. 
 
Figure 3.24: Co-culture secretomes derived from different AML patients induce variable CSF-1 and S100-
A4 abundance. The CM from five primary samples kept in AML/MS-5 co-cultures for 24 hours were 
fractionated, and 30µg of each >5kDA secretome were analysed by western blot. (A) Western blots for 
total CSF-1 and total S100-A4 proteins (B) Ponceau stain of concentrated >5kDa secretomes produced by 
patient blast/MS5 cell co-cultures (C) Densitometry of the western blots above, intensities calculated 
using ImageJ software, normalised protein abundances for CSF-1 and S100-A4, intensities normalised to 




Five primary AML patient samples were incubated with MS-5 cells for 24 hours and the 
>5kDa secretomes produced were separated and analysed by western blot. Primary AML cells 
as discussed earlier in the chapter are sensitive to ex vivo conditions and as a result for these 
experiments 10% FBS was included during primary cell co-culture. To control for FBS inclusion, 
additional FBS and IMDM media controls were included to be sure that neither CSF-1 nor S100-
A4 were present in the FBS being used. Western blot assessment of CSF-1 expression via western 
blot revealed that CSF-1 was highly expressed in MS-5 cell only controls (SM) – as seen in Mass 
Spectrometry analysis – and variable expression was picked up in the co-culture samples (Figure 
3.24A). The co-culture patient secretome from patient SC3 exhibited relatively high CSF-1 
expression, whereas, the patient SC2 co-culture secretome had a very low abundance of CSF-1 
in the co-culture secretome. 
 S100-A4 expression in the patient co-cultures was also variable, with the MS-5 only cells 
(SM) producing low levels of S100-A4 in secretomes, and this held true for most of the co-culture 
secretomes from patients (SC2-SC5). However, in patient SC1 there were extremely high levels 
of S100-A4 detected in the enriched co-culture secretome (Figure 3.24A). To quantify and 
compare conditions, densitometry was undertaken and protein bands were normalised. It was 
reasoned that due to the variable nature of secretome composition choosing a specific protein 
as a loading control could be misleading. Therefore, the complementary ponceau stain for the 
blot was used to normalise protein intensity (Figure 3.24B).  
Densitometric analysis of the western blots confirmed that CSF-1 was most abundant in 
the independent MS-5 cells (SM) and was substantially reduced in all of the patient co-culture 
secretomes (Figure 3.24C). S100-A4 following normalisation was expressed at consistent levels 
across the secretomes, with the exception of SC1, in which S100-A4 abundance was almost 4-
fold higher than any of the other patient secretomes. The green box in Figure 3.35C highlights 
the absence of any of the factors in the cell free media containing FBS. An oversight during 
analysis was that both the S100-A4 and CSF-1 antibodies lacked reactivity towards bovine 
species. Therefore, despite no band detection in the FBS only lane, the antibody used would not 
have detected bovine derived CSF-1 or S100-A4. The contribution of these factors from FBS was 
not possible to assess from this western blot. 
The substantial increase in S100-A4 specific to the SC1 sample and none of the other 
AML patient secretomes raised the possibility that S100-A4 was either secreted by stimulated 
MS-5 cells or alternatively secreted by the AML cells within the SC1 sample. To ascertain if either 
hypothesis was correct, the experiment was repeated with the same five patient samples with 
the addition of cultures containing just the primary AML cells alone – to observe if these factors 
could be secreted by AML cells. 
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Western blot analysis of CSF-1 expression revealed that CSF-1 was not observed in any 
of the AML patient cell only cultures and was only observed in MS-5 containing cultures (Figure 
3.25A). S100-A4 was lowly expressed in the MS-5 only sample and expression increased 
substantially in co-culture models. It became apparent that patient #1 AML cells were capable 
of secreting S100-A4, but this expression was not observed in the other AML cell only samples.  
These western blots highlight the heterogeneity of AML samples and perhaps their capacity to 
shape and interact within the environment they are presented with.  
 
Figure 3.25: Individual and co-culture secretomes produced by 5 AML patients exhibit variable CSF-1 
and S100-A4 abundance. The CM from five primary samples cultured in AML/MS-5 co-cultures for 24 
hours and independently were fractionated, and 30µg of each >5kDA secretome were analysed by 
western blot. (A) Western blots for total CSF-1 and total S100-A4 proteins, Ponceau stain used as loading 
control. Densitometry of (B) CSF-1 (C) S100-A4 western blots, intensities calculated using ImageJ software 



















Normalisation of CSF-1 band intensities to the loading control revealed that the patient 
#5 (SC5) co-culture secretome contained substantially more CSF-1 than the other samples 
measured (Figure 3.25B). The MS-5 only sample (SM) displayed low levels of CSF-1, which were 
matched by the SC1 and SC4 co-cultures. The AML only secretomes (S1-S4) had no detectable 
CSF-1, but S5 had trace levels of CSF-1. SC5 co-culture revealed that patient #5 cells drive MS-5 
cells expression of CSF-1 as there was 5-fold more CSF-1 in this secretome than what was 
produced by MS-5 cells alone. Co-culture secretomes SC2 and SC3 did exhibit detectable levels 
of CSF-1. These experiments mirror observations from the mass spectrometric analysis, such as 
comparatively low abundancy of CSF-1 and the variability in co-culture abundances between 
AML samples. One big difference however, was realised in SC5, in which co-culture induced high 
levels of CSF-1 – in cell lines, co-culture resulted in diminished CSF-1 compared to MS-5 only 
controls. 
Analysis of S100-A4 secretome expression revealed that co-culture induced increased 
S100-A4 expression for every AML patient sample. S100-A4 was expressed in patients S1 and S5 
to levels equivalent or higher than that which were observed in MS-5 cells alone (Figure 3.25C), 
and there were also trace levels detected in patients S2, S3 and S4. The co-culture secretomes 
SC1-SC4 had S100-A4 levels that were equivalent to the combination of SM and the appropriate 
patient sample. But when comparing the S100-A4 pattern of expression in SM, S5 and SC5, S100-
A4 secretion was increased. The relative S100-A4 abundance and the dynamics in expression 
between cultures mirrored observations from the mass spectrometric analysis. However, these 
experiments suggested that S100-A4 can be secreted by some AML patient samples. 
3.13 Summary 
It was proposed that stromal secretomes derived from MS-5 and HS-5 cells which 
positively affect AML survival likely contain pathologically relevant proteins that have yet to be 
implicated in the progression, resistance and fate of the disease. Accordingly, experiments were 
designed to identify these factors from the milieu that is the AML tumour microenvironment 
and use the resolving power of LC-MS/MS platforms to identify these secreted proteins.  
Firstly, it was reasoned that to stand the best chance of identifying such proteins we 
needed the CM by which stromal secretomes were going to be enriched, to be as supportive as 
possible. To ensure that conditions were optimal a number of elements in the production of 
stromal CM were assessed, such as cell line, days of conditioning, the effects of snap-freezing 
on supportive integrity and means to reduce the impact of acidic metabolites and nutrient 
exhaustion (Figures 3.3-3.8). Following adjustment of these parameters the supportive qualities 
of CM were enhanced.   
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Having confirmed the supportive qualities of the optimised HS-5 and MS-5 (clone #1) 
CM, it was important to assess the effects of the secretome on the activity of commonly 
upregulated signalling nodes in AML. To assess this, intracellular signalling in AML cells was 
measured by western blot following stimulation with MS-5 secretome (Figure 3.9). This data 
showed that the MS-5 stromal secretome did indeed lead to increased abundance of the known 
PAK phosphorylation sites, known markers of PAK activity. This suggested that the secretome 
was affecting the nature of cell signalling and therefore, could modulate the behaviour of AML 
cells. 
It had been observed that these stromal secretomes were able to modulate AML cell 
fate in our hands, and as such it was desirable to know exactly which components of these 
complex protein mixtures were capable of directing AML behaviour. LC-MS/MS based 
secretomic analysis was undertaken of both MS-5 and HS-5 cell lines to decipher their 
constituents. Analysis of the MS-5 secretome identified 293 proteins (Figure 3.11), of which 16 
were considered signalling molecules following GO protein class assignment (Figure 3.14). LC-
MS/MS analysis of the HS-5 secretome identified substantially more proteins (569) (Figure 
3.16A), however, this was probably due to a switch in mass spectrometer, as HS-5 secretomic 
analysis was conducted with the faster Q-Exactive plus, whereas the MS-5 secretome was 
analysed using an LTQ-XL. The HS-5 secretome comprised 68 signalling molecules according to 
uniprot GO assignment (Figure 3.16B), 35 of which were also recognised in Panther GO 
enrichment analysis (Figure 3.17). These experiments identified a number of stromal cell derived 
molecules with AML relevance that corroborated with the literature, but also provided a large 
number of potential signalling candidates. 
Following thorough LC-MS/MS characterisation of the stromal secretomes it was not 
possible to validate the relevance of all the potential candidates in AML as the list was too long. 
Therefore, to try and elucidate which proteins were relevant a series of cell line based co-culture 
experiments were devised. It was postulated AML co-culture with MS-5 cells would result in 
secretomes of variable abundance that would reveal proteins relevant in AML survival. This 
method revealed that a number of secretomic proteins changed during co-culture experiments, 
but there were a panel of six proteins that consistently and significantly changed across co-
culture experiments (Figure 3.23). 
 It was postulated that, these co-culture experiments had been conducted with AML cell 
lines and therefore, validation was required in primary AML cells to confirm that these findings 
translate in primary material. To assess factor expression in primary AML/MS-5 co-culture, 
western blot analysis was employed as these cells could not be maintained in a serum free 
environment – serum proteins would create too much background for LC-MS/MS analysis. 
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Analysis of S100-A4 and CSF-1 expression confirmed that these proteins do dynamically change 
in primary AML co-cultures (Figure 3.24). However, following repeats that included patient only 
secretomes, analysis revealed that some primary AML cells were able to secrete S100-A4 also 
(Figure 3.25). This was not anticipated, but it only served to highlight the heterogeneity of the 
disease and potentially the variable importance of different GFs in different patients. As the AML 
cells from patient #1 were able to produce S100-A4 independently and did so in relatively large 
quantities, whereas other patient samples required the microenvironment to provide or drive 
expression of those proteins (both S100-A4 and CSF-1). These preliminary findings hinted at the 
plasticity of the microenvironment and how it could be adapted to suit the needs of AML, be 
that in the supply of a GF, through helping to drive GF expression or a combination of both.  
 In summary, mass spectrometry-based detection of stromal secretomes relevant to the 
progression of AML and survival of ex vivo primary cells identified 293 MS-5 derived proteins 
and 569 HS-5 derived proteins. Analysis of these proteins revealed that the approach was able 
to identify well known supportive elements of AML survival as well as identify many novel 
stromal derived proteins. Western blot analysis was able to validate the approach as a means of 
identifying new secretomic factors. The following chapters describe experiments exploring the 














Chapter 4: Empirical determination of identified protein 
components from the BMSM and their role in AML survival 
 
4.1 Introduction and aims of the study  
The LC-MS/MS based approach reported in Chapter 3 revealed that a panel of six 
stromal secreted proteins may play a role in the supportive effects that CM confer to AML cell 
survival. These proteins were consistently observed in a series of co-culture models as well as in 
independent analysis of MS-5 and HS-5 secretomes. Proteins that were identified in both HS-5 
and early MS-5  secretomes (used for western blots and MS analysis) were of interest as these 
secretomes were both capable of increasing the phosphorylation of relevant AML signalling 
proteins (Figure 3.9) and extend primary AML cells ex vivo survival (Figure 3.1). As both CM had 
been observed as supportive at the time of LC-MS/MS analysis, it was rationalised that the 
supportive proteins would be present in both CM. The identified proteins included S100-A4, 
S100-A11, CTGF, BMP-1, CSF-1 and HGF.  
S100 proteins so called due to the solubility of these 10kDa proteins in 100% saturated 
ammonium sulphate are a group of proteins that share high sequence and structural similarity, 
yet each participate in a distinct function (399, 400).  The structure and function of S100 proteins 
is controlled by calcium binding, and as a result S100 proteins are very sensitive to calcium levels 
and can translate intracellular calcium changes into biological action (401). S100 proteins have 
both intracellular and extracellular functions and regulate their targets by binding to them (402). 
S100 expression in the extracellular space and their subsequent role in cell communication 
through cell-surface receptor binding is well described (400, 403).  
LC-MS/MS analysis of both the MS-5 and HS-5 stromal secretomes identified S100 
proteins A4 and A11. These proteins have not previously been described as having a role in 
leukaemia, but they have both been previously implicated in solid tumours (371, 389, 404-410). 
Instances when S100 proteins become dysregulated, S100 expression is typically upregulated, 
however, S100 protein expression can vary depending on the cancer type (371). S100-A11 
exhibits increased expression in non-small cell lung cancer, but is decreased in small-cell lung 
cancer (411). S100-A4 dysregulation has been previously heavily linked with cancer progression, 
in particular in breast, lung, prostate, colorectal, melanoma, renal and pancreatic. In each of 
these cases S100-A4 dysregulation correlates with poor prognosis and metastatic disease (412). 
Additionally, it is reported that S100-A4 both drives metastasis, and in the host stroma 
contributes to metastatic dissemination (413).  
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In many of these cases S100-A4 and S100-A11 have a described interaction with the 
receptor for advanced glycosylation end products (RAGE). It has previously been demonstrated 
that RAGE receptor activation is capable of downstream activation of RAS, ERK, PI3K-AKT, STAT3 
and NF-kB pathways, consequently activated cells then exhibit enhanced proliferation, 
migration and maintain an inflammatory environment (414). S100-A4 proteins have also been 
described as being able to interact with surface receptors Epidermal Growth Factor Receptor 
(EGFR), ErbB2 receptor and G-Protein Coupled Receptors (GPCRs), shown below in Figure 4.1 
(415, 416).   
 
Figure 4.1: Known receptors with specificity to selected secretome derived factors. Depicted secretomic 
proteins bind with specificity as ligands to known receptors and induce cell signalling. Except BMP-1 which 
is an astacin metalloprotease, instead of effecting receptor mediated signalling through traditional GF 
routes, BMP-1 cleaves pro-proteins into signalling proteins (such TGFβ), which then activate signalling 
cascades. 
CTGF the third selected secretome derived GF is a 38kDa mitogen known to be 
expressed and secreted in the BM (417). This GF promotes proliferation and differentiation of 
chondrocytes and mediates cell adhesion in many cell types including fibroblasts, endothelial 
and epithelial cells under physiological conditions (418).  In the pathological setting CTGF is 
thought to also be crucial in facilitating desmoplasia, adhesion, migration, potentiating 
angiogenesis and metastasis (419). The gene that encodes CTGF, CCN2 is considered both an 
oncogene and a tumour suppressor depending on the cancer in question, however, in the 
majority of cases its expression correlates with adverse outcome (418). Previous articles have 
noted that CCN2 expression is observed in tumour cells and cells of the microenvironment, 
which suggests that CTGF mediated tumour progression may not be driven by tumour cell 
secretion of CTGF (393). These aspects of CTGF make it an interesting candidate, coupled with it 
not previously being described in AML. The signalling capabilities of this GF have previously been 
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reported as being supportive of JNK and ERK signalling (420), this is thought to be mediated by 
interactions with the cell-surface receptors CTGFR and Insulin-like Growth Factor 1 Receptors 
(IGF1R) (421). 
HGF also known as scatter factor is a very well characterised GF. This mitogenic secreted 
factor has an extensively described interaction with the c-MET receptor and has been shown to 
be a potent mechanism in hepatic progenitor cell survival and migration (422, 423). In the 
pathological setting the HGF/c-MET axis has been also shown to be at the heart of certain drug 
resistant tumour phenotypes (224, 424). HGF has previously been shown to be a GF that 
facilitates aggressive invasive cancer phenotypes, helping to establish a permissive 
microenvironment, with experimental models demonstrating a dependence on the HGF/c-MET 
pathway in solid tumours (390, 425, 426). The role of HGF in AML has been investigated before, 
whereby it was described that some AML cell lines were able to produce HGF and activate c-
MET in an autocrine manner (392).  
CSF-1 is a very potent GF that is crucial in guiding haematopoietic cell fate (427). CSF-1 
is produced by monocytes/macrophages, endothelial cells, fibroblasts, and BMSCs (428). CSF-1 
only has one known receptor which is the CSF1R, and this receptor’s expression is limited to that 
of mononuclear myeloid cells (monoblasts, promonocyte, monocyte, macrophage) and 
osteoclasts (429). CSF-1 is the most pleiotropic macrophage GF, capable of stimulating survival, 
proliferation, motility and differentiation of mononuclear cells (428, 430). However, the ability 
of CSF-1 to support survival and proliferation depends on the cell’s differentiation status, in the 
case of early progenitor cells CSF-1 stimulation is described as not being sufficient for activation 
and synergy with co-receptors is necessary (431). However, following differentiation CSF-1 alone 
is sufficient (432). CSF-1 is important in the regulation of normal mononuclear myeloid cells, 
however, the precise role that this GF plays in AML is yet to be uncovered. CSF-1 has been 
discussed in the context of high risk AML, which are believed to be more resistant to therapy 
through the maintenance of an undifferentiated CD34+CD38- leukaemic initiator population. If 
CSF-1 is important in these populations it suggests that the cells would need co-activation of 
another receptor, the ligand of which could be present within the stromal secretome.  
BMP-1 is a unique protein in comparison to the other candidates, as it is an astacin 
metalloprotease and has not previously been described for any GF properties. However, this 
protein was first discovered due to the induction in bone formation that it was able to elicit 
(433). BMP-1 is capable of indirect activation of some TGFβ-like proteins which in turn bind to 
BMP receptors type 1 and type 2 activating BMP signalling cascades (395, 434, 435). BMP 
signalling can also be induced by a number of different BMPs that are members of the TGF- 
superfamily, signal transduction through the BMP pathway activates SMAD substrates (436). 
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BMP receptor activation can lead to the activation of numerous canonical and non-canonical 
pathways (TGF-, MAPK, PKC, PI3K/AKT, Wnt) (437), the specific destination to which the signal 
is transduced to is believed to be guided by the specific ligand that activates the BMP surface 
receptor (438, 439).  BMP signalling is critical in embryogenesis, and in maintaining adult tissue 
homeostasis (440). BMPs have been implicated in cell proliferation, differentiation, and 
apoptosis, however, they have yet to be investigated in AML.  
In this chapter, we sought to determine the effects of the individual identified 
secretome derived proteins and the bulk secretome on AML behaviour, and subsequently how 
these influence AML cell fate. In Chapter 3 we were able to identify proteins whose secretion or 
utilisation changed in response to AML cells. Following that work it was important to 
characterise the effects on AML survival and proliferation. 
In the literature the AML/BMSM relationship is mainly described in the context of 
treatment resistance, in particular resistance to chemotherapy (156, 441, 442). Taking this into 
consideration we also monitored AML sensitivity to targeted kinase inhibitors in the presence of 
the stromal secretome, as these proteins were likely to affect AML signalling.  
Finally, we examined how long primary AML cells could be maintained in culture with 
HS-5 CM alone, before examining these cells via CyTOF to study AML clonality and whether HS-
5 conditioning selected for specific AML clones.   
4.2 Optimisation of recombinant protein stimulation of primary AML cells 
The co-culture experiments undertaken in Chapter 3 enabled the selection of six 
proteins. These six proteins had previously been described as being secreted proteins and had 
the capacity to behave as a signalling molecule. These conclusions were based on text mining, 
therefore to establish if these proteins were relevant in AML we needed to functionally assess 
how these factors alter primary AML cells capacity for survival.  
To establish the relevance of each protein, we acquired pure (>99%), human, biologically 
active recombinant versions of the proteins, which were then used to maintain primary AML 
cells ex vivo; the cells came from a patient deemed high risk due to unfavourable cytogenetics 
(11Q23) (Patient #1). These cells were chosen as the sample contained a high blast count prior 
to enrichment for mononuclear cells using Ficoll (85%), following which blast percentage be 
close to if not 100%, this ensured that it was the AML population that was being measured. A 
high-risk patient was selected as it had previously been found by Pearce et al. that AML blasts 
from adverse-risk patients are faster and more successful at engrafting within the 
microenvironment (443), perhaps suggesting a greater dependency on crosstalk with the 
microenvironment.   
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The patient cells were plated in 18 conditions and grown in culture for 7 days, cell 
viability was assessed by Guava easyCyte flow cytometry on days 1, 2, 3, 5 and 7. Patient #1 cells 
began the experiment with a high viability of 96% (Day 0), which is unusual for primary cells 
following reanimation from LN2 storage. The cells were seeded in both serum containing (10%) 
and serum starved (0.5% FBS) conditions in the presence of 10ng/ml concentration of each 
recombinant protein (RP) (except the >5kDa MS-5 secretome which was added at 10µg/ml, as 
optimised in Chapter 3). This concentration was chosen as it was the recommended dose for 
each of the six RPs from their respective manufacturers, additionally GF supplementation of 
AML cultures with factors such as IL-3, FLT3 ligand and IL-6 are frequently used at 10ng/ml (444). 
   
 
Figure 4.2: Cell viability assay of high risk primary AML patient cells grown for seven days with growth 
factors in serum starved or serum stimulated setting. On Day 0 2x104 cells/well seeded with 10ng/ml of 
indicated GF, 10µg/ml >5kDa MS-5 Sec or 10ng/ml each of the GFs in the Mixed GF sample (+0.5%/ 10% 
FBS). Viability measured on Days 1, 3, 5 and 7, using the Guava Viacount assay on a Guava flow cytometer. 
Boxplots produced using ‘ggplots’ package on R workspace, technical replicates n=3 per condition; P value 
calculated by unpaired two-sided t-test comparing no GF controls to GF stimulated samples *p<0.05 




Comparing AML cell viability at Day 0 (measured on a Beckman Coulter vi-cell analyser) 
to Day 1 (measured on the Guava easyCyte flow cytometer) there was a significant drop in 
viability across all conditions regardless of treatment (Figure 4.2). This difference could be due 
to the accuracy of the analysers, with perhaps the Beckman Coulter overestimating cell viability 
at Day 0 (by including any cell like shape than has not taken up trypan blue). Alternatively, this 
could be demonstrating the selection of a particular AML clone, with all conditions displaying a 
decrease in cell viability after one day, which was followed by a recovery in FBS containing 
samples in subsequent time points. Analysis of cell viability at Day 1 revealed that the inclusion 
of 10% FBS did not have a significant effect on AML survival compared to starved conditions 
(Figure 4.2, blue box). There was also no significant difference in survival between cells 
stimulated with the secretome derived proteins compared to those with no GF treatments. 
However, AML cells in bulk factor conditions (>5kDa secretome and Mixed RP) were not as viable 
on the Day 1 time point (p=0.002 and p=0.045).   
At Day 2 differences in cell viability began to significantly change between serum 
containing and serum starved conditions, with the 10% FBS containing samples displaying higher 
viability (Figure 4.2). Additionally, at Day 2; CSF-1 (p=0.02), S100-A4 (p=0.015) and the Mixed GF 
samples (p=0.001) began to exhibit increased AML viability compared to untreated samples, 
particularly in the serum starved setting. At Day 3 the AML cells maintained in 10% FBS were 
clearly maintaining a higher viability than those in starved conditions. The GF effects were also 
becoming more pronounced in the starved conditions with CSF-1, S100-A4 and the Mixed GF 
samples containing AML cells with higher viability. Comparisons between serum starved and 
serum containing experiments at Day 3 showed that the removal of serum allowed for better 
visualisation of the individual GF effects, and in the serum starved conditions, all of the GFs 
increased viability compared to no GF supplementation.  
By Day 5 it was clear that including 10% FBS in samples had dramatic effects on AML cell 
survival, comparisons between the 10% and 0.5% FBS no GF treated samples (average across 
n=4, 88.4% [10%] and 59.3% [0.5%]) revealed there was a 29.1% difference in viability 
(p=0.0075). Analysis of GF treatments in 0.5% FBS samples showed that both CSF-1 (p=0.037) 
and Mixed GF (p=0.267) were very good at maintaining primary AML cells, with the viability 
significantly higher than no GF samples and almost reaching that conferred by 10% FBS. Finally, 
by Day 7 10% FBS containing samples were much healthier than serum starved samples. Serum 
starved, yet CSF-1 treated cells were almost as viable as AML cells grown with 10% FBS, which 
could suggest that CSF-1 has a role in anti-apoptotic signalling, as these cells did not exhibit 
markers of cell death like the other serum starved samples.  
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It is worth noting that in these experiments the MS-5 secretome was not particularly 
supportive, which is at odds with previous experiments as well as the literature. As the 
secretome was snap frozen following collection and concentration, it is possible crucial elements 
may have dropped below the supportive threshold. Finally, in some conditions there were 
outlier results, in these replicates big drops in viability were recorded (of note; Day 2 MS-5 
secretome and Day 3 S100-A11, CTGF, HGF). These instances demonstrate the fragility of these 
cells and the capacity for primary AML cells to quickly perish in culture.  
 
Figure 4.3: Cell growth assay of high risk primary AML patient cells grown for seven days with growth 
factors in serum starved or serum stimulated setting. On Day 0 2x104 cells/well seeded with 10ng/ml of 
indicated GF, 10µg/ml >5kDa MS-5 Sec or 10ng/ml each of the GFs in the Mixed GF sample (+0.5%/ 10% 
FBS). Viable cell numbers measured on Days 1, 3, 5 and 7, using the Guava Viacount assay on a Guava flow 
cytometer. Boxplots produced using ‘ggplots’ package on R workspace, technical replicates n=3 per 
condition; P value calculated by unpaired two-sided t-test comparing no GF controls to GF stimulated 
samples *p<0.05 **p<0.01 ***p<0.001.   
Cell proliferation during the same time course was assessed by measuring the growth 
of viable cells across the seven days. Assessment of cell growth during the same time course 
revealed strong differences to the viability assays. Initially all samples behaved similarly with a 
substantial drop in viable cell number, which could suggest that the conditions were not 
supportive for all AML cells (Figure 4.3). However, by Day 2 viable cell numbers begin to recover 
across all conditions, as cells started proliferating, except for the MS-5 secretome treated cells 
in a serum starved environment.  
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At time point Day 3 the results indicated a significant increase in proliferation of viable 
cells when Mixed GFs (p=0.0049) and S100-A4 (p=0.001) were introduced to cultures. This 
increase continued and by Day 5 it was clear that the GFs in the Mixed GF sample, and in 
particular S100-A4 based on the individual GF condition were conferring a strong proliferative 
signal (Figure 4.3, panel Day 5). CSF-1 cell numbers were also elevated, but this was likely due 
to a lack of cell death than an increase in proliferation based on the viability assays (Figure 4.2, 
Day 5 panel). Finally, on Day 7 the most supportive condition as hypothesised was the Mixed GF 
condition with 10% FBS. There was no significant difference in cell growth when assessing S100-
A11, BMP-1, CTGF, HGF and MS-5 secretome compared to no GF supplementation. CSF-1 
(p=0.035), S100-A4 (p=0.014) and the Mixed GF (p=0.001) samples in serum starved conditions 
were all able to maintain viable AML cell numbers, close to that seeded on Day 0. CSF-1 achieved 
this irrespective of serum starvation. S100-A4 in the presence of serum however, was capable 
of inducing significant cell proliferation (p=0.014), cell numbers at Day 1 dwindled as low as 
4.3x103 cells, but by Day 5 expansion reached 5.6x104 cells. The difference between Mixed GF 
and S100-A4 in serum containing conditions could have been due to a combination of the 
proliferative capacity conferred by S100-A4 with complementary serum activation, with the 
addition of the anti-apoptotic properties that CSF-1 possesses. Analysis of both Day 5 and Day 7 
cell numbers revealed that FBS supplementation combined with 10ng/ml of S100-A4 stimulated 
patient#1 cells to grow 2.49 fold more than S100-A4 stimulation in serum starved conditions 
(p=0.012). Consequently, serum supplementation was included in subsequent assays as it 
enhanced the proliferative effects of S100-A4. We could be confident it was S100-A4 that 
conferred the proliferative phenotype as the no GF control with serum elicited substantially less 
cell growth (p=0.014).       
4.3 Survival assays using purified recombinant forms of identified signalling 
molecules secreted by stromal cells 
Optimisation experiments demonstrated that these proteins effect cell viability, with 
CSF-1 and S100-A4 in particular able to support AML cell growth. This growth was significantly 
enhanced when the GFs were combined in the Mixed GF condition. Due to the heterogeneity of 
AML we thought it important to expand the cohort as it was probable that different AML 
patients would respond to different factors. 
To test this hypothesis four additional AML patient samples were acquired (clinical 
features described in Chapter 2.2) and seven day survival assays were conducted following the 
approach used in optimisation experiments. Patient samples comprised a mixed cohort of risk 
status, patients #1, #4 were high risk patients, patient #2 was intermediate risk and patients #3, 
#5 were favourable risk. This experiment did not contain the power to make conclusions on risk 
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group response to the potentially supportive factors, however, we believed by having a 
heterogeneous cohort we would increase the probability of identifying cells that would respond 
to all of the GFs. Common to all AML patient samples was FAB classification, M4 or M5, which 
means that morphologically these cells were considered monocytic leukaemias, expressing 
markers of differentiation. These markers of differentiation are regularly surface receptors, thus 
increasing the likelihood of these GFs being relevant to these cells survival in ex vivo conditions. 
Analysis of primary AML cell viability following seven days of ex vivo culture with 
different GFs in a serum containing setting revealed that all patient samples were more viable 
when treated with GFs. However, in line with the nature of AML biology, the extent of each GFs 
support was heterogeneous across the patients. The first observation that could be garnered 
from the results was that after seven days of GF treatment, AML viability was higher than after 
one day. Whereas samples with no GF treatment either displayed comparable or lower viability 
than AML cells at Day 1 (Figure 4.4).  
In the optimisation experiments it was speculated that the global decrease in cell 
number following the Day 1 time point was due to AML clones within the total population 
undergoing cell death, while the remaining clones persisted through utilisation of the available 
GFs, which lead to the subsequent proliferation of AML cells by Day 7. This pattern was 
reproduced in these assays too. At Day 1 each patient’s cell viability was comparable across 
conditions and by Day 7, every condition with supportive GFs had increased in viability compared 
to the equivalent at Day 1 or compared to the no control at Day 7 (Figure 4.4). There were only 
two exceptions, patient #1 with no GF treatment which managed to maintain a very high viability 
regardless of GF treatment, although this increase in viability was not significant (p=0.49). The 
other exception was observed in Mixed GF treatment of patient #3 cells. Although these cells 
had ~ 25% higher viability than the no GF condition by Day 7, they presented with a lower 




Figure 4.4: The effects of stromal derived growth factor panel on ex vivo survival of five primary AML 
patient samples. On Day 0, 2x104 cells/well seeded with 10ng/ml of indicated GF, 10ng/ml each of the 
GFs in the Mixed GF sample or MS-5 CM (+10% FBS). Viability measured on Days 1 and 7, using the Guava 
Viacount assay on a Guava flow cytometer. Patient samples n=5, technical replicates n=4 per condition; P 
value calculated by unpaired two-sided t-test comparing Day 7 no GF controls to GF stimulated samples 
*p<0.05 **p<0.01 ***p<0.001. Boxplots produced using ‘ggplots’ package on R workspace.  
Comparisons between the GFs individual ability to maintain patient viability revealed 
that CSF-1 always maintained the highest viability in all patients, while the S100 proteins were 
consistently the least supportive individual GFs in the panel. This was particularly evident in 
patient #3, where S100-A4 supplementation by Day 7 only maintained viability at 28.4% 
(p=0.09), whereas HGF (64.5%)(p=0.05), CSF-1 (66%)(p=0.011) and MS-5 CM (69.2%)(p=0.004) 
were able to sustain patient#3 primary AML cell viability at much higher levels. The other GF 
that maintained patient #3 cell viability was S100-A11 (69.3%) (p=0.005), as S100-A11 only has 
one known receptor, the RAGE receptor that it shares with S100-A4, it is notable that they 
elicited such opposing effects. One explanation for this could be the fact that S100-A4 has a 
number of other known receptors (EGFR, erbB2, GPCR) and its interactions with these receptors, 
or another receptor that either S100 protein has affinity to that is yet to be described, that yields 
the functional discrepancy between the GFs. Finally, in each of the patients the effect of Mixed 
GF treatment on cell viability was the average of each of the viability in the individual GF 
samples.    
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4.4 Proliferation assays using purified recombinant forms of identified 
signalling molecules secreted by stromal cells 
Cell survival is one metric for assessing the impact of these GFs on AML progression, but 
another aspect that characterises AML as a disease is the expansion and proliferation of these 
cells throughout a patient’s BM. The five patient samples used in the survival assays were also 
measured for cell growth in the presence of the panel of GFs. 
 
Figure 4.5: Cell growth assays reveal that factors induce increase cell growth across patients compared 
to no growth factor. On Day 0, 2x104 cells/well seeded with 10ng/ml of indicated GF, 10ng/ml each of the 
GFs in the Mixed GF sample or MS-5 CM (+10% FBS). Viable cell numbers measured on Days 0, 1 and 7, 
using the Guava viacount assay on a Guava flow cytometer (Day 1 and 7 counts normalised to respective 
Day 0 wells). Patient samples n=5, technical replicates n=4 per condition; P value calculated by unpaired 
two-sided t-test comparing Day 7 no GF controls to GF stimulated samples *p<0.05 **p<0.01 ***p<0.001. 
Boxplots produced using ‘ggplots’ package on R workspace. 
As discussed in the optimisation experiments seven days of incubation with the GFs led 
patient #1 cells to expand substantially, with S100-A4 in particular eliciting a spike in cell growth. 
This effect was only enhanced following the addition of the rest of the panel of GFs, as the Mixed 
GF treatment led to substantial growth in patient #1 cells (p=0.002) (Figure 4.5). Cell growth in 
patient #4 which based on risk group is the closest matched sample to patient #1 cells, was very 
different. These cells did not exhibit the same profound expansion in the presence of any of the 
GFs, however, there was increased growth in GF treated samples and the most confluent 
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samples were those grown with CSF-1, S100-A4 or samples that would have contained both in 
the CM.   
Patient #2 cells, showed some of the most profound and consistent cell growth in 
response to the panel of GFs (Figure 4.5, Panel Patient 2). Day 1 measurements of cell growth 
did not report the same drop in cell number that was observed in the optimisation experiments. 
Patient #2 derived cells instead proliferated by Day 1, although modestly from the 2x104 cells 
seeded on Day 0 and this proliferation continued through to Day 7. At the end of the experiment 
patient #2 were most responsive to HGF (p=0.001), as the variation between replicates was 
minimal, although every GF induced proliferation that was not observed in the no GF conditions. 
The S100 proteins were not the most potent GFs to induce growth in patient #2 cells, as CSF-1 
induced the most proliferation (p=0.05).  
Patient #3 derived cells did not proliferate in response to GF treatment, with the 
differences between the conditions representative of the GFs ability to maintain cell viability in 
the samples. All conditions by Day 7 had less viable cells remaining than what were seeded at 
the beginning of the assay, although patient #3 cells with no GF treatment were nearly all dead 
by Day 7. GF treatment of patient #5 cells lead to dramatic growth compared to the no GF 
controls across the time course (Figure 4.5, Panel Patient 5). Initially there was little difference 
between control and GF treated conditions at Day 1 assessment, with only small increases in cell 
number observed. However, by Day 7 no GF controls plummeted in viable cell numbers, whereas 
GF treated samples were all measured at higher densities than what was seeded, suggesting 
that this was proliferation and not just maintenance of the cells originally seeded. Discrimination 
between the GFs revealed that the S100 proteins induced the least proliferative phenotype in 
patient #5 cells. It is worth noting that S100 proteins were most influential in samples derived 
from high risk patients. Samples from other risk groups were not as responsive to the S100 
proteins, but these are just observations, conclusions cannot be drawn from such a low sample 
size. In patient #5 the factor that induced the most growth was CSF-1 (p=0.016) and the samples 






4.5 Gene expression analysis of secretome derived proteins within TCGA 
AML dataset   
Ex vivo functional experiments using the panel of stromal derived GFs showed that 
primary AML cells viability and growth were positively affected by these GFs, although the extent 
of which was heterogeneous across patients. These experiments were focussed on identifying 
proteins of the stromal secretome that positively affect AML progression, however, as 
experiments in Chapter 3 showed (Figure 3.25), there are instances where these proteins (S100-
A4) can be overexpressed and secreted by the AML cells too. To observe the expression of these 
factors across populations we examined gene expression data from AML and healthy 
populations. The data was sourced from the TCGA (The Cancer Genome Atlas), details of cohort 
in Table 4.1 (18). 




Human AML TCGA 183 
Various genetic aberrations, including 
t(8;21), inv(16), t(15;17), t(11q23), 
complex karyotype, WBM 
Table 4.1: Features of the dataset used to compare gene expression of growth factors in AML.  WBM = 
Whole Bone Marrow  
This cohort that contained 183 samples AML samples that were compared to the normal 
population and separated into groups based on whether they were above and below median 
expression of the genes that are translated into the potentially AML supportive proteins 
undergoing validation. Correlation of CSF-1 gene expression with patient survival showed that 
patients with higher expression of CSF-1 had a statistically significant (p=0.0175) worse 
prognosis than patients with lower expression of CSF-1 (Figure 4.6A). Following 2000 days (~5.5 
years) CSF-1 expression had no bearing on outcome, therefore patients with higher CSF-1 




Figure 4.6: Kaplan Meier curves displaying the difference in AML patient survival with higher or lower 
expression of growth factor genes. The gene expression of a 172 AML sample cohort were compared to 
the normal population and separated into groups based on whether they were above and below median 
expression of (A) CSF-1 (B) BMP-1 (C) HGF (D) S100-A4 (E) S100-A11 (F) CTGF, patient numbers were 
assessed at six time points across 2000 days.  
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BMP-1 gene expression was not as indicative of patient outcome as CSF-1. Analysis of 
BMP-1 expression and survival rates suggested that increased BMP-1 expression could lead to a 
more favourable outcome, as patients with lower than the median BMP-1 expression actually 
exhibit poorer survival (p = 0.0617) (Figure 4.6B).  
HGF gene expression data followed a similar pattern to that observed for BMP-1, 
although HGF expression leads to a statistically significant difference in survival (p=0.00717). In 
this analysis HGF expression positively correlated with greater survival (Figure 4.6C). This finding 
is paradoxical based on the known functional roles of HGF, including proliferation and invasion, 
traits that are commonly displayed by aggressive cancers.  
S100-A4 gene expression data followed a trend in keeping with experiments conducted 
in Chapter 3 that identified it as a candidate for investigation, as well as the strong induction of 
proliferation in patient #1. Higher S100-A4 gene expression correlated with poor survival when 
assessing 172 AML samples of mixed subtypes (Figure 4.6D), the difference in survival between 
higher and lower expression of S100-A4 was statistically significant (p=0.0118). 
The last two stromal proteins of interest S100-A11 (Figure 4.6E) and CTFG (Figure 4.6F) 
did not exhibit gene expression that correlated with survival, both S100-A11 and CTGF had non-
significant separations in survival when comparing high and low gene expression. When 
analysing these findings, it is important to consider how heterogeneous AML is and how the 
cohort that was assessed in the gene expression analysis consisted of very different AML. It is 
possible that if favourable risk AML patients were analysed separately to high risk AML patients, 
then correlations between expression of these genes and survival could have been very 
different. Unfortunately, these types of analysis are not possible to request of the TCGA 
repository. This analysis collectively reinforces the hypothesis that it is the stromal cells that are 
responsible for the panel of six identified proteins, with S100-A4 the only protein that this 
analysis correlates with AML gene expression. 
 
4.6 Kinase inhibition of common AML signalling nodes are altered following 
culture with stromal conditioned media 
Following the confirmation that the panel of stromal derived GFs were relevant to AML 
cell function and considering that these proteins were chosen based on potential capacity to 
behave as signalling proteins, we considered whether these proteins would alter AML response 
to targeted inhibition of the main AML effector signalling pathways. To investigate if stromal 
proteins effect AML sensitivity to kinase inhibition, a panel of kinase inhibitors were selected 
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that specifically targeted traditional AML mediators. Inhibition of mTOR, MAPK, JAK, PAK and 










Specific inhibitor of mTOR. 
Abnormalities of mTOR 
signaling are strongly 
associated with leukaemic 
cell proliferation, as a result 







Extremely specific inhibitor 
of MEK1 and MEK2, 
components of the MAPK 
pathway. MAPK is a 
downstream effector of the 







Highly selective inhibitor of 
JAK isoforms. Aberrant JAK-
STAT signalling has been 
associated with the 
proliferative leukaemic 
phenotype, at least partly 
due to over activation of 
the cytokine receptors that 









A potent inhibitor of PAK1 
previously been described 
as one of the most active 
kinases in AML, and the 
functions it mediates are 
commonly associated with 
microenvironment 
interactions (adhesion, 
migration, survival). (206, 
271) 










    
Currently the only FDA 
approved kinase inhibitor 
for treatment of FLT3 
mutant AML patients. (70) 
Table 4.2: Panel of targeted kinase inhibitors used in kinase inhibition studies. 
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MAPK inhibition with Trametinib 
Trametinib was selected as an agent as it is highly specific in targeting MEK1 and MEK2. 
We wished to target the MAPK pathway in these AML cells as it is one of the most frequently 
documented as being a downstream effector of aberrant upstream signalling (198). Targeting 
MEK1 and MEK2 with selective inhibitor Trametinib led to a substantial drop in AML cell viability 
when introduced to cells growing in IMDM (+10%FBS) media only (no HS-5 CM), with some 
patient samples almost completely succumbing to MEK inhibition. However, when the same 
AML patient cells were treated with Trametinib, but in the presence of HS-5 CM, they were not 
as compromised as cells in non-CM. In HS-5 CM some patient cells (2/11) exhibited no drop in 
viability when treated with the inhibitor (Figure 4.7A).  
Figure 4.7: Primary AML targeted MEK inhibition with/without HS5 conditioned media. Guava easycyte 
flow cytometry implemented to measure cell viability and proliferation of 12 primary AML samples. 
Measured fold change in (A) viability and (B) proliferation following 72 hours treatment with 1μM 
Trametinib compared to vehicle controls (+/-) HS-5 CM (+10% FBS). Patients n=11 for viability and n=12 
for proliferation, each data point represents the average of four technical replicates, significance 
determined by paired T-Test matching patient samples *p<0.05, ***p<0.001.  
Analysis of AML cell proliferation following Trametinib treatments revealed cells were 
profoundly affected by MEK inhibition, with proliferation on average reducing by half across 
patients when Trametinib was introduced without HS-5 CM (Figure 4.7B). The introduction of 
Trametinib in the presence of HS-5 CM, however, did not lead to the same reduction in 
proliferation, as proliferation was only reduced by 25% following Trametinib treatment 
compared to the untreated controls following 72 hours of culture. It is notable that the response 
to MEK inhibition was variable across the patients, in some cases MEK inhibition did not affect 
AML proliferation in the absence of HS-5 CM, while in the presence of HS-5 CM there were some 
patient’s samples where proliferation reduced by 75%.  
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Inhibition of mTOR with Torin-1 compound  
Canonically described being the downstream component of the PI3K/AKT/mTOR 
pathway, mTOR forms part of a signalling axis frequently mutated in cancer. Although the 
pathway does not accumulate the level of genetic aberrations in AML that are witnessed in other 
cancers, it is directly downstream of frequently mutated receptors such as FLT3 and c-KIT. The 
pathway mediates proliferation, differentiation and survival in haematopoietic cells, the 
activation of which is controlled by the extracellular binding of ligands to the insulin receptor 
(IR), FLT3R, c-KITR, EGFR, insulin-like growth factor receptor (IGF-1R) and CSF1R (446, 450-452). 
Importantly a number of these receptors recognise the identified secretome candidate proteins. 
Previous studies have investigated intrinsic routes of pathway activation and dysregulation, 
namely through mutation as well as potential autocrine activation of the pathway through IGF-
1 secretion (453). The role of the microenvironment pathologically modulating this axis in the 
AML setting has not yet been investigated, however.  
To establish if the microenvironment is able to modulate AML cell signalling through the 
identified GFs, and possibly factors that we have failed to identify, the primary AML patient cells 
used to investigate MEK inhibition were maintained ex vivo, in both conditioned and non-
conditioned media. Simultaneously cells were treated with the mTOR inhibitor Torin-1, which is 
a potent, highly selective ATP-competitive inhibitor of both mTORC1 and mTORC2 (454). This 
approach should have revealed if the HS-5 stromal secretome effects AML signalling networks 
to the extent of fundamentally modulating cell sensitivity to the inhibition of mTOR or the 
downstream effects of PI3K and AKT activity (assuming that there is significant canonical activity 
of the pathway).  
72 hours of 1µM Torin-1 treatment [concentration as used in Pan et al. (455)] on primary 
AML cells maintained in the absence of HS-5 CM decreased AML viability compared to that of 
the matched DMSO control cells. This was not surprising, due to the reported role of the mTOR 
pathway in haematopoietic precursor cells (445, 456, 457), the average viability in these cells 
dropped to 0.72 of that recorded for the DMSO control cells, both cultured in the absence of 
HS-5 CM (Figure 4.8A). Torin-1 treatment of primary AML cells cultured in the presence of HS-5 
CM revealed that primary AML cells were more sensitive to mTOR inhibition in these conditions 






Figure 4.8: Primary AML targeted mTOR inhibition with/without HS5 conditioned media. Guava 
easycyte flow cytometry implemented to measure cell viability and proliferation of 11 primary AML 
samples. Measured fold change in (A) viability and (B) proliferation following 72 hours treatment with 
1μM Torin-1 compared to DMSO vehicle controls (+/-) HS-5 CM (+10%FBS). Patients n=11, each data point 
represents the average of four technical replicates, significance determined by paired T-Test matching 
patient samples *p<0.05, **p<0.01, ***p<0.001.  
In the same patients, assessment of cell proliferation following Torin-1 treatment in the 
absence of HS-5 CM observed patient cells respond in a heterogeneous manner (Figure 4.8B). 
Approximately four of the eleven patient samples exhibited no change in proliferation compared 
to the matched DMSO control cells, while others decreased by half compared to the untreated 
controls. On average mTOR inhibition with Torin-1 in the absence of HS-5 CM reduced 
proliferation to 0.66 of that recorded in the same AML patient cells that were not treated with 
Torin-1. When proliferation was measured in the same patient cells treated with Torin-1, but 
this time in the presence HS-5 CM, proliferation very potently and consistently decreased. 
Combining Torin-1 treatment with HS-5 CM led proliferation to drop to 0.39 of that recorded in 
the same AML patient cells which were not treated with Torin-1.  
Collectively these results suggest that either mTOR or pathways associated with mTOR 
are being activated by components of the HS-5 CM. Thus, increasing the AML cells sensitivity to 
Torin-1 treatment, as these cells now had increased activation of substrates whose activity is 
regulated by mTOR. Additionally, Torin-1 had profound effects on functions such as proliferation 
– a function that mTOR regulates. This kinase is documented as being a nutrient and GF sensing 
kinase, which would rationalise the mTOR response to changes in media composition.   
Multi-kinase inhibition with Midostaurin 
In Chapter 1 the significance of the FLT3 tyrosine kinase was discussed, in particular the 
FLT3 gene which is the most frequently mutated gene in AML and as a result has been the focus 
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of targeted kinase inhibitor therapies in AML. To this end, Midostaurin is currently the only FDA 
approved kinase inhibitor for the treatment of AML. Although Midostaurin is licensed as a FLT3 
inhibitor, it is a very promiscuous compound as demonstrated in Table 4.2. For clinical relevance 
this compound was included in the panel of inhibitors.  
 
Figure 4.9: Primary AML pan kinase inhibition with/without HS5 conditioned media. Guava easycyte 
flow cytometry implemented to measure cell viability and proliferation of 8 primary AML samples. 
Measured fold change in (A) viability and (B) proliferation following 72 hours treatment with 1μM 
Midostaurin compared to DMSO vehicle controls (+/-) HS-5 CM (+10%FBS). Patients n=8, each data point 
represents the average of four technical replicates, significance determined by paired T-Test matching 
patient samples *p<0.05, **p<0.01, ***p<0.001.  
72 hours of 1µM Midostaurin treatment on primary AML cells maintained in an absence 
of HS-5 CM led to a decrease in AML viability to 0.86 on average, compared to matched DMSO 
control cells (Figure 4.9A). In the presence of HS-5 CM, treatment with Midostaurin reduced 
AML viability to 0.76 compared to matched DMSO controls whilst in the presence of HS-5 CM. 
Coupled with the spread of data these differences were not statistically significant. Analysis of 
specific data points revealed that Midostaurin effected some patient cells profoundly with 
viability in these patient cells reducing to levels 0.5 of that recorded in the untreated patient 
samples. These changes however, were not dependent on HS-5 secreted proteins.  
 Assessment of cell proliferation revealed that Midostaurin was potent at lowering the 
abundance of primary AML cells in both the presence (0.58) and absence (0.69) of HS-5 CM after 
72 hours of incubation (Figure 4.9B). As observed when assessing viability, the variance in the 
results were non-statistically significant changes between conditions. It is notable that some of 
the primary AML samples were unperturbed by the presence of Midostaurin with relative 
proliferation levels registering on par with the untreated viability.  
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 These experiments showed that Midostaurin can effect AML proliferation, which is 
reasonable considering that FLT3 is upstream of numerous proliferative pathways (458-460). It 
was also observed that in some cases the stromal proteins contributed by HS-5 cells were unable 
to modulate the primary AML response to Midostaurin. This finding suggested that for some 
patients the HS-5 proteins were not strong mediators of pathways that are targeted by 
Midostaurin or that the response to inhibition with Midostaurin is dominant over such agonists. 
The heterogeneity within the subset demonstrates the unpredictability of non-specific kinase 
inhibitors. As one may expect a compound that inhibits many kinases to consistently reduce 
AML viability due to its indiscriminative approach. However, in the viability assays there were 
primary samples that exhibited no change in viability compared to their untreated controls 
(Figure 4.9A).  
JAK1-3 inhibition with Tofacitinib 
The JAK-STAT pathway is a critical signalling cascade in the transduction of extracellular 
signals to the nucleus. It has been documented that many GFs and cytokines regulate cellular 
functions such as haematopoiesis, growth and immunity through this pathway (208, 461, 462). 
Pathologically increased activity of STAT3 has been reported in 20-50% of AML patients, as well 
as there being reported instances of STAT5 and STAT1 activation which are mediated by JAK 
activity (209-211, 463). These observations made the JAK-STAT pathway a likely mediator of the 
AML response to the presence of stromal proteins. Tofacitinib as detailed in Table 4.2 is a very 
selective compound for just the JAK isoforms 1-3, and therefore was a suitable agent for 
inhibiting this pathway. 
Treating primary AML cells with Tofacitinib for 72 hours in non-HS-5 CM on average 
barely reduced AML viability (0.89) compared to that of match DMSO control cells (Figure 
4.10A). In the presence of HS-5 CM, JAK inhibition with Tofacitinib led to no discernible change 
in AML viability (0.89) compared to the matched DMSO treated  primary AML in similar 
conditions. This suggested that either the concentration of Tofacitinib was too low or the activity 
of this pathway in these patient samples was not high. 
Assessment of cell proliferation following treatment revealed that Tofacitinib was 
capable of lowering the abundance of primary AML cells in the presence of HS-5 CM (0.69), 
however, in the absence of HS-5 CM, Tofacitinib barely effected proliferation (0.96) (Figure 
4.10B). This difference was statistically significant, but as observed in inhibition experiments 
with other agents, there was heterogeneity within the response. Paradoxically a number of the 
primary AML samples exhibited higher rates of proliferation following treatment compared to 
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matched DMSO controls when HS-5 CM was absent. Experiments and cell response were more 
consistent when performed in HS-5 CM. 
Figure 4.10: Primary AML targeted JAK inhibition with/without HS5 conditioned media. Guava easycyte 
flow cytometry implemented to measure cell viability and proliferation of 8 primary AML samples. 
Measured fold change in (A) viability and (B) proliferation following 72 hours treatment with 1μM 
Tofacitinib compared to DMSO vehicle controls (+/-) HS-5 CM (+10%FBS). Patients n=8, each data point 
represents the average of four technical replicates, significance determined by paired T-Test matching 
patient samples *p<0.05, **p<0.01, ***p<0.001.  
The observed proliferation drop that occurred in the presence of stromal proteins 
suggested that within the stromal complement there were proteins that activated JAK and 
therefore, the cells predominantly started utilising the JAK-STAT pathway for proliferative signal 
relay, hence the drop in proliferation following administration of Tofacitinib. This was not 
observed in the viability experiments and could have been due to a number of other GFs 
(perhaps mitogenic) within the stromal secretome that activated other survival pathways, 
leading to a net effect of unaffected viability following JAK inhibition. 
PAK inhibition with PF-3758309 
 The final inhibitor incorporated into the inhibition studies was PF-3758309 which is a 
potent inhibitor with specificity towards PAKs, in particular group 2 PAKs as detailed in Table 
4.2. PAK was selected as a target due to its previously reported status as one of the most active 
kinases in AML (271). The PAKs are also known effector proteins of the Rho GTPases (464), this 
makes them potential mediators of key AML cell functions that can be influenced by the 
microenvironment, such as migration and survival.     
Incubating primary AML cells with PF-3758309 for 72 hours in the absence of HS-5 CM 
decreased AML viability substantially (0.28) compared to that of the matched DMSO control 
cells (Figure 4.11A). This compound was highly potent in primary AML cells, with three patient 
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samples exhibiting less than 25% viability compared to the matched untreated cells after a 
relatively small interval. The same AML patient cells treated in the presence of HS-5 CM did 
experience improvements in cell viability, however, this improvement was marginal (0.4). As all 
of the patients demonstrated modest increases in viability, these differences were in fact 
statistically significant.  
 
Figure 4.11: Primary AML targeted PAK inhibition with/without HS5 conditioned media. Guava easycyte 
flow cytometry implemented to measure cell viability and proliferation of 4 primary AML samples. 
Measured fold change in (A) viability and (B) proliferation following 72 hours treatment with 1μM PF-
3758309 compared to DMSO vehicle controls (+/-) HS-5 CM (+10%FBS). Patients n= 4, each data point 
represents the average of four technical replicates, significance determined by paired T-Test matching 
patient samples *p<0.05, **p<0.01, ***p<0.001.  
 The effects of PF-3758309 treatment on AML cell proliferation were consistent between 
HS-5 CM absent and HS-5 present conditions, suggesting that PAK inhibition significantly 
compromised AML cell proliferation. Regardless of the HS-5 CM, AML proliferation relative to 
matched untreated cells was profoundly compromised (Figure 4.11B). The observed effects of 
PAK inhibition could be explained by a few options, firstly the PAKs as previously described could 
be so pivotal to AML function that inhibition was not tolerable. Secondly, it could have been that 
the concentrations used were excessive or that PF-3758309 is in fact more promiscuous than 
first thought.  
 Considering the response of AML patient samples to kinase inhibitors collectively, there 
was a trend for the HS-5 secreted stromal proteins present in the CM to effect AML cell signalling 
and importantly cellular fate. This is a consequence of HS-5 CM induced cell signalling as 75% 
patients were more sensitive to mTOR inhibition following in the presence of HS-5 CM, 
simultaneously the same patient cohort were less sensitive (89% of the patients) to MEK 
inhibition in the presence of HS-5 CM (Table 4.3A).  Patient samples #0, #10, #14 and #15 
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received Torin-1, Trametinib and PF-3758309 treatment and although these represent a small 
cohort, MEK and PAK inhibition were more effective at reducing cell viability in non-conditioned 
media. Whereas Torin-1 inhibition was more effective at lowering patient cell viability in the 
presence of HS-5 CM. Tofacitinib and Midostaurin were more heterogeneous in response and 
did not share a relationship with any of the responses to the other inhibitors.  
 
Table 4.3: Overview of primary AML response to kinase inhibitors across patients. Tables reflect the 
relative changes in (A) viability and (B) proliferation observed in primary AML cells treated with kinase 
inhibitors compared to untreated cells +/- HS-5 stromal factors. Each relative value is averaged across 4 
replicates and FDRs represent the p-values generated using paired T-Tests. If a patient sample in CM 
demonstrated a >0.05< relative change in viability/proliferation after inhibition compared to the same 
cells in non-conditioned media, then effect is marked with ↑ or ↓.  
 The effects of targeted kinase inhibition on proliferation whilst under the influence of 
stromal factors generated trends similar to that observed in changes to viability (Table 4.3B). As 
with viability Torin-1 treatment had more profound effects on proliferation in the presence of 
HS-5 stromal factors than in non-conditioned media. Trametinib induced a more heterogeneous 
proliferative response, with 7/12 patients experiencing positively altered proliferation in the 
presence of stromal proteins compared to without.  Midostaurin and Tofacitinib were both more 
effective at inhibiting proliferation in the presence of stromal proteins than without, although 
Tofacitinib was the only condition to do so with statistical significance (p=0.037). PAK inhibition 












4.7 Investigating the influence of stromal derived factors on phenotypic 
 heterogeneity and selection in AML 
 Having established that individual proteins present within both the HS-5 and MS-5 
stromal secretomes had the capacity to alter AML cell fate and that targeted kinase inhibition 
was altered in the presence of the full stromal secretome produced by HS-5 cells. I then sought 
to establish if the microenvironment derived proteins were selecting for specific AML clones or 
if AML clones were adapting to their microenvironment. It was hypothesised that sub-
populations within a particular sample may be more responsive to the microenvironment; 
samples that can be maintained in culture contained populations that were responsive to 
elements that comprise the stromal secretome or they adapted to these elements. These 
responsive cells would likely activate particular signalling nodes, hence the changes in response 
to compounds such as Torin-1 in the presence of stromal factors. Therefore, CyTOF analysis was 
undertaken to see if responsive AML populations that displayed extended life in culture could 
be characterised.  
4.7.1 AML cells survive 36 days in culture due to HS-5 conditioned media  
Optimisation experiments testing CM from MS-5 and HS-5 cells determined that HS-5 
secretome was ultimately superior to MS-5 CM in sustaining primary AML cells from patient 0. 
During these experiments it was observed that cell counts could initially drop before stabilising 
and eventually increase. It was speculated that the HS-5 stromal secretome was inducing the 
selection and expansion of specific AML populations.  
Figure.4.12: HS-5 conditioned media is the most successful at maintaining Patient #0 cell viability across 
seven days. On Day 0, 1x105 cells/well with 2ml indicated CM (+10% FBS) in a 6-well plate. Viability was 
measured across seven days, using the Guava viacount assay on a Guava flow cytometer. Patient #0 cells 
run in n=6 technical replicates per condition. Red circle indicates the initial drop in viability at Day 1.  
To test this an extension of previous experiments was devised with patient #0 cells, 
instead of ceasing experiments at Day 7 we sought to see how long we could maintain these 
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cells, as well as establish if independent AML cells could be rescued following incubation with 
HS-5 CM. Across seven days, primary AML cell viability was significantly affected by the medium 
in which they were grown (Figure 4.12). Monitoring the effect of HS-5 CM, AML viability was 
maintained close to 90% across the seven days. Utilisation of CM produced through HS-5/AML 
(P31/FUJ) co-culture offered no benefit compared to what is achieved by HS-5 CM alone. 
Unexpectedly, MS-5 clones were poor at sustaining primary AML cells in culture. It was reasoned 
that this was likely due to MS-5 clone #1 being past supportive passage age, hence the 
introduction of clone #2. Clone #2 was probably not ideal for producing AML supportive media 
as guidelines for this new cell line recommended -mem media supplemented with serum, 
essential amino acids, L-glutamine and sodium pyruvate. It is likely that this medium was not 
suitable for AML growth and it would have probably been more supportive if IMDM medium 
was utilised for conditioning. 
 
Figure 4.13: Relative primary AML cell proliferation. On Day 0, 1x105 cells/well with 2ml indicated CM 
(+10% FBS) in a 6-well plate. Viable cell numbers were measured across seven days, using the Guava 
viacount assay on a Guava flow cytometer and the count at each time point was normalised to the 
matched well recording on Day 1 to correct for any seeding differences. Patient #0 cells run in n=6 
technical replicates per condition. Red circle indicates the initial drop in viability at Day 1.  
Assessment of cell growth over seven days (with seeding correction) revealed that compared to 
the growth after Day 1, HS-5 only media was sufficient to generate a ten-fold increase in cell 
number (Figure 4.13), this is substantially higher than that recorded for the IMDM only control 
in which maximum cell number was recorded at Day 5 around four-fold higher than Day 1. The 
HS-5/AML co-culture medium was slightly more supportive than the IMDM only conditions, 
however, the presence of P31/FUJ cells in the media depleted the media of supportive 
components conferred by HS-5 cells (as seen in Chapter 3). The primary AML cells from patient 
#0 were still growing and dividing in the HS-5 media by the Day 7 timepoint,  other conditions 
reached a growth plateau at Day 5. 
 
 138 
The patient #0 cells grown in HS-5 media were collected, reseeded and maintained in 
culture. During this period each time cells were replated and media replenished cell viability was 
measured (Figure 4.14A). Over the course of the culture the AML cells maintained a very high 
viablilty from Day 5 onwards. There was a drop in viability between days 20 and 30, this was due 
to a low cell density replating which took the cells a while to recover from. However, after 30 























      
Figure 4.14: Patient #0 cells during 36 day time-course in culture. Viable Patient #0 cells from figure 4.13 
grown in HS-5 CM pooled and reseeded in 2ml fresh HS-5 CM (+10% FBS) in 6 well plates. From Day 7 to 
Day 36 cell (A) viablilty and (B) viable cell counts measured using Luna 2 cell counter, measurements 
averaged across 3 counts.    
 In parralel to AML viability assessment of the viable AML cell count indicates that over 
the time-course as long as the supportive media was maintained and that cells were not 














































4.14B). It is not documented in the literature that primary AML cells can survive this long ex vivo 
without stromal co-culture. Therefore, this population of ‘Day 36’ ex vivo primary cells that were 
acquired from patient #0 (clinical features in Chapter 2) were selected for characterisation. 
4.7.2 Mass cytometry (CyTOF) principles 
Mass cytometry or (Cytometry – Time Of Flight) is a technique that couples the 
inductively coupled plasma MS (ICP-MS) with time of flight MS to measure metal-conjugated 
antibodies, whose binding enables the distinction of single cell expression of target proteins 
(Figure 4.15). Currently this technique serves as the best means by which to undertake single 
cell proteomics.  
 
Figure 4.15 CyTOF principle. 
The principles of CyTOF are based around the conjugation of heavy metal isotopes to 
antibodies raised to specific target proteins. Following blocking and binding of the antibodies to 
the target cell population, cells are fixed and inducted into the instrument. Upon induction into 
the machine cells are separated to single cell droplets and nebulised. This removes most of the 
biological matter and water leaving a predominantly heavy metal aerosol to be carried to the 
inductively coupled plasma (ICP) torch. The aerosol droplets are then vaporised, atomised and 
ionised at the ICP source for MS analysis. Ionisation occurs as a result of collisions with free 
electrons that are released by the collision induced ionisation of argon gas within the plasma 
torch. The ion beam that leaves the plasma torch enters the ion optical chamber before high 
mass ions are guided by the quadrupole to the TOF chamber. This stage is important as 
quadrupole selection removes any endogenous cellular or low molecular weight argon ions. 
Heavy mass ions are then pushed into the TOF chamber where electrostatic force orthogonally 
accelerates the ions to the detector and ions are separated by m/z. The mass cytometric data is 
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then integrated to give single cell read outs of heavy metal abundance. This heavy metal 
corresponds to protein expression, combining and grouping cells by these signatures allows 
clonality to be elucidated.  
4.7.3 Understanding the AML response to stromal conditioned media using AML 
phenotype antibody panel 
Lapidot et al. were the first to describe that only AML cells, which display a CD34 + CD38− 
phenotype, are capable of engraftment and generating leukaemia (138). Since this paper, it was 
generally accepted that selecting for a CD34+CD38− population enriches for the leukaemia 
initiating LSCs (138). This is not a hard and fast rule though, as this phenotype can actually 
encompass a heterogeneous cell population consisting of both normal and leukemic cells. 
Identifying leukaemic initiating cells is harder still as there have been a number of publications 
since that contradict the doctrine of a CD34+CD38− exclusive phenotype in AML. These 
publications stated that it is possible for CD38+ CD34- AML cells to engraft and induce leukaemia 
in immuno-deficient mice (143, 465-467). Despite this evidence, CD34+CD38− are still widely 
considered necessary for LSC identification (11, 138). Considering the lack of consensus in 
identifying AML sub-populations and importantly those clones that can initiate leukaemia - 
which historically are believed to be most treatment resistant and interactive with the BMM - it 
was difficult to select just a few markers to measure the effects of stromal factors on AML 
clonality. Therefore, to monitor how particular AML populations within a patient sample 
responded to the complement of HS-5 stromal secretome, an already characterised panel of 
antibodies optimised for AML phenotyping was utilised to monitor any changes in the 
phenotype of patient #0 cells over 36 days in culture. The antibody panel is comprised of 17 












Target Clinical significance Function Refs 
CD7 Immature AML cells, poor 
response to standard 
therapy 
T cell antigen (468) 
CD34 High expression correlative 
with poor outcome 
Cell adhesion factor indicative of a 
haematopoietic precursor cells 
(469, 
470) 
HLA-DR Expressed in most AML, 
generally absent in APL 




CD38 Heterogeneous expression, 
but most patients have 
CD38+ blasts – believed to 
be absent in LSCs 
Type II transmembrane glycoprotein  (138, 
473) 
CD33 Detected on 85-90% AML 
patient blasts 
Myeloid cell marker indicative of 
monocytic differentiation 
(474) 
CD184 High relapse rates and poor 
outcome 
CXCR4 the receptor of SDF-1/CXCL12 (475) 
CD123 Observed as being present 
in AML blasts and LSCs 
IL-3 receptor (476) 
CD64 Strong expression 
distinguishes monocytic 
disease, especially if co-
expressed with CD15 
Fc gamma receptor – indicative of 
monocytic differentiation 
(477) 
CD14 CD14 positivity associated 
with lower complete 
remission rates 
Myeloid Cell-Specific Leucine-Rich 
Glycoprotein, indicative of monocytic 
differentiation 
(478) 
CD45 Located on all 
haematopoietic cells 
except erythrocytes and 
platelets 
Marker for a protein tyrosine 
phosphatase (PTP). CD45 is also called 
the common leukocyte antigen 
(479) 
CD44 Marker of LSC Directs HSCs to the bone marrow. 
Expression crucial to leukaemogenesis 
(193, 
475) 
CD11b Indicator of adverse 
disease 
NK cell marker (480) 
CD3 T cell marker  Part of the T-cell receptor complex and 
defining feature of T cell lineage 
(481) 
CD19 B cell marker, although 
aberrant expression has 
been described in AML  
Antigen receptor of B-lymphocytes (482) 
CD117 Stem cell marker Immature precursor, c-KIT (483) 
CD16 Potential therapeutic 
target  
Fcγ receptor III is a marker of NK cells, 
neutrophils, leukocytes, monocytes and 
macrophages 
(484) 
CD15 Expressed on AML blasts 
and correlates with a 
favourable prognosis 
Myeloid cells, adhesion molecule 
normally expressed on neutrophils that 
mediates phagocytosis and chemiotaxis 
(485) 
Table 4.4: Panel of CyTOF antibodies used to characterise potential AML clones within patient samples. 
To monitor the changes that may have occurred within patient #0 cells across the 36 
days, three conditions/time points were selected; patient #0 cells at Day 0, Day 1 following 24 
hours of maintenance in HS-5 CM and Day 36 – all the cells maintained from Figure 4.14. All of 
these samples were processed at the same time; this was possible as there was access to 
multiple vials of patient #0’s cells (stored in liquid nitrogen). Therefore, at Day 35 one vial was 
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thawed and maintained in HS-5 media for 24 hours, the following day the ‘Day 0’ sample was 
prepared by thawing another vial. Once all samples were ready on day 36, cells were fixed and 
stained with the heavy-metal conjugated antibodies and analysed by CyTOF. 
 To analyse the effect of HS-5 CM on the primary AML cells from patient #0, single cell 
expression of each of the markers were interpreted by performing viSNE analysis. viSNE allows 
visualization of multi-dimensional single-cell data by finding a two dimensional representation 
of single-cell data that best preserves local and global geometry of the population (486). viSNE 
maps are similar to a biaxial plot, but the positions of cells reflect their proximity in a multi-
dimensional space rather than two-dimensional space. Colour, the third dimension, is integrated 
into the plot to represent the single-cell expression of a particular feature (i.e. CD34). 
 Analysis of the generated viSNE plots revealed that 36 days of HS-5 influence caused the 
cells which comprised the patient #0 AML population to spatially change (Figure 4.16, red 
arrows). The gating employed in pre-processing meant that only live cells were measured in the 
viSNE analysis. Analysis of the spread of data at each of the time-points revealed that Day 0 cells 
did not cluster as tightly suggesting the starting population of cells were quite heterogeneous. 
Following 24 hours of HS-5 conditioning, the geometry of the data indicated that there was a 







Figure 4.16: ViSNE analysis of markers CD7, CD19, CD16 and CD15 during 36 days in culture. Application 
of viSNE to patient #0 samples at Day 0, 1 and 36, cells stained with 17 markers and measured with mass 
cytometry. Cells separated into spatially distinct subsets based on the combination of markers that they 
express. Each point in the biaxial plots represents an individual cell, colour represents expression of 
indicated marker on a particular cell (see colour scale for expression levels). The axes are in arbitrary units. 
 This first set of markers were grouped based on a shared absence of expression at Day 
0, followed by the gradual emergence of expression of sub populations that highly expressed 
these markers by Day 36 (Figure 4.16). The strongest marker of this set, CD16 (Fcγ receptor) was 
expressed in a particular population of cells that arose following 24 hours of HS-5 conditioning 
(green circle), and as detailed in Table 4.4, CD16 is considered a potential therapeutic target. By 
Day 36 this population expanded considerably, and within this population of cells, there were 
varying degrees of CD7, CD19 and CD15 co-expression (red circles). These markers are all 
considered lymphoid markers, suggesting the emergence of biphenotypic subpopulations or 
lymphoid cells. These markers could aid in microenvironment interactions, CD15 is an adhesion 
molecule that helps to facilitate cell interactions and niche localisation.  
 The second set of markers were grouped together as cells that began at Day 0 with 
modest expression and were consistently expressed after 24 hours of HS-5 conditioning. 
However, following 36 days in culture under the influence of HS-5 secreted proteins, there was 
the emergence of high CD14, CD45, CD44 and CD11b expression (Figure 4.17). All of these 
markers have previously been described as indicators of adverse risk and poor outcome (Table 
4.4) – patient #0 had been classified adverse risk based on cytogenetics. CD11b is regarded as a 
surrogate for poor performing leukaemias, commonly found in patients that are non-responsive 
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to standard treatments. During the time course, cells harbouring this marker expanded, to the 
extent where nearly all cells exhibited expression. Additionally, there was marked increase in 
monocytic markers (CD14 and CD45), these are usually more differentiated expressing proteins 
that aid in microenvironment interactions. Finally, CD45 which has low expression in 
haematopoietic cells, except in erythrocytes and platelets, was consistently expressed 
throughout the duration of the experiment.   
 
Figure 4.17: ViSNE analysis of markers CD14, CD45, CD144 and CD11b during 36 days in culture. 
Application of viSNE to patient #0 samples at Day 0, 1 and 36, cells stained with 17 markers and measured 
with mass cytometry. Cells separated into spatially distinct subsets based on the combination of markers 
that they express. Each point in the biaxial plots represents an individual cell, colour represents expression 
of indicated marker on a particular cell (see colour scale for expression levels). The axes are in arbitrary 
units. 
 The third selected group of markers comprise known AML cell surface receptors. CD184 
(CXCR4) expression was minimal at Day 0, however, 24 hours after HS-5 conditioning a small 
population of cells emerged that had very strong CD184 expression (Figure 4.18, red circle). This 
population of cells was not sustained, as CyTOF measurements at Day 36 shows that most cells 
are CD186-, with only a small subset exhibiting modest expression. CD123 (IL-3 receptor) was 
moderately expressed at Day 0 (Figure 4.18), following CD184, cells that harboured CD123 
expression increased in the presence of HS-5 CM, although expression was not as focussed and 
more global. Nevertheless, by Day 36 there were no cells remaining that were CD123+. CD64 (Fc 
gamma R1 receptor), unlike the previous two receptors was not strongly expressed at either Day 
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0 or Day 1 time points. However, by Day 36 a small population of cells that strongly expressed 
the receptor emerged (Figure 4.18, blue circle). This particular cluster of cells also co-expressed 
the marker CD15 (Figure 4.16, red circle) and the combined expression is an indicator of 
monocytic AML cells. 
  
Figure 4.18: ViSNE analysis of markers CD184, CD123 and CD64 during 36 days in culture. Application of 
viSNE to patient #0 samples at Day 0, 1 and 36, cells stained with 17 markers and measured with mass 
cytometry. Cells separated into spatially distinct subsets based on the combination of markers that they 
express. Each point in the biaxial plots represents an individual cell, colour represents expression of 
indicated marker on a particular cell (see colour scale for expression levels). The axes are in arbitrary units. 
 The last panel of markers represent common AML markers. CD3 (T cell co-receptor) is 
an aberrantly expressed T cell marker in AML (487), this marker was not strongly expressed over 
the time-course, although there was consistent and moderate expression (Figure 4.19). CD117 
(c-kit receptor) is a marker that is described as an early stem cell marker (456).  This marker was 
sporadically expressed at the beginning of the time course and did not increase in expression 
following 24 hours of HS-5 conditioning. By the last time point there was strong expression 
observed in a small cell population (Figure 4.19, red circle). CD33 is a myeloid cell marker that is 
widely expressed in AML and its expression was present throughout the duration of this 
experiment, with very pronounced expression recorded on Day 1. HLA-DR is a major 
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histocompatibility complex (MHC) 2 cell surface receptor that is used to distinguish APL, as APL 
cells do not usually express HLA-DR. In these experiments, HLA-DR was strongly expressed at 
Day 0, with a notable cluster of very high expressing cells. HLA-DR was moderate after 24 hours. 
By Day 36 however, a localised population of cells emerged that were positive for other AML 
markers such as CD33, but now have low or absent HLA-DR expression (Figure 4.19, blue circles). 
HLA-DR is usually expressed on immature cells; therefore, this may represent a population of 
more mature cells that have arisen following 36 days of culture.  
 
Figure 4.19: ViSNE analysis of markers CD3, CD117, CD33 and HLA-DR during 36 days in culture. 
Application of viSNE to patient #0 samples at Day 0, 1 and 36, cells stained with 17 markers and measured 
with mass cytometry. Cells separated into spatially distinct subsets based on the combination of markers 
that they express. Each point in the biaxial plots represents an individual cell, colour represents expression 
of indicated marker on a particular cell (see colour scale for expression levels). The axes are in arbitrary 
units. 
 The final two markers to be assessed CD34 and CD38 are the traditional markers that 
are used for characterising LSCs (as discussed at the beginning of this section). Assessment of 
these markers expression at Day 0 observed that all cells in the sample expressed moderate to 
high levels of both CD34 and CD38 – the markers of AML initiating cells (Figure 4.20). This 
expression was varied with pockets of CD34highCD38high cells, but also a small cluster of 
CD34highCD38low cells (red circles). At Day 1, there was still consistent expression of both markers, 
with an increase in CD38high cells, as well as the persistence of the CD34highCD38low cells.  The last 
condition measured at Day 36 showed that all cells were CD34-; this could have been because 
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all CD34+ cells had all undergone cell death or possibly cell differentiation and now expressed 
CD33 instead. There was persistent expression of CD38+ cells, initially these finding would 
suggest that these HS-5 CM was not optimal for maintaining the leukaemia initiating population. 
However, there are a number of papers that report the capacity of CD34-CD38+ cells to behave 
as leukaemia initiators and induce engraftment (75-78); this population was abundant by Day 
36 (Figure 4.20, blue circles).  
 
Figure 4.20: ViSNE analysis of key LIC markers CD34 and CD38 during 36 days in culture. Application of 
viSNE to patient #0 samples at Day 0, 1 and 36, cells stained with 17 markers and measured with mass 
cytometry. Cells separated into spatially distinct subsets based on the combination of markers that they 
express. Each point in the biaxial plots represents an individual cell, colour represents expression of 
indicated marker on a particular cell (see colour scale for expression levels). The axes are in arbitrary units. 
 By interpreting the CyTOF results collectively, it was clear that the AML cells adapted to 
their environment, as the global population changed considerably over the 36 days, the changes 
in global marker expression are summarised in Figure 4.21. The total AML population showed 
an increase in differentiation over time through the loss of naïve markers such as CD34, CD123 
and HLA-DR, while at the same time acquiring strong expression of CD14 which is a marker of 
monocytic differentiation. Notably, the expression of markers that are reported to facilitate 
microenvironment interactions increased in expression (CD44, CD15, CD16), as well as the 
transient expression of CXCR4 (CD184) which would have been initially important in niche 
localisation if in vivo. Many of the markers that increased in expression over 36 days are also 
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indicators of poor outcome (CD117, CD7, CD44, CD45, CD14, CD11b), demonstrating the support 
that the microenvironment can provide AML cells.  
 
Figure 4.21: Heatmap of surface marker expression during 36 days of ex vivo cell culture. Calculated Log2 
fold change of Day 1 and Day 36 mean surface marker expression on live-gated cells relative to marker 
expression on Day 0.   
The unexpected finding in the analysis was the ability of HS-5 media to induce the 
expression of markers or select for clones that were not present at Day 0, but by Day 36 clones 
that highly expressed these markers could be identified in the sample. A marker that followed 
this pattern was CD16 (Figure 4.16 and 4.21), this is interesting as the marker has recently been 
described as a novel therapeutic target (488). Thus, HS-5 CM may be able to induce the 
expression of subpopulations that confer poor patient outcome, but at the same time could be 












 The initial objective of the experiments presented in this chapter was to functionally 
validate the selected panel of stromal derived proteins in primary AML cells and characterise 
how these proteins and the secretome as a whole could potentiate AML progression. This was 
achieved by utilising purified human RPs in addition to the described stromal secretomes in 
Chapter 3 to maintain primary AML cells in long term ex vivo cultures. Simultaneously, survival 
and proliferation assays were conducted to examine primary AML response, and when 
exogenous proteins potentiated survival, CyTOF analysis captured how this shaped AML 
clonality. 
 Initially, recombinant versions of the six identified proteins (S100-A4, S100-A11, BMP-1, 
CTGF, HGF, CSF-1) were acquired and adverse risk primary AML cells were treated with 10ng/ml 
of each RP in both serum starved and serum containing (10% FBS) environments and maintained 
in culture for seven days. Assessment across the time-course observed that S100-A4, CSF-1 and 
a combination of all the RPs induced significant proliferation in the primary cells (Figure 4.3), 
while at the end of the time-course each of the proteins were more supportive than the No GF 
controls (Figure 4.2). Although not all proteins affected proliferation, all modulated viability to 
some degree, and it was concluded that the concentrations were sufficient to induce a 
functional response. Serum inclusion was maintained to reduce cellular stress, additionally it 
was postulated that serum may have been necessary for a full response to the stromal derived 
proteins. This reasoning was based on the response of patient #1 cells to stimulation with S100-
A4.   
 Following the validation that these proteins effected patient #1 cells, both survival and 
proliferation assays were conducted on a larger cohort of five primary AML samples. Survival 
assays determined that despite heterogeneity in the degree of response to each GF, 4/5 patients 
exhibited substantially higher viability after seven days in culture compared to the No GF 
controls (Figure 4.4) An interesting but underpowered observation in these studies was that the 
AML response to GFs correlated with age in the albeit small sample set, with AML cells that 
responded to the proteins being from older patients that have poorer outcome and the least 
responsive being from younger patients that usually respond better to treatment (Table 2.8).  
The heterogeneous response of different primary samples to the secretome derived 
proteins suggested that these proteins were indeed important in AML, but which GF(s) and the 
degree of impact will vary from patient to patient. To estimate the impact of these GFs in a wider 
cohort gene expression analysis of the proteins was undertaken using the TCGA AML dataset 
which compared the gene expression of the proteins of 183 patient samples to the normal 
population. Although this did not measure stromal cell expression, this revealed that patients 
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with above median gene expression of CSF-1 (p=0.0175) and S100-A4 (p=0.0118) had a 
statistically significant worse survival than those below the median (Figure 4.6). Patients with 
above median gene expression of HGF on the other hand, demonstrated better survival 
(p=0.00717). The gene expression of the other proteins did not significantly correlate with 
outcome. Although these observations substantiated CSF-1 and S100-A4, the gene expression 
analysis did not rule out the other proteins as there are aspects of protein function and 
behaviour that cannot be captured using this approach.    
To further characterise how the HS-5 secretome supports primary AML, kinase 
inhibition studies were undertaken targeting key signalling nodes in AML (MAPK, mTOR, FLT3, 
JAK and PAK) (Figure 4.2). It was hypothesised that signalling molecules that comprise the HS-5 
stromal secretome would engage these pathways to mediate survival and proliferation. 
Experiments revealed that instead of the inhibitors abrogating the effects of the supportive 
effects of the secretome, the secretome modulated AML sensitivity to the kinase inhibitors. 
Patient cohorts in the presence of the stromal secretome would become less sensitive to MAPK 
inhibition (Figure 4.7), and more sensitive to mTOR inhibition (Figure 4.8). FLT3 and JAK 
inhibition were not significantly altered and regardless of secretome PAK inhibition profoundly 
affected cells (Figure 4.11). This suggested that stromal cells can influence AML cell signalling, 
thus demonstrating a means by which AML could withstand kinase inhibitor therapies – in 
accordance with the poor clinical response observed to FLT3 inhibition (54, 489).   
In parallel to kinase inhibition experiments, a sample of primary AML cells had been 
maintained in culture for 36 days and with peaks and troughs in viable cell numbers observed 
during the 36 days (Figure 4.12 and Figure 4.14), it was hypothesised to be indicative of clonal 
selection. In order to assess the clonality of the sample and changes that may have occurred in 
the population CyTOF was performed on the cells that had been maintained in culture for 36 
days using an AML phenotyping panel (Table 4.4), in addition to samples from the same patient 
at Day 0 and following 24 hours in culture exposed to the same factors. This study identified that 
the clonality of the patient populations did indeed change over the course long-term culture 
(Figure 4.16), and assessment of the phenotypic markers changed considerably (Figure 4.21). 
Cells that expressed the traditional LIC marker combination CD34highCD38low were not 
maintained, instead it was the CD34-CD38+ cell population that persisted, which have also been 
shown to behave as leukaemia initiators and induce engraftment (143, 465-467). Collectively, 
the long-term maintenance of primary AML cells in HS-5 CM induced the selection of clones that 




 In summary, primary AML functional studies validated that these secretome derived 
proteins (S100-A4, S100-A11, BMP-1, CTGF, HGF and CSF01) are a group of proteins that can 
extend and maintain primary AML cells ex vivo and as these are proteins that are secreted by 
mesenchymal cells of the BM (as well some AML cells), these proteins are also likely to be 
important in vivo. Particularly, as short-term exposure to bulk HS-5 factors was sufficient to 
modulate the sensitivity of primary AML cells to targeted kinase inhibitors. Thus, implying that 
proteins endogenous to the BMSM can modulate signalling activity in AML cells away from 
inherent signalling node dependencies. CyTOF analysis revealed the AML cells maintained long 
term developed expression of microenvironment sensing molecules and markers symptomatic 
of aggressive disease, which respond poorly to treatment. It remained to be proven, however, 
the means by which the stromal secretome and cells of the microenvironment modulate AML 




















Chapter 5: Determining the heterogeneity of AML cell signalling and 
the response of the phosphoproteome to BMSM stimulation 
 
5.1 Introduction and aims of the study  
Results described in Chapter 3 and 4 identified that MS-5 and HS-5 derived secretomes 
along with selected components S100-A4, S100-A11, CTGF, BMP-1, CSF-1 and HGF support AML 
cell survival. Chapter 4 also revealed the heterogeneity in response to these proteins as well as 
the effects that stromal GFs can have on the viability and growth of primary AML.  
Building on these findings we sought to map the signalling that underpinned the 
functional data produced so far. As we observed that the patient response varied during both 
bulk stromal secretomes and individual GF treatments, it was speculated that these conditions 
likely activated different signalling nodes and that each patient AML’s dependency on those 
nodes, was responsible for the heterogeneity observed in the previous chapter.  
Once the topology of single GF stimulation on cell signalling pathways was established 
in these AML patient cells, signalling experiments could be expanded to characterise patient 
response to bulk HS-5 secretome. In Chapter 3 we observed that HS-5 CM was the most 
supportive media. This biologically relevant and complex stimulant was utilised to stimulate a 
number of patient samples and map the effected signalling nodes. Following the literature and 
previous genomic studies (23, 32) it was unlikely that there would be considerable consensus 
for activated signalling nodes in these experiments. AML is a group of diseases which possess 
distinct clinicopathologic and genomic signatures that present with the classical expansion of 
myeloblasts in the BM (490). Therefore, AML is profoundly heterogeneous due to various routes 
of leukaemogenesis. In each patient sample the formation of kinase networks will be somewhat 
distinct from patient to patient, thus it was hypothesised that HS-5 CM would possess a broad 
range of agonists to adequately monitor stromal derived factors effects on kinase network 
activity. 
Secretomic stimulation of AML signalling pathways is one mechanism for stromal cells 
to influence AML cell signalling which is a form of chemical signalling as discussed in Chapter 1. 
It is a well described means of communication that facilitates heterotypic signalling (491) (Figure 
5.1A). This however, does not adequately encompass the communication that occurs between 
leukaemic blasts and the BMSM, as cell-cell adhesion is a well described phenomenon in this 
scenario that can serve to promote malignant haematopoietic cell survival  (60, 492-496) (Figure 
5.1B). In addition to these studies there is a strong body of research investigating integrins role 
in leukaemic blast interaction with cells of the BMSM in the context of both AML and acute 
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lymphoblastic leukaemia (ALL) (495). Integrins which are surface glycoproteins enable leukaemic 
cell adhesion to the extracellular matrix, as well as crucially, integrin receptors of BMSM cells 
(497, 498). Examples of this type of interaction include integrin β3 signalling and very late 
antigen 4 (VLA-4) binding to stromal adhesion molecules vascular cell adhesion molecule 1 
(VCAM-1), OPN and fibronectin (492, 499-502). All of these interactions have been shown to 
activate critical pro-survival and proliferative nodes in leukaemic blasts and BMSM cells. The 
best described example includes the interaction of ALL blasts with BMSM cells, which led to the 
subsequent activation of NF-κβ signalling in surrounding stromal cells (503).   
 
Figure 5.1: Concept of cell signalling and the means of signal transduction. (A) Chemical signalling, 
signalling molecule binds to complimentary receptor leading to a series of molecular events - commonly 
phosphorylation mediated by protein or lipid kinases, culminating in a cellular response. (B)  Contact-
dependent signalling, membrane bound-ligands (notch), integrins, ECM proteins (fibronectin) or surface 
glycoproteins on one cell interact with the appropriate receptor on an adjacent cell, initiating signal 
transduction. (C) Complex communication networks enable non-cell autonomous responses.   
We proposed that a primary co-culture between AML blasts and the MS-5 cell line 
(represents the BMSM), would expand upon previous models that have been used to study the 
intricate cross talk between these populations and mediate leukaemia progression (144, 504, 
505). The aim was that this model coupled with MS based phosphoproteomics would enable 
characterisation of the AML-BMSM signalling as represented in Figure 5.1C.  
In this chapter we aimed to: 
(i) Dissect the signalling nodes that are activated in AML cells following RP panel 
stimulation. 
(ii) Characterise kinase activity heterogeneity in patients to bulk HS-5 CM.  
(iii) Establish the heterotypic signalling that exists between BMSCs and AML cells, utilising 
AML-BMSM cell co-culture.  
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5.2 Analysis of AML signalling response to network perturbation following 
GF stimulation 
5.2.1 GF response of major signalling nodes  
Having established a panel of RPs that are secreted by both MS-5 and HS-5 cells that 
possess the capacity to extend primary AML ex vivo survival, as well as positively regulate cell 
proliferation, it was sought to understand how these proteins activated signalling pathways 
within an AML network. It was hypothesised that, the signalling axis MAPK and PI3K/AKT/mTOR 
would likely be perturbed by these signalling molecules due to the effects of HS-5 conditioned 
medium on AML sensitivity to targeted inhibitors of these pathways in Chapter 4. 
The RPs were first used to treat the AML cell line P31/FUJ. This cell line is very resistant 
to chemotherapy agents and is an M5 FAB classification, therefore it displays a higher level of 
differentiation and should express more surface receptors than some of the less differentiated 
cell lines such as CTS.  
 
Figure 5.2: MAPK and PI3K-AKT-mTOR signalling axis. Red circles denote targets assessed by western 
blot. 
P31/FUJ cells were serum starved for 4 hours to bring basal signalling levels in P31/FUJ 
cells to a basal state. Subsequently cells were stimulated for 15 minutes with 10ng/ml of each 
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of the recombinant GFs, as well as all the GFs combined and the MS-5 secretome (10ug/ml). We 
observed that CSF-1 and the MS-5 secretome induced downstream activity in MAPK signalling 
axis, with a modest increase represented by phosphorylation of ERK1T185/Y187/ERK2T202/Y204 (Figure 
5.3). More significant was the phosphorylation of ERK1T185/Y187 in the mixed GF sample, which 
was substantially increased compared to that of the starved sample and the phosphorylation 
observed in the CSF-1 and secretome samples. Stimulation with the remaining GFs was 
insufficient to activate the MAPK signalling axis in P31 cells.  
 
Figure 5.3: Western blot analysis of MAPK signalling in P31/FUJ cells. Cells starved 4hr prior to 15 
minutes stimulation with 10ng/ml of recombinant factor. Western blots for the activatory 
phosphorylation sites on ERK1/2. Loading controls for the total p44 and p42 MAPK proteins and B-actin 
are shown in each case.  
 
Assessment of the PI3K-AKT-mTOR signalling axis was more complex than that of the 
MAPK pathway. First observing AKT status in P31/FUJ cells stimulated with the GFs revealed the 
preference P31/FUJ cells have on the pathway, with AKTS473 phosphorylation elevated in serum 
starved cells (Figure 5.3A).  Each of the GFs maintained AKT phosphorylation, with the complex 
mixtures (Mixed GF and secretome) resulting in the stongest bands, HGF was the only GF to 
decrease AKT phosphorylation.  
Downstream of AKT in the signalling axis is mTOR (506, 507). To assess the recombinant 
factors effects on mTOR activity, known mTOR substrate p70 S6K was measured at p70T389 and 
p85T412 (508, 509), mTOR has been described as positively responding to the environment through 
activation of p70 S6K and these phosphorylation sites are critical for the activation of p70 S6K 
(510). Analysis revealed that again there was activity in the pathway following 4 hours of 
starvation, however, there was also strong phosphorylation of the pathway in the Mixed GF and 
secretome samples (Figure 5.3B). These findings correlated with the observations from Chapter 
4 where increased sensitivity of primary AML cells to Torin-1 was observed in the presence of 
HS-5 stromal factors (Figure 4.8). This suggested that the combination of these factors that are 
represented in both the Mixed GF and stromal secretome samples are capable of activating 
mTOR and therefore increase AML cell sensitivity to Torin-1 treatment. It is worth noting the 
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CTGF and HGF treatment alone reduced the phosphorylation of p70 S6K compared to that 
expressed in the serum starved control.  
 
Figure 5.4: Western blot analysis of AKT/mTOR signalling in P31/FUJ cells. Cells starved 4hr prior to 15 
minutes stimulation with 10ng/ml of recombinant factor. (A) Western blots for the activatory 
phosphorylation sites on AKT, mTOR activation markers (B) p70 S6K and (C) 4EBP1. Loading controls for 
the total proteins and B-actin are shown in each case.  
4EBP1 is another substrate that is regulated by mTOR (511). 4EBP1 is a translation 
inhibitor protein due to its binding of translation initiation factor eIF4E (512). This action is 
abrogated though by phosphorylation of Ser65 and Thr70 (513), and mTOR primes 4EBP1 for 
this phosphorylation by phosphorylating residues Thr37 and Thr46 (514). Assessment of 4EBP1 
status following stimulation with the GFs revealed that the s100 proteins A4 and A11 slightly 
increased phosphorylation of the Thr37 and Thr46 residues, with little change observed in these 
markers between starved and the rest of the single GFs (Figure 5.4C). Stimulating P31/FUJ cells 
with more complex mixtures however, profoundly impacted phosphorylation of 4EBP1 at these 
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sites, with both Mixed GF and MS-5 secretome stimulation driving expression markers 
associated with cell growth and translation initiation. These finding suggest that the individual 
GFs alone were not enough to stimulate upstream pathways sufficiently to impact on 
downstream targets like 4EBP1. However, the binding of upstream receptors (multiple or the 
same) with numerous molecules was potent enough to modulate 4EBP1.        
 
Figure 5.5: Western blot analysis of PAK signalling in P31/FUJ cells. Cells starved 1hr prior to 15 minutes 
stimulation with 10ng/ml of recombinant factor. (A) Western blots for the activatory phosphorylation 
sites of group 1 PAK1 (Ser199; Ser204) and group 2 (B) PAK4 (Ser474). Loading controls for the total 
proteins and B-actin are shown in each case.  
The PAKs are a group of kinases that were hypothesised to be important due to PAKs 
potential to facilitate AML-stromal crosstalk. PAK is a kinase observed as being frequently 
overactive in AML (206, 207, 271) and PAKs functions range from cell migration, survival, 
proliferation and actin cytoskeleton remodelling (515). In Chapter 3 it was observed that the 
MS-5 stromal secretome was able to induce PAK1 phosphorylation, and kinase inhibition studies 
in Chapter 4 revealed that the PAK specific inhibitor PF-3758309, which has more selectivity 
towards group 2 PAKs (such as PAK4), was very effective at inducing cell death in primary AML 
cells.  In accordance with results from Chapter 3, secretome stimulation of P31/FUJ cells leads 
to strong PAK1S199 phosphorylation, a surrogate marker of induced kinase activity (516, 517). 
Treatment with HGF also phosphorylated PAK1S199 which has previously been observed as being 
able to activate PAK via Rac (518). Most of the GFs individually activated PAK1 except CSF-1 
which inhibited PAK1S199 phosphorylation (Figure 5.5A). Unlike the secretome treatment, Mixed 
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GF treatment of P31/FUJ cells was insufficient to phosphorylate PAK1S199. As each of the GFs 
were individually capable of inducing PAK1 phosphorylation except CSF-1, it may be that CSF-1’s 
inhibitory effect was dominant over the other GFs.  
The phosphorylation of PAK4, marketed as the primary target of PF-3758309, was 
examined following recombinant GF treatment (Figure 5.5B). PAK4 has not previously been 
linked with AML, but all primary AML samples were very sensitive to its chemical inhibition. 
Western blot analysis showed that BMP-1, CTGF and HGF induce phosphorylation of PAK4S474 
(marker of activity), as with PAK1, the combined mixture of GFs did not induce phosphorylation. 
Unlike PAK1, the secretome was unable to induce phosphorylation in PAK4S474.  
5.2.2 Phosphoproteomic analysis of GF stimulated primary AML cells 
Western blot analysis of P31/FUJ individually treated with the stromal GFs confirmed 
that these proteins at a concentration of 10ng/ml were capable of inducing changes in key 
signalling nodes that are important in cell function and thought to be important in AML 
progression. These studies however, only observed changes to an AML cell line and AML cell 
lines are not truly representative of AML biology – principally as cell lines are able to survive 
independently, a characteristic that primary AML cells do not possess. Resultantly we felt it 
appropriate to study these GF effects in primary AML cells, as it was likely that the P31/FUJ cells 
were not responding to the GFs in a manner that cells dependent on the microenvironment and 
the stromal secretome would. This raised the possibility that in cell lines we could be observing 
changes that would not occur in primary AML cells, as well as minimising the potential impact 
these GFs could have on AML cell signalling and cell survival. 
In Chapter 4 primary patient samples had a very strong albeit heterogeneous response 
to the panel of recombinant GFs. Due to the number of proteins in the panel, it was reasoned 
that selecting one patient that displayed a strong functional response to the proteins would be 
a good approach to establish pathways that mediate AML survival, as well as mechanistically 
determine how these proteins support AML. Therefore, patient #1 was selected for 
experimentation as these patient cells responded in a very pronounced manner to S100-A4 and 
Mixed GF stimulation during proliferation assays (Figure 5.6), additionally CSF-1 was very 






Figure 5.6: Patient #1 selected to for phosphoproteomic analysis based on functional response to GF 
stimulation. Results from Chapter 4 that demonstrate treatment with S100-A4, CSF-1 and Mixed GF 
conditions elicit statistically significant changes in patient #1 AML cell growth. * denotes p-value <0.05 
**<0.01 ***<0.001, n=4 technical replicates per condition. 
 
For phosphoproteomic analysis of patient #1 AML cell response to the stromal 
secretome derived proteins, cells were first serum starved for 60 minutes prior to stimulation 
with the GFs. Serum starvation was employed as it was reasoned that the serum GFs and 
cytokines could activate many pathways that otherwise would be inactive, possibly masking the 
effects of the stromal derived proteins. To control for the serum starvation a ‘No GF’ condition 
was included in which cells were starved and then processed, with no GF treatment. Secondly a 
‘basal’ condition was included where for the duration of the starvation and stimulation patient 
#1 cells were kept in serum complete IMDM media prior to processing with the rest of the 
samples. In GF stimulated samples, once patient #1 cells had been starved for 60 minutes, 
10ng/ml of the chosen GF or 10µg/ml of bulk secretome were spiked into the media. Cells were 
then stimulated for 15 minutes to capture early phosphorylation events that were induced by 





Figure 5.7: Experimental design used to define the activity of kinase signalling following growth factor 
stimulation. Primary AML cells from patient #1 were reanimated and starved 1hr prior to 15 minutes 
stimulation with 10ng/ml of single GF or Mixed GFs, 10µg/ml MS-5 secretome or starved only. In parallel 
resting cells that were not starved were also processed (basal). The cells were then lysed, proteins 
digested, and phosphopeptides enriched using TiO2. Each sample was then analysed by LC-MS/MS in 
triplicate. This MS data was searched against the Swissprot database using MASCOT and the subsequent 
output of peptide identifications were combined to make a unique database. Each phosphopeptide within 
the database was then quantified using in house software PESCAL and the quantitative data analysed 
using a combination of Excel and R environments. 
5.2.2.1 Mass spectrometry data quality control 
To assess the quality of the data derived through mass spectrometry experiments, 
quality control steps were undertaken regarding the datasets which included quantification of 
the area under the total ions chromatogram (TIC) (Figure 5.8A); assessment of the identity 
assignment to each phosphopeptide (Figure 5.8B); assessment of the chromatography linearity 
by calculating the linear relation in retention times across all samples (Figure 5.8C); evaluation 
of the distribution of phosphopeptide intensities; and determination of intensity normalisation 
efficiency that is employed to remove technical noise (Figure 5.8D).    
The performance of an LC-MS/MS run can be estimated by calculating the sum of the 
area under the chromatographic peaks per scan before totalling. Xcalibur software was used to 
visualise TIC intensities and quantification of the sum of chromatographic areas determined the 
mean intensity was in the E12 range (Fig 5.8A). Following protein identification using the MASCOT 
database, the number of peptide ions whose identity was assigned with high confidence 
(FDR<0.05) for each of the total 30 LC-MS/MS runs that were used to generate the database 
were determined. A total of 3,857 unique phosphopeptide ions were identified with FDR<0.05, 
which is less than previous experiments generated in the same laboratory (Fig 5.8B) (215), 
however, those experiments utilised cell lines and not primary tissue so it is possible that the 
lower than expected number of identifications was down to the fragile nature of the source 
material. The accuracy of the peptide quantitation that is performed by the PESCAL algorithm 
relies upon accurate retention time alignment (tR). This was assessed by tracing the tR which 
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are populated in a database for each peptide ion for all the samples. The linearity of the pairwise 
alignments between peptide retention times of two samples illustrates the consistency in of tR 
alignments (Figure 5.8C). Finally, after label-free quantification by the PESCAL algorithm, the 
data were log2 transformed. Normal distribution of the data was deduced by visual inspection 
of the peptide intensities, which enabled following parametric statistical analyses (Figure 5.8D). 
Normalisation of the Log2-transformed data and inspection of these data proved the capacity of 
normalisation to make distributions across the samples homogenous in statistical properties. 
 
Figure 5.8: Quality control of MS data used to analyse the phosphoproteomes of GF stimulated AML 
cells. (A) Quantification of total area under the chromatographic peaks contained in 30 LC-MS/MS runs. 
(B) The average number of identified peptide ions (FDR<0.05) per condition across 30 LC-MS/MS to 
generate the phosphopeptide database. (C) Representative alignment between retention times of two 
experimental. (D) Box plots demonstrating the distribution of log2-transformed peptide peak intensities 
post-quantile normalisation. 
 
The steps undertaken to assess the quality of these experiments advocate the quality of 
the dataset and demonstrate that the pre-processing applied is capable of removing 
confounding variables. It was therefore appropriate to conduct downstream analysis of this 






5.2.2.2 Differential abundance induced by GF stimulation  
The data shown in Figure 5.9 served as preliminary indication of the differential 
modulation of the phosphoproteomes of patient #1 following 15 minutes stimulation with the 
recombinant factors in comparison to the phosphoproteome patient #1 cells that had not been 
stimulated with a single GF or combination of factors.  
 
 
Figure 5.9: Differential abundance analysis of the patient #1 phosphoproteomics data following GF 
stimulation. Differential abundance analysis of the phosphoproteomics data. The number of 
phosphopeptides either significantly increased (red) or decreased (blue) in abundance are shown when 
compared to starved patient #1 that were not subjected to GF stimulation. Fold change, log2 fold-change 
vs No GF control; adjusted P, is the corrected P-value for multiple testing by the Benjamini-Hochberg 
method. 
The experimental condition that generated the greatest global increase in 
phosphopeptide expression was from S100-A4 treatment (195 phosphopeptides), which was 
also the GF that generated the most proliferation in previous functional experiments, and the 
condition that yielded the least change when compared to starved cells was generated by the 
basal conditions.  
The notable trend in this dataset was the decrease in phosphopeptide expression 
following GF stimulation that occurs in CSF-1, Mixed GF and MS-5 secretome conditions. In 
particular the Mixed GF condition induced a significant decrease in phosphopeptide expression 
with 480 peptides decreasing by 1.5 Log2 fold that were significant compared to unstimulated 
cells. 
5.2.2.3 Associations between patient #1 AML phosphoproteomes following stimulation with 
GFs 
To compare the phosphoproteomes of patient #1 cells following treatment, hierarchical 
clustering of the phosphopeptide fold changes between GF stimulated and unstimulated 
samples was performed as presented in Figure 5.10. This analysis demonstrated that the two 
phosphoproteomes that were globally remarkably different to the unstimulated and basal 
samples were that of the Mixed GF and S100-A4 stimulated cells. The basal phosphoproteome 
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was not too dissimilar to the unstimulated sample, which was reassuring as it suggested that the 
starvation did not significantly compromise the cells.  
 
Figure 5.10: Hierarchical clustering analysis of recombinant factor stimulated phosphopeptide 
expression in patient #1 cells. Heatmap represents the Log2 Fold change phosphopeptide expression of 
patients #1 cells following (10ng/ml) GF stimulation compared to unstimulated patient #1 cells. Expression 
averaged across 3 analytical replicates, heatmap and dendrograms produced using ggplots package in R 
workspace. 
This pattern of clustering suggested that S100-A4 was the GF contributing to the 
proliferative phenotype observed in patient #1 following Mixed GF treatment, as this sample 
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group closest to the Mixed GF sample. CSF-1 and HGF clustered together with the MS5 
secretome treated cells, and had a similar expression profile to that of the Mixed GF sample. 
CTGF and BMP-1 on the other hand, did not cluster with the Mixed GF sample.   
5.2.2.4 KSEA analysis of phosphoproteomes to examine differences in kinase activity  
Kinase substrate enrichment analysis as described in the methods (section 2.12), is an 
approach to infer kinase activity from the phosphoproteomics data. The method groups 
substrates into sets that are known to be phosphorylated by a particular kinase and global 
differences in the abundance of these substrate groups across samples enables the inference of 
kinase activity. In this analysis, KSEA can indicate kinases in patient #1 cells that putatively 
increased or decreased following GF stimulation by comparing the expression of substrate 
groups to that recorded in the No GF stimulation samples (Figure 5.11).  
Systematic assessment of putative kinase activity changes in patient #1 cells following 
GF stimulation showed that S100-A4 treatment lead to potent increases in casein kinase 2 
subunit alpha (CK2A2), Lck kinase, InsR and ATR. Secondary to these increases were putative 
increases in AKT, Src and glycogen synthase kinase-3 beta (GSK3B) activities. All of these kinases 
that increased in activity are implicated in cell growth and proliferation. The kinases that 
significantly decreased in activity following S100-A4 treatment were casein kinase 1 alpha 
isoform (CK1A), casein kinase 2 alpha subunit (CK2A1) and homeodomain-interacting protein 
kinase 2 (HIPK2). These kinases have defined roles in p53 mediated apoptosis. 
S100-A11 treatment in this experiment led to strong putative increases in mTOR activity, 
with activity also detected in the Fes tyrosine kinase and cyclin dependent kinase 1 (CDK1). 
Protein kinase C alpha (PKCA), Calcium/calmodulin-dependent protein kinase type 1 (CAMK1A), 
PAK1, Rho-associated protein kinase 1 (ROCK1), citron rho-interacting kinase (CRIK), MRCKA, 
myosin light chain kinase (smMLCK) all decreased in activity compared to the untreated cells.  
BMP-1 treatment strongly activated mTOR, ERK1, ERK2, CDK1 and S6K kinases in 
primary AML cells compared to untreated cells. To a lesser extent Fes and CK2A1 were also more 
active compared to untreated cells. BMP-1 treatment led to a significant drop in Rho kinases 
including ROCK1, MRCKA, CRIK and smMLCK. 
CTGF treatment in patient #1 cells putatively activated mTOR signalling as well as its 
upstream binding partner AKT1, the only other kinases to significantly increase in activity were 
ERK1 and ERK2. Putative kinase activities that relatively decreased to that of the untreated 





Figure 5.11: Heatmap of kinase substrate enrichment analysis (KSEA). The phosphorylation status of 
known kinase substrates are quantified and compared between (10ng/ml) GF treatments to determine 
relative kinase activities in Patient #1 cells. Growth factor (GF), Mixed recombinant growth factors (Mixed 
GF), q – no of substrates. *p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001  
 
HGF treatment like CTGF treatment activated AKT1 and mTOR as well as the MAPK 
kinases ERK1 and ERK2. HGF however, also led to a decrease in p70S6K, DNA damage kinases 
ATR and checkpoint kinase 2 (chk2), and the Rho kinases ROCK1, MRCKA, CRIK and smMLCK. 
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CSF-1 treatment induced putative increases in AKT1 and mTOR activity and non-
significantly increased ERK1 and ERK2 kinase activities. CSF-1 treatment led to a profound 
reduction in the putative kinase activity of the Rho kinases (ROCK1, PAK1, MRCKA, CRIK and 
smMLCKs), DNA damage kinases (ATR and Chk2), metabolic kinases pyruvate dehydrogenase 
kinases 1,2,3,4 (PDHK), cell cycle regulators (CDK1, CDK2, CDK5) and protein kinase c alpha and 
delta isoforms (PKCD and PKCA). 
The complex secretome of MS-5 cells effected patient #1 kinase activity identically to 
CSF-1 treatment typified by the global putative reduction in activity except for three kinases. In 
addition, MS-5 secretome led to a decrease in ERK1, ERK2 and AKT1 activity. The Mixed GF 
sample profoundly reduced kinase activity relative to that of unstimulated patient #1 AML cells, 
further than that observed for the MS-5 secretome. No kinases were recorded as increasing in 
activity following treatment.  
Comparing kinase activity in the resting basal sample to unstimulated (but starved) 
samples revealed a decrease in the activity of the Rho kinases, therefore starvation possibly 
increases the activity of these kinases in patient #1 cells. Additional kinases that were observed 
as less active following starvation were ATR and PKCA. Kinases that increased in activity 
following starvation included AKT1, CK2A1, GSK3B and Fes.  
The PCA presented in Figure 5.12A demonstrates how the phosphoproteome/network 
of the patient #1 cells was most different following S100-A4 and Mixed GF (a greater distance 
from these points in PC space) compared to the no GF control sample. This was a robust 
response as it was observed in each of the replicates and reassuringly the phosphorylome of 
basal cells also occupied the same position in the PC-space as the no GF control. Equally, this 
showed that the patient #1 phosphoproteome following stimulation with CSF-1, HGF and BMP-
1 did not significantly separate.  
The data shown in Figure 5.10 also suggested that, as seen in Figure 5.12A, that patient 
#1 cells responded minimally to many of the single GF treatments. However, when taking into 
account another principal component, analysis reveals subtler changes in the signalling 
responses, and the routes through which the secretome derived GFs induced signals in patient 
#1 cells (Figure 5.12B).  The PC space segregates into composites of s100 proteins (bottom left), 
complex mixtures (bottom right), metalloprotease (top left), GFs (top right) and the 
unstimulated and basal samples cluster together centrally. These observations support findings 
in Figures 4.4 and 4.5 and corroborate the hypothesis that these stromal derived proteins can 





Figure 5.12: Multivariate analysis of GF stimulated patient #1 datasets highlights the distinct effect 
S100-A4 and Mixed GF conditions can have on the AML phosphorylome. PCA of the log2 fold-ratios for 
























5.3 Characterise kinase activity heterogeneity in patients to bulk HS-5 
conditioned media 
The observations gathered in the last experiment confirmed that the panel of stromal 
derived GFs do in fact alter signalling networks in primary AML samples. However, the 
experiment only compared the effect of the GFs on AML signalling in one patient sample. Those 
experiments revealed particular aspects of AML signalling networks that are perturbed by single 
GF treatment, however, in reality the cells would not experience these proteins in isolation. 
Additionally, multi-variate analysis showed that secretome stimulation of AML cells lead to 
similar effects on the phosphoproteome to that observed for the Mixed GF condition. Therefore, 
it was hypothesised that bulk HS-5 CM could be used to understand the effects these signalling 
molecules have on a larger cohort of AML patient samples, while simultaneously assessing the 
heterogeneity of AML kinase network activity. 
 
Figure 5.13: Experimental design to determine the heterogeneity in AML signalling network response 
to growth with HS-5 conditioned media.  
Eight patient samples were obtained, and cells were reanimated before being seeded in 
one of three conditions. Each patient sample was seeded for 1 hour in control IMDM media 
(supplemented with 10% FBS), this condition was included to measure the endogenous baseline 
signalling that these cells employ. Patient samples were also kept for 24 hours in the IMDM 
control media, this was used to be able to control for the effects of culture, as well as the 
inevitable levels of hypothesised apoptosis – AML cells do not like being maintained ex vivo. The 
final test condition was to maintain cells in the supportive HS-5 CM for 24 hours to be able to 
visualise the heterogenic patient responses to the complex mixture of stromal proteins that 
make up HS-5 CM (full schematic detailed in Figure 5.13). 
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5.3.1 Differential abundance  
Analysis of this experiment retrieved 19,484 peptides, of which 17,360 were 
phosphorylated (89.1% phospho-enrichment). The data shown in Figure 5.14 served as 
preliminary indication of the differential modulation of the phosphoproteomes of primary AML 
grown in HS-5 CM for 24 hours in comparison to the phosphoproteome of either basal or HS-5 
independent primary AML cells.  
 
Figure 5.14: Differential abundance analysis of the primary AML phosphoproteomics data. Differential 
abundance analysis of the phosphoproteomics data. The number of phosphopeptides either significantly 
increased (red) or decreased (blue) in abundance compared to HS5 CM independent cells are shown. Fold 
change, log2 fold-change vs 1hr Basal or 24hr HS5 independent control; adjusted P, is the corrected P-
value for multiple testing by the Benjamini-Hochberg method. 
 
5.3.2 Heterogeneous phosphoproteomic signature 
 In order to systematically analyse the biochemical modulations after maintaining 
primary AML cells with HS-5 CM or stromal independent media and establish how an expanded 
patient cohort behaves in response to stromal derived proteins, the phosphoproteomics dataset 
was filtered and clustered using k-means. This analysis included only those peptides that were 
significantly modulated in at least one condition compared to the 1 hour IMDM control and 
peptides were grouped into 9 clusters using the method described in Section 2.12.4.  
 The data shown in Figure 5.15 indicated that there were high levels of heterogeneity in 
phosphorylation kinetics upon culture with and without HS-5 CM between patient samples. For 
all clusters differences in the HS-5 maintained patient phosphoproteomes were more 
pronounced with the 1 hour control conditions, compared to the 24 hour control conditions 
(Figure 5.15A). Assessment of the nine k-means assigned clusters revealed that clusters 1, 2, 3, 
and 9 contained peptides that increased following HS-5 conditioning and clusters 4 and 5 went 
down respectively. Cluster 1 represented phosphopeptides that increased in expression for 
patients #1, #9, #11 and #13 following 24 hours of HS-5 conditioning, these peptides strongly 




Figure 5.15: Heterogeneous response of primary AML to HS-5 conditioning. (A) Heatmap of the Log2 
fold-ratios for each of the phosphopeptides grown in HS-5 CM compared to no conditioning control. K-
means clustering assigns phosphopeptides into 9 clusters each comparison n=3 technical replicates, GO 





























Cluster 3 contained phosphopeptides that increase following HS-5 conditioning (Figure 
5.15C), with significant enrichment of the S1P3 pathway, NF-kB pathway and pathways 
associated with signal transduction that results in activation of MAPK and AKT. Cluster 9 
represents phosphopeptides that were highly abundant after 24 hours, compared to 1 hour 
conditions and these phosphopeptides enriched for GOs associated with DNA-PK activity, BARD1 
signalling events and PI3K signalling mediated by AKT (Figure 5.15E).   
 Clusters 4, 5, 6 and 8 demonstrate phosphopeptides that decreased in HS-5 conditioned 
cells compared to non-conditioned cells. Clusters 4 and 6 contain peptides that strongly 
decreased in patients #1, #7 and #8, however, cluster 5 contains phosphopeptides that 
decreased in all patients. GO analysis of these phosphopeptides revealed a consensus for DNA 
repair, and apoptotic signalling, suggesting that there was less DNA damage and cell death 
occurring in HS-5 conditioned samples than in the non-conditioned samples (Figure 5.15D). 
5.3.3 Implementation of KSEA reveals temporal effects of HS-5 factors on kinase 
activity    
 KSEA analysis of this data echoed findings revealed by k-means analysis, principally that 
there was profound heterogeneity in both basal and HS-5 induced kinase activity between 
patient samples. The KSEA output was processed using a multivariate approach, hierarchical 
clustering demonstrated that samples separated by time with HS-5 conditioned samples 
compared to 1-hour and 24-hour controls segregating (Figure 5.16). One patient sample (patient 
#8) did not group with the other samples by time and instead both time points involving this 
sample clustered together. An observation that suggested this patient sample was not 
significantly modulated by the experimental conditions. 
 Assessment of kinase behaviour between the conditions revealed that kinase activity on 
average was higher in patient cells following 24 hours of cell culture than what was observed at 
1 hour. Global kinase activity was substantially increased in HS-5 conditions compared to the 
kinase activity in the 1-hour controls, this difference was not as pronounced during comparison 
to the 24-hour controls. Notable kinases that putatively increase in activity over time included, 
the AKT-mTOR pathway (AKT1, mTOR, p70S6K, RSK2, p90RSK), substrates of the tyrosine kinases 
(Brk, Syk, Lck), Src, mitogen activated protein kinases (JNK1, JNK2, JNK3, MEK2), JAKs (JAK2, 
JAK3) and PAK1. 




Figure 5.16: KSEA heatmap of temporal effects of HS-5 derived factors on AML kinase activity. The 
phosphorylation status of known kinase substrates were quantified and compared between HS-5 
conditioning treatments to determine relative kinase activities, each comparison contains n=3 technical 
replicates. Heatmap and dendrograms produced using ggplots package in R workspace. 
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There were few kinases that demonstrated consistent HS-5 induced activity across the 
patient samples, however, there were kinases whose putative activity decreased in most patient 
samples following HS-5 conditioning, and these included CK2A1 and CK1A. Patient specific HS-5 
induced kinase activities were observed in patient #6, in which DNA damage kinases DNAPK, 
ATM and ATR were all highly activated. Patient #8 was observed as having HS-5 induced putative 
activity of c-Kit, AKT2 and Dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3). 
Patient #1 had HS-5 induced high activity of JAK2 and patients #7, #11 and #13 all exhibited a 
consistent increase in kinase activity in a set of 9 kinases (MRCKA, smMLCK, ILK, DLK, DAPK1, 
DAPK3, CRIK, CamK1A and ROCK1). 
5.3.4 Condensing the global and heterogeneous effects HS-5 conditioning has on 
seven primary AML phosphoproteomes     
 Having established that the effect of HS-5 CM had quite substantial effects on the 
phosphoproteome of these seven AML patient samples, thus causing sizable shift in kinase 
behaviour. PCA analysis of the phosphoproteomics data was undertaken in an effort to visualise 
if these very different AML proteomes globally responded in a similar manner to the influence 
of HS-5 cells. Analysis of PCA scores demonstrated the heterogeneity within this data set, with 
three PCs being required to reach a cumulative proportion of 0.9 and twenty PCs being required 
to fully comprise the variances within the data (Table 5.1).  
  
Table 5.1: Summary table of the PCA scores for the HS-5 phosphoproteomics analysis.  
 To capture the variance within the dataset a PCA was employed to represent the 
experiment (Figure 5.17). The heterogeneity of these samples was apparent by the lack of 
shared PC space occupied by any of the 1 hour basal control samples, all of these samples were 
positioned in distant locations, samples 6b, 7b, 8b and 13b do not cluster together. Interestingly 
HS-5 conditioning for five of the patient samples (6H, 7H, 8H, 9H, 11H and 13H) led these 
conditions to converge and cluster together centrally within the PC plot. Although 1H does not 
cluster with the other HS-5 treated samples. Next to 1H is also the respective 24-hour control of 
Importance of components: PC1 PC2 PC3 PC4 PC5 PC6 PC7
Standard deviation 4.013 1.02481 0.8875 0.71022 0.64069 0.5441 0.48071
Proportion of Variance 0.8052 0.05251 0.03938 0.02522 0.02052 0.0148 0.01155
Cumulative Proportion 0.8052 0.85772 0.8971 0.92232 0.94285 0.9577 0.9692
PC8 PC9 PC10 PC11 PC12 PC13 PC14
Standard deviation 0.37307 0.32925 0.2849 0.24826 0.22384 0.20123 0.17032
Proportion of Variance 0.00696 0.00542 0.00406 0.00308 0.00251 0.00202 0.00145
Cumulative Proportion 0.97616 0.98158 0.98564 0.98872 0.99123 0.99325 0.9947
PC15 PC16 PC17 PC18 PC19 PC20
Standard deviation 0.16207 0.16059 0.13881 0.12497 0.1017 0.09325
Proportion of Variance 0.00131 0.00129 0.00096 0.00078 0.00052 0.00043
Cumulative Proportion 0.99601 0.9973 0.99827 0.99905 0.99957 1
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this condition, suggesting that this sample did not respond to HS-5 conditioning, but responded 
to the stresses and influence of cell culture.  
 
Figure 5.17: Principal component analysis of primary AML cells grown in HS-5 CM. For each sample an 
average was taken across 3 technical replicates. The subsequent variance in the average phosphopeptide 
expression per sample could be explained through 20 principle components. Principle component (PC) 1 
and PC2 have been selected to visually display the data, collectively they explain 86% of the variance in 
the data. 
 Collectively these results were in line with the literature highlighting that in AML the 
clonal and genetic heterogeneity that characterises the disease (519, 520) extends through to 
the formation of AML kinase networks. This defines the response of primary AML cells to bulk 
factors that comprise forms of the stromal secretome.  In trying to characterise the 
heterogeneity of AML kinase activity in response to bulk secretome, it is clear that the common 
dysregulated kinases in cancer are implicated in AML (MAPK, PI3K-AKT-mTOR, and JAK) and 
mediate the AML response to the microenvironment. However, there are a number of other 
factors contributing to AML behaviour, that include but not limited to receptor expression, ECM 
protein expression, nutrient sensors, feedback mechanisms and the precise wiring of kinase 
networks for a given cell type.  
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5.4 AML/Stromal cell co-culture: how MS-5 cells modulate AML signalling 
networks 
Experiments investigating the influence of stromal cells using CM and GFs explain means 
by which these cells could communicate. However, using a preconditioned media or fixed 
concentration of reagent does not capture many of the dynamic elements of cell 
communication. Therefore, to investigate the heterotypic signalling that exists between BMSCs 
and AML cells in more detail, we used a similar approach to the one used to identify dynamically 
expressed proteins of the secretome, AML/MS-5 cell co-culture. For this set of investigations 
experimental models sought to exploit two technical considerations of these cell types; species 
and adherent/non-adherent nature of cell types.  
 
Figure 5.18: Experimental design for MS-5/AML cell co-culture. Experimental design is similar to that 
employed in secretome co-culture experiments. On this occasion cells were separated by taking 
advantage of distinct characteristics of adherent MS-5 cell features and non-adherent features of the 
primary AML cell populations prior to phospho-enrichment and LC-MS/MS analysis. 
Adherent MS-5 cells were seeded 24 hours prior to co-culture to provide an 
unperturbed stromal cell layer. Following which seeding media was removed, MS-5 cells were 
washed with PBS and fresh media containing non-adherent primary AML patient cells were 
introduced. In parallel the same primary AML cells were incubated independently and cultures 
incubated for 24 hours. Following incubation, non-adherent primary AML cells were gently 
extracted and processed for phosphoproteomics. After which MS-5 cells were gently washed 
with ice cold PBS to remove any residual AML cells and then lysed with urea on plate (Figure 
5.18). Finally, to control for any cross-over stromal MS-5 cells were of murine origin and 
therefore protein identification was conducted against murine proteomes and primary AML cell 
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protein identification was against the human proteome, this approach takes advantage of the 
specificity of mass spectrometers. 
5.4.1 Examination of co-culture induced relationships  
 In order to globally assess the effects stromal cell co-culture has on primary AML cells 
both hierarchical clustering and PCA were undertaken to identify global trends induced by co-
culture on primary AML cell phosphoproteomes. Hierarchical clustering analysis of the 
experiment revealed that samples clustered primarily by patient, which is in accordance with 
results produced in section 5.3. Samples then segregated according to co-culture status, the 
order by which patient samples separated did not clearly correlate with any of the clinical 
features of the patient samples (Table 2.7). Qualitatively, it is good that the most closely 
matched samples were those of the experimental replicates. 
 
Figure 5.19: Hierarchical clustering analysis of AML phosphoproteomes following MS-5 cell co-culture. 
Heatmap produced by comparing phosphopeptides expression in an individual sample to the average 
expression of the phosphopeptide across all samples, each condition n=3 analytical replicates and 
dendrograms produced using ggplots package in R workspace. 
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 PCA inspection of the phosphoproteomic data mirrored the findings of the hierarchical 
clustering analysis. Each patient sample occupied a distinct region within the PC environment 
particularly patient samples #10-12, although samples #1, #6, #7, #9 clustered quite tightly 
(Figure 5.20). Some samples such as patient #6 did not change substantially following MS-5 co-
culture with these conditions clustering very tightly, however, co-culture and independent 
conditions of patient #12 samples did separate substantially in the PC space.  
 
Figure 5.20: PCA of 7 primary AML samples representing the changes in phosphoproteomic expression 
that co-culture with MS-5 cells induces in these AML cells. PCA of the Log2 fold-ratios for the 8,045 
peptides that significantly changed, presenting PC1 and PC2. Each dot represents an analytical replicate; 
each condition is coloured denoting sample.  
  There were examples of unexpected correlations such as that observed between the 
patient #1 independently cultured and patient #9 co-cultured samples, these both cluster 
together, suggesting that the influence of MS-5 cells induced one AML population to behave 
similarly to another independent AML subpopulation.  
5.4.2 KSEA analysis of phosphoproteomes identifies three groups of responders  
 Following the patient specific relationships of the multivariate analysis, it was 
hypothesised that interrogation of kinase specific responses within patient samples maybe more 




Figure 5.21: KSEA of significantly modulated kinases in primary AML cells following MS-5 co-culture. 
The phosphorylation status of known kinase substrates were quantified and compared between co-
cultured and independently grown primary AML cells to determine relative kinase activities. Heatmap and 
dendrograms produced using ggplots package in R workspace. Analytical replicates n = 3. Red box signifies 
that these samples both harbour an NRAS(p.G13D) mutation.  
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comparing the relative kinase activity of MS-5 co-cultured primary AML cells to the same primary 
AML cells grown independent of MS-5 cells. Hierarchical clustering of significant changes to 
kinase activity between samples identified three groups of kinase response to stromal co-culture 
(Figure 5.21). 
 Two patient samples clustered separately to the other samples, by relative putative 
kinase activity change to MS-5 co-culture and formed group 1. Group 1 was distinguished by the 
strong increase in Polo-like kinase 3 (PLK3), VRK1, ERK7, CDK3, CDK4, CDK6, and JNK2. These 
patients also had an increase in JAK2 and Ret activity that was also observed in group 3. These 
patient samples also did not exhibit increased activity of the pyruvate dehydrogenase kinases 1-
4 (PDHK1-4) which occurred in both groups 2 and 3. A notable feature that was shared by 
patients #6 and #7, was that these two patients that segregated most from the other patient 
samples (Group 1), possessed a significant NRAS mutation (p.G13D) detailed in Table 2.7. This 
mutation is believed to render NRAS constituently active. What is notable about the clustering 
of these samples is that it suggested this mutation could influence the way an AML cell 
population interprets and interacts with other cell types; however, this observation is from a 
sample size n=2 and therefore, it is not possible to make any conclusions.  
 The group 2 response comprised patients #1, #10 and #11. These patient samples all 
were characterised by a strong increase in PDHK1-4 activity but lacked the putative MEK and 
CDK activity that was present in other response groups. PDHK1-4 activity can lead to a decrease 
in glucose metabolism and altered glucose metabolism has been described as a means of 
reducing apoptosis and inducing chemo-resistance (521).  
 Group 3 was made up of patients #9 and #12. These patients clustered as they had high 
PDHK1-4 activity, however, unlike group 2, group 3 also displayed increased MEK1 and MEK2 
activity following MS-5 co-culture. Additionally, as observed in group 1 there was also increased 
putative activity in JAK2 and Ret kinases. Patient #9 in this group did have a mutation on TET2 
and exhibited a relatively modest increase in PDHK1-4 activity compared to other samples. This 
was notable, as both patients in group 1 had mutations in epigenetic modulators (patient #6 
TET2, patient #7 IDH2 mutant), and these are commonly mutated epigenetic genes that also 
have complex roles in metabolism (522).   
 Finally, there were three kinases that displayed increased activity in all patient samples 
following MS-5 co-culture, PDK1, AKT2, and LATS1. The AKT2 and LATS1 kinases have previously 
been implicated in regulating cell growth and proliferation.  LATS1 is most commonly reported 
as a tumour suppressor, helping to regulate cell growth and size. However, with previous 
theories on AML treatment resistance including microenvironment mediated quiescence of AML 
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cells, the increase in cell growth regulator (LATS1) following MS-5 interactions would fit this 
theory (523). 
5.4.3 K-means clustering analysis of primary AML phosphoproteomics to study the 
influence of MS-5 stromal co-culture on ‘ex vivo’ leukaemic behaviour  
 Similar to the systematic analysis employed in section 5.3.2, k-means clustering was 
used to study the biochemical modulations in primary AML cells following 24 hours of MS-5 co-
culture. The phosphoproteomics dataset was filtered and clustered using k-means to include 
only those peptides that were significantly modulated in at least one co-culture compared to 
the respective primary sample maintained in culture independently. Of the 9,065 peptides 
quantified in this experiment, 7,794 were phosphorylated (86% enrichment efficiency). Peptides 
were grouped into 8 clusters using the method described in Section 2.12.4.  
 The data in Figure 5.20 revealed the heterogeneity in patient cell response to the 
presence of MS-5 cells during 24 hours of ex vivo culture. The k-means analysis of this data 
further showed how distinct each AML sample can be, exemplified by the varying significance of 
each clusters per sample (Figure 5.22A).  One big difference between this analysis of co-culture 
induced signalling changes and that of single GF stimulation (Figure 5.10) and HS-5 secretome 
experiments (Figure 5.15), was the trend for increased phosphopeptide expression, whereas in 
other experiments there was a quite substantial drop in the expression of many 
phosphopeptides.  
 Analysis of the eight identified clusters and the expression of the phosphopeptides that 
comprise them suggested each primary sample had a different relationship with the MS-5 cells. 
All of the clusters except cluster 6, contained phosphopeptides that did not significantly change 
in expression for most of the primary samples. However, in each of clusters 2, 3, 4 and 7 there 
was one primary sample that would exhibit a strong increase in expression for the 
phosphopeptides that comprised that particular cluster following co-culture.  
The peptides (n=424) that comprised cluster 2 were highly expressed in patient #6 co-
cultured cells relative to independently cultured AML cells, with expression increasing 8.4 Log2 
fold on average. GO analysis using approaches previously outlined (section 5.3.2) revealed 
enrichment of Ras protein signal transduction, small GTPase mediated signal transduction, cell 
surface receptor signalling and VEGF production (Figure 5.22Bi). These ontologies would be 
consistent with the means by which MS-5 cells could activate AML cells and VEGF production is 







Figure 5.22: K-means clustering analysis comparing AML cells grown in MS-5 co-culture compared to 
those independently grown. (A) Heatmap of the Log2 fold-ratios for each of the phosphopeptides grown 
in MS-5 co-culture compared to no co-culture, each comparison includes n=3 analytical replicates. K-
means clustering assigns phosphopeptides into 8 clusters (B) GO analysis of phosphopeptides that 
comprise clusters (i) 2 (ii) 3 (iii) 4 (iv) 7. 
Cluster 3 was relevant for patient #9 cells as these phosphopeptides (n=381) increased 








phosphopeptides are associated with Aurora B signalling, caspase cascade in apoptosis, LPA 
receptor events, canonical Wnt signalling, ILK signalling and FAK mediated signalling events 
(Figure 5.22Bii). Cluster 4 contains phosphopeptides (n=484) that were on average 8.9 Log2 fold 
higher in patient #10, 3.0 Log2 fold in patient #11 and 2 Log2 fold in patient #12 following co-
culture (Figure 5.22A).  GO enrichment analysis of these phosphopeptides reported processes 
including negative regulation of both intrinsic and extrinsic apoptotic signalling, cell 
proliferation, cytokine mediated signalling pathway activity and positive regulation of cell cycle 
arrest (Figure 5.22Biii).   
 The last cluster to represent a group of phosphopeptides relevant to one primary AML 
sample’s response to MS-5 co-culture was cluster 7. This cluster represented 504 
phosphopeptides and on average the expression of these peptides increased 7.4 Log2 fold in 
patient #12 cells following MS-5 co-culture. GO enrichment of these phosphopeptides revealed 
that these enriched for both PKC and PLC activated GPCR signalling, PDGFR signalling and 
receptor guanylyl cyclase signalling (Figure 5.22Biv). The enrichment of these ontologies 
suggested that MS-5 co-culture interactions with patient #12 cells were mediated through GPCR 
pathways, pathways that were not as significant in the other primary AML co-cultures.   
5.4.4 Phosphopeptides that are increased in all AML primary samples following MS-
5 cell co-cultures  
 Having established and analysed the k-means in which one primary AML sample 
exhibited a strong increase in expression, cluster 6 contained phosphopeptides (n=176) that 
were enriched for in all patient samples following co-culture (Figure 5.23A). This was also the 
only cluster in which phosphopeptide expression increased following co-culture for patients #1, 
#7 and #11.  
KSEA analysis of these 176 phosphopeptides revealed that there were four kinases that 
significantly increased in activity; AKT, CDK5, Dual-specificity tyrosine-regulated kinase 2 
(DYRK2) and LATS1 (Figure 5.23B). AKT as discussed previously is a key mediator of cell growth, 
proliferation and survival. CDK5 is a pleiotropic kinase with defined roles in a myriad of cellular 
processes (524). CDK5 notably has previously been described as an inhibitor of apoptosis 
through phosphorylation of AKT at Ser473 (525), which supports the increased AKT activity. CDK5 
has also previously been implicated in regulating actin cytoskeleton and mediating cell adhesion 
and migration in the microenvironment, an action executed through PAK1 phosphorylation 
(frequently seen as one of the most active kinases in AML) (526, 527). Finally, CDK5 has recently 
been described as being able to exert control on the expression of HIF1α target genes, vascular 
endothelial growth factor (VEGF)-A and VEGF receptor 1 (528) to drive tumour angiogenesis and 
induce secretion of pro-angiogenic molecules (529). DYRK2 has previously been described as a 
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regulator of cancer cell metastasis (530) and a determinant of epithelial mesenchymal transition 
(EMT) in solid tumours (531), however, DYRK2 inhibits an invasive phenotype. The last kinase 
that was identified as more active was LATS1, as discussed in section 5.4.2 LATS1 is a regulatory 
kinase that typically controls cell size and proliferation. GO analysis of cluster 6 determined that 
these peptides that were increased in all patients enriched for the biological processes: negative 
regulation of extrinsic apoptotic signalling, negative regulation of apoptotic signalling and the 
cellular component disassembly involved in the execution of apoptosis (Figure 5.23C). These 
findings suggest that MS-5 co-culture induced increased survival in each of the primary samples, 
through the activation of anti-apoptotic pathways.  
 
 
Figure 5.23: K-means analysis reveals that there is enrichment for phosphopeptides that are indicative 
of AKT2 activity and an increase in anti-apoptotic signalling. (A) Average Log2 Fold change in 
phosphopeptide expression for patient sample following co-culture with MS-5 cells, n=176 
phosphopeptides, run in analytical triplicate. (B) KSEA determined changes in kinase activity following co-
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5.5 AML/Stromal cell co-culture: identifying patterns of MS-5 response to 
different primary AML disease 
Phosphoproteomic analysis of the primary AML cells following MS-5 co-culture 
confirmed our predictions that the secretome was not the only means by which BMSCs can 
influence AML cell signalling, with the observation of additional signalling events in a co-culture 
system to that elicited by CM alone. Simultaneously to the analysis of the primary AML patient 
phosphoproteomes, we additionally collected the MS-5 cells that had been used to provide the 
supportive network for these AML cells. These cells while supporting the AML cells were in turn 
being influenced and therefore we predicted that it may be possible to identify activated positive 
feedback mechanisms induced by AML cells in the MS-5 cells by once again employing a global 
LC-MS/MS based phosphoproteomic approach. Upon completion of lysis, the eight MS-5 
populations underwent the same phosphoproteomic workflow as the primary AML cells to 
determine the heterotypic signalling in this co-culture model. 
5.5.1 Differential abundance  
Analysis of this experiment retrieved 8,961 peptides, of which 8029 were 
phosphorylated (90% phospho-enrichment efficiency). The data shown in Figure 5.24 served as 
preliminary indication of the effect that each primary AML sample had on respective MS-5 
phosphoproteomes. Superficially, these results indicated that AML samples from patent #7 and 
patient #12 had quite profound effects on the MS-5 cells, with patient #7 cells inducing 235 
phosphopeptides to significantly increase >1.5 Log2 fold and 726 phosphopeptides to 
significantly decrease <1.5 Log2 fold – collectively nearly 1x103 phosphopeptides significantly 
changed as a result of 24 hours of co-culture with patient #7 cells.  
 
Figure 5.24: Differential abundance analysis of MS-5 phosphoproteomes following co-culture. 
Differential abundance analysis of the phosphoproteomics data. The number of phosphopeptides either 
significantly increased (red) or decreased (blue) in abundance compared to independent MS-5 cells are 
shown. Fold change, log2 fold-change vs MS-5 independent control; adjusted P, is the corrected P-value 
for multiple testing by the Benjamini-Hochberg method. 
Patient #12 cells substantially altered phosphopeptide expression of the MS-5 cells that 
they were cultured with, 602 phosphopeptides increased >1.5 Log2 fold and 501 
phosphopeptides decreased <1.5 Log2 fold. Those two MS-5 populations were outliers, with all 
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other AML co-cultures only inducing 100-200 significant changes in the MS-5 global LC-MS/MS 
phosphopeptides analysis. 
5.5.2 Global phosphoproteomic analysis of MS-5 cells following AML co-culture 
To compare the phosphoproteomes of the MS-5 cells following primary AML co-culture, 
hierarchical clustering of the phosphopeptide fold changes between co-cultured MS-5 cells and 
independent MS-5 culutres was performed as presented in Figure 5.25. This analysis revealed 
that for many of the MS-5 populations the effects of different primary AML cells in culture were 
homogeneous, as MS-5 cells cultured with cells from patients #1, #6, #8 and #9 all clustered 
together following mutlivariate analysis. MS-5 cells cultured with patient samples #10 and #11 
did not produce remarkably different expression profiles to that of the MS-5 cells described as 
closely clustering (MS-5 cells with patients cells #1, #6, #8 and #9), as there were only a few 
clusters of proteins in which MS-5 cells cultured with patients cells #10 and #11 differed from 
the other MS-5 populations. These differences though distinguished  the phosphoproteome of 
MS-5 cells cultured with patients cells #10 and #11 as distinct from other MS-5 cells. 
MS-5 cells incubated with patient #7 cells clustered separatly to the left of the clustering 
plot, this was likely due to the clusters of decreased phosphopetide expression, which  were 
apparent in the differential analysis in Figure 5.24. The other MS-5 sample identified as being 
different compared to the other samples was that cultured with patient #12 cells. In the 
clustering analysis this sample distinctly segregated by itself, with a number phosphopeptides 




Figure 5.25: Hierarchical clustering of MS-5 phosphopeptide expression fold changes in response to co-
culture with patient AML cells.  Fold change is relative to phosphopeptide expression of MS-5 cells grown 
in presence of AML to those grown in the absence, averaged across 3 analytical replicates, heatmap and 
dendrograms produced using ggplots package in R workspace. 
 
To understand how these changes in phosphopeptide expression functionally effected 
the MS-5 populations, GO enrichment analysis was conducted as outlined in the methods and 
displayed in Figure 5.26. Ontologies are ranked by the number of samples that the ontology was 
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enriched in following AML co-culture (highest to lowest) and ontologies were only included if 
the process was enriched (p<0.05) in 2 or more samples.  
 
Figure 5.26: Heatmap of enriched GO processes in MS-5 cells following AML co-culture. Enrichment 
measures change phosphopeptide expression of MS-5 cells grown in presence of AML to those grown in 
the absence, averaged across 3 analytical replicates. m; no of substrates. 
 The most frequently enriched process is that of activity in the insulin receptor signalling 
pathway (n=6), followed by signal transduction and CDK1 activity (both n=5). Other notable 
processes included the positive regulation of protein kinase activity, Ras protein signal 
transduction and GF activity. These ontologies are collectively indicative of increased RTK 
activity and receptor mediated signalling. Thus, strongly suggesting that the primary AML cells 


















































Insulin receptor signaling pathway 0 0 0 0 0 0.1 0.1 0 70
Signal transduction 0.1 0 0 0 0 0 0.1 0.1 133
Cycl in-dependent protein kinase activi ty 0 0.1 0 0 0 0.1 0.1 0 52
Positive regulation of ERK1 and ERK2 cascade 0.1 0 0.1 0 0 0.2 0 0.2 16
Positive regulation of protein kinase activity 0.1 0 0 0 0 0.1 0.1 0.1 32
Regulation of Rho protein s ignal  transduction 0.1 0 0 0.1 0 0.1 0.1 0 32
Ras protein signal transduction 0 0.1 0 0.2 0.1 0 0.1 0 17
Insulin-like growth factor receptor signaling pathway 0.1 0 0 0.1 0.1 0.2 0 0.1 18
Regulation of ARF protein signal transduction 0 0.2 0.1 0.1 0.1 0 0 0.2 11
Lipopolysaccharide-mediated s ignal ing pathway 0.2 0 0.2 0 0 0.3 0.2 0.1 15
Protein kinase binding 0.1 0.1 0 0 0.1 0.1 0 0.1 83
Rac protein s ignal  transduction 0.2 0.3 0 0 0.2 0.3 0 0.3 6
1-phosphatidyl inos i tol -4-phosphate 5-kinase activi ty 0 0.3 0.1 0.2 0.2 0 0 0.3 5
Growth factor activity 0.2 0.1 0.2 0 0 0.3 0 0.2 12
Phosphatidyl inos i tol -3,4,5-trisphosphate binding 0.1 0 0.1 0 0.1 0.2 0.1 0 8
Protein kinase C activi ty 0 0.1 0.1 0.1 0 0 0.2 0.2 12
MAPK cascade 0.2 0.1 0.1 0.1 0 0 0.2 0 14
Regulation of cycl in-dependent protein kinase activi ty 0 0.1 0.2 0 0 0.3 0.1 0.2 9
Phosphatidyl inos i tol -3,5-bisphosphate binding 0.2 0.3 0 0 0.1 0.6 0.3 0.4 3
Phosphatidyl inos i tol -mediated s ignal ing 0.2 0.1 0.2 0.2 0.2 0.2 0 0 12
Pos itive regulation of Notch s ignal ing pathway 0.2 0.1 0.2 0.2 0.2 0 0.1 0 7
Intracel lular s ignal  transduction 0 0.1 0.1 0.1 0.1 0.1 0 0.1 94
Phosphatidyl inos i tol -3-phosphate binding 0.2 0.1 0.2 0.2 0.1 0.1 0 0 11
Pos itive regulation of TOR s ignal ing cascade 0.2 0.2 0.1 0 0.2 0.4 0.3 0 7
Interkinetic nuclear migration 0 0.1 0.1 0.1 0.2 0 0.2 0.1 16
cAMP-mediated s ignal ing 0.2 0.2 0.2 0 0.3 0 0.3 0.3 6
Rho protein s ignal  transduction 0.1 0.2 0.2 0.1 0.1 0 0.1 0 17
Insul in-l ike growth factor receptor binding 0.2 0.1 0 0.1 0 0.2 0.1 0.1 10
Protein kinase C binding 0.1 0.1 0.1 0.1 0.1 0 0 0.1 85
Activation of MAPK activi ty 0 0.2 0.2 0.1 0.1 0 0.1 0.1 19
p-value key
< 0.0001 0.001 0.01 0.05 >0.1
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5.5.3 KSEA analysis of MS-5 following AML co-cultures reveals two patterns of 
 kinase activity 
 To establish the effect that these primary AML cells were having on MS-5 kinase 
networks, KSEA was implemented as described in the methods section 2.12. Hierarchical 
clustering of the KSEA output showed that the kinase response to the primary AML cells was in 
agreement with Figure 5.25 showing that there were two signatures of response (Figure 5.27). 
The first sample group included MS-5 populations that were cultured with samples from 
patient’s #7, #10, #11 and #12, although the dendrogram did indicate a segregation between 
patient sample #12 and the rest of group 1. The remaining MS-5 populations cultured with 
patient samples #1, #6, #8 and #9 clustered together to form group 2.  
Figure 5.27: KSEA of significantly modulated kinases in MS-5 cells following co-culture. The 
phosphorylation status of known kinase substrates were quantified and compared between co-cultured 
and independently grown MS-5 cells to determine relative kinase activities. Each comparison calculated 
using 3 analytical replicates. Heatmap and dendrograms produced using ggplots package in R workspace.  
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 Assessment of specific kinase expression patterns showed that the kinase to be 
putatively upregulated across all MS-5 cell populations following AML co-culture was MAP 
kinase-activated protein kinase 2 (MAPKAPK2). In addition there was also consistent putative 
upregulation in the phosphorylation of PKC and GSK-3 isoform 2 substrates. Group 2 MS-5 
populations consistantly demonstrated increased putative activity in CAMK2A, GSK-3, PKC 
and cAMP-dependent protein kinase catalytic subunit alpha (PKACA). Whereas, MS-5 
populations in group 1 exhibited putative decreases in these three kinases following co-culture. 
CDK1 was moderately increased in group 2 MS-5 populations, and strongly decreased in group 
1 populations, this observation was in accordance with GO findings in Figure 5.26. In general 
many kinases assessed by KSEA decreased in activity following  AML co-culture, in particular 
kinases mediated by Rho family GTPases, the AKT-mTOR pathway, and the RAF-MEK-ERK 
signalling axis.   
5.5.4 AML blast independence and embedding in MS-5 stromal cells could correlate 
 with PCA observations 
The hierarchical clustering analysis suggested that, as seen in Figure 5.27, MS-5 cells 
separated into patterns of response. MS-5 cells incubated with patient #1, #6, #8 and #9 cells 
responded similarly, whereas other MS-5 phosphoproteomic signatures were not as predictable. 
PCA analysis of the phosphoproteomics data was undertaken to further visualise spatially how 
different MS-5 populations were responding to the AML patient cells. (Figure 5.28).  
 
Figure 5.28: Multivariate analysis of MS-5 cells following co-culture demonstrates AML influence. PCA 
of the Log2 fold-ratios for the 8029 phosphopeptides that significantly changed in PC1 vs PC3. 
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The MS-5 populations that all responded in a similar manner to AML co-culture with 
patient #1, #6, #8 and #9 cells shared the same PC space (blue circle), and these cells were 
derived from the same parent MS-5 cells as controls 1 and 2. GO analysis suggested that all these 
cell populations had increased RTK activity and were being regulated by the AML cells, whether 
this is responsible for the supportive behaviour MS-5 cells exhibit towards AML cells is to be 
confirmed.  
MS-5 populations cultured with patient #10 and #11 cells shared PC space with the two-
separate control MS-5 conditions (MS-5 cells maintained in culture 24 hours independently) that 
had no exposure to AML cells. These samples also displayed no insulin receptor pathway 
enrichment in MS-5 populations following co-culture, additionally there was no enrichment for 
protein kinase activity or CDK1 activity. As these ontologies were suggestive of increased RTK 
activity in MS-5 cells as a consequence of AML influence and that these cells share PC space with 
the control MS-5 cells, collectively this data suggests that the AML cells did not significantly 
integrate or impact on MS-5 cell behaviour in these samples. 
 The MS-5 cells co-cultured with patient #12 and patient #7 cells did not display either of 
these two phenotypes and in PC space were isolated, and this was not due to irreproducible 
replicates not clustering together. As MS-5 cells cultured with patient #12 cells separated so 
profoundly from the other MS-5 populations it was hypothesised that perhaps there was 
something clinically different about these AML cells that would explain the polarity in MS-5 
phosphoproteomic expression to the other samples. This analysis revealed that that patient #12 
was distinct in that this patient’s AML was classified as M0 – denoting minimal differentiation. 
If these cells did not possess the receptors or machinery to manipulate the MS-5 cells as the 
other AML cells did, then this would go some way to explaining these observations. Additionally, 
these patients tend to have a higher percentage of CD34+ cells, and it is these cells that are 
documented as having a preference for niche engraftment (11) – meaning that the MS-5 
population being analysed may have contained some patient #12 AML blasts.  
 Assessment of patient #7’s clinical features identified that these cells were the only non-
adverse risk sample included in the experiment. Patient #7 cells were of intermediate risk, when 
analysing PC1 these MS-5 cells cultured with this AML do align with the control cells and it is 
only after considering PC3 that MS-5 cultured with patient #7 cells deviate from other cultures. 
These results suggest that AML of different risk groups, likely have different relationships and 
impact on the microenvironment, a recent paper has already suggested that de novo AML 




 Phosphoproteomic analysis of MS-5 cells co-cultured with primary AML cells suggested 
that there were signatures being identified that were indicative of environmental dependence 
and independence. To try and functionally validate these observations, images were taken of 
primary AML cells from the same patients in co-culture to assess interactions. Analysis of 
cultures by microscopy showed that patient #10 cells in co-culture morphologically appeared to 
cluster into defined round groups, almost appearing to be resting on top of the MS-5 cells (Figure 
5.29). Similarly, cultures containing patient #11 cells looked to have more of these clusters that 
rest above MS-5 cells. Patient #8 cells on the other hand, were not as abundant and nor did 
there appear to be any clusters of AML cells. Instead the AML cells were integrated within the 
stromal cells, possibly suggestive of a more microenvironment-interactive cell. Patient #9 cells 
in this assessment were definitely more abundant than the patient #8 AML cells and had the 
signs of some clusters. But they too, were not very rounded and had the morphology of a spread 
cell that was interacting. Additionally, patient #9 cells did not look like they were resting atop 
the MS-5 cells like patient’s #10 and #11. 
 
Figure 5.29: Bright field images of primary AML/MS-5 co-cultures prior to phosphoproteomic analysis. 
Arrows indicate the clusters of AML blasts and MS-5 cells in co-culture. Patient samples #10 and #11 in 
co-culture do not integrate with the MS-5 cells (microenvironment independent), with the presence of 




 Relating these morphological observations to the phosphoproteomics data, MS-5 cells 
that had been cultured with patients #10 and #11 clustered with the AML independent MS-5 
cells in Figure 5.28. Under the microscope these cells looked to favour clustering with other AML 
cells as opposed to integrating with the MS-5 stromal layer. This would correlate with the less 
divergent phosphoproteome of MS-5 cells that were cultured with these AML cells. Whereas, 
patients #8 and #9 did not share PC space with independent control MS-5 cells, they instead 
clustered with MS-5 cells that had been cultured with other primary AML cells. Thus, suggesting 
that these could be representative phosphoproteomes of AML influenced MS-5 cells.  
5.6 Summary  
 The experiments described in this chapter aimed to decipher the role of BMSCs in AML 
kinase signalling. The initial objective was to define the signalling pathways activated in AML 
cells following stimulation with both the identified secretomic components from Chapter 3, as 
well as the complete secretome. Due to the heterogeneity of the disease, experiments were 
expanded to identify frequently activated signalling nodes in AML by treating primary samples 
with bulk HS-5 secretome. Subsequently, to establish the heterotypic signalling that exists 
between BMSCs and AML cells co-culture models were designed and label-free 
phosphoproteomics used to assess signalling dynamics. 
P31/FUJ cells were serum starved and treated with 10ng/ml of the six secretome derived 
proteins, the proteins mixed and 10g/ml of the bulk secretome. Western blot analysis was 
employed to investigate the influence of these proteins on the targets of the kinase inhibition 
studies detailed in Chapter 4 - principally components of the MAPK and PI3K-AKT-mTOR axis 
(Figure 5.2). The experiments revealed that CSF-1 and the complex mixtures activated MAPK in 
these cells (Figure 5.3). Assessment of AKT showed that these cells in all conditions, AKT was 
highly active (Figure 5.4), this is likely due the constituent activation of AKT observed in P31/FUJ 
cells. Western blot analysis of the mTOR substrates S6K and 4EBP1 suggested that the individual 
GFs alone were not enough to stimulate upstream pathways sufficiently to impact on 
downstream targets like S6K and 4EBP1. However, binding of upstream receptors (multiple or 
the same) with numerous molecules was potent enough for activation of mTOR substrates. PAK 
activity was also positively regulated by the S100 proteins, conversely the Mixed GF condition 
inhibited PAK phosphorylation (Figure 5.5), whereas the stromal secretome activated PAK1 
suggesting there are other molecules in the secretome capable of activating PAK1. These data 
confirmed the differential effects that kinase inhibitors had on AML cells in the presence of the 
complete stromal secretome (Table 4.3).  
Following this validation that the RPs were capable of activating key AML signalling 
nodes in P31/FUJ cells, the phosphoproteome of patient # 1 cells was chosen to assess pathway 
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activity in primary AML, as these cells displayed dynamic responses to the secretome derived 
protein treatments (Figure 5.6). This was achieved through the use of mass spectrometry-based 
phosphoproteomic profiling of patient #1 cells under treatment with the panel of stromal 
derived proteins individually and in combination (Figure 5.7). Prior to any biological 
interpretation, a thorough quality control analysis of the dataset determined that the data were 
of high qualitative and quantitative quality, both in terms of the identification of 
phosphopeptides and the retention time alignment for accurate label-free quantification across 
samples (Figure 5.8). Previous papers (533, 534) have reported the strength of fitting linear 
models to quantitative data to then assess differential abundance of phosphopeptides against 
the control sample (No GF). This assessment revealed that S100-A4 caused the most 
phosphopeptides to significantly (P<0.05) increase in abundance by >1.5 Log2 fold and mixed 
secretomes, in particular the Mixed GF condition induced the largest  significant (P<0.05) 
decrease in phosphopeptide expression with 480 peptides decreasing by >1.5 Log2 fold relative 
to unstimulated cells (Figure 5.9). 
To assess relationships between the effects of the secretome derived proteins on the 
patient #1 phosphoproteome, the similarity between the log2 fold-ratios of all the 
phosphopeptides across the treatments were assessed using hierarchical clustering and PCA 
(Figure 5.10 and Figure 5.12). This analysis demonstrated that the two phosphoproteomes that 
were remarkably different to the unstimulated and basal samples were that of the Mixed GF 
and S100-A4 stimulated cells, which was in agreement with the proliferative response observed 
when patient #1 cells were treated with the secretome derived proteins in Chapter 4 (Figure 
4.5). Relative changes in kinase activity across patient #1 phosphoproteomes was achieved using 
in house KSEA software, systematic assessment determined that the single protein treatments 
induced increased activity in AKT, mTOR, ERK1 and ERK2, with S100-A4 also increasing ATR, 
CK2A2 and InsR activity which was not observed in the other treatments (Figure 5.11). Complex 
protein mixtures induced global decreases in kinase activity, which was unexpected. If this was 
not a technical issue or anomaly, it could be that as these mixtures were supportive, and stress 
induced activation of signalling pathways had subsided. Alternatively, it could have been due to 
a lack of signal perpetuation, as a result of receptor internalisation from high GF concentrations. 
This needed to be repeated and investigated in a larger cohort, to determine if the stromal 
secretome mediates survival through the activation/inactivation of particular signalling nodes.  
To investigate the global effects of the stromal secretome on AML kinase networks, a 
cohort of primary AML samples were maintained for 24 hours both with and without HS-5 
stromal derived proteins prior to label-free phosphoproteomics (Figure 5.13). Previous studies 
had shown that basal levels of kinase activity in primary AML cells can be extremely 
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heterogeneous (535, 536), however, as HS-5 CM had proved effective at maintaining AML 
viability (Chapter 3) and modulating kinase inhibitor efficacy (Chapter 4). Differential abundance 
demonstrated that patient phosphoproteomes were profoundly modulated by HS-5 CM 
compared to the same patient cells maintained in independent cultures for both 1 and 24 hours 
(Figure 5.14).  
Following this, k-means clustering analysis was undertaken to determine relationships 
patient phosphoproteomes following 24 hours of HS-5 secretome treatment. This analysis 
grouped phosphopeptides into 9 clusters based on significant (P<0.05) log2 fold changes in 
expression relative to the 1 hour and 24 hour independent patient phosphoproteomes (Figure 
5.15). Primary AML phosphoproteomes displayed heterogeneous expression signatures across 
the clusters, however there was a broad consensus for increased phosphopeptide expression in 
clusters (1, 3 and 9), and decreased expression in cluster 5. GO enrichment analysis of 
phosphopeptides assigned to these clusters identified enrichment for increased NF-B mediated 
signalling, DNA-PK pathway activity and AKT mediated PI3K signalling, while cluster 5 (decreased 
expression) phosphopeptides enriched for apoptosis processes (Figure 5.15D). This 
demonstrated that despite huge heterogeneity in phosphoproteomes there is consensus for 
anti-apoptotic signalling. In addition, hierarchical clustering of KSEA data demonstrated the 
breadth of kinases that are temporally activated and deactivated in response to the HS-5 CM 
(Figure 5.16). To compare patient phosphoproteome similarity across conditions, the data was 
analysed using PC analysis (Figure 5.17). This analysis demonstrated that the basal 
phosphoproteomes at 1 hour were distinct and did not cluster to share the same PC space; 
following 24 hours of HS-5 conditioning 6/7 samples had migrated centrally to occupy a similar 
region. This indicated that despite their different basal phosphoproteomes, stimulation with the 
HS-5 secretome effected the phosphoproteomes similarly, suggesting that signals may have 
been transmitted via different routes in the network that ultimately induce the same cellular 
response.  
To investigate the effects of the BMSM on AML cell signalling, whilst accounting for 
contribution of juxtacrine signalling and the ability of cells to respond to each other dynamically 
(heterotypic signalling), a label-free phosphoproteomic study was conceived to analyse primary 
AML cells and MS-5 cells following 24 hours co-culture (Figure 5.18). Seven primary AML samples 
were seeded in MS-5 co-culture and to assess the effects of co-culture on patient 
phosphoproteomes, hierarchical clustering and PC analysis were undertaken (5.19 and Figure 
5.20). These results showed that individual phosphoproteomes clustered by biological replicates 
and then by co-culture, suggesting the analysed populations were pure and that as observed 
previously each patient phosphoproteome was quite distinct. KSEA measuring the influence of 
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MS-5 co-culture on kinase activity was more defined than what was observed during secretome 
stimulation (Figure 5.21). Changes in kinase activity were now consistent, with activity 
signatures clustering into three groups. These groups were defined by increases in kinase 
activity, as opposed to decreases in kinase activity as observed in both single GF and HS-5 
secretome treated AML phosphoproteomic experiments. Group 1 patients were distinguished 
by the strong putative increases in PLK3, VRK1, ERK7, CDK3, CDK4, CDK6, and JNK2 kinas activity. 
The group 2 response was characterised by a strong putative increase in PDHK1-4 activity, but 
lacked both the MEK and CDK activity that was present in other response groups. Finally, group 
3 patients displayed increased MEK1 and MEK2 activity following MS-5 co-culture, in addition to 
increased activity in JAK2 and Ret. Group 1 responders also harboured an NRAS mutation 
(p.G13D) detailed in Table 2.7, and this suggested that the NRAS mutations could influence 
patient cells ability to respond to MS-5 cells, although this requires further investigation.  
To attribute biological significance to these changes in kinase activity K-means clustering 
analysis was undertaken to assign phosphopeptides to similar clusters prior to GO analysis. 
(Figure 5.22). This exercise demonstrates the heterogeneity in how MS-5 cells can modulate 
AML phosphoproteomes, as clusters 2, 3, 4 and 7 each contained phosphopeptides that were 
exclusively upregulated in one patient sample. Each of these clusters comprised substrates that 
enriched for specific pathways; Ras signalling and VEGF production (in cluster 2); aurora B, ILK 
and Wnt signalling (in cluster 3), anti-apoptotic signalling (in cluster 4); PKC and PLC mediated 
GPCR signalling (in cluster 7). The patient specific expression in these clusters suggests that these 
are examples of the heterogeneous signalling network dependencies that can arise in AML cells, 
which then shape how AML cells interact with other cells. Phosphopeptides that comprised 
cluster 6 were more abundant in all patient samples following MS-5 co-culture. GO analysis of 
these peptides suggested that MS-5 cells are able to support these primary AML cells in culture 
by upregulating anti-apoptotic pathways, while KSEA analysis implicated these phosphopeptides 
as substrates of AKT2, LATS1, CDK5 and DYRK2 signalling pathways (Figure 5.23).   
Finally, recent studies had demonstrated that other tumour types can engage and 
instigate reciprocal signalling with surrounding stromal cells (491) to regulate cancer cell growth 
and survival. Following experiments that demonstrated how MS-5 cells could potentiate both 
anti-apoptotic signalling and modulate the activity of proliferative kinases AKT and LATS1 in 
primary AML, phosphoproteomic experiments were undertaken to characterise how AML co-
culture affected MS-5 cell phosphoproteomes. To determine if such reciprocal mechanisms 
could be identified within the devised co-culture system, the phosphoproteomes of co-cultured 
MS-5 cells were compared those of AML naïve MS-5 cells. These experiments showed that the 
phosphoproteome of MS-5 cells across co-cultures were modulated by the presence of AML 
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cells (Figure 5.24) and hierarchical clustering of the log2 fold changes in phosphopeptide 
expression demonstrated that MS-5 cell populations clustered into two groups, with one MS-5 
population that did not cluster with either group (Figure 5.25).  GO enrichment analysis of all 
significantly modulated peptides (P<0.05) revealed that 6/8 of MS-5 populations exhibited 
increased insulin receptor signalling and signal transduction following AML co-culture (Figure 
5.26). This suggested that different AML cell populations were capable of modulating MS-5 cell 
signalling and KSEA revealed all MS-5 cells that had been cultured with AML cells exhibited 
increased activity of MAPKAPK2, PKCD and GSK3 pathways (Figure 5.27). Previous studies have 
demonstrated that cytokine production is suppressed during loss of MAPKAPK2 function (537), 
thus representing a potential means of AML mediated heterotypic signalling to regulate cell 
survival. It remains to be mechanistically proven however, whether this finding is biologically 
relevant. 
To integrate signalling and biological observations, KSEA and PC analysis were 
conducted on the significantly (p<0.05) modulated log2 phosphopeptide fold changes (Figure 
5.28). Analysis determined that there were two kinase signatures, an AML/MS-5 interacting 
group that separated in PC space from AML naïve MS-5 cells (Figure 5.28, blue circle) and a 
AML/MS-5 independent group that did not separate. Further, these findings matched 
phenotypic microscopy observations of the cultures (Figure 5.29), “interactive” co-cultures 
exhibited increased AML single cell embedding in the stromal layer, whereas the “independent” 
co-cultures were typified by clusters of AML cells separate from the stromal layer. 
Taken together, these experiments showed that AML kinase signalling network 
underwent significant and heterogeneous shifts in activity following stimulation with stromal 
secreted proteins. Most strikingly, different primary AML samples were able to respond to 
stromal cells through both homogeneous and heterogeneous network routes, while 












Chapter 6: Functional and biochemical characterisation of PAK 
signalling in AML 
6.1 Introduction and aims of the study  
Our group using a kinase substrate enrichment approach (KSEA) had previously analysed 
a panel of primary AML samples comparing the relative activity of the protein kinases, this work 
revealed that the substrates of PAK were frequently overexpressed in the samples compared to 
healthy controls (Figure 6.1) (271). Experiments in Chapter 3 showed that PAK is modulated by 
the stromal secretome (Figure 3.9) and subsequent work demonstrated that in culture primary 
AML cells were profoundly sensitive to PAK inhibitors compared to that of other kinase inhibitors 
(Chapter 4). Other studies have also shown PAK to be a key mediator of leukaemogenesis in FLT3 
and KIT driven leukaemia and these neoplasms also exhibited sensitivity to current PAK 
inhibitors (IPA-3 and PF-3758309) (207, 538, 539).  
 
Figure 6.1: Global kinase substrate enrichment analysis (KSEA) reveals substrates of PAK are one the 
most frequently enriched groups in primary AML cells. Phospho-peptide enrichment followed by liquid 
chromatography-mass spec/mass spec (LC-MS/MS) quantification was conducted on primary cells from 
20 AML patients and granulocyte colony-stimulating factor-mobilised peripheral blood (GMPB) cells from 
5 healthy donors. The heatmap on the left shows enrichment of the PAK substrate groups in AML patients 
compared to the healthy donors, of which there is quite a large increase in expression. The right heatmap 
shows the statistical significance of the changes/patient. Definitions m, no of substrates in the substrate 
group for that particular PAK; n, no of cases significant change in the PAK substrate group; %, proportion 
of AML patients with significant enrichment of PAK. Figure adapted from (271). 
PAKs are a group of highly conserved serine/threonine protein kinases that sit directly 
downstream of the Rho GTPases, most notably CDC42 and Rac (540, 541). The PAKs have been 
shown to function as effectors of GTPases as well as with PDK1 (542), PKA (543) , PI3K (544)  and 
AKT (545). Through their kinase activity they mediate the downstream signalling that induces 
the physiological effects of GTPase signalling (Figure 6.2). PAKs regulate apoptotic pathways 
through interactions with the apoptotic effectors like BAD, BimL and DLC1. Hormone 
independence through phosphorylation of the oestrogen receptor (ER) and cell cycle 
progression can be regulated through PAK interactions with Histone 3 (H3), Aurora A kinases 
and polo-like kinase (PLK1). PAK can also modulate cell growth through its influence of 
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transcription factors and co-regulators SNAI1, SHARP, FKHR and CtBP1. These same substrates 
also enable PAK to influence the epithelial-mesenchymal (EMT). 
 
Figure 6.2: PAK signalling cascade in a physiological context.  Upstream of PAK lie many signalling 
pathways. Signals can be initiated through signalling molecules binding to G-protein coupled receptors 
(GPRC), receptor tyrosine kinases (RTK) or integrin’s. Downstream effectors of these membrane proteins 
eventually activate PAK through Rho GTPases such as Cdc42 and Rac. Once activated PAK can influence a 
myriad of functions; cell proliferation through the MAPK pathway by phosphorylating Raf1, cytoskeletal 
dynamics by phosphorylating regulators such as myosin light chain kinase (MILCK), Lim domain 
kinase(LIMK), and filamin A. Figure adapted from (546). 
There are six isoforms described in mammalian cells, and based on structural and 
functional characteristics these isoforms can be further sub-divided into two groups (546).The 
group I PAKs comprise of the isoforms PAK1, PAK2 and PAK3; group II is comprised of PAK4, 
PAK5/7 and PAK6 (547). Both groups of PAKs have distinct and shared functions and are 







Figure 6.3: Oncogenic PAK signalling characterised in solid tumours. (A) Describes PAKs implications in 
signalling pathways effecting cell survival and growth signal autonomy. PAK has been implicated in the 
activation of AKT and NF-κB however, the exact mechanism of action is currently unknown. It is known to 
interact with apoptotic proteins such as BAD and caspases 7 and 8 to influence cell survival. Interactions 
with MEK1 and β-catenin are known to effect cell cycle progression and therefore growth and 
proliferation. (B) Over activity of PAK in an oncogenic context is essential for angiogenesis, cell 
proliferation, survival, attachment and migration. The phosphorylation of BAD and C-RAF by PAK protects 
against apoptotic stimuli. The ERK pathway is exploited for cellular proliferation and migration by the 
RAC–PAK pathway. Vascular permeability is mediated by PAK through modulation of cell–cell adhesion 
molecules. MLCK phosphorylation by PAK generates increased contractility and permeability. 
Oncogenic overexpression of PAK has been described in a number of solid tumours 
including breast, colorectal, pancreatic and ovarian, with expression positively correlating with 
advanced disease and poor outcome (515, 547-549). In these tumours PAK promotes cell 
growth, helps evade apoptosis and mediates invasion and metastasis (Figure 6.3) (515, 548-551). 
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It has been shown that PAK is overexpressed in AML (271) and due to the position of 
PAK in the signalling cascade it is postulated that PAK either helps drive or facilitate disease 
progression. We hypothesised that for some patients PAK is a key contributor to the AML 
pathophysiology. If this is the case then targeting PAK could be a viable means of treatment for 
these patients, results in Chapter 4 demonstrate how sensitive AML cells can be to PAK 
inhibition. But to effectively target PAK it is important to understand the mechanisms that 
underpin and regulate PAK activity in AML. Work presented in this chapter sought to functionally 
and biochemically characterise PAK signalling in AML utilising proteomic approaches.  
The aims of this chapter were to: 
(i) Determine factors that lead to PAK activation in AML.  
(ii) Optimise a co-immunoprecipitation coupled mass spectrometry approach. 
(iii) Identify PAK binding partners in AML using co-immunoprecipitation. 
(iv) Validate identified interactions and the contribution to AML. 
 
 
6.2 Meta-analysis of genetic mutations in AML 
 To account for the increased PAK activity in AML (271), we investigated the mutational 
status of PAK in AML with a meta-analysis of published large-scale genomics data. Using this 
approach, we aimed to establish if the increased activation of PAK had foundations in mutations 
that could induce constitutive activation, loss of substrate specificity or overexpression of the 
protein. To evaluate an appropriate cohort we conducted a search of the catalogue of somatic 
mutations in cancer (COSMIC) generated by the Sanger institute. This is the largest repository of 
whole genome sequenced AML patient samples (n=390). In total there were 8178 separate 
genes identified as carrying a mutation in at least one individual across 390 AML patients. The 
frequency of these mutations was as previously described in the literature with NPM1, FLT3, 




Figure 6.4: Meta-analysis of genetic mutations from COSMIC repository of 390 whole genome 
sequenced AML patients. The graph shows genes that were mutated in at least 3% of patients, 8178 
mutated genes identified across a screen of 390 AML patients. Genes that are well annotated in the 
literature as being implicated in AML are highlighted red. None of the PAK genes were mutated in this 
dataset. 
 This repository contained many of the characteristics that the literature has previously 
described in AML, such as NPM1, FLT3 and epigenetic regulators frequently harbouring the most 
mutations, thus we believed it to be representative of AML. Within this dataset there were no 
mutations in PAK, with the independent Sanger annotated resources also listing PAK as a gene 
that harbours no mutations in these 390 AML genomes. This finding suggests that there are 
mechanisms other than genetic, in AML that contribute to disease progression. 
 In the instances where PAK exhibits a high level of activity there are many routes by 
which this activity could be facilitated. Protein expression can be affected by epigenetic 
regulation; ligand binding and cell-cell interactions can activate cell-signalling pathways, as 
demonstrated by work in Chapter 5. Despite an absence of PAK mutations in these screens, that 
is not to say there is no genetic contribution as these screens were only in coding regions of the 
genome and deregulation of a particular target protein can arise through the acquisition of 
mutations in non-coding DNA elements. 
6.3 Western blot analysis of PAK expression in AML cell lines 
Following the revelation that AML frequently lacks PAK mutations it was deemed 
pertinent to establish PAK activity in cell models MV4-11 and P31/FUJ. Previously Chapters 3 
and 5 have demonstrated that PAK activity can be altered by elements of the microenvironment 
(Figure 3.9 and Figure 5.5). For these experiments it was important to establish that between 
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the cell lines we possessed models that displayed both good protein expression of all PAK 
isoforms and displayed strong basal levels of activity. 
 
Figure 6.5: Western blot showing the activity and basal expression of the PAK isoforms AML cell line. 
Equal numbers of MV4-11 and P31/FUJ cells were lysed in 500µl of Tris-Triton lysis buffer. 30µg of samples 
analysed by western blot for PAK isoforms, and α-tubulin loading control. 
     Western blot analysis of MV4-11 showed that the cell line strongly expressed the group 
1 PAKs (PAK1 and PAK2) and had mild expression of PAK4 (Figure 6.5). MV4-11 also exhibited 
high expression of the activatory phosphorylation sites of PAK1S199/204, PAK2S192/197 and PAK4S474. 
P31/FUJ had very strong expression of PAK1 and PAK4 isoforms, however, PAK2 was only 
moderately expressed. Assessment of the PAK activity markers revealed that P31/FUJ had high 
basal levels of PAK1 and PAK2 activity, but very low basal levels of PAK4 activity. Collectively 
these results suggested that both MV4-11 and P31/FUJ were good models for studying the 
importance of PAK1 and PAK2 activity in AML, however, MV4-11 was a better candidate to study 
PAK4. 
6.4 Co-immunoprecipitation optimisation 
Having identified a suitable model of AML that expressed high levels of phosphorylated 
PAK, the aim of this section was to optimise an approach that would enable the study of dynamic 
PAK binding partners (i.e. proteins that bind PAK as a function of its activation status), as these 
could provide a read out of activity and downstream could even serve as additional drug targets 
for patients with overactive PAK signalling.   
 
 203 
6.4.1 Principle of approach 
Co-immunoprecipitation (co-IP) is a common technique used to identify protein-protein 
interactions. The technique relies on the ability to identify a good antibody and requires the 
optimisation of multiple aspects to ensure that the user is able to capture an accurate 
representation of the protein interactions that occur in cells.  
 In a bid to identify the proteins that regulate PAK activity in AML and thus map the 
functional mechanisms involved in executing PAK function, it was decided that an optimised co-
IP represented the most powerful and practical means of investigation. Initial optimisation 
experiments investigated the efficiency of isolating PAK complexes using different lysis buffers, 
wash buffers, varying antibody incubation times and employing different protein elution steps 





 Antibodies were used at different concentrations to achieve optimal ratio of 
antibody to target protein 
 Investigated PAK antibody incubation times (15min – 12 hours) to try and 
maximise the resolution of different interaction types (transient-constituent 
binders) 
Lysis Buffer  Tested different detergents (Triton X-100, NP-40 and CHAPS) 
 Tested HEPES based and Tris based lysis buffers 
Wash buffer  Varied ionic stringency and pH of buffers that washed non-specific proteins 
away from complexes – too strong and weak interactors are lost 
Non-specific 
protein control 
 The inclusion of a pre-clear step – incubation with solid support before 
antibody, which allowed for the removal of non-specific proteins from the 
lysate 
 In some samples a pre-clear step was not included in case it was removing 
actual binding partners 
Bead elution  Optimised a faster and cleaner elution technique of direct trypsin digestion of 
proteins from protein A/G sepharose beads. This reduced contaminants. 
Protein 
Detection 
 The western blot detection required a lot of optimisation. In particular with 
detection antibodies and overcoming the light/heavy chain interference from 
the co-IP antibody when probing with detection antibody (many antibodies 
are raised in rabbit, leading to cross reactivity). 
Table 6.1: Co-Immunoprecipitation optimisation. Aspects of the technique that were optimised in an 





Figure 6.6: Optimised co-immunoprecipitation workflow: First cells are prepared in culture under desired 
experimental conditions. After treatment cells are washed in PBS and protease inhibitors before 
harvesting and lysis using a CHAPS HEPES based buffer. Cellular debris is spun down and removed, 
resultant supernatant is normalised for each sample so that they each contain the same amount of 
protein. Protein A/G beads are pre-conditioned in lysis buffer before pre-clearing sample lysate with the 
beads (10 min). Beads are then removed with the non-specific proteins bound, ready to incubate the 
sample lysate with the PAK specific antibody. After allowing enough time for immune complexes to form 
(40min – overnight), freshly conditioned protein A/G beads are introduced so antibody complexes can be 
captured (20 min – 4 hours). It is important to get the timing right otherwise associated proteins could 
disassociate. After capture protein complexes are eluted and washed to remove any non-specific binders 
or non-constituent binders (3x washes lysis buffer, 3x washes Tris-buffer, 3x washes NH4HCO3). At this 
point it is possible to directly digest elute from the beads and analyse the sample using mass spectrometry 
or the sample can be mixed with Laemmli buffer and interactions probed for by western blot. Figure 
adapted from (552).       
6.4.2 Effects of detergent type on PAK protein yield 
 To effectively capture protein interactions, it is important to try and preserve protein 
complex formation during the immunoprecipitation process. One element that has previously 
been shown to have a large effect on complex preservation is the composition of the lysis buffer 
used to extract proteins (552). Therefore, to increase PAK yield and preserve potential 
interactions a series of detergents and buffer combinations were tested.  
 Three detergents Triton-X100 (1%), NP-40 (1%) and CHAPS (0.3%) were tested as part 
of a Tris based buffer, Triton X-100 was also tested as part of the typically strong RIPA buffer and 
a Hepes based CHAPS buffer was included. These investigations sought to establish which 
buffers/detergents led to good PAK recovery across isoforms. Equal numbers of P31/FUJ cells 
(1x107) were harvested and lysed with 500l of each lysis buffer according to methods section 
2.4. 30g of each lysate was then subjected to SDS-PAGE and protein recovery assessed via 




Figure 6.7: Hepes based CHAPS lysis buffer is optimal for PAK analysis. Equal numbers of P31/FUJ cells 
were lysed in 500µl of Tris or Hepes buffers containing Triton X-100, CHAPS or NP40 detergent. 30µg of 
samples analysed by western blot for PAK isoforms, vinculin, AKT, Histone 2B and lactate dehydrogenase.  
 The results of the experiment revealed that all lysis buffers performed well in recovering 
the group 1 PAKs, however, PAK 4 was not recovered well in RIPA and Tris-CHAPs based buffers. 
PAK4 was well recovered in Tris-Triton, Tris-NP40 and Hepes-CHAPs buffers. Analysis of the 
other cytosolic proteins such as AKT and vinculin demonstrated that CHAPs was the best 
detergent for the recovery of these proteins. Finally, H2B recovery was assessed to measure the 
recovery of nuclear proteins and analysis showed that the CHAPs based buffers yielded the 
highest recovery. Collectively these results indicated that the Hepes based CHAPs buffer was the 
most efficient buffer for both the recovery of PAK proteins, and also the preservation of proteins 
from both cytosolic and nuclear fractions. If PAK does localise to other compartments during 
certain conditions, it is important to be able to capture these events or potential binding 
partners would be lost. 
6.4.3 On-bead protein digestion 
As previously discussed, efforts were made to optimise PAK recovery prior to co-IP 
through lysis buffer optimisation, in these same experiments PAK antibody specificity was also 
optimal as the antibodies used were also co-IP compatible. Utilising the approach as detailed in 
Figure 6.6, PAK complexes were pull down, washed and subjected to SDS PAGE. The Subsequent 
gel was stained with Coomassie blue and proteins visualised (Figure 6.8A). Samples 1 (PAK1 Ab) 
and 2 (PAK2 Ab) had no detectable protein bands, samples 3 (PAK3 Ab) and 4 (PAK4 Ab) had 
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bands around the region of PAK and the total lysate (TL) and empty bead (EB) controls both 
displayed that large amounts of protein were still present in lysates. The TL sample had 
undergone no form of immunoprecipitation and the EB sample was that of the lysate following 
incubation with the sepharose beads, this control was desirable as protein loss in this sample 
represents non-specific proteins that have affinity to the solid support used to elute co-IP 
complexes. 
 
Figure 6.8: In-gel digestion of PAK co-IP complexes leads to no PAK detected in mass spectrometer. (A) 
Coomassie stain of PAK pulldown experiments following SDS PAGE. Sample lanes 3 and 4 cut into five 
bands (marked 1-5) for protein extraction and sample clean-up. (B) Pooled fractions run analysed by LC-
MS/MS, 20 most abundant identified proteins displayed, PAK not identified. L; ladder, TL; total lysate, EC; 
Empty bead control.      
The Coomassie stain suggested that no protein had been enriched in samples 1 and 2. 
Therefore, as samples 3 and 4 did have bands in the appropriate regions, bands were excised, 
proteins extracted from gel pieces and processed for LC-MS/MS detection. This approach failed 
to identify any peptides derived from PAK proteins in the mass spectrometer, with the most 
common peptides being that of the contaminant keratin (Figure 6.8B).   
In order to remove the contaminants and streamline the protocol, as lengthy processing 
only increases the chances for immuno-complexes to dissociate, the experiment was repeated. 
However, following wash steps, tryptic digestion was undertaken whilst the protein complexes 
were still immobilised on-bead. Proteins identified in these experiments (Figure 6.9, red 
markers) that met the selection criteria (MASCOT score > 50, >2 peptides counted, protein 
absent in antibody free negative control, >2 Log2 fold enrichment in targeted pull-down over 
control) supported using co-immunoprecipitation as a means to identify PAK binding partners. 
The pull-down experiments in Figure 6.8 were successful when targeting PAK1, PAK2 and PAK4 
with identification of these target proteins consistently the most abundant proteins. The PAK3 
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targeted pull-down, however, was not successful, as the target protein was not identified in the 
experiment (Figure 6.9C). This could have been either due to the quality of the antibody, or more 
likely, because PAK3 expression occurs nearly exclusively in the brain. 
 
Figure 6.9: Co-Immunoprecipitation optimised pull-down results. Co-immunoprecipitation of PAK 
proteins led to the identification of proteins highlighted in red, which following analysis were deemed to 
be enriched for in target protein pull down experiments. (A) Pull-down of PAK1 and proteins in complex. 
(B) Pull-down of PAK2 and proteins in complex. (C) Pull-down of PAK3 and proteins in complex, PAK3 not 
identified so experiment considered unsuccessful. (D) Pull-down of PAK4 and proteins in complex. 
An assessment of proteins identified in each of the successful pull-down experiments 






PAKs (PAK4) pull-downs. In the PAK1 and PAK2 pull-downs known binders of PAKs were present 
(PAK1, PAK2, GIT1, GIT2, ARHGEF6, ARHGEF7) providing a positive control (553), although PAK3 
was identified this was likely due to identical peptide sequences shared between PAK1 and 
PAK3. The PAK4 pull-down did not identify any known protein interactions, but this probably 
reflects the lack of known interactions. Other proteins that were shared across the conditions 
were Ras-related protein Rab-8A (RAB8A) Ras GTPase-activating protein nGAP (RASAL2), 
Histone H1t (HIST1H1T), Histone H1.4 (HIST1H1E), Medium-chain specific acyl-CoA 
dehydrogenase, mitochondria (ACADM), Erlin-2 (ERLIN2), Neuroblast differentiation-associated 
protein AHNAK (AHNK) and Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex, mitochondrial (DLAT). 
 
Figure 6.10: Proteins identified in pull-down experiments of PAK1, PAK2 and PAK4. Protein string 
analysis confirms the pull-down of known binding partners of PAK1 and PAK2. Although no known binders 
of PAK4 were pulled down, this is probably more of a reflection of the lack of knowledge to date.  
 
6.5 Optimisation of conditions for dynamic complex formation 
Having established a co-immunoprecipitation protocol that showed specificity to PAK 
and its known binding partners, investigations focussed on conditions that may promote 
dynamic PAK complex formation. Work presented in Chapter 3 and Chapter 5 demonstrated 
that the secretome can stimulate PAK1 and PAK2 phosphorylation (Figure 3.9 and Figure 5.5A), 
however, it was also observed that secretome treatment led to a reduction in PAK4 
phosphorylation (Figure 5.5B). Accordingly, a number of preliminary PAK pulldown experiments 
were conducted investigating the effects of secretome stimulation on the composition of PAK 
pull-down complexes. As serum modulation had been a successful approach in revealing 
regulatory binding partners of PI3K by Beltran et al. (552), this too was employed to modulate 
PAK interactions (Figure 6.11). The final set of studies performed to modulate PAK interactions 




Figure 6.11: PAK co-immunoprecipitation strategy. For each treatment MV4-11 or P31/FUJ cells were 
serum starved for 4 hours first to bring signalling to a baseline so that dynamic binders of an active 
pathway would bind after 15 minutes of 10% serum stimulation. Subsequent co-immunoprecipitation of 
PAK followed by LC-MS/MS analysis should reveal dynamic PAK binding partners (X and Y) between the 
conditions, whereas the abundance of non-specific binders (NS) should not change across the conditions. 
 
6.5.1 Serum deprivation followed by secretome stimulation  
To investigate the impact of the secretome on PAK activity and therefore, PAK behaviour 
and interactions, the optimal conditions for secretome induced or inhibited PAK 
phosphorylation needed to be determined. Western blot experiments were devised to 
understand PAK response during serum starvation and following stimulation with either MS-5 





Figure 6.12: Western blot analysis of PAK1 and PAK2 status during secretome and serum stimulation. 
AML cells starved for 4 hours (except basal condition [C]) prior to 15 minutes stimulation with 10% serum, 
5µg/ml >5kDa/<5kDa secretome or MS-5 CM as indicated above. Western blots for the activatory 
phosphorylation sites on PAK1, PAK2 and FLT3. Loading controls for GAPDH are shown in each case. C; 
basal conditions. 
 Western blot analysis revealed that both the basal condition (C) and serum starvation 
(1, blue square) did not induce phosphorylation of PAK1, while minimal phosphorylation of PAK2 
was recorded in the starved sample (Figure 6.12). Stimulation with the >5kDa secretome fraction 
after starvation induced large amounts of PAK phosphorylation (3, red square), the <5kDa was 
able to induce PAK phosphorylation in the presence of serum and conversely CM alone could 
induce PAK phosphorylation, but in the presence of serum it could not. It was concluded from 
these results that PAKs (1, 2, 4) would be pulled down following MV4-11 cells undergoing the 
treatments highlighted with the blue and red squares (Figure 6.12) alongside an empty antibody 
pull down control.   
Co-IP of PAK proteins from MV4-11 cells stimulated with MS-5 secretome identified 41 
proteins in these experiments (Figure 6.13A, red zone) that met the selection criteria (MASCOT 
score > 50, >2 peptides counted, protein absent in antibody free negative control, >2 Log2 fold 
enrichment in targeted pull-down over control). The 41 proteins identified are listed in Figure 
6.13B and as in early controls PAK proteins (coloured red) were the most enriched proteins 
(except PAK4) and known binders such as ARHG7, GIT1, ARGH6, GIT2 and ARHG8 (coloured 




Figure 6.13: Co-Immunoprecipitation of PAK in MV4-11 cells following secretome stimulation. Co-
immunoprecipitation of PAKs led to the identification of proteins which following analysis were enriched 
in target protein pull down experiments. (A) Eluents of pull-down using PAK1, 2 and 4 antibodies 
combined compared to no antibody control (B) Table listing fold change enrichment, mascot score and 
number of peptides detected. (C) STRING protein analysis of pull down proteins that had a fold enrichment 
of >2 Log2 fold, >2 proteins identified, >50 mascot score between conditions. Independent technical 
replicates n=2. Red = Bait proteins, orange = known interactors. 
 Comparisons between the PAK co-IPs however, were not as revelatory. When protein 
enrichment was compared between conditions (secretome stimulated vs serum starved) there 
were no significant enrichments, with only Ig lambda chain V-I region (LV105) being enriched 
and this had a borderline mascot score of 51.29 and only 2 peptides identified (Figure 6.14). The 
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proteins that were more abundant in the starved conditions are represented in the blue region 
and mainly comprised of keratins. These findings suggested that secretome stimulation would 
not be the best means to elicit dynamic PAK binding. 
Figure 6.14: Comparison between secretome stimulation PAK pulldown and unstimulated reveals no 
substantial enrichment. Co-immunoprecipitation of PAKs led to the identification of proteins which 
following analysis were enriched in target protein pull down experiments. (A) Eluents of pull-down using 
PAK1, 2 and 4 antibodies combined compared to no antibody control (B) Table listing fold change 
enrichment, mascot score and number of peptides detected. Independent technical replicates n=2. Red = 
Bait proteins, orange = known interactors. 
6.5.2 PAK pulldown following PAK inhibition treatment 
 Earlier experiments had shown that PAK is active during basal conditions and this was 
also observed in the Casado et al. study, where all patient samples were measured following no 
stimulation (271). Thus, it was proposed that PAK pulldown of all isoforms in an AML model 
would include known interactors and unknown interactors that were important in the disease 
context. To reveal the unknown interactors, one could also treat AML cells with PAK inhibitors 
and observe across the experiments which proteins consistently followed the stoichiometry of 
known interactors.  
 MV4-11 cells were treated for 2 hours with the PAK inhibitors IPA-3 (20µM) and PF-
3758309 (1µM), subsequently PAK1, PAK2 and PAK4 were separately pulled down in each of the 
untreated and treated conditions. Co-IPs were processed as described in previous optimisation 




Figure 6.15: Heatmap of PAK pull-down in MV4-11 following PAK inhibitor treatment. AML cells treated 
with 20µM IPA-3 or 1µM PF-3758309 for 2 hours, then lysed with 0.1% CHAPS buffer. Co-IP baits targeted 
PAK1, PAK2 and PAK4. Heatmap made using sum normalised peptide ion intensities average across 2 
independent technical replicates. Relative abundance determined by comparing Log2 fold change of 
individual samples to the average across all samples. Proteins labelled in orange are known PAK 
interactors.  
 Assessment of each of the proteins identified in the pull-down experiments showed that 
none of the presented proteins were detected in the antibody free controls and that the PAK2 




































































































































PAK2 0 0.2 1.5 0 0 -0 1.6 0 0 0 1.6 0 702.15
PAK3 0 0.3 1.5 0 0 0.6 1.3 0 0 -0 1.6 0 245.11
PAK1 0 0.5 1.3 0 0 0.5 1.4 0 0 0.9 1.1 0 380.83
K1C25 0 1 1 0 0 2 0 0 0 0 2 0 106.27
GIT2 0 1.4 0.3 0 0 0 0 0 0 1.4 0.4 0 107.99
RAC1 0 2 0 0 0 0 0 0 0 0 0 0 50.5
ASH1L 0 1.4 0.4 0 0 0 2 0 0 0 0 2 54.787
PFKAP 0 0.5 0 1.4 0 0 0 0 0 0 0 2 77.96
RAB8A 0 -2 0 1.9 0 0 0 0 0 0 0 2 54.89
DAB2P 0 0 1.5 0.1 0 0 0 0 0 -1 0 1.8 52.5
EFCB5 0 0 0 0 0 0 2 0 0 0 2 0 50.223
H2AV 0 0 0 2 0 0 0 0 0 0 0 0 54.91
HSP77 0 0 0.6 1.3 0 0 2 0 0 1.1 0.9 0 68.07
K1C20 0 0 2 0 0 0 0 0 0 0 0 0 119.46
K22O 0 0 2 0 0 0 0 0 0 0 0 0 306.46
K2C71 0 0 2 0 0 0 2 0 0 0 0 0 105.48
PABP1 0 0 0 2 0 0 0 0 0 0 0 0 227.97
PABP3 0 0 0 2 0 0 0 0 0 0 0 2 71.4
PABP4 0 0 0 2 0 0 0 0 0 0 0 0 65.31
PAK4 0 0 0 2 0 0 0 0 0 0 0 2 213.71
PAP1L 0 0 0 2 0 0 0 0 0 0 0 0 79.36
RAB1A 0 0 0 0 0 0 0 0 0 2 0 0 60.82
RAB1C 0 0 0 2 0 0 2 0 0 0 2 0 60.33
RL19 0 0 0 2 0 0 0 0 0 0 0 2 54.35
RL26 0 0 0 2 0 0 0 0 0 0 0 2 56.503
RL31 0 0 0 2 0 0 0 0 0 0 0 2 83.1
RL7 0 0 0 2 0 0 0 0 0 0 0 2 69.26
RL8 0 0 0 2 0 0 0 0 0 0 0 2 71.99
RS24 0 0 0 2 0 0 0 0 0 0 0 0 70.77
RS9 0 0 0 2 0 0 0 0 0 0 0 2 148.53
SACS 0 0 2 0 0 0 0 0 0 2 0 0 52.193
TFR1 0 0 0 2 0 0 2 0 0 0 2 0 55.413
H12 0 0.5 0 1.4 0 0 0 0 0 0 0 0 64.593
SMC1A 0 0.9 1.1 0 0 0 0 0 0 1.8 0 -1 53.14
MYCB2 0 0 0 0 0 0 0 0 0 2 0 0 54.319
POTEE 0 0 0 2 0 0 0 0 0 0 0 0 376.78
RAB35 0 0 0 2 0 0 0 0 0 0 0 0 60.06
RAB4B 0 0 0 0 0 2 0 0 0 0 0 0 53.52
-5 -4 -3 -2 -1 0 1 2 3 4 5
Log2 Fold change in abundance relative to the 
average across samples
1 2 3 4 5-5 -4 -3 -2 -1 0
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consistently pull down the group 1 PAK isoforms. The PAK 1 antibody was good at pulling down 
PAK1, but not PAK2. The PAK4 antibody was very good at pulling down PAK4 in the untreated 
and PF-3758309 conditions, but PAK4 was absent in the IPA-3 condition, suggesting the pull 
down didn’t work (Figure 6.15). 
 Known PAK interactors identified in this experiment included GIT2 and RAC1 (Figure 
6.15, orange text), these proteins were abundant in the PAK1 pulldown of untreated AML cells 
and GIT2 was detected in the PAK2 pulldown of untreated cells, this was probably due to the 
antibodies ability to enrich PAK1. IPA-3 treatment led to the loss of these known interactors in 
PAK co-IPs. PF-3758309 treatment also inhibited RAC1 binding across co-IPs, however, there was 
still detectable GIT2 in the PAK 1 pulldown. The only enriched proteins that followed this trend 
were the keratins K1C20 and K22O which are unlikely to be key regulators of PAK activity in AML. 
 No known PAK4 interactors were identified in the co-IP experiments, however, there 
were a number of proteins that only appeared strongly in the PAK4 co-IP of untreated cells, 
which were completely absent in all other conditions. These included histones H2AV, H12, 
Transferrin receptor protein 1 (TFR1), the small Rab GTPase (RAB35), Polyadenylate-binding 
proteins 1 and 3 (PABP1, PABP3), ribosomal protein (RS24) and Polyadenylate-binding protein 
1-like protein (PAP1L). These proteins represented an encouraging list of candidates, particularly 
RAB35 as it is similar to known PAK4 binders which are predominantly small GTPases like CDC42. 
To have more confidence in these candidates, it would have been desirable to have had a known 
PAK4 interactor to compare pulldown affinity behaviour. Due to the amount of further 
optimisation that would have been required regarding inhibitor concentrations, other means of 
inducing variable PAK complex formation were pursued.    
6.5.3 Serum deprivation followed by serum stimulation  
Despite the lack of enrichment for PAK pulldown proteins following secretome 
stimulation, the western blot experiments during secretome optimisation (Figure 6.12) 
indicated serum manipulation significantly affected PAK phosphorylation. Considering further, 
that there were more enriched proteins in the serum starved pull down previously undertaken 
(Figure 6.14) and that previous studies had been successful using this approach (552), a strategy 
was employed that would starve MV4-11 cells, before stimulation with serum. 
Co-IP of PAK proteins from MV4-11 cells stimulated with serum identified 20 proteins in 
these experiments (Figure 6.16A) that met the selection criteria (MASCOT score > 50, >2 
peptides counted, protein absent in antibody free negative control, >2 Log2 fold enrichment in 
targeted pull-down over control). Figure 6.16 demonstrates that PAK was successfully pulldown 
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and compared to the non-targeting control PAK was significantly enriched (red proteins), along 
with known binders (orange proteins).  
 
Figure 6.16: Co-Immunoprecipitation of PAK in MV4-11 cells following both serum starvation and 
stimulation. Co-immunoprecipitation of PAKs led to the identification of proteins which following analysis 
were deemed to be enriched, in target protein pull down experiments. (A) Eluents of pull down using 
PAK1, 2 and 4 antibodies combined (B) Table listing fold change enrichment, mascot score and number of 
peptides detected. Independent technical replicates n=2. Red = Bait proteins, orange = known interactors. 
 Analysis comparing the serum stimulated AML cell PAK co-IPs to the serum starved AML 
cell co-IPs revealed 29 proteins enriched with >2 Log2 fold enrichment in the serum stimulated 
pull-down and 13 proteins showed >2 Log2 fold enrichment in the serum starved pull-down 
(Figure 6.17A). Proteins that increased in abundance following stimulation included known PAK 
interactor MYH9 (coloured blue) as well as numerous histones (coloured red). Fewer proteins 
were enriched in the starved sample but this should display a preference for proteins that are 
not dependant on PAK phosphorylation. Proteins such as Leupaxin (LPXN) which is a negative 
regulator of known PAK interactor paxillin and B cell receptor signalling was an interesting 
protein to be enriched in PAK pull downs following serum starvation (554, 555), as well as Ikaros 
(IKZF1) a transcription regulator of haematopoietic cell differentiation and Thyroid receptor-
interacting protein 6 (TRIP6) (Figure 6.17B). 
 Proteins that were enriched following serum modulation are presented in interaction 
complexes that display previously described interactions (Figure 6.17C). Proteins identified as 
enriched in the PAK pulldown following serum stimulation were very well interlinked even 
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though none had previously been implicated with any of the PAK isoforms (except MYH). This 
could explain the presence of these proteins, if one member bound PAK it is possible the whole 
complex was pulled down too, this may explain why so many histones were identified. The 
serum starved enrichment interactors are not as well interlinked, however, LPXN did have one 
known interactor also identified. These finding were encouraging, but required more biological 
replicates, as to date only two had been performed. 
 
         
Figure 6.17 Comparison of PAK complex co-eluents between serum stimulated and starved cells reveals 
enrichment for histones. (A) Analysis comparing dynamic co-IP proteins following PAK pulldown in serum 
stimulated and serum starved conditions. (B) Table listing fold change enrichment, mascot score and 
number of peptides detected. (C) STRING protein analysis of pull down proteins that had a fold enrichment 
of >2 Log2 fold, >2 proteins identified, >50 mascot score between conditions. Independent technical 
replicates n=2. Red = Bait proteins, orange = known interactors. 
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6.6 Investigation of PAK signalling dynamics across isoforms  
 Following the optimisation results it was decided that to determine PAK regulatory 
binding proteins, serum starvation followed by stimulation would be employed as preliminary 
experiments suggested a novel PAK interaction with histones. Experiments were devised to 
investigate basal, serum starved, and serum stimulated interactors of PAK1, PAK2, and PAK4 in 
biological and technical triplicates. It was postulated that starving the cells for 4 hours would 
lower the activation status of signalling pathways and subsequent stimulation with serum for 15 
minutes would then mobilise PAK interactions. Subsequent comparisons between the serum 
starved and serum-stimulated conditions should then reveal the dynamic binders of PAK 
isoforms (Figure 6.11). Experiments to date extended antibody incubation overnight in the hope 
of maximal PAK binding, however, trouble shooting previous co-IPs postulated that due to the 
transient nature of kinases, and the susceptibility of protein complexes to dissociation, 
identification of binders may be enhanced by shorter PAK antibody incubations. Accordingly, 
this step was shortened to 1 hour. 
Co-IP of PAK1 and PAK2 proteins from cells grown under basal conditions identified 
known PAK binders (including Filamin A and Filamin C), in addition to PAK1 and PAK2, to be more 
abundant in the relevant IP experiment (containing a specific anti-PAK antibody) than in the non-
specific binding controls (no anti-PAK antibody present, Figure 6.18a, part i) (556). The co-IP was 
repeated using cells that had been starved of serum for 4 hours; under these conditions, FLNA, 
FLNC and Serine/threonine-protein kinase PLK4 were identified as being significantly enriched 
for across 3 biological replicates compared to the non-specific binding controls (Figure 6.18a, 
part ii). Finally, in the cells that were starved for 4 hours before serum stimulated for 15 minutes 
only PAK1 and FLNA were consistently enriched for across the replicates relative to the non-
specific binding controls (Figure 6.18a, part iii). 
 Co-IP of PAK4 grown under basal conditions enriched for known PAK binder FLNA, PLK4 
which was observed in the group I PAKs under basal conditions, as well as Four and a half LIM 
domains protein 1 (FHL1) compared to the non-specific binding control (Figure 6.18b, part i). Co-
IP of PAK4 in cells that had been serum starved for 4 hours enriched for FLNA and Toll like 
receptor 5 (TLR5) compared to the non-specific binding controls after serum starvation (Figure 
6.18b, part ii). Finally, cells that were serum stimulated for 15 minutes following serum 
starvation led to the enrichment of FLNA, FLNC, FHL1, as well as E3 ubiquitin-protein ligase 
TRIM21 (RO52) and 40S ribosomal protein S18 (RS18) compared to the non-specific binding 








Figure 6.18: Volcano plots of proteins identified in targeted PAK1, 2, 4 pull-downs coupled with LC-
MS/MS detection. (A) Shows enriched proteins in PAK1 and PAK2 pull-downs compared to non-specific 
binding control [i] under basal conditions [ii] following 4 hours serum starvation [iii] after 15 minutes 
serum stimulation with 10% FBS following 4 hours serum starvation. (B) Shows enriched proteins in PAK4 
pull-downs compared to non-specific binding control [i] under basal conditions [ii] following 4 hours 
serum starvation [iii] after 15 minutes serum stimulation with 10% FBS following 4 hours serum starvation.  
Red markers indicate statistically significant changes that are greater than 2 Log2 fold changes between 
the samples. (C) Displays enriched proteins when comparing serum stimulated and serum starved co-IP 
complexes in [i] non-specific protein controls [ii] between PAK1/2 co-IPs [iii] between PAK4 co-IPs. 
Proteins on the right are enriched for in serum stimulated pull-downs and left are enriched for in serum-
starved pull-downs. 
 Comparisons between non-specific binding control complexes immunoprecipitated 
from serum starved cells and serum stimulated cells following starvation revealed histone H33 
and PLK4 as being consistently more abundant in the serum stimulated conditions, with no 



























the PAK1 and PAK2 co-IP’s no proteins were significantly more abundant in serum stimulated 
cells compared to the serum starved cells, or vice versa (Figure 6.18c, part ii). However, PAK4 
co-IP complexes exhibited significant enrichment for histones H2B1A, H2AJ, H2A3, H2AZ, H2B3B, 
H2AX, Immunoglobulin lambda-like polypeptide 5 (IGLL5) and Ubiquitin-like protein 4A (UBL4A) 
in the P31/FUJ cells that were stimulated with serum for 15 minutes compared to the PAK4 co-
IP of P31/FUJ cells that were only serum starved (Figure 6.18c, part iii). This suggested that these 
proteins bind to PAK4 dynamically upon cell stimulation. No proteins were significantly more 
abundant in the PAK4 co-IP following serum starvation of P31/FUJ cells compared to the PAK4 
co-IP serum stimulated P31/FUJ cells. 
The proteins identified as putative dynamic binders of PAK4 (Figure 6.18c, part iii) were 
searched against the literature and Figure 6.19 shows the current knowledge of these proteins 
interactions. PAK4 is not described as interacting with histones but they show a specific 
enrichment across 3 biological replicates and showed a significant enrichment over the non-
specific controls. The observation of a dynamic histone interaction that appears upon PAK4 
activation is very interesting, as this would be suggestive of PAK4 migration to the nucleus where 
it could influence many cellular functions in AML progression.   
 
Figure 6.19: Protein string of PAK4 pull-down proteins that are significantly enriched for in serum 
stimulated P31/FUJ.  PAK4 complexed with histones - H2B1A, H2AJ, H2A3, H2AZ, H2B3B, H2AX, 








6.7 Summary  
It had been proposed in previous studies that in cancer and in particular treatment 
resistant neoplasms that kinase networks undergo network rewiring and establish interactions 
that would not necessarily occur under physiologically conditions (215, 216). Having observed 
that the underlying kinase networks that help govern AML response to the microenvironment 
were extremely heterogeneous, it had been a quandary that PAK inhibition was always so potent 
in undermining AML cell survival (Figure 4.11). This observation coupled with previous studies 
(206, 271) that documented PAK as one the most active kinases in AML (Figure 6.1), led to 
experiments that studied the nature of PAK activation in AML and protein interaction studies to 
try and establish mechanistically the relevance of high PAK activity. 
Firstly, to determine the source of PAK activity and the underlying source of this 
constituent binding interactions, a meta-analysis was conducted of 390 AML exomes. In this 
cohort it was observed that there were no mutations on PAK reported. This finding was 
unexpected as AML is a disease which is characterised by high levels of genetic instability that 
aids in the acquisition of further genetic aberrations to help perpetuate disease progression. 
Therefore, for a kinase that is so frequently overactive in patients to not harbour any genetic 
aberrations suggests that there must be either epigenetic elements, exogenous factors (i.e. 
microenvironment) or dysregulated upstream signals and/or binding partners that help drive 
this signalling.  
Experiments conducted as part of Chapters 3 and 5 had already revealed that the 
exogenous factors from the microenvironment had the ability to modulate PAK signalling in the 
AML cell lines; MV4-11 and P31/FUJ – especially in the isoforms PAK1 and PAK2. Therefore, 
these were believed to be appropriate models to study PAK interactions in AML.  Further to 
these findings, it was deemed important to establish PAK isoform expression in these lines. 
Subsequent western blots demonstrated that both cell lines highly expressed PAK1, MV4-11 
expressed higher levels of PAK2 and P31/FUJ expressed higher levels of PAK4. These findings 
were important as they suggested that MV4-11 would be a better model for studying PAK2 and 
P31/FUJ with PAK4. However, the relative levels of phosphorylation to expression highlight that 
the cell lines that expressed less protein also displayed relatively more active protein, as seen 
with PAK4 expression in MV-411 and PAK2 expression in P31/FUJ (Figure 6.5).  
Having validated appropriate models that collectively had high expression of all PAK 
isoforms present in haematopoietic cells (PAK1, PAK2 and PAK4), the focus shifted to 
optimisation of protein interaction studies. Following the success of co-IP in identifying novel 
kinase regulatory proteins (552), studies began to implement a co-IP protocol that effectively 
immunoprecipitated PAK isoforms and known PAK binding partners. Following optimisation of 
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a number of elements that effected the enrichment of PAK protein complexes (summarised in 
Table 6.1) an MS based protocol that displayed both specificity and sensitivity to all PAK isoforms 
(except PAK3 as not expressed in haematopoietic cells), while being able to detect the known 
interactors (GIT1, GIT2, ARHGEF6 and ARHGEF7) was established (Figure 6.9 and 6.10).       
Once a suitable protocol had been established a number of conditions were 
experimented with to reveal dynamic PAK binding partners, including secretome stimulation, 
PAK inhibition and serum modulation. PAK co-IP of secretome stimulated MV4-11 cells was able 
to identify PAK and known PAK interactors (Figure 6.12), however, this treatment was not 
capable of revealing any secretome induced PAK binding partners (Figure 6.13). This finding was 
surprising as western blot analysis had demonstrated potent effects on the expression of 
phosphorylation sites PAK1 (Ser199/204) and PAK2 (Ser192/197) (Figure 6.11). Retrospectively this 
line of enquiry should have been pursued further, only owing to MS issues were experiments 
not repeated.  
Co-IP experiments using PAK Inhibitors served as a demonstration of these inhibitors 
ability to disrupt PAK complexes. IPA-3 was more efficient at disrupting group 1 PAKs, as known 
PAK binders (GIT2 and RAC1) were lost completely following treatment which PF-3758309 only 
partially achieved. One caveat to this is that IPA-3 was used at higher concentrations. 
Unfortunately, there were no proteins in the PAK1 or PAK2 co-IPs that followed the pattern of 
expression that known binders exhibited (Figure 6.18). Conversely PAK4 co-IPs, did uncover a 
number of dynamically expressed nuclear proteins that included histones and PABPs, however, 
these could not be corroborated as no known PAK4 binders were identified.  
Despite the promising findings that PAK4 pulldowns revealed following inhibitor 
treatments, experiments focussed again on the effects serum modulation had on PAK 
behaviour. This shift away from PAK inhibition studies was fuelled by suspicions that inhibitor 
treatments may create artefacts or drastically change the behaviour of potential binders 
independent of the inhibitors PAK specific effects.  Experiments investigating the effects of 
serum starvation followed by stimulation on PAK complex formation revealed a number of 
dynamic binders that met confidence thresholds (Figure 6.15). Notable candidates included 
LPXN which PAK enriched for during serum starved conditions, previous studies have 
demonstrated LPXN as negatively regulating known PAK binder paxillin (557, 558), this appeared 
as strong evidence for LPXN as an interactor of group 1 PAKs. Numerous proteins were enriched 
in the serum stimulated PAK co-IPs compared to serum starved and these were mostly histones 
(6.15C). Histones had also been prominent proteins in the inhibitor based co-IPs that were lost 
following PAK inhibition, as these candidates had now been identified in two different 
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experiments it was concluded that a co-IP with sufficient statistical power should be undertaken 
to validate these findings.  
Having established optimal conditions for both the co-IP technique and conditions by 
which to elicit dynamic PAK protein complexes, these aspects were brought together to identify 
PAK binding partners. These experiments revealed that only PAK4 with statistical significance 
enriched for H2B1A, H2AJ, H2A3, H2AZ, H2B3B, H2AX, IGLL5 and UBL4A (Figure 6.19). This 
supported previous observations of histone enrichment in PAK4 co-IPs, as this had been 
observed in 5 independent biological replicates. The group 1 PAK serum modulated co-IPs did 
not reveal any enriched PAK binding partners (Figure 6.18Cii), despite LPXN being observed in 
the first serum modulated experiment. This was probably a symptom of the shorter 1hour 
incubation. 
Taken together, these experiments showed that PAK activity and expression in AML is 
variable, and this heterogeneity cannot directly be explained through accumulation of genetic 
aberrations. Following the optimisation of a co-IP coupled MS approach it was possible to 
investigate dynamic binding partners of PAK principally focussing on PAK response following 
compound inhibition or starvation and rapid stimulation. Most strikingly, PAK4 – the least 
described of the PAK isoforms – consistently demonstrated binding of H2 histones during serum 
modulation that was not observed under other conditions, indicating an interaction not 














Chapter 7: Discussion 
AML is a complex disorder encompassing a collection of distinct sub-types that present 
with excessive proliferation of undifferentiated progenitor cells in the BM (23). Consequently, 
this disease is characterised by its profound molecular heterogeneity, sustained by clonal 
populations that continually acquire new genetic aberrations, thus creating a repertoire of 
resistors to therapeutic intervention (18). 
Kinases are commonly dysregulated to help promote leukaemogenesis, typified by 
frequent activating mutations in FLT3 and RAS proteins, these are believed to help induce a 
proliferative phenotype (31, 32). Kinases and the networks they signal within, manage cellular 
responses to both external and internal stimuli. The response to and shaping of the 
microenvironment has been demonstrated to be a key feature in leukaemic progression and 
resistance to therapeutic strategies (559-561).  Cross-talk with surrounding niche cells is thought 
to be important in mechanisms relating to survival, proliferation, self-renewal and immune 
evasion (122, 124, 145, 154, 343).  
 The work presented in this thesis focused on investigating how components of the 
microenvironment impact cell signalling networks in leukaemic cells and in turn how these 
leukaemic cells modulate stromal cell signalling. In order to examine this, three approaches were 
taken: (i) the secretome of known AML supportive stromal cells were assessed by MS to 
elucidate novel proteins; (ii) functional characterisation of secretome derived proteins assessed 
any supportive qualities in primary AML; and (iii) how these proteins and the BMSM as a whole 
impact cell signalling in leukaemia. 
 Understanding the mechanisms by which the microenvironment can facilitate 
leukaemic cell survival and propagation are increasingly becoming more important in the pursuit 
of effective therapeutic strategies that can achieve complete clearance of leukaemia (46, 145). 
Despite the previous identification of stromal GFs that can mediate leukaemia behaviour (such 
as niche localisation), and agreement of extensive cross-talk between cell populations, there has 
been a lack of unbiased global proteomic strategies to identify novel proteins of the 
microenvironment that could support and aid in the propagation of AML (47, 125, 562-564).  
Therefore, protocols for generating CM of known AML supportive BMSC lines were optimised 
and the resultant secretomes enriched and analysed by LC-MS/MS based proteomics (Chapter 
3). BMSC secreted proteins that exhibited modulated abundance in the presence of leukaemic 
cells, suggested relevance in cellular processes. In an effort to establish roles for such proteins, 
the purified recombinant forms relevance in survival, proliferation and treatment resistance 
were functionally assessed (Chapter 4). Kinases that regulate cell signalling pathways are 
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frequently dysregulated in cancer and leukaemia (70, 565, 566). The phosphoproteomes of 
heterogeneous primary AML cells were exposed to both single/bulk stromal proteins and BMSC 
co-culture, these investigations sought to define basal kinase network activities of both AML and 
BMSCs, then subsequently infer how they are regulated by one another (Chapter 5).  
PAK has previously been described as one of the most active kinases in AML (271). We 
observed that (unlike other kinase inhibitors) secretomic components were unable to modulate 
AML’s profound sensitivity to PAK inhibition, this suggested a fundamental dependency on PAK 
signalling. To investigate this activity, interaction studies were developed to identify novel 



















7.1 Characterising the composition of AML supportive secretomes derived 
from stromal MS-5 and HS-5 cell lines 
7.1.1 Context and motivation for stromal secretome dissection  
 As discussed in Chapter 1, the propagation of AML and the treatment resistance it 
commonly displays is at least in part mediated through cross-talk and interactions with the BMM 
(122, 567-570). Aspects of this interaction have been previously utilised in culture to extend ex 
vivo survival of primary AML material (355-359). It has been reported in previous studies that 
the supportive nature of the microenvironment can be harnessed using stromal cell lines (MS-
5, HS-5), which are capable of retaining expression of the naïve CD34+CD38- cell populations 
(353, 571-573). 
In this group of studies, it was hypothesized that the full complement of stromal derived 
proteins – where previous works have shown are imperative for leukaemic cell progression - are 
yet to be defined (122, 568, 569). The importance of identifying these proteins is multi-faceted: 
firstly knowing the precise proteins that drive aspects of the disorder can serve as important 
biomarkers to characterise a patient’s disease - which has been proven to be crucial in disease 
maintenance to date (574). This motivation is a long-term outcome, but the immediate benefit 
of understanding the proteins at play, is their utilisation in studying AML biology. Identification 
of these molecules enables avenues of investigation which are not possible if cells cannot be 
maintained in culture for any extended periods of time. Further, to induce such viable 
phenotypes through secreted proteins means that the AML cells would be responding to these 
signalling molecules through receptor mediator signalling. Thus, secretomic studies offered an 
opportunity to identify novel signalling molecules by which to investigate AML kinase networks.  
Due to the unsupervised nature by which secretomic components were to be identified, 
the supportive elements of the stromal secretome needed to be as abundant and preserved as 
possible before LC-MS/MS analysis (Figure 3.9). Additionally, at the time of the experiments an 
untargeted label-free LC-MS/MS method for the study of secretomic changes was not readily 
available. Therefore, prior to identifying components of the stromal secretome, aspects of the 
workflow had to be optimised to ensure sufficient coverage of the secretome could be achieved 
(Figure 3.18).   
7.1.2 Variables that characterise conditioned media and secretomes  
The extensive testing of BMSC conditioning regimens and the aspects that contribute to 
the production of a substrate for primary AML maintenance, culminated in the optimisation of 
a media that can extend primary AML cell culture longer than previously documented without 
physical co-culture (575, 576). What became apparent early during experimentation was the 
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lack of effect BMSC models were having on AML cell lines (Figure 3.2). Many historical studies 
have documented CM being important for the growth of cell lines (such as HL60) however, it 
was FBS that was more of a determinant in cell line growth (346). Serum starved conditions did 
not record notable effects until the HS-5 secretome was enriched and fractionated. This is 
pertinent as it questions the suitability of cell lines as a model for AML, clinically, AML cells (or 
at least the disease propagating cells) are extensively documented as being dependent on the 
microenvironment for progression, if a cell line does not exhibit this feature, it questions the 
suitability of such a model when investigating AML survival. 
The process of optimisation also highlighted the extensive variability that can be 
observed in CM. A multitude of proteins effected the supportive capacity of the media (Figures 
3.3-3.8). The literature does not go to any great lengths in detailing how CM were produced 
(364, 427, 577, 578). Consequently, this makes results from such research hard to standardise 
and reproduce.  
Following extensive investigation, it was possible to deduce a set of parameters that, if 
adhered to, produced supportive media that could maintain primary AML cells longer than 
routinely observed. Due to availability it was not possible to assess or compare how CM from 
primary BMSCs differed to that which was used in these studies. 
7.1.3 Label free LC-MS/MS based secretomics  
Previous studies of the leukaemia microenvironment have focussed on preconceived 
protein arrays that can limit both the scope of investigations and inherently introduce selection 
bias (579-581). In the work presented here, an unbiased approach identified a plethora of 
candidate proteins that could be relevant to particular AML cells, or indirectly, cells of the 
microenvironment that can support AML (Figure 3.12 and Figure 3.16). The co-culture 
experiments revealed 133 statistically significant changing proteins (Figure 3.20) which is 
competitive with most approaches (275, 289, 386, 582, 583). Analysis of secretomic changes in 
abundance across the co-cultures culminated in the selection of 6 identified stromal proteins 
that had also been identified previously in MS-5 and HS-5 independent secretome analysis. 
These candidates would be substantiated as modulators of AML behaviour following validation 
experiments in Chapter 4.  
7.1.4 Technical considerations and limitations of the study 
When drawing conclusions from this study it is always important to consider the source 
of these data. Although MS-5 and HS-5 are appreciated as reliable models of the BMSM that 
support primary AML in culture (573, 584, 585), these are not primary BMSCs and therefore, 
identified GFs need to be substantiated in primary tissue. Preferably primary cells would have 
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been used to investigate the secretome, but this material was unavailable. An advantage of cell 
lines is that they are homogeneous populations, primary BMSCs on the other hand are not and 
would have observed even higher levels of heterogeneity between experiments due to the 
nature of these cells, which would have impacted reproducibility. Having primary cells in culture 
(especially non-tumour) does not mean they would respond in a manner reminiscent to what is 
observed in vivo, which would have also served to make meaningful results difficult to obtain. 
Therefore, a more robust model, would follow that employed in these studies with subsequent 
histological assessment of BM trephines to compare expression in healthy and leukaemic 
cohorts to validate findings (586).  
The inherent limitations of the LC-MS/MS based secretomic approach used in these 
investigations include: CM needed to be produced in a serum free environment, this could have 
had an impact on cell behaviour and secretome production; utilisation of AML cell lines that are 
not dependent on the microenvironment for survival; lost coverage of the proteome in co-
culture. Distinguishing cell specific synthesised proteins based on species specific protein 
sequences meant that there were a number of peptides that were excluded from analysis due 
to species sequence homology, thus reducing coverage.  
LC-MS/MS analysis of the HS-5 secretome identified substantially more proteins than 
those identified when analysing the MS-5 secretome. This is primarily down to the HS-5 
secretome being analysed on a Q-Exactive plus compared to the LTQ-XL which was used for the 
MS-5 secretome. The Q-Exactive as described in Chapter 1 allows for much greater sensitivity 
and throughput, with better spacing. In the western validation experiments only S100-A4 and 
CSF-1 were validated. This was due to the unavailability of suitable antibodies raised against the 
other 4 proteins at the time.  
7.1.5 Implications and future work 
This study, whilst highlighting the utility of discovery-based MS methods for 
investigating the BMSC secretome and the efficacy of label-free methods in this context, it 
serves to expand our knowledge regarding the complexity and variability that occurs in 
secretome composition. Efforts to increase coverage of the secretome, culminated in a method 
that can reliably quantify approximately 700 extracellular proteins per sample which is 
competitive with other labelled MS methods (288, 289, 587). The most important advantage of 
this approach is that it is compatible with any cell origin, unlike SILAC approaches for example 
(261, 284). In addition, this approach enables the examination of the secretome in an unbiased 
manner, given the variability of secretome composition this is an extremely desirable feature 
when searching for novel players that mediate disease phenotypes. 
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Building on the foundations presented in this chapter it would be useful to compare 
directly label free approaches to those of labelled approaches. A plausible primary cell model 
could be achieved through the transduction of an enzyme-based tagging system in a stromal cell 
line, which could be utilised in co-culture with primary cells (583). A caveat to this approach is 
that the efficiency of labelling can be variable, while it is debatable whether the transduction 
produces cells with altered protein behaviour. Otherwise this may be another effective method 
to investigate the supportive contribution of such cells, in a human system. 
Both MS-5 and HS-5 cell lines are used by numerous labs to facilitate leukaemia research 
and knowing the precise proteins that constitute the supportive complement produced by these 
cells has merit. As described in Chapter 4 the understanding of such proteins can help to identify 
cleaner and more reproducible means of sustaining leukaemic cells in culture that do not involve 
introducing other cell populations (346, 364, 584, 585, 588, 589). Western blot experiments 
(Figure 3.25) showed the heterogeneity in cross-talk that occurs in leukaemia. S100-A4 
expression was shown to be present in some AML, with patient #1 cells secreting an abundance 
of the protein. Conversely, patient #2-4 cultures did not secrete S100-A4 and relied upon MS-5 
cells for production. Patient #5 co-cultures on the other hand, displayed a synergistic process as 
neither cell type could secrete high levels of S100-A4 independently, but in co-culture high S100-
A4 levels were detected. Due to cross-species reactivity it was not possible to conclude which 
cells were responsible for the elevated secretion.   
CXCL12 was not observed in experiments, this is unsurprising as CXCL12 is known to be 
secreted specifically by cells defined by their secretion of the protein (333, 590, 591). This 
highlights subsequent experiments that should be conducted. Determination of the secretome 
from other cell types that compose the BMM are all avenues of investigation that need to be 
explored to fully understand the cross-talk of the BMM. Ideally the model would comprise 
multiple cell types, as a multicellular model would induce differential secretome production to 








7.2 Empirical determination of identified protein components from the 
BMSM and their role in AML survival 
7.2.1 Introduction and context of investigations 
 The microenvironment is critical for AML survival, influencing cell behaviour and 
ultimately being a determinant of cell fate (164, 165, 559). Having established six stromal cell 
derived proteins whose expression dynamically changed in the presence of AML cell lines – 
S100-A4, S100-A11, BMP-1, CTGF, HGF, CSF-1 – it was important to functionally validate the role 
of these proteins in primary AML cells, if any. AML is extremely heterogeneous and as a result, 
each patient’s disease is unique (594). Consequently, to establish if these proteins were relevant 
in AML, survival and proliferation were investigated as a metric of response in a mixed cohort of 
primary AML cells.  
 An extension of this work looked to characterise the bulk HS-5 secretomes ability to 
recapitulate other observed aspects of the in vivo microenvironment, namely does it sculpt the 
phenotype of primary AML cells across extended conditioning, and/or aid in tolerating targeted 
kinase inhibition. Previous studies had investigated stromal cell co-culture and shown that these 
models could help AML cells resist chemotherapy (346, 354, 595). If the aforementioned 
hypothesis were true, then these studies would support that these proteins are important in 
AML progression, while providing the appropriate conditions by which to measure the signalling 
network response to these proteins.  
7.2.2 Validation of secretomic protein function in AML 
 To test the strength of the label free MS approach to identify secretomic proteins that 
positively affect AML cells, purified human recombinant forms were used individually and in 
combination to maintain primary AML cells in culture for seven days. Guava easycyte flow 
cytometry was used to assess both the viability and proliferation of these cells. 
 Initial analysis of the guava flow cytometric data revealed that the different RPs were 
able to maintain viability in AML cells to varying degrees across the patients. However, in all 
patient samples the inclusion of a GF was more supportive than no GF control (Figure 4.4). The 
CM and Mixed GF treatments elicited similar responses in each patient tested, suggesting that 
components responsible for MS-5 CM support in primary AML culture were present in the Mixed 
GF sample. Thus, providing evidence that the label-free MS approach undertaken was able to 
identify supportive components of the MS-5 secretome.  
The GFs influence on cell proliferation differed to their effects on viability. Cells in some 
patient samples underwent substantial growth in response to GFs. In particular patient #1 to 
S100-A4 and the Mixed GF; patient #2 cells responded to all GFs except to the S100 proteins; 
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patient #3 and #4 cells increased in growth when compared to no GF, but this change was not 
profound; and patient #5 cells were responsive to most GFs, in particular CSF-1 (Figure 4.5). S100 
proteins are known to stimulate proliferation and invasion in other cancers (371, 389, 400), 
therefore the profound response that patient #1 cells had to the GFs supported this role. CSF-1 
is known to only have one receptor, CSF1R (450, 596). CSF1R possesses tyrosine kinase activity, 
which upon binding to CSF-1 can activate PI3K mediated proliferation in myeloid cells (597). 
Proliferation studies demonstrate that CSF-1 is capable of stimulating proliferation in primary 
AML patients. The heterogeneous response of different primary samples to the secretome 
derived proteins suggested that these proteins were indeed important in AML, but which 
protein(s) and the degree of impact will vary from patient to patient. Taken together these 
functional data provide strong support for the validity of the secretome derived proteins being 
key constituents of the CM that potentiates primary AML survival ex vivo. 
7.2.3 Analysis of kinase inhibition to abrogate stromal secretome response 
To further characterise how the HS-5 secretome supports primary AML, kinase 
inhibition studies were undertaken targeting key signalling nodes in AML (MAPK, mTOR, FLT3, 
JAK and PAK) (Table 4.2) (197, 206, 271, 447, 460, 598). It was hypothesised that signalling 
molecules that comprise the HS-5 stromal secretome would engage these pathways to mediate 
survival and proliferation. The caveat to this approach was that it was not possible to define 
protein specific responses to kinase inhibition. A switch to the HS-5 bulk secretome was 
employed for both practical and economic reasons, as the heterogeneous nature of primary 
AML cells meant it was important to test these studies in a larger cohort. To test these GFs 
individually in a larger cohort with multiple kinase inhibitors conceivably would have resulted in, 
(12 [patients] x 4 [replicates] x 6 [inhibitors conditions] x 9 [GF conditions] = 2592 samples). 
Therefore, treatment with the complex mixture that contained all the GFs meant that supportive 
mechanisms should have been engaged. If there was a consensus for downstream pathway 
activation to mediate response to supportive elements, then kinase inhibition of AML implicated 
pathways would have abrogated such support.  
Patient cohorts in the presence of the stromal secretome were able to tolerate MAPK 
inhibition (Figure 4.7) but became sensitive to mTOR inhibition (Figure 4.8). FLT3 and JAK 
inhibition were not significantly altered and, regardless of secretome, PAK inhibition profoundly 
affected cells (Figure 4.11). Retrospectively Midostaurin treatment was too high in 
concentration, studies (599) have reported nM range for FLT3 selectivity. Therefore, during 
treatment there were probably multiple kinases inhibited, hence no discrimination between +/- 





Figure 7.1: Theory for bone marrow stromal cell-initiated activation of AML cell signalling nodes. (A) 
AML cells that are grown independent of a BMSCs or CM, inherently rely upon particular signalling (such 
as MAPK). (B) If these cells are then treated with a specific kinase inhibitor (Torin-1) to a kinase that is not 
dependent, then the cells are unaffected by the inhibitor. (C) When the same AMLs are grown in the 
presence of BMSCs or CM, other signalling nodes may now become activated by factors or cell contact 
(such as mTOR). (D) Treatment with the same Torin-1 inhibitor now will effect cell behaviour, as active 
nodes are now being inhibited, while previous inherent dependencies may not be as crucial. 
These data revealed aspects of AML cell signalling not previously explored, with the 
stromal proteins potentially able to switch signalling node dependencies within samples. These 
experiments suggested that these AML cells had a predisposition for MAPK mediated signalling, 
which had previously been investigated in AML (198). The simultaneous increase in sensitivity 
to Torin-1 in patients that decrease in sensitivity to MAPK inhibition following the introduction 
of HS-5 stromal proteins, suggested that signalling node dependencies were being altered 
(Figure 7.1). Unpublished studies by Dr Hijazi in the Cutillas lab have shown that Trametinib and 
Torin-1 are extremely specific in vivo inhibitors of MEK and mTOR kinase activity. Knowledge of 
these observations had an influence on the interpretation of the described findings and the 
relevance of the HS-5 secretome in the context of MAPK and mTOR activity.  
For kinases that would have previously been active/inactive, the binding of a stromal GF 
stimulated pathway activity of otherwise relatively inactive pathways, altering the overall state 
of kinase networks and response to inhibition. As a whole, these analyses confirm the plasticity 
of signalling in AML. The dual targeting of pathways such as MAPK and mTOR is a recently 
proposed means of therapy (600, 601) in AML, which could prove effective in achieving a 
complete response if the treatment is not toxic. Collectively, the AML response to four targeted 















environment elements and were more plastic as a result. PAK and JAK inhibition revealed a 
uniform response to inhibition irrespective of the presence of signalling molecules used in the 
study, AML were either unaffected by the HS-5 conditioning or these pathways are not as plastic. 
7.2.4 Analysis of AML adaption to stromal conditioned medium 
 To test how HS-5 secretome shapes the clonality of AML cell populations, primary cells 
were grown ex vivo with HS-5 CM and assessed at three time points. The phenotype of these 
cells was monitored by CyTOF using a panel of antibodies raised against validated markers of 
AML phenotypes (485, 574, 602, 603). The resulting data were extracted and analysed 
computationally using established cytobank software and ViSNE algorithms to visualise changes 
in the AML cellular populations (486). 
 Initial analysis of the CyTOF data revealed that the AML population changed 
considerably in culture. This was posited based on the change in cluster shape and position of 
the cell populations as represented in the VISNE analysis (Figure 4.16). Positioning in the ViSNE 
plot follows much the same principles of a PC plot in that the position occupied in the PC space 
is indicative of the expression of all markers being assessed (486). The Day 36 sample was the 
only sample of Figure 4.12 to survive in culture and what distinguished this sample was the 
presence of HS-5 CM.  
CyTOF analysis revealed that long-term maintenance of these AML cells developed 
clones possessing microenvironment sensing molecules and markers symptomatic of aggressive 
disease that responds poorly to treatment (Figure 4.21). Based on the literature, it was 
unexpected that CD34+CD38- populations decreased, a population normally maintained under 
influence of the microenvironment (138, 604). However, there are now a number of papers that 
report the capacity of CD34-CD38+ cells to behave as leukaemia initiators and induce 
engraftment (143, 465-467); this population was abundant by Day 36 (Figure 4.20, blue circles). 
7.2.5 Technical considerations 
 It is important to note that all experiments with the recombinant GFs were conducted 
at the concentrations recommended by manufacturers, as being within the biologically active 
range. These concentrations are equivalent to those used by other studies, when adding GFs to 
support primary AML (352-354). Expansion of the patient cohort would have given the necessary 
power to extract clinical feature related observations (such as risk group associated responses 
to the secretome derived proteins).  
To fully validate the patient response to secretome derived proteins, it would have been 
desirable to execute primary AML maintenance experiments using BMSC CM with the inclusion 
of individual neutralising antibodies. These experiments were not possible due to the 
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unavailability of neutralising antibodies to the secretome derived proteins. If these became 
available, then full validation would be possible. 
 Kinase inhibition studies used concentrations previously used in the laboratory for AML 
based kinase inhibition experiments (536). Although IC50 experiments were not conducted on 
each inhibitor in the primary AML samples, experiments were deemed appropriate as the 
investigation was assessing the ability of CM to alter response, for these purposes the 
experiments were controlled. Following these observations, it would have been desirable to 
continue to expand the inhibitor panel and patient numbers. These investigations will be 
continued in the future. In addition, kinase inhibition will be repeated with the panel of 
secretome derived GFs, patient selection shall be guided by the results of Chapter 5.  
The results of the CyTOF experiment although informative, need to be expanded. The 
nature of the experiment dictated that there were only enough cells by Day 36 to run the 
experiment once. Therefore, these experiments need to be repeated in multiple patient 
samples. At the same time it would be useful to include antibodies that target other relevant 
receptors, those important in AML and known receptors to components of the secretome (such 
as FLT3, CSF1R, c-MET) (Figure 4.1) (392, 450, 458, 605, 606). These were not included as the 
delicate nature of the cells dictated the implementation of an already optimised AML 
phenotyping panel. 
7.2.6 Implications and future work 
Despite heterogeneity in patient response, the six proteins identified in Chapter 3 
induced increased cell survival compared to no GF conditions. Validation of these proteins being 
secreted in AML were observed in western experiments (Section 3.12) and these are proteins 
known to be present in the BM (607).  However, histological staining of BM trephines from both 
healthy and leukaemic bone samples would give clinical confirmation. 
The immediate scientific benefit from identifying a panel of purified proteins that extend 
ex vivo culture, is the increased capacity for experimentation of primary AML tissue. The study 
of primary cells is traditionally difficult, before the characterisation of any new disease elements 
can be undertaken, researchers need to first take necessary steps to stop leukaemic cells from 
succumbing to an ex vivo environment. This can then confound and limit studies, as cells in 
culture are already initiating apoptotic machinery, this is not true in the BM (346, 608). When 
studying means of effectively treating relevant AML cells, it is necessary to work with cells that 
are going to respond in a manner that is akin to in vivo, otherwise findings are unlikely to 
translate or be very informative. Increasing stromal cell independent survival in culture opens 
the opportunity to study these cells in previously difficult platforms, as experiments with 
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primary cells that need to embed in a stromal feeder layer to survive can make investigations of 
the primary cells difficult. As removal of the feeder cells for analysis of the target cells can alter 
the behaviour of the primary cells being investigated.  
Kinase inhibition studies highlighted the impact that stromal secretomes can have on 
kinase signalling in AML, and therefore, the secretome has implications on kinase inhibitor 
efficacy. These experiments showed the context in which kinase inhibitors are deemed 
appropriate changes with the environment. Inherently certain AML clones may utilise particular 
signaling nodes, but in the microenvironment the dependence on such nodes may shift, as 
observed with MAPK and mTOR signalling in the presence and absence of HS-5 stromal proteins 
(Figure 4.7 and Figure 4.8). The extent of this phenomena could be further tested to identify 
other pathways that respond accordingly, as well as include more inhibitors in the analysis. It 
would be desirable to address whether this pertains specifically to inhibitors with limited off-
targets, or if this behavior is specific to particular pathways.  
The CyTOF study has profiled cells in a condition not previously documented. This 
experiment tracked the effects of the HS-5 CM on the clonality of primary AML cells that without 
such adaption would have succumbed in culture, as observed in parallel conditions. Although 
there was the loss of the CD34+CD38- population which has previously been documented as 
maintained by MSCs (for up to 6 weeks) by other studies (576, 609), this investigation revealed 
the expansion of an aggressive, pro-microenvironment population with previously defined 
initiator properties (143). These findings reinforce the concept of the microenvironment 











7.3 Determining the heterogeneity of AML cell signalling and the response 
of the phosphoproteome to BMSM stimulation 
7.3.1 Context  
 The pathophysiology that underpins AML cannot be fully explained for most patients, 
with only those that present with APL having a defined driving event (t[15;17]) – which makes 
this the only AML subtype to be successfully treated with a targeted therapy (612). For other 
patients the disease is profoundly heterogeneous, as demonstrated by many of the large-scale 
genome studies undertaken (18, 31, 32). The findings of these studies have been used to help 
guide targeted therapies over the past 20-30 years, which as discussed in Chapter 1 has not lead 
to any significant innovation in AML (23). As many of the most frequently mutated genes encode 
signalling proteins, tyrosine kinase inhibitors (TKI) have become the focus of many targeted 
strategies (613, 614).  
 It was hypothesised that many patients could be non-responsive to TKI-based therapies 
due to inaccurate stratification. When patients are selected for treatment on the assumption of 
aberrant kinase activity driving a phenotype (i.e. FLT3) due to genetic aberrations, then 
treatment selection is assuming that mRNA expression and protein expression, and neglects a 
host of other biological factors (epigenetic regulation, protein-protein interactions, phosphatase 
activity, amongst others) that effect network composition and activity (290, 291). Kinase 
mutations are unlikely to be the sole driver of disease, however. A recent paper by Creixell et al. 
(216) demonstrated some of the means by which the accumulation of minor genetic events can 
lead to the rewiring of signalling networks. Considering these factors, it was posited that these 
types of alterations could influence the kind of relationship that AML cells have with the 
microenvironment, and by extension the response to the secretome derived proteins.    
In Chapter 1, the study of phosphoproteomics was discussed, in particular how the 
measurement of phosphopeptide abundance using unbiased MS-based techniques is the most 
comprehensive readout of putative protein function, as it considers the biological contribution 
of numerous factors (Figure 1.10). Thus, to study the heterogeneity of kinase networks in AML 
and the impact of the microenvironment on kinase network activity, primary AML cells were 
stimulated with the identified proteins from Chapter 4 (Figure 5.7), the bulk secretome (Figure 
5.13) and by direct co-culture with MS-5 cells (Figure 5.18). These experiments set out to 
understand if there were inherent features that determine how AML cells interact with the 
microenvironment or if cell signalling networks do respond in a homogenous manner (360, 560). 
Additionally, were cells wired to respond in a homogenous manner to certain stimuli (contact 
dependent), and a heterogeneous manner to other stimuli (chemical).  
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Finally, Tape et al. (491) recently demonstrated that cancer cells can utilise the signalling 
networks of stromal cells in a non-cell autonomous manner, to regulate cancer signalling and 
function in a reciprocal manner – heterotypic signalling. Considering this concept, it was 
investigated whether primary AML cells in culture were able to direct the behaviour of MS-5 
cells to propagate their own progression.  
7.3.2 Analysis of single GF stimulated pathways in AML 
In order to examine how the panel of secretome derived GFs stimulated proliferation 
and supported cell survival it was important to characterise how these molecules modulate 
signalling networks (611). To assess this, GF treatments were first optimised for signalling 
experiments by examining the status of well described signalling nodes in AML by assessing 
activity markers following stimulation with 10ng/ml of each GF in P31/FUJ cells (Figure 5.2)(207, 
600). These concentrations were selected as these were effective in maintaining viability and 
inducing proliferation in previous experiments (Figure 4.4 and Figure 4.5). Assessment of key 
signalling nodes (MAPK, AKT, mTOR substrates, PAK) (207, 600, 601, 615, 616) revealed that GF 
combination conditions had profound effects on MAPK activity (Figure 5.3), and phosphorylation 
of the mTOR substrates 4EBP1 and p70S6K (Figure 5.4). The PAK kinases were more 
phosphorylated following single GF treatments or secretome treatment in PAK1 respectively 
(Figure 5.5). Collectively these results suggested that the tested concentrations were sufficient 
to activate signalling nodes of AML cells. 
Following validation that the GFs were capable of activating key AML signalling nodes in 
P31/FUJ cells, the phosphoproteome of patient # 1 cells was chosen to assess pathway activity 
in primary AML, as these cells displayed dynamic responses to the secretome derived protein 
treatments (Figure 5.6). 
 To assess relationships between the effects of the secretome derived proteins on the 
patient #1 phosphoproteome, the similarity between the log2 fold-ratios of all the 
phosphopeptides across the treatments were assessed using hierarchical clustering and PCA 
(Figure 5.10 and Figure 5.12). This analysis demonstrated that phosphoproteomes of the 
samples were in agreement with the proliferative response observed when patient #1 cells were 
treated in Chapter 4. Both S100-A4 and Mixed GF phosphoproteomes clustered independently 
to the other samples, all of which did not show substantial proliferative difference in patient #1 
cells. KSEA analysis of the experiment revealed that changes in kinase activity as a result of 
tratment were very heterogeneous (Figure 5.11). Systematic assessment determined that the 
single protein treatments induced increased activity in AKT, mTOR, ERK1 and ERK2, with S100-
A4 also increasing ATR, CK2A2 and InsR activity which was not observed in the other treatments 
(Figure 5.11). The multivariate analysis captured the proliferative phenotypes of these cells, 
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whereas the KSEA analysis was correlative with the maintained viability observed in survival 
assays, with single GF treatments leading to consistent enrichment for AKT and mTOR. Excluding 
S100 proteins ERK signalling was also enriched in these scenarios of high viability. S100-A4 
treatment induced signalling in ATR, Src and InsR pathways, which were not observed in the 
other single GF treatments. As these are the only kinases whose activity did not decrease in 
Mixed GF conditions, results indicate that these are the pathways that S100-A4 and Mixed GF 
conditions stimulate to induce proliferation. 
It is important to note that the discrepancy between kinase activities in individual GF 
treatments and the complex mixtures could be due to time of analysis. Fifteen minutes post 
stimulation was optimal for capturing the activated pathways of single GF treatment at a 
concentration of 10ng/ml. Whereas,  the complex mixtures that contained 10ng/ml each of the 
six GFs (Mixed GF) or 10µg/ml of >5kDa MS-5 secretome led to an onset of signal transduction 
that was not captured and not sustained. Previous studies of receptor regulation and signal 
transduction maintenance have reported that when receptors such as EGFR are exposed to low 
levels of ligand, they are endocytosed via clathrin-mediated endocytosis and recycled to the 
surface to help sustain and prolong signalling (617). However, when EGFR is exposed to high 
ligand levels the receptor it is internalised and committed to lysosomal degradation through 
clathrin-independent endocytosis, thus ceasing signalling (618). Expanding on EGFR, clathrin-
independent endocytosis has been reported to regulate adaptor proteins, HGFR, IFN, TGF and 
GPCRs (619, 620). It is therefore possible, that the reduced kinase activity in the complex 
samples (Mixed GF and >5kDa MS-5 sec) was due to ligand concentration being saturated, 
inducing receptor internalisation and degradation. Whereas, the lower ligand concentrations 
may have induced sustained receptor signalling, producing the higher activities observed in 
Figure 5.11. To clarify if this was indeed the case the experiment could be repeated at different 
time points to ascertain optimal pathway activation because of complex ligand mixtures. Varying 
GF concentration combinations could be investigated; however, altering GF concentration 
would then create a discrepancy between the conditions that increased primary AML survival 
(Figure 5.6) and those being used to investigate the pathways responsible for such phenotypes. 
7.3.3 Analysis of kinase network heterogeneity in response to secretome 
 In order to examine the similarities and differences between the effects of the 
secretomic proteins on the AML phosphoproteome of numerous patients, a panel of seven 
primary AML patients were grown with HS-5 CM prior to phosphoproteomic analysis. Initial 
analysis of the data revealed that both phosphoproteome expression and kinase activity levels 
were extremely heterogeneous (Figure 5.15 and Figure 5.16). 
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The relationship between the effects of the HS-5 secretome on the seven patient 
samples were assessed by means of several multivariate analyses. To compare patient 
phosphoproteome similarity across patients, the data was analysed using 3-dimensional PC 
analysis (Figure 5.17). This analysis demonstrated that the basal phosphoproteomes at 1 hour 
were all distinct and did not share the same PC space. Following 24 hours of HS-5 conditioning 
5/7 samples had migrated centrally to occupy a similar region. This indicates that, despite 
substantially different basal phosphoproteomes, stimulation with the HS-5 secretome affected 
the phosphoproteomes similarly, suggesting that although signals may have been transmitted 
via different routes within the network, ultimately the same cellular response can be achieved 
(216, 621). 
7.3.4 Analysis of co-culture on AML signalling networks  
To investigate the effects of the BMSM on AML cell signalling fully, it was essential to 
incorporate the contribution of juxtacrine signalling and the ability of cells to respond to each 
other dynamically (heterotypic signalling) (491, 622). To establish how these cells regulate each 
other’s signalling networks a label-free phosphoproteomic study was conceived to analyse 
primary AML cells and MS-5 cells following 24 hours co-culture (Figure 5.18). Careful enrichment 
and the utilisation of human and mouse genomes made it possible to distinguish co-culture 
phosphopeptide origin by MS (237). 
 Comparing the K-means cluster analysis of primary AML cells in MS-5 co-culture to that 
of the primary AML following HS-5 conditioning, suggests that for consistent and stable AML 
survival, the secretome alone is insufficient. Principally, this could be due to the lack of 
bidirectional signalling, which has been demonstrated in other cancer models to be necessary 
to positively regulate pro-tumorigenic effects (491). Some patient cells can survive in CM (as 
seen in Chapter 4), which as observed in the CyTOF experiments is owing to the endogenous 
expression of the necessary complimentary receptors to proteins that comprise the stromal 
secretome (450, 623). Other features such as low metabolic rate, network topology and a good 
anti-apoptotic predisposition would also facilitate and contribute to extended survival (624-
627). These findings capture the inherent heterogeneity observed between patients visualised 
by the ability to survive alone (594). In co-culture, however, the environment is dynamic and 
responsive, therefore, AML cells can also potentially shape the environment in which they find 
themselves, if independent survival is not possible (560). This is probably why the primary AML 
response was more consistent during MS-5 co-culture, encapsulated by the uniform increase in 
phosphorylation of anti-apoptotic substrates (Figure 5.23, cluster 6). 
The consensus for increased expression of the phosphopeptides contained within k-
means cluster 6 is interesting, as functions for each of the four kinases (AKT, DYRK2, CDK5 and 
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LATS1) that’s activity increased (determined by KSEA) following MS-5 co-culture form aspects of 
the microenvironment mediated hypothesis that encapsulates AML persistence, treatment 
resistance and relapse. Increased AKT activity is known to promote cell survival through anti-
apoptotic signalling (545, 628, 629), CDK5 activity can maintain the pro-angiogenic environment, 
which is crucial to sustain AML cells (529). DYRK2 and LATS1 are regulatory kinases that are 
capable of regulating AML and drive the features that have led the field to believe the 
microenvironment induces a quiescent phenotype in AML (630, 631). DYRK2 and LATS1 could 
be the mediators that lead to the drop in AML growth and proliferation, while promoting 
nestling in small niches, thus making them chemo-resistant (568, 624, 625, 632).  These are 
hypotheses, however, and require further investigation. But these are reported functions of 
these kinases that were consistently enriched as activated kinases in AML following co-culture 
with MS-5 cells. 
7.3.5 Analysis of co-culture on MS-5 signalling networks 
Recent studies had demonstrated that other tumour types can engage and instigate 
reciprocal signalling with surrounding stromal cells (633) that could regulate cancer cell growth 
and survival. MS-5 co-culture enabled primary cells from patient samples that exhibited 
profound phosphoproteomic heterogeneity in HS-5 conditioning experiments (Figure 5.16), to 
respond in a homogeneous manner while facilitating survival. This included potentiating both 
anti-apoptotic signalling and modulating the activity of proliferative kinases AKT and LATS1. To 
establish the phosphoproteomic landscape in MS-5 cells and identify pathways modulated by 
AML during co-culture, label-free LC-MS/MS based phosphoproteomics were undertaken 
(Figure 5.18). 
Differential abundance analysis demonstrated that there was not profound modulation 
across the whole proteome, with approximately 300 phosphopeptides significantly changed per 
co-culture (Figure 5.24). GO enrichment analysis of all significantly modulated peptides (P<0.05) 
revealed that 6/8 of MS-5 populations exhibited increased insulin receptor signalling and signal 
transduction following AML co-culture (Figure 5.26). This suggested that different AML cell 
populations were activating signalling pathways in the MS-5 cells (634). KSEA identified three 
kinases that increased in activity in all eight AML co-culture experiments, which are MAPKAPK2, 
PKC and GSK3. These are all candidates with roles in reciprocal signalling as these kinases 
were ubiquitously upregulated in AML co-culture compared to independent MS-5 cells. It may 
be argued that kinases such as PKC are traditionally associated with tumour suppressive 
effects, in these circumstances however, there are well established hypothesises that the BMM 




The nature of cross-talk and cell-cell interactions is more nuanced than the single 
mechanism described above (456). KSEA analysis identified two signalling signatures, that in PC 
space separate, one away from the control cells and one that cluster with them (Figure 5.28). 
These two groups also exhibited different morphology and behaviour that are being referred to 
as BM independent and BM interactive (Figure 5.29).  
7.3.6 Implications and future work 
 Using an untargeted approach, the results of Chapter 5 provide insight to the nature of 
kinase networks in AML cells and MS-5 cells, and the means by which these cells are able to 
respond to each other. Experiments revealed that, in spite of the increased understanding the 
field has garnered in AML biology and the heterogeneity that underpins it (456, 565, 566, 638, 
639), knowledge of AML signalling networks, pathway plasticity and adaptations are still greatly 
limited. Thus, these investigations serve to highlight the heterogeneity of such kinase networks 
and how they are activated or inactivated by the stromal cells of the BM (615).  
Single GF treatments displayed how P31/FUJ cells can be used as an appropriate model 
to study aspects of AML biology (535), although this cell line did not respond in a manner 
consistent with the patient#1  primary AML cells tested in single GF studies. Results in section 
5.3 showed that primary cells grown in independent culture do not respond to stromal 
secretomes in a consistent manner either. Single GF treatment experiments in primary AML cells 
revealed that there were increases in pathway activity relative to untreated cells during single 
GF treatments (typically mTOR or ATR activity), however, complex mixtures induced relative 
decreases in global kinase signalling compared to unstimulated cells. These experiments need 
to be explored in further patients, as the explanation to these observations could relate to a 
number of factors (patient specific, saturated ligand concentration leading to receptor 
internalisation, reduction in stress signals, and means of quiescence).  
Co-culture signalling experiments notably observed a clustering of patients based on 
response to the MS-5 cells, these cells also harboured the same NRAS mutation (p.G13D)(448). 
These signatures did not cluster on inherent basal kinase activity, but on changes in kinase 
activity following co-culture, this is suggestive of a mutation that influences the way an AML cell 
population interprets and interacts with other cell types (640). As mentioned previously, this 
needs to be assessed in further patients that harbour this genotype. 
Analysis of MS-5 cells kinase activity following co-culture revealed that RTK signalling 
was increased in many samples (Figure 5.26). Multivariate analysis of KSEA data revealed two 
MS-5 phosphoproteomic signatures, one for a group of MS-5 cells seeded with cells that 
integrated within the stromal network and one for a group MS-5 cells that were seeded with 
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AML cells that clustered separately. These signatures combined with phenotypic observations 
are suggestive of stromal interactive AML cells and stromal independent AML cells (641). 
Taken together, these experiments showed that AML kinase signalling networks 
underwent significant and heterogeneous shifts in activity following stimulation with stromal 
secreted proteins. Most strikingly, different primary AML samples were able to respond to 
stromal cells through both homogeneous (contact dependent AKT, LATS1 activations) and 
heterogeneous network routes (response to BMSC secretome), while simultaneously 
stimulating signalling nodes implicated in cytokine production (such as MAPKAPK2). 
Experiments to substantiate this potential heterotypic mechanism are of great interest and 


















7.4 Functional and biochemical characterisation of PAK signalling in AML 
7.4.1 Context  
It had been proposed in previous studies that in cancer and in particular treatment 
resistant neoplasms, kinase networks undergo network rewiring and establish interactions that 
would not necessarily occur under physiologically conditions (215, 216). Having observed that 
the underlying kinase networks that help to govern the AML response to the microenvironment 
are extremely heterogeneous, it had been a quandary that PAK inhibition was always so potent 
in undermining AML cell survival (Figure 4.11). This observation coupled with the study from 
Casado et al. (271) that documents that PAK is one the most active kinases in AML (Figure 6.1), 
lead to experiments that studied the nature of PAK activation in AML and protein interaction 
studies to try and establish mechanistically the relevance of high PAK activity. 
7.4.2 Findings 
Collectively, these experiments showed that PAK activity and expression in AML is 
variable, and this heterogeneity cannot directly be explained through accumulation of genetic 
aberrations. In agreement with previous works, analysis of AML models tested showed high PAK 
phosphorylation (Figure 6.5) (206, 207, 271, 551, 642).  
Co-IP techniques were optimised so that PAK could be consistently immunoprecipitated. 
Following the establishment of a robust technique that was able to pulldown known PAK binders 
in complex to be identified by MS detection (Figure 6.9), PAK complex formation was tested to 
identify dynamic PAK binders in AML. To elicit such complexes, cells were serum starved before 
stimulation as used in previous works (552). In addition, preliminary experiments assessed 
secretomic stimulation and PAK inhibition, all of which revealed preliminary interaction 
candidates. Further investigations revealed that PAK4 – the least described of the PAK isoforms 
(540, 541, 550)– consistently demonstrated binding of H2 histones during serum modulation 
that was not observed under other conditions, indicating either a nuclear function or localisation 
that PAK4 has previously not been implicated in (539).    
7.4.3 Technical considerations 
Limitations of the co-IP experiments were the low number of biological replicates (n=2) 
in Figure 6.13 and Figure 6.14. These experiments may have identified a viable PAK interacting 
candidate for the group 1 isoforms if enough replicates were conducted, such as LPXN (554, 643, 
644). This is an antibody-based approach and therefore, the technique was at the mercy of 
antibody quality (645). It was notable that serum starved optimisation experiments were able 
to identify known PAK interactors GIT1, GIT2, ARHGEF6 and ARHGEF7 (539, 646-648), although 
these were not identified in the large serum-based co-IP experiments. Other known PAK 
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interactors Filamin A and Filamin C were identified in the larger studies, these binding dynamics 
can be explained by the antibody incubation step, which was reduced from overnight to 1 hour. 
It was reasoned that excessive incubation would only lead to the accumulation of non-specific 
binders and dissociation of transient and important interactors, a type of interaction that would 
be common for PAK, given that it is a kinase (649, 650). This suggests that the Filamins are more 
transient PAK interactors and that the ARHGEFs and GITs interactors are more constitutive PAK 
interactors.  
Unexplored means of optimisation included chemical preservation with cross linking 
agents (such as glutaraldehyde) as previously shown to be an effective means to identify weak 
interactions, although this requires extensive optimisation to ensure artefacts are not produced 
(651). Pulldown with magnetic beads was posited as an alternative solid support, potentially 
offering better bead retention and therefore, complex retention – this should be explored 
further (652). Approaches not selected due to their potential effects on protein structure, 
binding and behaviour, were techniques that involved the ectopic expression of protein 
GFP/FLAG-/HA-tags or BioID/APEX approaches (653-655).  
The final aspect of consideration for this chapter, was the lack of primary tissue used in 
these experiments. Cell lines were used exclusively as it was deemed inappropriate to use 
primary cells in such experiments. However, this is probably necessary to reveal AML specific 
interactions for PAK. The previous chapters have discussed the impact of disease heterogeneity 
on AML kinase networks formation and kinetics, an overactive sample compared to a sample 
with relatively low PAK activity may have helped reveal the aberrant PAK interactors. 
Additionally, the inclusion of a non-AML sample would also have helped identify AML specific 
interactions. 
7.4.4 Implications and future work 
 Studies conducted as part of this project help to substantiate PAKs importance in AML, 
augmenting previous research (206, 207, 271). Collectively, experiments showed that PAK 
activity and expression in AML is variable, and this heterogeneity cannot directly be explained 
through accumulation of genetic aberrations. Following the optimisation of a co-IP coupled MS 
approach it was possible to investigate dynamic binding partners of PAK principally focussing on 
PAK response following starvation and rapid stimulation. Experiments to date have identified 
PAK4 and a consistent dynamic binding of H2 histones during serum modulation that was not 
observed under other conditions, indicating either a nuclear function or localisation that PAK4 
has previously not been implicated in.   
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 Future work will look to validate the PAK4-H2 histone interaction further. The novel 
association of PAK4 with histones, coupled with AML’s well described epigenetic component, 
represents an exciting mechanism to be explored (4, 18, 69, 656-660). PAK pulldown following 
treatment with epigenetic modulators (such as voronistat or Azacitidine) could reveal other 
important interactors. A dynamic relationship between a kinase and histones could offer insight 
to the mutual regulation of gene expression and kinase signalling (661).  
The inclusion of primary AML based experiments; in particular, the comparison of the 
PAK interactome in a sample that exhibits high PAK activity to one that exhibits normal to low 
PAK activity could uncover aspects of the upregulated PAK signalling network. Abrogating PAK 
activity in culture is extremely lethal to AML (Figure 4.11) (536). However, PAK inhibition is not 
a viable means of therapy in the clinic, due to related toxicities (540). Therefore, more 
sophisticated means of targeting are required. Understanding of the adaptor proteins that 


















7.5 Concluding remarks 
Due to the combinatorial complexity of the number of variables involved in 
leukaemogenesis and resistance of a single clone (genomic aberrations, epigenetic factors, 
kinase signalling dynamics, metabolic abnormalities and environmental factors) AML has 
remained largely incurable (19, 442, 532, 567, 625, 662). The combination of factors also 
explains why targeted therapy has yet to really establish itself in this disease (excluding APL) and 
why chemotherapy-based regimens followed by SCT have been the only means of cure (23).  
The increased understanding of disease biology is important in the pursuit of 
therapeutic innovation and the discovery of new targets (40, 569, 570). Therefore, the more that 
is understood about the contributing factors of disease heterogeneity the greater the likelihood 
of identifying new therapeutic strategies. Studies performed as part of this thesis highlight the 
power of MS-based proteomics in understanding the role of the microenvironment in AML. This 
represents the first time that an MS based approach was used to identify components of the 
AML supportive secretome and results have shown that these proteins alone can maintain 
primary cells for an extended period of weeks. It remains to be established what determines 
response to these proteins in leukaemic cells, and whether these proteins are transiently 
important in disease pathology or if they are a constant feature that define AML. These 
questions extend to other exogenous factors, touching on the role of the microenvironment in 
disease initiation and whether it has a larger role to play in the definition of inherent leukaemic 
features (164). 
This work has posed pertinent questions in the pursuit and implementation of targeted 
therapies in AML, in particular the suitability of FLT3 kinase inhibitors. The selection of kinase 
inhibition based on mutational status assumes that profound molecular heterogeneity does not 
affect the topology and plasticity of kinase networks (39, 47, 446, 663-665). It has been hard to 
identify kinase mutations that have penetrance in the activity of global kinase networks in these 
studies. In addition, divergent network configurations also highlighted the difficulty in 
deciphering the precise configuration and activity of kinase networks across both cell types and 
patients (271, 456).  
Finally, an unexpected and potentially significant observation was the switch in cell 
sensitivity to kinase inhibition – in both directions – whilst in the presence of proteins from the 
microenvironment.  In the burgeoning field of kinase inhibitor therapeutics, the biological 
context in which kinase activity is measured in patient samples could result in significant 
variance from the in vivo situation. Inherently certain AML clones may utilise particular signalling 
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nodes, but in the microenvironment the dependence on such nodes may shift. These are 
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